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The	  obesity	  epidemic	  
Western	  style	  diets,	  excess	  calorie	  intake	  and	  low	  physical	  activity	  levels	  have	  resulted	  in	  
an	   obesity	   epidemic.	   This	   epidemic	   is	   currently	   affecting	   500	   million	   adults	   worldwide,	  
more	  than	  one	  in	  ten	  of	  the	  world’s	  population,	  with	  percentages	  approaching	  20	  percent	  
in	  Europe	  and	  30	  percent	  in	  the	  USA	  [1].	  The	  obesity	  epidemic	  is	  expanding	  dramatically	  in	  
adults	  as	  well	  as	   in	  children	  [1,	  2].	  Obesity	  can	  be	  considered	  a	  whole-­‐body	  distortion	  of	  
metabolism;	   frequent	  comorbidities	   include	  cardiovascular	  disease,	   liver	  disease,	  chronic	  
obstructive	   pulmonary	   disease	   (COPD),	   cancer,	   musculoskeletal	   disorders	   and	   type	   2	  
diabetes	  mellitus	  [3].	  Therefore,	  the	  obesity	  trend	  implies	  a	  major	  health	  burden	  affecting	  
quality	  of	  life	  and	  imposes	  a	  large	  economic	  burden	  on	  the	  health	  care	  system.	  
	  
Obesity	  and	  type	  2	  diabetes	  mellitus	  
One	   of	   the	   major	   complications	   of	   obesity	   is	   impaired	   glucose	   tolerance.	   A	   sedentary	  
lifestyle	   and	   obesity	   are	   considered	   the	  main	   determinants	   in	   the	   etiology	   of	   impaired	  
glucose	  tolerance,	  which	  is	  characterized	  by	  reduced	  insulin	  secretion	  by	  the	  pancreas	  and	  
insulin	   resistance.	   Insulin	   resistance	   is	   defined	   as	   an	   impaired	   ability	   of	   the	   hormone	  
insulin	   to	   stimulate	   glucose	   disposal	   by	   skeletal	  muscle	   and	   liver	   and	   to	   inhibit	   hepatic	  
glucose	  production.	  Impaired	  glucose	  tolerance	  may	  deteriorate	  towards	  type	  2	  diabetes	  
(T2D),	   which	   is	   characterized	   by	   β-­‐cell	   dysfunction	   and	   hyperglycemia,	   reflecting	   the	  
disability	   of	   the	   pancreatic	   β-­‐cells	   to	   compensate	   for	   the	   peripheral	   insulin	   resistance.	  
Approximately	  90	  percent	  of	  type	  2	  diabetics	  are	  overweight	  [4].	  Weight	  loss	  and	  exercise	  
can	  alleviate	   the	   symptoms	  and	  may	  even	   reverse	   insulin	   resistance	   [5,	   6].	   Yet,	   the	   fact	  
that	  ‘only’	  approximately	  30	  percent	  of	  obese	  people	  have	  T2D	  [7]	  indicates	  that	  genetic	  
and/or	   epigenetic	   predisposition	   plays	   an	   important	   role	   in	   the	   etiology	   of	   obesity-­‐
associated	  insulin	  resistance	  and	  progression	  towards	  T2D.	  
Several	  hypotheses	  have	  been	  put	  forward	  trying	  to	  explain	  the	  relationship	  between	  
obesity	  and	   type	  2	  diabetes,	   including	   theories	  on	   lipid	  oversupply,	  endocrine	  disorders,	  
proinflammatory	  states,	  mitochondrial	  dysfunction	  and	  endoplasmic	  reticulum	  (ER)	  stress	  
[8,	  9].	  There	  is	  no	  uniform	  single	  etiology;	  several	  pathologies	  lead	  to	  T2D	  and	  these	  paths	  
are	   highly	   interrelated	   and	   involve	   multiple	   organs,	   in	   particular	   the	   adipose	   tissue,	  
pancreas,	   liver	   and	   skeletal	   muscle.	   Most	   likely	   lipid,	   endocrine	   and	   inflammatory	  
parameters	  in	  addition	  to	  mitochondrial	  and	  ER	  function	  together	  determine	  susceptibility	  
and	  development	  towards	  insulin	  resistance,	  β-­‐cell	  failure	  and	  ultimately	  T2D.	  One	  causal	  
factor	  may	  trigger	  other	  parameters	  inducing	  a	  cascade	  of	  deterioration.	  	  
	  
Lipid	  overflow	  
In	  this	  thesis,	  the	  focus	  is	  on	  the	  lipid	  overflow	  hypothesis,	  which	  is	  considered	  the	  major	  
explanation	   for	   obesity-­‐associated	   insulin	   resistance.	   The	   lipid	   overflow	   hypothesis	  
considers	  T2D	  to	  result	  from	  a	  general	  state	  of	  increased	  lipid	  levels.	  When	  adipose	  tissue	  
is	  no	  longer	  capable	  of	  providing	  sufficient	  storage	  capacity	  for	  lipids	  in	  situations	  of	  lipid	  
oversupply,	   lipids	  will	   accumulate	   in	  nonadipose	   tissues	   such	  as	   liver,	  heart	   and	   skeletal	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muscle.	   Thus,	   ectopic	   lipid	   accumulation	   has	   been	   considered	   causative	   in	   obesity-­‐
associated	  insulin	  resistance	  and	  T2D	  (reviewed	  in	  [8,	  10]).	  In	  this	  thesis	  I	  will	  concentrate	  
on	   lipid	   accumulation	   in	   skeletal	  muscle,	   which	   is	   quantitatively	   a	  major	   contributor	   to	  
whole	   body	   glucose	   handling.	   The	   muscle	   accounts	   for	   more	   than	   80	   percent	   of	  
postprandial	   whole	   body	   glucose	   disposal.	   Initially,	   impaired	   skeletal	   muscle	   glucose	  
disposal,	  as	  seen	  in	  obesity,	  was	  explained	  by	  the	  Randle	  cycle;	  elevated	  intramyocellular	  
fatty	   acid	   (FA)	   oxidation	   was	   considered	   to	   increase	   acetyl-­‐CoA/CoA	   and	   NADH/NAD+	  
ratios	   thereby	   inducing	   a	   cascade	   of	   events	   inhibiting	   the	   glucose	   catabolic	   enzymes	  
pyruvate	   dehydrogenase,	   phosphofructokinase	   and	   hexokinase	   resulting	   in	   reduced	  
glucose	   utilization	   [11,	   12].	   However,	   subsequent	   studies	   showed	   that	   intramyocellular	  
glucose-­‐6-­‐phosphate	  levels	  were	  decreased	  rather	  than	  increased	  upon	  lipid	  infusion	  and	  
were	  decreased	  in	  insulin	  resistant	  subjects	  compared	  to	  insulin	  sensitive	  controls	  without	  
a	   compensatory	   increase	   in	   intracellular	   glucose	   levels	   [13-­‐16].	   This	   indicated	   that	   the	  
Randle	   cycle	   cannot	   fully	   explain	   the	   effects	   of	   elevated	   circulating	   free	   fatty	   levels	   on	  
glucose	   disposal.	   Thus,	   glucose	   uptake,	   rather	   than	   the	   subsequent	   glucose	  
phosphorylation/	   utilization,	   was	   identified	   as	   the	   rate-­‐limiting	   determinant	   for	   skeletal	  
muscle	   glucose	   disposal.	   After	   the	   discovery	   of	   the	   glucose	   transporter	   GLUT4	   [17,	   18],	  
which	   translocates	   from	   the	   cytosol	   to	   the	   plasma	  membrane	   upon	   insulin	   stimulation,	  
interest	  shifted	  towards	  lipid-­‐related	  factors	  that	  have	  the	  potential	  to	  interfere	  with	  the	  
insulin-­‐dependent	   pathways	   involved	   in	   GLUT4	   translocation	   to	   the	   sarcolemma	   as	  
potential	  causes	  for	  obesity-­‐associated	  skeletal	  muscle	  insulin	  resistance	  [19].	  	  
Skeletal	  muscle	  lipid	  levels	  –	  intramyocellular	  lipids	  (IMCL)	  –	  correlate	  negatively	  with	  
insulin	  sensitivity	  in	  a	  sedentary	  population	  [20-­‐24]	  and	  hence	  were	  considered	  predictive	  
for	   insulin	   resistance	   and	   causative	   in	   obesity-­‐associated	   insulin	   resistance.	   However,	  
endurance	  athletes	  also	  have	  high	   IMCL	   levels	  despite	  being	  highly	   insulin	   sensitive	   [25-­‐
27]	   and	   exercise	   training	   in	   obese	   and	   T2D	   subjects	   (which	   alleviates	   insulin	   resistance)	  
increases	  rather	  than	  decreases	  IMCL	  levels	  [6,	  28].	  This	  so-­‐called	  athlete’s	  paradox	  gave	  
new	   insight	   into	   the	   role	   of	   skeletal	  muscle	   lipid	   accumulation	   in	   insulin	   resistance	   and	  
indicated	  that	  neutral	  IMCL	  accumulation	  per	  se	  does	  not	  lead	  to	  insulin	  resistance.	  Lipid-­‐
induced	   insulin	   resistance	   in	   skeletal	   muscle	   probably	   depends	   on	   the	   intramyocellular	  
lipid	   composition	   and	   subcellular	   distribution.	   Thus,	   the	   athlete’s	   paradox	   has	   been	  
explained	  by	  differential	  effects	  of	  training	  and	  diabetes	  on	  IMCL	  turnover,	  accumulation	  
of	   lipid	   intermediates,	  and	  oxidative	  capacity.	  Proper	  balancing	  between	  skeletal	  muscle	  
lipid	  influx	  and	  fat	  oxidative	  capacity	  as	  well	  as	  an	  efficient	  rate	  of	  lipid	  turnover	  (i.e.	  lipid	  
depletion	   and	   efficient	   resynthesis	   to	   prevent	   lipid	   intermediate	   build-­‐up)	   have	   been	  
suggested	  to	  be	  beneficial	  for	  insulin	  sensitivity	  [28-­‐31].	  	  
	  
Lipid	  intermediates	  
In	   contrast	   to	   neutral	   lipids,	   i.e.	   triacylglycerol	   (TAG),	   certain	   lipid	   subspecies	   -­‐	   lipid	  
intermediates	   -­‐	   are	   considered	   to	   interfere	   with	   the	   insulin	   signaling	   cascade,	   thereby	  
impairing	   insulin	  sensitivity.	  Following	  FA	  uptake,	  FAs	  can	  be	  channeled	  directly	   towards	  
mitochondrial	  β-­‐oxidation,	  but	   the	  majority	  of	  FAs	  will	   first	  be	  utilized	  as	  building	  blocks	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for	  TAG	  synthesis.	  TAGs	  serve	  as	  a	  neutral	  intracellular	  lipid	  storage	  form	  for	  later	  use	  as	  a	  
substrate	   for	   energy	   production.	   Subsequent	   lipolysis	   can	   liberate	   FAs	   for	   downstream	  
catabolic	   metabolism.	   Lipid	   intermediate	   accumulation	   can	   result	   from	   an	   imbalance	  
between	   FA	   uptake	   and	   TAG	   (re)synthesis	   capacity	   and/or	   from	   a	   mismatch	   between	  
lipolysis	  and	  FA	  oxidation.	  To	  date,	  the	  lipid	  intermediates	  diacylglycerol	  (DAG),	  ceramide,	  
fatty	  acyl-­‐CoAs	  (FA-­‐CoAs)	  and	  acylcarnitines	  are	  considered	  potentially	  lipotoxic	  (reviewed	  
in	  [31-­‐35]).	  	  
	  
Skeletal	  muscle	  oxidative	  capacity	  
Oxidative	   capacity,	   the	   capability	   to	   burn	   substrates,	   is	   considered	   an	   important	  
determinant	   for	   lipid-­‐induced	   insulin	   resistance.	   Oxidative	   capacity	   is	   determined	   by	  
mitochondrial	   density,	   mitochondrial	   function	   and	   oxidative	   catabolism-­‐related	   enzyme	  
capacities.	   Obese	   and/or	   diabetic	   subjects	   have	   an	   increased	   supply	   of	   lipids	   to	   the	  
skeletal	  muscle	  [21]	  in	  addition	  to	  a	  lower	  oxidative	  capacity	  and	  impaired	  mitochondrial	  
function	   [36-­‐38].	   Consequently,	   FAs	   may	   accumulate	   in	   the	   form	   of	   toxic	   lipid	  
intermediates.	  Strategies	  to	  improve	  skeletal	  muscle	  oxidative	  capacity	  and	  mitochondrial	  
function	  have	  been	  shown	  to	   improve	  insulin	  sensitivity	  [39-­‐41].	   In	  addition	  to	   increased	  
oxidative	  rates	  due	  to	  increased	  energy	  demand,	  the	  explanation	  for	  the	  improvements	  in	  
insulin	   sensitivity	   upon	   improvements	   in	   mitochondrial	   function	   and	   oxidative	   capacity	  
may	   lay	   in	   a	   better	   coupling	   of	   lipolysis,	   β-­‐oxidation,	   the	   TCA	   cycle	   and	   oxidative	  
phosphorylation	   thus	   lowering	   intermediate	   accumulation	   (reviewed	   in	   [42]).	  
Paradoxically,	   increased	   oxidative	   capacity	   and	   energy	   demand	   are	   associated	   with	  
increased	   (neutral)	   IMCL	   storage	   [40,	   43-­‐45],	   indicating	   that	   these	   two	   processes	   are	  
tightly	  interrelated.	  	  
	  
Intramyocellular	  lipid	  droplets	  and	  lipid	  droplet	  coat	  proteins	  
Lipid	  droplets	  are	  the	  main	  storage	  sites	  for	  intracellular	  lipids,	  providing	  lipid	  reservoirs	  in	  
the	   hydrophilic	   environment.	   Besides	   storage	   in	   lipid	   droplets	   (LDs),	   lipid	   species	   can	  
accumulate	   at	   other	   subcellular	   locations	   like	   the	   plasma	  membrane,	  mitochondria	   and	  
the	   endoplasmic	   reticulum	   (ER),	   where	   accumulation	   of	   lipids	   is	   potentially	   toxic.	  
Therefore,	  LDs	  represent	  a	  neutral	  lipid	  storage	  site	  –	  consisting	  mainly	  of	  TAG	  –	  that,	  very	  
importantly,	  also	  serves	  as	  the	  interface	  for	  intracellular	  lipid	  metabolism.	  Therefore,	  LDs	  
are	   highly	   dynamic	   organelles;	   they	   are	   continuously	   synthesized	   and	   degraded,	   they	  
traffic	  within	  the	  cell	  and	  they	  interact	  with	  other	  organelles	  like	  the	  ER	  and	  mitochondria	  
[reviewed	   in	   46,	   47].	   The	   neutral	   lipid	   core	   is	   surrounded	   by	   a	   phospholipid	  monolayer	  
decorated	  with	  LD	  coat	  proteins	  that	  modulate	   lipid	  droplet	  dynamics	  (Figure	  1).	  Londos	  
and	  colleagues	  were	  the	  first	  to	  identify	  a	  LD	  coat	  protein,	  perilipin	  1,	  in	  1991	  [48].	  Since	  
then,	  numerous	  other	  LD	  coat	  proteins	  have	  been	  characterized,	  while	  a	  large	  proportion	  
of	   the	   protein	   coat	   remains	   uncharacterized	   to	   date.	   The	   first	   and	   best-­‐characterized	  
family	   of	   LD	   coat	   proteins	   is	   the	   perilipin	   protein	   family,	   consisting	   of	   five	   proteins.	  
Perilipin	   1	   (PLIN1)	   is	   specific	   for	   adipose	   tissue	   and	   is	   considered	   to	   be	   an	   important	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regulator	   of	   lipolysis.	   PLIN1	   restrains	   basal	   lipolysis	   and	   facilitates	   hormone-­‐stimulated	  
lipolysis	   [48-­‐52].	   PLINs	   2-­‐4	   are	   ubiquitously	   expressed	   [53].	   PLIN2	   (adipophilin,	   ADRP)	  
function	  was	  mainly	   studied	   in	   fibroblasts,	  macrophages	  and	   liver,	   it	   is	   considered	   to	  be	  
involved	   in	   both	   LD	   biogenesis	   and	   inhibition	   of	   lipolysis	   [54-­‐57].	   PLIN3	   (TIP47)	   was	  
implicated	   to	   be	   involved	   in	   LD	   biogenesis	   [58].	   Little	   is	   known	   about	   PLIN4	   (S3-­‐12)	  
function,	  except	  for	   its	   localization	  to	  nascent	  (i.e.	  early	   in	  development)	  LDs	  [59].	  PLIN5	  
(OXPAT,	   MLDP,	   LSDP5)	   is	   expressed	   in	   cells	   with	   a	   high	   oxidative	   capacity	   like	   type	   1	  
muscle	  fibers,	  brown	  fat	  and	  liver.	  Based	  on	  research	  in	  hepatocytes	  and	  cardiomyocytes,	  
PLIN5	   is	   considered	   to	   facilitate	   stimulated	   lipolysis	   [60-­‐65].	   Information	   on	   the	   role	   of	  
perilipins	  in	  skeletal	  muscle	  is	  still	  limited.	  
	  
	  
Figure	  1.	  Illustration	  of	  the	  organization	  of	  
an	   LD.	   LD	   coat	   proteins	   like	   perilipin	   are	  
conditionally	   present	   in	   the	   LD	   coat,	  
dependent	   on	   the	   cellular	   energy	   status	  




Most	   research	   in	   the	   field	   of	   LD	   coat	   proteins	   has	   focused	   on	   adipose	   tissue	   and	   liver.	  
Moreover,	  most	   knowledge	   is	   based	   on	   in	   vitro	   studies.	   Skeletal	  muscle	   is	   very	   distinct	  
from	   adipose	   tissue	   given	   its	   high	  metabolic	   rate,	   which	   is	   accelerated	   during	   exercise.	  
Therefore,	   intramyocellular	   lipid	   metabolism	   needs	   to	   be	   tightly	   controlled.	   A	   recent	  
paper	  on	  the	  skeletal	  muscle	  LD	  proteome	  identified	  324	  proteins	  to	  localize	  to	  LDs	  [67].	  
The	   regulation	   of	   lipid	   droplet	   dynamics	   is	   therefore	   highly	   complex	   and	   individual	  
pathways	  involved	  can	  barely	  be	  studied	  separately.	  Twenty	  percent	  of	  the	  proteins	  in	  the	  
LD	   fraction	  were	   shown	   to	  be	  associated	  with	  mitochondria	   [67].	   Furthermore,	   electron	  
microscopy	  imaging	  shows	  close	  proximity	  of	  LDs	  to	  mitochondria	  in	  skeletal	  muscle	  [68,	  
69],	  indicating	  close	  interactions	  of	  these	  organelles.	  Furthermore,	  interventions	  resulting	  
in	   increased	   energy	   demand	   and	   oxidative	   capacity	   are	   paralleled	   with	   increased	  
intramyocellular	  LD	  storage	  [40,	  43-­‐45],	  indicating	  a	  close	  interrelationship	  between	  these	  
parameters	   that	   together	   may	   be	   the	   major	   determinants	   for	   alleviation	   of	   obesity-­‐
associated	   insulin	   resistance.	   By	  modulating	   lipid	   storage	   capacity	   and	   LD	   dynamics,	   LD	  
coat	   proteins	   may	   be	   regulatory	   factors	   in	   lipid-­‐induced	   insulin	   resistance.	   Hence,	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interindividual	  variation	  in	  perilipin	  expression	  and	  function	  and	  interventions	  targeted	  at	  
improving	  perilipin	   capacity	   and	   function	   can	  be	   considered	   important	  determinants	   for	  
susceptibility	  to	  and	  prevention	  of	  lipid-­‐induced	  insulin	  resistance.	  
	  
Outline	  of	  this	  thesis	  
In	   this	   PhD	   project	   the	   role	   of	   lipid	   droplet	   coat	   proteins	   in	   skeletal	   muscle	   lipid	  
metabolism	  and	  insulin	  sensitivity	  was	  investigated.	  A	  translational	  approach	  was	  used;	  a	  
combination	   of	   cell,	   animal	   and	   human	   studies,	   as	   well	   as	   in	   vitro,	   ex	   vivo	   and	   in	   vivo	  
approaches.	   Given	   their	   high	   expression	   levels	   in	   skeletal	   muscle,	   the	   LD	   coat	   proteins	  
perilipin	  2	  and	  5	  were	  selected	  as	  the	  primary	  focus.	  
	  
Chapter	   2	  provides	   an	   overview	   of	   the	   current	   literature	   regarding	   lipid-­‐induced	   insulin	  
resistance	  in	  skeletal	  muscle.	  The	  major	  parameters	  involved	  are	  discussed,	  including	  lipid	  
metabolism,	   lipid	   intermediate	   accumulation,	   and	   LD	   dynamics.	   This	   chapter	   reviews	  
evidence	   from	   human	   studies,	   linked	   with	   supporting	   information	   from	   mechanistic	  
studies.	  	  
Intramyocellular	   neutral	   lipid	   storage	   capacity	   and	   LD	   coat	   protein	   expression	  may	  
determine	   susceptibility	   to	   lipid-­‐induced	   insulin	   resistance.	   In	   chapter	   3	   the	   effects	   of	  
increased	   lipid	   supply	   on	   insulin	   sensitivity,	   intramyocellular	   lipid	   accumulation	   and	  
expression	   of	   LD	   coat	   proteins	   was	   investigated.	   Two	   models	   for	   lipid	   oversupply	   in	  
humans	  are	  reported:	  fasting	  for	  60h	  and	  consumption	  of	  a	  high	  fat	  diet	  for	  3	  weeks.	  	  
To	  determine	  whether	  impaired	  IMCL	  storage	  and/or	  a	  reduced	  fat	  oxidative	  capacity	  
may	  characterize	  T2D	  subjects,	  we	  used	  a	  translational	  approach	  to	  elucidate	  differences	  
in	  lipid	  metabolism	  and	  mitochondrial	  function	  in	  T2D	  subjects	  and	  BMI-­‐matched	  controls	  
in	  vivo,	  ex	  vivo	  and	   in	  vitro	  (chapter	  4).	   In	  this	  study,	  an	  extensive	   in	  vivo	  phenotyping	  of	  
the	  subjects	  was	  performed	  and	  lipid	  metabolism	  and	  oxidative	  capacity	  were	  studied	   in	  
detail	   in	   muscle	   biopsy	   tissue	   and	   muscle	   cells	   cultured	   from	   the	   biopsies	   obtained.	  
Cultured	  muscle	  cells	  are	  derived	  from	  satellite	  cells,	  which	  mainly	  represent	  the	  genetic	  
and	  epigenetic	  characteristics	  of	  the	  donor.	  Therefore,	  this	  study	  allowed	  us	  to	  study	  both	  
primary	  defects	   (predisposition)	   as	  well	   as	   acquired	  defects	   in	   lipid	  metabolism.	   In	   vitro	  
pulse-­‐chase	   experiments	   were	   utilized	   to	   study	   individual	   components	   of	   lipid	  
metabolism,	  such	  as	  lipid	  synthesis,	  lipolysis	  and	  oxidation	  of	  LD-­‐derived	  FAs.	  	  
LD	   coat	   proteins	   were	   recently	   characterized	   as	   important	   modulators	   of	   lipid	  
metabolism.	  Chapter	  5	   focuses	  on	  the	  role	  of	  PLIN2	   in	  skeletal	  muscle	   lipid	  metabolism,	  
lipotoxicity	  and	   insulin	  sensitivity.	  The	  function	  of	  PLIN2	  was	  extensively	  studied	  using	   in	  
vitro	   knockdown	   and	   overexpression	   in	   muscle	   cells	   and	   in	   vivo	   overexpression	   in	   rat	  
skeletal	  muscle.	  PLIN5	  is	  a	  LD	  coat	  protein	  expressed	  specifically	  in	  tissues	  with	  a	  high	  fat-­‐
oxidative	  capacity.	  PLIN5	  may	  have	  a	  role	   in	  facilitating	  fatty	  acid	  oxidation.	   In	  chapter	  6	  
the	  subcellular	  localization	  of	  PLIN5	  was	  identified	  and	  effects	  of	  PLIN5	  overexpression	  on	  
fatty	   acid	   oxidative	   capacity	   and	   mitochondrial	   function	   were	   investigated.	   Chapter	   7	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builds	  on	   the	  previous	   chapter	  and	   further	   identifies	  effects	  of	  PLIN5	  overexpression	  on	  
skeletal	  muscle	  lipid	  accumulation,	  insulin	  sensitivity	  and	  transcriptomic	  profiles.	  
Insulin-­‐sensitizing	   strategies	   may	   involve	   adaptations	   in	   intramyocellular	   LD	  
dynamics.	   Endurance	   training	   is	   an	   intervention	   that	   improves	   skeletal	  muscle	   oxidative	  
capacity	  and	   insulin	  sensitivity.	   In	  chapter	  8	  the	  effects	  of	  a	  12-­‐week	  endurance	  training	  
program	  on	  IMCL	  storage	  and	  perilipin	  protein	  expression	  are	  described.	  Finally,	  chapter	  9	  
summarizes	  and	  integrates	  the	  major	  findings	  of	  this	  thesis	  project	  and	  places	  my	  findings	  
in	  the	  light	  of	  recent	  advances	  in	  the	  field.	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ABSTRACT	  
Ectopic	  fat	  accumulation	  has	  been	  linked	  to	  lipotoxic	  events,	  including	  the	  development	  of	  
insulin	   resistance	   in	   skeletal	   muscle.	   Indeed,	   intramyocellular	   lipid	   storage	   is	   strongly	  
associated	  with	  the	  development	  of	  type	  2	  diabetes.	  Research	  during	  the	  last	  two	  decades	  
has	  provided	  evidence	  for	  a	  role	  of	  lipid	  intermediates	  like	  diacylglycerol	  and	  ceramide	  in	  
the	   induction	  of	   lipid-­‐induced	   insulin	   resistance.	  However,	   recently	  novel	   data	  has	  been	  
gathered	  that	  suggest	  that	  the	  relation	  between	  lipid	  intermediates	  and	  insulin	  resistance	  
is	   less	   straightforward	   than	   has	   been	   previously	   suggested,	   and	   that	   there	   are	   several	  
routes	   towards	   lipid-­‐induced	   insulin	   resistance.	   For	   example,	   research	   in	   this	   field	   has	  
shifted	   towards	   imbalances	   in	   lipid	   metabolism	   and	   lipid	   droplet	   dynamics.	   Next	   to	  
imbalances	  in	  key	  lipogenic	  and	  lipolytic	  proteins,	  lipid	  droplet	  coat	  proteins	  appear	  to	  be	  
essential	   for	  proper	   intramyocellular	   lipid	   storage,	   turnover	  and	  protection	  against	   lipid-­‐
induced	  insulin	  resistance.	  	  
Here,	   we	   discuss	   the	   current	   knowledge	   on	   lipid-­‐induced	   insulin	   resistance	   in	   skeletal	  
muscle	  with	   a	   focus	   on	   the	   evidence	   from	  human	   studies.	   Furthermore,	  we	  discuss	   the	  
available	  data	  that	  provides	  supporting	  mechanistic	  information.	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INTRODUCTION	  
Obesity	   is	   a	   growing	   public	   health	   problem,	   with	   a	   prevalence	   of	   at	   least	   500	   million	  
people	  worldwide	  [1].	  Although	  obesity	  will	  not	  always	  result	  in	  metabolic	  abnormalities,	  
most	  severely	  obese	  persons	  suffer	  from	  metabolic	  comorbidities.	  Likewise,	  obesity	  is	  the	  
number	  one	   risk	   factor	   for	   the	  development	  of	   insulin	   resistance,	  which	  may	  eventually	  
result	  in	  type	  2	  diabetes.	  The	  etiology	  of	  type	  2	  diabetes	  is	  complex,	  with	  a	  broad	  range	  of	  
organs	   involved.	   Several	   hypotheses	   have	   been	   put	   forward	   trying	   to	   explain	   the	  
relationship	   between	   obesity	   and	   diabetes,	   including	   lipid,	   endocrine	   and	   inflammatory	  
hypotheses	   [2].	   In	   this	   review	   we	   will	   focus	   on	   the	   lipid	   overflow	   hypothesis,	   which	  
considers	  type	  2	  diabetes	  to	  result	  from	  a	  general	  state	  of	  increased	  lipid	  levels.	  Lipids	  will	  
overflow	  into	  the	  circulation	  as	  a	  result	  of	  impaired	  storage	  capacity	  in	  adipose	  tissue	  and	  
as	   a	   consequence	   lipids	  may	   accumulate	   ectopically	   in	   tissues	   like	   skeletal	  muscle,	   liver	  
and	  heart.	  The	  link	  between	  ectopic	  lipid	  accumulation	  in	  obesity	  and	  the	  development	  of	  
insulin	  resistance	  was	  first	  demonstrated	  in	  the	  early	  nineties	  [3]	  and	  had	  a	  great	  impact	  
on	   our	   understanding	   of	   the	   etiology	   of	   type	   2	   diabetes	   (T2D).	   Since	   then,	   numerous	  
animal	   and	   cellular	   experiments	   have	   provided	   evidence	   for	   the	   link	   between	   lipid	  
intermediates	  and	  insulin	  resistance.	  On	  the	  other	  hand,	  data	  from	  human	  studies	  are	  less	  
straightforward	  and	  have	  pointed	  towards	  multiple	  factors	  that	  may	  be	  involved	  in	   lipid-­‐
induced	  insulin	  resistance,	  including	  lipid	  intermediates,	  lipid	  metabolism	  and	  lipid	  droplet	  
dynamics.	  Here	  we	  will	  review	  these	  data	  with	  a	  focus	  on	  human	  studies.	  
	  
Intramyocellular	  lipids	  and	  insulin	  sensitivity	  
Obesity	  is	  associated	  with	  increased	  lipid	  supply	  to	  skeletal	  muscle.	  Intramyocellular	  lipid	  
(IMCL)	   accumulation	   correlates	   with	   BMI,	   waist-­‐to-­‐hip	   ratio,	   central	   adiposity,	   and	  
percentage	  body	  fat	  [4-­‐8].	  Skeletal	  muscle	  is	  quantitatively	  the	  major	  contributor	  to	  whole	  
body	   insulin-­‐mediated	   glucose	   disposal.	   Fat	   accumulation	   in	   muscle	   negatively	   impacts	  
insulin	   mediated	   glucose	   uptake.	   In	   insulin	   resistant	   subjects,	   the	   negative	   correlation	  
between	  IMCL	  accumulation	  and	  insulin	  sensitivity	  has	  been	  firmly	  established	  in	  multiple	  
studies	  [9-­‐11].	  Furthermore,	  diet-­‐induced	  weight	  loss	  results	  in	  decreased	  IMCL	  storage	  in	  
parallel	  with	  improvements	  in	  insulin	  sensitivity	  [12-­‐16].	  Also,	  lipid	  infusion	  impairs	  insulin	  
sensitivity	   concurrent	   with	   increased	   IMCL	   levels	   [17].	   However,	   despite	   the	   strong	  
correlation	  of	  IMCL	  levels	  with	  insulin	  resistance,	  the	  exact	  mechanistic	  link	  between	  IMCL	  
accumulation	   and	   impairment	   of	   insulin	   sensitivity	   is	   unclear.	   Furthermore,	   IMCL	   levels	  
are	  similar	  in	  obese	  normoglycemic	  and	  obese	  type	  2	  diabetic	  subjects	  [18,	  19],	  indicating	  
that	  total	  IMCL	  levels	  per	  se	  do	  not	  induce	  diabetes.	  	  
An	   important	   finding	   that	   has	   shed	   some	   light	   into	   the	   role	   of	   IMCL	   in	   insulin	  
resistance	  comes	  from	  exercise	  studies.	  Exercise	  training	  has	  been	  shown	  to	  increase	  IMCL	  
levels,	   and	   endurance-­‐trained	   athletes,	   who	   are	   highly	   insulin-­‐sensitive,	   have	   increased	  
IMCL	   compared	   with	   lean	   sedentary	   controls,	   with	   levels	   even	   exceeding	   those	   of	  
diabetics	  [18,	  20].	  In	  addition,	  12-­‐16	  weeks	  of	  exercise	  training	  in	  obese	  subjects	  improved	  
insulin	   sensitivity	   in	   conjunction	   with	   increased	   IMCL	   levels	   [21,	   22].	   This	   so-­‐called	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athlete’s	  paradox	  gave	  new	  insight	  in	  the	  role	  of	  IMCL	  in	  insulin	  resistance	  and	  indicated	  
that	   IMCL	  accumulation	  per	  se	  does	  not	   lead	  to	   insulin	  resistance.	  The	  athlete’s	  paradox	  
has	   been	   explained	   by	   differential	   effects	   of	   training	   and	   diabetes	   on	   lipid	   subspecies,	  
oxidative	   capacity	   and	   IMCL	   turnover.	   Proper	   balancing	   between	   lipid	   influx	   and	   fat	  
oxidative	   capacity	   as	   well	   as	   an	   efficient	   rate	   of	   lipid	   turnover	   (i.e.	   lipid	   depletion	   and	  
efficient	  resynthesis)	  have	  been	  suggested	  to	  be	  beneficial	  for	  insulin	  sensitivity	  [18,	  20].	  It	  
is	  still	  unclear,	  however,	  how	  IMCL	  can	  become	  harmful.	  In	  this	  review,	  we	  will	  discuss	  the	  
current	   knowledge	  on	   lipid-­‐induced	   insulin	   resistance	   in	   skeletal	  muscle	  with	  a	   focus	  on	  
the	   evidence	   from	   human	   studies,	   combined	   with	   supporting	   information	   of	   the	  
mechanisms	  involved	  from	  animal	  and	  cell	  studies.	  
	  
LIPID	  INTERMEDIATES	  
It	  was	  demonstrated	  in	  multiple	  studies	  that	  intramyocellular	  lipid	  levels	  are	  increased	  in	  
obese	   type	  2	  diabetics	   versus	   lean	  controls	   [9-­‐11].	   The	  observation	   that	   IMCL	   storage	   is	  
increased	   in	   athletes	   and	   mainly	   consists	   of	   intramyocellular	   triacylglycerol	   (TAG)	   [23]	  
strongly	   indicated	   that	   neutral	   lipid	   storage	   in	   the	   form	   of	   TAG	   per	   se	   does	   not	   impair	  
insulin	   sensitivity.	   However,	   increased	   intramyocellular	   TAG	   might	   be	   paralleled	   with	  
increased	   levels	   of	   lipid	   intermediates	  with	   lipotoxic	   potential.	   Lipotoxicity	   is	   defined	   as	  
the	  accumulation	  of	  excess	  lipids	  in	  non-­‐adipose	  tissues	  leading	  to	  cell	  dysfunction	  or	  cell	  
death	   [24].	   Enhancing	   the	   partitioning	   of	   fatty	   acids	   (FAs)	   entering	   the	  muscle	   towards	  
TAG	  synthesis	  prevents	  lipotoxicity	  [25,	  26].	  Under	  conditions	  of	  increased	  lipid	  influx,	  lack	  
of	   TAG	   storage	   capacity,	   or	   uncontrolled	   lipolysis,	   FAs	   might	   be	   converted	   to	   lipid	  
metabolites	  other	  than	  TAG.	  	  
The	   array	   of	   lipid	   intermediates	   with	   insulin	   desensitizing	   properties	   includes	  
diacylglycerols	   (DAGs),	   long	   chain	   fatty	   acyl-­‐CoAs	   (LCFA-­‐CoAs),	   acylcarnitines,	   and	  
ceramides	  (Fig.	  1)	  all	  differing	  in	  chain	  length,	  level	  of	  saturation	  and/	  or	  stereo	  specificity.	  
At	  this	  moment	  there	  is	  a	  lack	  of	  consensus	  on	  the	  primary	  lipotoxic	  intermediate.	  These	  
intermediates	  all	  have	  the	  potential	  to	  reduce	  insulin-­‐mediated	  glucose	  disposal	  in	  in	  vitro	  
and	  animals	  studies,	  partly	  via	  selective	  interference	  with	  insulin	  signaling.	  However,	  most	  
if	   not	   all	   available	   data	   from	   in	   vitro	   and	   animal	   studies	   are	  merely	   correlative,	   as	   it	   is	  
impossible	   to	   alter	   intracellular	   levels	   of	   one	   single	   lipotoxic	   intermediate.	   Therefore,	  
interpretation	  of	  causality	  is	  difficult,	  especially	  with	  regard	  to	  their	  implication	  in	  obesity-­‐
associated	   insulin	   resistance	   in	   humans.	   Most	   attention	   has	   been	   given	   to	   DAG	   and	  
ceramide.	  Table	  1	  gives	  an	  overview	  of	  the	  human	  studies	  in	  which	  DAG	  and/or	  ceramides	  
were	  measured	  in	  skeletal	  muscle	  biopsies	  of	  obese,	  type	  2	  diabetic	  and/or	  lean	  controls.	  	  
	  
Diacylglycerol	  
DAG	   is	   an	   intermediate	   in	   TAG	   synthesis	   and	   breakdown.	   In	   addition,	   DAG	   and	   its	  
metabolite	  phosphatidic	  acid	  (PA)	  are	  important	  intracellular	  second	  messengers	  involved	  
in	  metabolic	  and	  mitogenic	  responses	  and	  are	  important	  metabolites	  in	  de	  novo	  synthesis	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of	   phospholipids	   [27,	   28].	   Hence,	   fluctuations	   in	   DAG	   levels	   can	   lead	   to	   impaired	  
intracellular	   signaling.	   Animal	   and	   cell	   studies	   have	   sought	   to	   unravel	   the	   mechanisms	  
involved	   in	   DAG-­‐induced	   insulin	   resistance	   [29,	   30].	   In	  muscle,	   elevated	   DAG	   levels	   are	  
associated	   with	   increased	   activities	   of	   PKCθ	   and	   PKCε	   [31,	   32].	   DAG-­‐activated	   PKCs	  
inactivate	   insulin	   receptor	   substrate	   1	   (IRS-­‐1)	   by	   phosphorylation	   of	   one	   or	  more	   of	   its	  
inhibitory	  serine	  residues	  and	  by	  direct	  association	  of	  PKCε	  with	  IRS-­‐1,	  thereby	  reducing	  its	  
kinase	   activity.	   Through	   this	   mechanism,	   DAG	   reduces	   insulin-­‐induced	   tyrosine	  
phosphorylation	  of	  IRS-­‐1	  and	  suppressing	  the	  activity	  of	  its	  downstream	  targets	  PI3-­‐kinase	  
and	  PKB/Akt,	  leading	  to	  impaired	  insulin-­‐induced	  GLUT4-­‐translocation	  and	  glucose	  uptake	  
[33].	  Several	  DAG-­‐subspecies	  exist	  that	  differ	  in	  FA	  composition	  and	  the	  position	  of	  the	  FA	  
on	  the	  glycerol	  backbone	  (1,3-­‐DAG,	  2,3-­‐DAG,	  and	  1,2-­‐DAG).	  Only	  1,2-­‐DAG	  accumulates	  in	  
membranes	  and	  is	  capable	  of	  activating	  PKCs	  [34-­‐36],	  2,3-­‐DAG	  and	  1,3-­‐DAG	  can	  arise	  from	  
TAG	  hydrolysis	  at	  the	  lipid	  droplet.	  
Intramuscular	  DAG	  levels	  are	  increased	  in	  several	  animal	  models	  of	  obesity	  [37,	  38].	  
However,	   evidence	   is	   lacking	   on	   the	   importance	   of	   intramyocellular	   DAG	   levels	   in	   the	  
development	  of	  obesity-­‐associated	  insulin	  resistance	  in	  humans.	  Although	  lipid	  infusion	  in	  
humans	   induces	   insulin	   resistance	   in	  parallel	  with	   increased	   intramyocellular	  DAG	   levels	  
[39],	   the	   support	   for	  a	   role	  of	   skeletal	  muscle	  DAG	  accumulation	   in	   the	  development	  of	  
type	   2	   diabetes	   is	   inconsistent	   (Table	   1).	   Two	   studies	   identified	   the	   DAG	   level	   as	   an	  
important	  predictor	   for	   insulin	  resistance	  using	  multivariate	  regression	  analyses	  [40,	  41].	  
However,	   the	   remainder	   of	   the	   studies	   did	   not	   find	   differences	   in	   total	   skeletal	  muscle	  
DAG	  levels	  between	  obese	  and	  lean	  subjects	  [42,	  43]	  and	  between	  obese	  normal	  glucose	  
tolerant	  (NGT)	  and	  obese	  insulin	  resistant	  subjects	  [44-­‐46].	  Perreault	  et	  al.	  showed	  inter-­‐
gender	   differences	   in	   intramuscular	   DAG	   accumulation,	  with	   prediabetic	  women	   having	  
higher	  DAG	  levels,	  while	  being	  more	  insulin	  sensitive	  compared	  with	  prediabetic	  men	  [47].	  
Strategies	   that	   resulted	   in	   improved	   insulin	   sensitivity	   did	   not	   consistently	   reduce	   DAG	  
levels,	  which	  indicates	  that	  the	  role	  of	  DAG	  in	  insulin	  resistance	  in	  humans	  is	  not	  yet	  clear.	  
DAG	  levels	  decreased	  with	  weight	   loss	  and	  exercise	   in	  several	  studies	   [21,	  48,	  49]	   (Table	  
2),	  while	  pioglitazone	  treatment	  [50]	  and	  10%	  diet-­‐induced	  weight	  loss	  [51]	  did	  not	  show	  a	  
decrease	   in	  DAG	   levels.	  Moreover,	  while	  Dubé	  et	   al.	   showed	   that	   total	   intramyocellular	  
DAG	  decreased	  with	  weight	  loss	  and	  exercise,	  there	  was	  no	  correlation	  between	  changes	  
in	   DAG	   and	   improvements	   in	   insulin	   sensitivity	   suggesting	   that	   DAG	   is	   not	   the	   sole	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Table	  1.	  Lipid	  intermediates	  in	  lean,	  obese	  and	  T2D	  subjects.	  
Author	  and	  
reference	  







Van	  Hees	  et	   al.	  
2011	  [52]	  
30	   male	   subjects	   with	   the	  
metabolic	   syndrome,	   15	   insulin	  
resistant	  subjects	  and	  15	  controls	  
-­‐	   n.i.	   Increased	  saturation	  of	  DAG	  
is	   associated	   with	   insulin	  
resistance	  
	  
Perreault	   et	   al.	  
2010	  [47]	  
Obese	   NGT	   (n=7	   men	   and	   n=12	  
women)	   and	   prediabetics	   (n=13	  
men	  and	  n=7	  women)	  
-­‐	   n.i.	   Turnover	   of	   DAG	   is	   more	  
important	   than	   the	   DAG	  
level,	  DAG	  level	  the	  same	  in	  
NGT	  and	  prediabetics	  
	  
Jocken	   et	   al.	  
2010	  [42]	  
Lean	  (n=13)	  and	  obese	  (n=10)	  
men	  (study	  1)	  and	  nonobese	  T2D	  
(n=11),	  obese	  
T2D	   (n=11),	   and	   lean	   male	  
controls	  (n=11)	  (study	  2)	  
	  
-­‐	   n.i.	   Lower	   DAG	   in	   obese	   men	  
versus	  lean	  controls	  
Coen	   et	   al.	  
2009	  [45]	  
Insulin	   sensitive	   (n=10)	   and	  
insulin	   resistant	   (n=12)	   obese	  
women	  
	  
-­‐	   +	   No	   difference	   in	   DAG,	  
increased	   ceramides	   in	  
insulin	  resistance	  
Bergman	   et	   al.	  
2010	  [23]	  
Endurance-­‐trained	   male	   athletes	  
(n=11)	   and	   sedentary	   male	  
controls	  (n=11)	  
	  
+	   n.i.	   Saturation	   of	   DAG	   is	   of	  
importance,	   no	   differences	  
in	  total	  DAG	  
Thrush	   et	   al.	  
2009	  [43]	  
Lean	   (n=8)	   and	   obese	   (n=15)	  
women	  
-­‐	   +	   No	  role	   for	  DAG,	  ceramides	  
increased	  in	  obese	  
	  
Moro	   et	   al.	  
2009	  [7]	  
48	  subjects	  with	  a	  wide	   range	  of	  
BMI	  (m/f:	  24/24)	  
+	   +	   Increased	   DAG	   and	  
ceramides	   in	   obese	   and	  
type	   2	   diabetic	   subjects.	  
DAG	   is	   the	   main	   predictor	  
for	   insulin	   resis-­‐tance,	  
lipolytic	  enzymes	  determine	  
DAG	  levels	  
	  
Anastasiou	   et	  
al.	  2009	  [44]	  
Nondiabetic	   obese	   (n=19,	  
male/female:	   9/10)	   and	   diabetic	  
obese	  (n=11,	  m/f:	  2/9)	  
	  
-­‐	   n.i.	   No	  role	  for	  DAG	  
	  
Skovbro	   et	   al.	  
2008	  [67]	  
Type	  2	  diabetics	  (n=8),	  IGT	  (n=9),	  
healthy	   controls	   (n=8),	  
endurance-­‐trained	  athletes	   (n=8)	  
(all	  male	  subjects)	  
	  
n.i.	   -­‐	   No	  role	  for	  ceramides	  
Serlie	  et	  al.	  
2007	  [66]	  
Lean	   (n=8,	   m/f:	   7/1)	   and	   obese	  
(n=6,	  m/f:	  4/2)	  subjects	  
	  
n.i.	   -­‐	   No	  difference	  in	  ceramides	  
Straczkowski	   et	  
al.	  2007	  [41]	  
Male	   lean,	   obese,	   type	   2	  
diabetics	   and	  offspring	   of	   type	   2	  
diabetics	  (n=12	  per	  group)	  
	  
+	   +	   DAG	   and	   ceramides	   inde-­‐
pendently	  determine	  insulin	  
resistance	  
Adams	   et	   al.	  
2004	  [65]	  
Obese	   insulin	   resistant	   (n=10,	  
m/f:	   5/5)	   and	   lean	   controls	  
(n=10,	  m/f:	  6/4)	  
	  
n.i.	   +	   Increased	   ceramides	   in	  
obese	   insulin	   resistant	  
subjects	  
IS:	  insulin	  sensitivity,	  m/f:	  male/female	  ratio,	  n.i.	  =	  not	  investigated.	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Based	  on	   the	  data	   summarized	  above,	   it	   can	  be	   concluded	   that	   total	  DAG	   levels	  do	  not	  
necessarily	  mirror	  insulin	  resistance.	  Recent	  evidence	  suggests	  that	  it	  is	  not	  total	  DAG	  per	  
se	  but	  rather	  specific	  DAG-­‐subspecies	  that	  may	  be	  important.	   In	  the	  study	  of	  Dubé	  et	  al.	  
[49],	   it	   was	   shown	   that	   exercise	   caused	   greater	   reductions	   in	   specific	   FAs	   in	   the	   DAG	  
fraction	   compared	   to	   diet-­‐induced	  weight	   loss	   [49].	   Exercise	   lowered	   the	   content	   of	   all	  
DAG	   species	   examined	   to	   a	   greater	   degree	   than	   diet-­‐induced	   weight	   loss,	   which	   only	  
reduced	   the	   content	   of	   all	   DAG	   C14:0	   species,	   and	   of	   DAG	   C16:0/18:0,	   C16:0/18:1,	  
C16:1/18:1,	  di-­‐C16:0	  and	  di-­‐C18:1	  [49].	  Moreover,	  it	  was	  demonstrated	  that	  athletes	  have	  
a	   lower	   saturation	   of	   the	  DAG-­‐fraction	   compared	   to	   sedentary	   controls	   or	   an	   increased	  
proportion	   of	   C18:1	   and	   C18:2	   in	   the	   DAG	   fraction	   [23].	   Recently,	   Van	   Hees	   et	   al.	  
investigated	   the	   FA	   composition	   of	   intramyocellular	   DAG	   and	   TAG	   in	   men	   with	   the	  
metabolic	  syndrome,	  either	  with	  or	  without	   insulin	  resistance.	  While	   total	  DAG	  and	  TAG	  
levels	  were	  similar	  in	  both	  groups,	  insulin	  resistant	  men	  had	  a	  higher	  degree	  of	  saturation	  
of	  skeletal	  muscle	  DAG	  compared	  to	  controls	  [52],	  consistent	  with	  the	  study	  of	  Bergman	  
et	  al	  [23].	  This	  higher	  degree	  of	  saturation	  was	  largely	  explained	  by	  a	  higher	  percentage	  of	  
palmitic	  acid	  and	  a	  lower	  percentage	  of	  oleic	  acid	  [52].	  	  
Next	   to	  differences	   in	  FA-­‐composition,	  DAG-­‐subspecies	  can	  differ	   in	   the	  position	  of	  
the	   FA-­‐binding	   to	   the	   glycerol	   backbone	   (1,3-­‐DAG,	   2,3-­‐DAG,	   and	   1,2-­‐DAG).	   1,2-­‐DAG	  
accumulates	   in	  membranes	   and	   only	   this	   isoform	   is	   capable	   of	   activating	   PKCs	   [36].	   No	  
human	  study	  performed	  to	  date	  has	  examined	  specifically	   the	  accumulation	  of	  1,3-­‐,	  2,3-­‐	  
and	  1,2-­‐DAG	  in	  insulin	  resistant	  and	  insulin	  sensitive	  subjects.	  Moreover,	  the	  fact	  that	  DAG	  
can	  be	  present	   at	  different	   subcellular	   locations,	   including	   cell	  membranes,	   ER	  and	   lipid	  
droplets	   (LDs)	   [53],	   may	   complicate	   the	   relationship	   between	   DAG	   levels	   and	   insulin	  
resistance.	   The	   DAG	   membrane-­‐to-­‐cytosol	   ratio	   has	   been	   used	   as	   a	   measure	   for	   DAG-­‐
induced	  PKC	  activation	  [54-­‐56],	  but	  data	  from	  human	  studies	  is	  lacking.	  
In	  summary,	  total	  DAG	  levels	  are	  not	  consistently	  associated	  with	   insulin	  resistance	  
in	  humans.	  While	   it	   is	  apparent	  that	   increased	  DAG	   levels	  per	  se	  do	  not	  promote	   insulin	  
resistance,	   lipid-­‐induced	   insulin	   resistance	   may	   be	   dependent	   on	   the	   accumulation	   of	  
bioactive	  DAG	   species	   at	   specific	   intracellular	   sites,	   including	   the	   plasma	  membrane	   for	  
PKC-­‐mediated	   interferences	   with	   insulin	   signaling.	   However,	   few	   data	   are	   available	   in	  
humans	   and	   further	   research	   is	   needed	   to	   investigate	   the	   relationship	   between	   various	  
DAG	  species	  and	  their	  intracellular	  localization,	  and	  insulin	  resistance	  in	  skeletal	  muscle.	  	  
	  
Sphingolipids	  
Another	   group	   of	   lipid	   intermediates	   that	   has	   received	   a	   lot	   of	   attention	   are	   the	  
ceramides,	   which	   belong	   to	   the	   sphingolipids.	   Ceramides	   are	   structural	   components	   of	  
biological	   membranes	   and	   can	   be	   deacetylated,	   phosphorylated	   and	   glycosylated	   [57].	  
Ceramides	  are	  important	  membrane	  building	  blocks	  and	  intracellular	  messengers	  that	  are	  
believed	  to	  interfere	  with	  insulin	  signaling.	  Sphingolipid	  production	  mainly	  depends	  on	  de	  
novo	  biosynthesis.	  In	  as	  much	  as	  long	  chain	  saturated	  FAs	  like	  palmitate	  are	  precursors	  for	  
ceramide	   synthesis,	   rates	  of	   ceramide	   synthesis	  depend	  on	   the	  availability	  of	   those	  FAs.	  
Consistent	  with	  this	  notion,	  incubation	  of	  muscle	  cells	  with	  palmitate	  promotes	  ceramide	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accumulation	   [29]	   and	   diets	   high	   in	   saturated	   fats	   induce	   intramyocellular	   ceramide	  
accumulation	   [58].	   In	   addition	   to	   FAs	   serving	   as	   precursors	   for	   ceramide	   synthesis,	   FAs,	  
inflammatory	   agonists	   and	   glucocorticoids	   have	   been	   shown	   to	   increase	   ceramide	  
biosynthesis	   via	   upregulation	   of	   serine	   palmitoyltransferase,	   the	   limiting	   enzyme	   for	  
ceramide	   synthesis	   [57,	   59-­‐61].	   Evidence	   abounds	   that	   accumulation	   of	   ceramides	   can	  
impair	  insulin	  signaling	  (reviewed	  in	  [57]).	  Indeed,	  ceramide	  was	  identified	  as	  an	  essential	  
intermediate	   linking	   saturated	  FAs	   to	   insulin	   resistance	   [62].	  According	   to	   some	   reports,	  
ceramides	   inactivate	   IRS-­‐1,	   leading	   to	   blockage	   of	   PI3-­‐kinase.	   However,	   the	  majority	   of	  
studies	   suggest	   that	   ceramide	   inhibits	   phosphorylation	   and	   activation	   of	   Akt/PKB	   via	  
protein	  phosphatase	  2A	  (PP2A)	  and	  PKCζ,	   independent	  of	  potential	  effects	  on	  IRS-­‐1	  [57].	  
Additionally,	   glycosylceramides	   have	   been	   shown	   to	   interact	   with	   the	   insulin	   receptor,	  
thereby	   displacing	   it	   from	   the	   caveola	   thus	   preventing	   downstream	   signaling	   [63].	  
Interestingly,	   Novgorodov	   et	   al.	   recently	   showed	   that	   next	   to	   ER-­‐derived	   ceramide,	  
ceramides	   are	   also	   produced	   in	  mitochondria	   by	   the	   coupled	   activities	   of	  mitochondrial	  
thioesterase,	   which	   hydrolyses	   palmitoyl-­‐CoA	   to	   CoA	   and	   palmitate,	   and	   neutral	  
ceramidase	   (NCDase),	   which	   utilizes	   sphingosine	   and	   released	   palmitate	   in	   a	   reverse	  
reaction	   to	   produce	   ceramide	   [64].	   Thus,	   increased	   FA-­‐CoA	   levels	   in	   or	   near	   the	  
mitochondria	  might	  result	  in	  increased	  ceramide	  production	  thus	  impairing	  mitochondrial	  
function	  and	  eventually	  inducing	  apoptosis	  [64].	  	  
Inhibition	  of	  ceramide	  synthesis	  was	  shown	  to	  improve	  insulin	  sensitivity	   in	  rodents	  
[59].	  Consistent	  with	  a	  role	   for	  ceramide	   in	   insulin	  resistance	   in	  humans,	   the	  majority	  of	  
human	   studies	   found	   increased	   ceramide	   levels	   in	   skeletal	   muscle	   of	   type	   2	   diabetic	  
subjects	   (Table	   1).	  Most	   [7,	   41,	   43,	   65],	   but	   not	   all	   [66,	   67]	   studies	   observed	   increased	  
accumulation	  of	  ceramides	  in	  skeletal	  muscle	  of	  obese	  subjects	  compared	  to	  lean	  controls.	  
Furthermore,	   ceramides	   were	   shown	   to	   be	   higher	   in	   insulin	   resistant	   obese	   subjects	  
compared	   to	   insulin	   sensitive	   obese	   subjects	   [41,	   45],	   indicating	   a	   potential	   role	   of	  
ceramides	   in	   insulin	   resistance.	   Two	   reports	  did	  not	   show	   increased	   ceramides	   in	  obese	  
IGT	   [66]	   and	   obese	   diabetics	   versus	   lean	   controls	   [67].	   Moro	   et	   al.	   found	   increased	  
ceramides	   in	   T2D,	   but	   identified	   DAG	   as	   the	   key	   mediator	   of	   lipid-­‐induced	   insulin	  
resistance	  based	  on	  multivariate	  stepwise	  regression	  analyses	  [7].	  Interestingly,	  acute	  and	  
chronic	   exercise	   interventions	   have	   been	   shown	   to	   decrease	   ceramide	   levels	   [48,	   68]	  
(Table	  2).	  As	  the	  sphingolipid	  family	  consists	  of	  a	  range	  of	  different	  subspecies	  (different	  
ceramides	  and	  non-­‐ceramide	  sphingolipids),	  (total)	  ceramide	  levels	  might	  not	  reflect	  levels	  
of	   bioactive	   sphingolipid	   subspecies	   appropriately.	   Likewise,	   saturated	   ceramides	   were	  
shown	  to	  be	  increased	  in	  obese	  compared	  to	  lean	  subjects	  [7,	  43,	  65]	  and	  type	  2	  diabetes	  
patients	   versus	   NGT	   BMI-­‐matched	   controls	   [45].	   Furthermore,	   Dubé	   et	   al.	   showed	   that	  
dihydroceramides	   increased	   with	   both	   diet-­‐induced	   weight	   loss	   and	   exercise	   training,	  
whereas	   sphingosines	   and	   total	   ceramide	   species	   were	   decreased	   with	   exercise,	   while	  
only	  C14:0,	  C20:0	  and	  C24:0	  ceramides	  were	  decreased	  with	  diet-­‐induced	  weight	  loss	  [49],	  
indicating	   that	   certain	   bioactive	   ceramide	   subspecies,	   rather	   than	   total	   ceramide	   levels,	  
may	  be	  causative	  in	  obesity-­‐associated	  insulin	  resistance.	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Figure	   1.	   Lipid	   intermediate	   metabolism	   and	   subcellular	   localization.	   Potential	   lipotoxic	  
intermediates	  are	  indicated	  with	  a	  red	  box.	  Blue	  arrows:	  routes	  towards	  storage	  in	  the	  lipid	  droplet;	  
green:	  routes	  towards	  lipid	  synthesis	  on	  the	  ER,	  orange:	  routes	  related	  to	  lipolysis	  and	  β-­‐oxidation	  in	  
the	  mitochondria,	  black:	  membrane-­‐related	  processes.	  
AcylCarn:	   acylcarnitines,	   DAG:	   diacylglycerol,	   FA:	   fatty	   acid,	   FA-­‐CoA:	   fatty	   acyl-­‐CoA,	   MAG:	  
monoacylglycerol,	  PA:	  phosphatidic	  acid,	  TAG:	  triacylglycerol.	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Table	  2.	  Interventions.	  
Author	  and	  
reference	  







Dubé	   et	   al.	  
2011	  [49]	  
Male	   (n=7)	   and	   female	   (n=9)	  
overweight	   (IGT	   and	   NGT)	  
subjects,	  16	  week	  diet	  or	  exercise	  
intervention	  (n=8	  per	  group)	  
+	   +	   No	  correlation	  of	  changes	  in	  DAG	  
and	   ceramides	   and	  
improvements	   in	   insulin	  
sensitivity.	   Differences	   in	   DAG	  
and	   ceramide	   subspecies.	  
Ceramides	   decreased	   only	   with	  
the	  exercise	  training.	  
	  
Hoeg	   et	   al.	  
2011	  [69]	  
Young	   healthy	   men	   (n=8)	   and	  
women	   (n=8),	   lipid	   infusion-­‐
induced	  insulin	  resistance	  
-­‐	   -­‐	   Intralipid	  infusion	  did	  not	  lead	  to	  
accumulation	   of	   DAG	   or	  




al.	  2010	  [51]	  
A	   weight	   loss	   program	   in	   obese	  
women	  (n=5)	  
-­‐	   n.i.	   TAG	   was	   depleted	   upon	   weight	  
loss,	  DAG	  was	  unchanged	  
	  
Bajaj	   et	   al.	  
2010	  [50]	  
Pioglitazone	   treatment	   in	  
diabetics	   (n=24;	   both	   male	   and	  
female)	  
-­‐	   n.i.	   FA-­‐CoA	   was	   decreased	   and	  
associated	  with	  improvements	  in	  
insulin	  sensitivity,	  no	  differences	  
in	  DAG	  
	  
Dubé	   et	   al.	  
2008	  [21]	  
Exercise	   program	   in	   obese	   men	  
(n=9)	  and	  women	  (n=16)	  
+	   +	   Decreased	   DAG	   and	   ceramides	  
after	   the	   exercise	   intervention	  
period	  
	  
Vistisen	  et	  al.	  
2008	  [71]	  
Obese	  women	  and	  men	  (n=8	  per	  
group),	   lipid	   infusion-­‐induced	  
insulin	  resistance	  
-­‐	   -­‐	   The	   lipid-­‐induced	   inhibition	   of	  
glucose	   disposal	   is	   similar	   in	  
obese	   females	   and	   males.	   DAG	  
and	   ceramides	   were	   similar	  
between	  sexes.	  
	  
Schenk	   et	   al.	  
2007	  [72]	  
Acute	   exercise	   in	   non-­‐obese	  
women	   (n=8),	   followed	   by	   an	  
overnight	   lipid	   infusion-­‐induced	  
insulin	  resistance	  
+	   +	   1	   exercise	   session	   completely	  
reversed	   FA-­‐induced	   insulin	  
resistance,	   decreased	   DAG	   and	  
ceramides	  
	  
Serlie	   et	   al.	  
2007	  [66]	  
Lean	  (n=8,	  both	  sexes)	  and	  obese	  
(n=6)	   subjects,	   lipid	   infusion	   and	  
Acipimox	  treatment	  (6h)	  
n.i.	   -­‐	   No	   differences	   in	   ceramides	   at	  
baseline	  and	  no	  differences	  after	  
6h	   lipid	   infusion	   or	   Acipimox	  
treatment	  
	  
Bruce	   et	   al.	  
2006	  [48]	  
Exercise	   intervention	  with	   obese	  
subjects	  (n=9;	  both	  sexes)	  	  
+	   +	   Exercise	   decreases	   ceramides	  




et	   al.	   2004	  
[70]	  
Healthy	   male	   subjects	   (n=10),	  
lipid	   infusion-­‐induced	   insulin	  
resistance	  
n.i.	   +	   A	  4h	  intralipid	  infusion	  increased	  
ceramide	   levels	   concurrent	  with	  
the	   induction	   of	   insulin	  
resistance.	  
	  
Itani	   et	   al.	  
2002	  [39]	  
Healthy	   male	   subjects	   (n=12),	  
lipid	   infusion-­‐induced	   insulin	  
resistance	  
+	   -­‐	   Increased	   DAG	   levels	   with	   lipid-­‐
induced	   insulin	   resistance,	   no	  
changes	  in	  ceramides	  
	  
IS:	  insulin	  sensitivity,	  n.i.	  =	  not	  investigated.	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Several	  studies	   investigated	  the	  effects	  of	   lipid	   infusion-­‐induced	  insulin	  resistance	  on	  the	  
accumulation	   of	   ceramides	   in	   skeletal	   muscle	   [39,	   66,	   69-­‐71].	   A	   4-­‐6h	   lipid	   infusion	  
(intralipid)	   in	   four	   out	   of	   five	   studies	   did	   not	   result	   in	   increased	   levels	   of	   ceramides,	  
despite	   inducing	   insulin	   resistance	   [39,	   66,	   69,	   71].	  Only	   Straczkowski	   et	   al.	   did	   observe	  
increased	  ceramide	  levels	  [70].	  However,	  as	  intralipid	  mainly	  consists	  of	  unsaturated	  fats	  
(20%	  triglyceride	  emulsion,	  generally	   safflower-­‐	  and	  soy-­‐oil),	   ceramides	  might	  not	  play	  a	  
main	   role	   in	   acute	   lipid-­‐infusion	   mediated	   insulin	   resistance.	   Holland	   et	   al.	   tested	   this	  
hypothesis	   of	   different	   fatty	   acids	   inducing	   insulin	   resistance	   in	   muscle	   via	   distinct	  
mechanisms	   by	   infusing	   either	   a	   lard-­‐oil	   based	   solution	   (mainly	   saturated	   fats)	   versus	   a	  
soy-­‐based	   cocktail	   (mainly	   unsaturated	   fats)	   into	   rats	   [59].	   Indeed,	   while	   both	   lipid	  
infusions	   resulted	   in	   insulin	   resistance,	   only	   the	   lard-­‐oil	   infusion	   induced	   ceramide	  
accumulation.	  Thus,	  ceramide	  accumulation	  may	  be	  involved	  in	  saturated	  fat-­‐induced	  but	  
not	   intralipid-­‐induced	   insulin	   resistance	   in	   human	   skeletal	  muscle.	   Further	   investigation	  
into	   sphingolipid	   subspecies	   and	   their	   intracellular	   localization	   could	   provide	   more	  
information	  on	  the	  mechanisms	  involved.	  
	  
Fatty	  acyl-­‐CoA	  
Lipid	   intermediates	   that	   have	   received	   less	   attention	   so	   far	   are	   fatty	   acyl-­‐CoAs	   and	  
acylcarnitines.	   Upon	   entry	   into	   muscle	   cell	   either	   by	   diffusion	   or	   FA-­‐transporters,	   fatty	  
acids	   are	   trapped	  within	   the	   cell	   after	   a	   CoA	   group	   is	   bound	   by	   acyl-­‐CoA	   synthetase.	   If	  
fatty	  acid	  uptake	  exceeds	  the	  capacity	  for	  fatty	  acid	  channeling	  towards	  lipid	  synthesis	  or	  
β-­‐oxidation,	  FA-­‐CoA	  will	   accumulate	   in	   the	  cell,	  either	   in	   the	  cytosol	  or	   in	  mitochondria.	  
Indeed,	  rats	  fed	  a	  high	  fat	  diet	  showed	  an	  increased	  accumulation	  of	   long	  chain	  FA-­‐CoAs	  
(LC-­‐CoAs)	  in	  skeletal	  muscle	  [72].	  Currently,	  the	  importance	  of	  FA-­‐CoA	  in	  insulin	  resistance	  
remains	   unclear.	   In	   a	   number	   of	   human	   studies,	   LC-­‐CoA	   levels,	   like	   other	   lipid	  
intermediates,	   were	   observed	   to	   be	   elevated	   in	   insulin	   resistant	   muscle.	   LC-­‐CoA	   levels	  
were	   increased	   in	   skeletal	   muscle	   biopsies	   from	   obese	   subjects	   [73]	   and	   correlated	  
negatively	   with	   whole	   body	   insulin	   action	   (i.e.	   glucose	   infusion	   rates	   during	   a	  
hyperinsulinemic	   euglycemic	   clamp)	   [72].	   Furthermore,	   LC-­‐CoA	   levels	   were	   increased	  
upon	   short-­‐term	   (4-­‐6h)	   lipid	   infusion	   in	   parallel	   with	   PKC-­‐mediated	   inhibition	   of	   insulin	  
signaling	  [74,	  75]	  and	  insulin-­‐sensitizing	  strategies	  were	  described	  to	  lower	  intramuscular	  
LC-­‐CoA	  levels	  [50,	  76,	  77].	  In	  contrast,	  in	  the	  study	  of	  Bruce	  et	  al.,	  both	  basal	  and	  insulin-­‐
stimulated	   skeletal	   muscle	   LC-­‐CoA	   content	   were	   similar	   between	   young	   trained,	   young	  
sedentary	  subjects,	  type	  2	  diabetics	  and	  obese	  controls	  [78].	  	  
It	   is	   unclear	   whether	   FA-­‐CoAs	   as	   such	   are	   interfering	   with	   the	   insulin	   signaling	  
cascade.	  There	  are	  indications	  for	  PKC	  activation	  by	  FA-­‐CoA,	  but	  it	  is	  unclear	  whether	  this	  
is	  a	  direct	  or	  an	  indirect	  effect	  (via	  DAG)	  [79].	  Next	  to	  being	  substrates	  for	  TAG	  synthesis	  
and	   energy	   production,	   FA-­‐CoAs	   are	   used	   as	   substrates	   for	   protein	   acylation	   reactions.	  
Interestingly,	   Jenkins	   et	   al.	   recently	   showed	   that	   LC-­‐CoA	   is	   capable	   of	   inhibiting	  
phosphofructokinase-­‐1	   (PFK1)	   activity	   by	   reversible	   acylation,	   resulting	   in	   a	   lowered	  
glycolytic	   flux	   under	   high	   intracellular	   ATP	   conditions	   [80].	   Intracellular	   accumulation	   of	  
LC-­‐CoA	  may	  thus	  inhibit	  glycolysis	  downstream	  of	  insulin	  signaling,	  without	  affecting	  non-­‐
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oxidative	  glucose	  disposal	  [80].	  LC-­‐CoAs	  are	  also	  substrates	  for	  synthesis	  of	  phospholipids,	  
TAG,	   DAG	   and	   ceramides.	   Hence,	   accumulation	   of	   LC-­‐CoAs	   can	   lead	   to	   increased	  
formation	  of	  lipid	  intermediates	  with	  the	  potential	  to	  impair	  insulin	  signaling.	  Additionally,	  
intramitochondrial	  accumulation	  of	  acyl-­‐CoAs,	  as	  a	  result	  of	  a	  disbalance	  in	  mitochondrial	  
FA	  transport	  and	  downstream	  oxidative	  metabolism,	  and	  their	  metabolites	  ceramides	  [64]	  
and	   acylcarnitines	   [81]	   might	   contribute	   to	   mitochondrial	   failure.	   Based	   on	   available	  
evidence,	   it	   is	   too	   early	   to	   draw	   conclusions	   about	   the	   importance	   of	   FA-­‐CoA	   in	   the	  
etiology	   of	   insulin	   resistance	   in	   skeletal	  muscle.	   Information	   on	   intracellular	   localization	  
and	  verification	  of	  its	  inhibitory	  effects	  on	  glucose	  metabolism	  is	  warranted.	  
	  
Acylcarnitines	  
Upon	   entrance	   into	   the	  mitochondria,	   FA-­‐CoAs	   are	   degraded	   during	  β-­‐oxidation,	   which	  
yields	  one	  acetyl-­‐CoA	  molecule	  in	  each	  successive	  cycle.	  When	  β-­‐oxidation	  rates	  outpace	  
the	  capacity	  of	  the	  TCA	  cycle,	  CRAT	  lowers	  short-­‐chain	  acetyl-­‐CoA	  levels	  by	  coupling	  of	  a	  
carnitine	  moiety	   thus	  producing	  acylcarnitines.	  CPT2,	  present	   in	   the	   inner-­‐mitochondrial	  
membrane,	   is	   best	   known	   for	   its	   capacity	   to	   convert	   acylcarnitines	   to	   carnitine	  plus	   FA-­‐
CoA.	   However,	   CPT2	   has	   a	   dual	   role;	   the	   enzyme	   can	   operate	   in	   the	   reverse	   direction	  
generating	  medium	  and	  long-­‐chain	  acylcarnitines	  produced	  from	  intramitochondrial	  acyl-­‐
CoAs	   and	   transporting	   those	   to	   the	   cytoplasm	   [82].	   A	   sustained	   mitochondrial	   FA	  
oversupply	   and	   incomplete	   fatty	   acid	   oxidation	   therefore	   results	   in	   mitochondrial	  
accumulation	   of	   FA-­‐CoAs	   and	   acylcarnitines.	   In	   contrast	   to	   FA-­‐CoAs,	   acylcarnitines	   can	  
cross	  membranes	  and	  end	  up	  in	  the	  cytoplasm	  or	  in	  the	  blood.	  	  
Incomplete	   FA	   oxidation	   resulting	   in	   intramyocellular	   accumulation	   of	   (C6	   to	   C22)-­‐
acylcarnitines	  and	  other	  intermediates	  has	  been	  demonstrated	  to	  be	  increased	  in	  obesity	  
[83-­‐86].	  Furthermore,	  blood	  plasma	  acylcarnitine	  levels	  were	  increased	  in	  obese	  subjects	  
compared	   to	   lean	   controls	   [87,	   88]	   and	   in	   type	   2	   diabetes	   patients	   compared	   to	   BMI-­‐
matched	   controls	   [89,	   90].	  Additionally,	   exercise	   training	   improved	   rates	  of	   complete	  β-­‐
oxidation	   in	   parallel	  with	   improved	   insulin	   sensitivity	   in	  mice	   [91]	   and	   in	   obese	  humans	  
subjected	  to	  caloric	  restriction	  [92].	  It	  was	  therefore	  suggested	  that	  mitochondria	  are	  very	  
vulnerable	  to	  substrate	  overloads	  and	  therefore	  might	  serve	  as	  the	  principal	  lipid	  sensor	  in	  
skeletal	  muscle	  [81].	   In	  contrast,	  Boyle	  et	  al.	  observed	  lower	   levels	  of	  short	  and	  medium	  
chain	   acylcarnitines	   in	   obese	   compared	   to	   lean	   subjects,	   long	   chain	   acylcarnitines	  were	  
similar	   [84].	   Interestingly	   though,	   following	   a	   5	   day	   high	   fat	   diet	   the	   obese	   subjects	  
showed	   increased	  short	  and	  medium	  chain	  acylcarnitines	  compared	   to	   the	   lean	  controls	  
[84].	  
The	   association	   of	   acylcarnitine	   levels	   with	   insulin	   resistance	   is	   based	   on	  
observational	   studies	   and	   might	   be	   a	   reflection	   of	   lipid	   overload	   rather	   than	   that	  
acylcarnitines	   are	   causative	   in	   lipid-­‐induced	   impairments	   in	   insulin	   signaling.	   Further	  
research	  is	  warranted	  to	  identify	  the	  importance	  of	  mitochondrial	  acylcarnitine	  species	  in	  
insulin	  resistance.	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Lipid	  intermediates	  and	  insulin	  resistance;	  concluding	  remarks	   	   	  
Taken	  together,	  human	  studies	  are	   far	   from	  consistent	  with	   regard	   to	   lipid	   intermediate	  
accumulation	   in	   skeletal	   muscle	   of	   type	   2	   diabetes	   patients.	   The	   inconsistencies	   in	   the	  
study	   outcomes	   could	   be	   explained	   by	   differences	   in	   analytical	   tools,	   differences	   in	   the	  
timing	   of	   the	   biopsies,	   age	   of	   the	   subjects,	   inter-­‐gender	   variation	   [47,	   69],	   and	   inter-­‐
individual	   (genetic)	   variation.	   Ceramides,	   acyl-­‐CoAs	   and	   DAG	   have	   the	   potential	   to	  
interfere	  with	  insulin	  signaling.	  The	  prevailing	  importance	  of	  one	  over	  the	  other	  may	  well	  
be	   related	   to	   specific	   (experimental)	   circumstances.	   For	   example,	   lipid	   infusion-­‐induced	  
insulin	   resistance	   seems	   to	   be	   predominantly	   associated	   with	   increased	   DAG	   levels,	  
whereas	  ceramides	  are	  mainly	  associated	  with	   saturated	   fat	   intake.	   It	  deserves	  mention	  
though,	  that	  although	  lipid	  infusion	  is	  often	  used	  to	  mimic	  lipid-­‐induced	  insulin	  resistance,	  
it	  is	  questionable	  whether	  the	  effects	  of	  the	  supraphysiological	  plasma	  FFA	  levels	  due	  to	  a	  
short-­‐term	  infusion	  of	  a	  lipid	  mixture	  reflect	  the	  mechanisms	  involved	  in	  obesity-­‐induced	  
insulin	  resistance.	  	  
Exercise	   interventions	   generally	   decrease	   both	   intramyocellular	   DAG	   and	   ceramide	  
levels.	   Acylcarnitine	   levels	   seem	   to	   be	   important	   indicators	   of	   substrate	   overload,	   but	  
evidence	  for	  a	  role	   in	   lipid-­‐induced	   insulin	  resistance	   is	   limited.	  Support	   for	  a	  role	  of	  FA-­‐
CoA	   on	   insulin	   signaling	   is	   most	   limited,	   but	   is	   also	   the	   least	   examined	   option.	  
Nevertheless,	   FA-­‐CoA	   accumulation	   may	   well	   be	   involved	   in	   blunting	   oxidative	   glucose	  
disposal	   by	   inhibiting	   glycolysis	   without	   an	   effect	   on	   non-­‐oxidative	   glucose	   disposal.	  
However,	   in	   general	   total	   skeletal	   muscle	   DAG,	   ceramide	   or	   FA-­‐CoA	   levels	   are	   not	  
consistently	  elevated	  in	  insulin	  resistant	  subjects.	  It	  is	  therefore	  questionable	  whether	  one	  
of	   these	   lipid	   intermediates	   has	   a	   causal	   role	   in	   obesity-­‐associated	   insulin	   resistance.	  
However,	   given	   the	   lipotoxic	  potential	  of	   these	   lipid	   intermediates,	   it	   is	   likely	   that	   there	  
are	   several	   routes	   towards	   lipid-­‐induced	   insulin	   resistance.	   Further	   specification	   of	   the	  
lipotoxic	   intermediates	   by	   (de)saturation	   [7,	   23,	   48,	   93],	   chain	   length	   [45,	   49],	   stereo	  
specific	   isomers,	  and	   intracellular	   localization	  could	  give	  further	   insight	   into	  the	   lipotoxic	  
mechanisms	  involved	  in	  the	  development	  of	  type	  2	  diabetes	  in	  obese	  subjects.	  	  
	  
INTRAMYOCELLULAR	  LIPID	  DYNAMICS	  	  
Although	   research	   in	   the	   last	   decades	   has	   focused	   primarily	   on	   levels	   of	   lipid	  
intermediates	   to	  explain	  muscular	   insulin	   resistance,	  more	   recent	  data	  also	   suggest	   that	  
intramyocellular	  lipid	  dynamics	  may	  play	  an	  important	  role	  in	  regulating	  insulin	  sensitivity.	  
Next	   to	   alterations	   in	  myocellular	   lipid	   influx,	   an	   altered	   rate	   of	   lipid	   turnover,	   either	   a	  
decreased	   triglyceride	   synthesis,	   or	   increased	   lipolysis	   (not	   matched	   by	   increased	   fatty	  
acid	   oxidation),	   and	   reductions	   in	   oxidative	   capacity	   have	   been	   suggested	   to	   be	   the	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TAG	  synthesis	  	  
Upon	   entrance	   of	   fatty	   acids	   into	   the	  muscle	   cell,	   fatty	   acids	   can	   be	   incorporated	   into	  
IMCL	   for	   storage	   and/or	   can	   be	   directed	   to	  mitochondria	   for	   oxidation.	  One	   hypothesis	  
explaining	   the	   athlete’s	   paradox	   says	   that	   as	   long	   as	   fatty	   acids	   are	   efficiently	   directed	  
towards	   storage	   as	   TAG,	   there	   is	   no	   interference	   with	   insulin	   signaling.	   Based	   on	   this	  
notion	   it	  could	  be	  argued	  that	  the	  expression	  of	  enzymes	   involved	   in	   lipid	  synthesis	  may	  
be	  an	  important	  determinant	  of	  obesity-­‐induced	  insulin	  resistance.	  	  
Initiation	  of	  lipid	  synthesis	  requires	  coupling	  of	  fatty	  acids	  to	  a	  glycerol	  backbone.	  Glycerol	  
3-­‐phosphate	   acyltransferase	   (GPAT)	   and	   diacylglycerol	   acyltransferase	   (DGAT)	   are	  
important	   rate	   limiting	   enzymes	   in	   this	   process.	  Multiple	   acyltransferase	   isoforms	   exist,	  
including	   GPATs	   1-­‐4	   and	   DGAT1	   and	   DGAT2.	   GPATs	   1	   and	   2	   are	   present	   in	   the	   outer	  
mitochondrial	  membrane,	  GPATs	  3	  and	  4	  localize	  to	  the	  ER	  [94].	  At	  least	  90%	  of	  the	  GPAT	  
activity	   in	   skeletal	   muscle	   is	   contributed	   by	   GPAT1	   [95].	   DGAT1	   resides	   in	   the	   ER	   [96],	  
whereas	  DGAT2	  localizes	  to	  ER,	  mitochondria	  and	  lipid	  droplets	  [53,	  97,	  98].	  Both	  DGAT1	  
and	   DGAT2	   are	   present	   in	   skeletal	   muscle	   [99,	   100],	   but	   DGAT1	   is	   the	   predominant	  
skeletal	   muscle	   DGAT	   isoform	   [99].	   Little	   is	   known	   about	   the	   expression	   of	   glyceride	  
synthesis	  enzymes	  in	  human	  skeletal	  muscle	  of	  healthy,	  obese	  and	  diabetic	  subjects.	  Two	  
reports	  on	  lipogenic	  enzyme	  expression	  in	  skeletal	  muscle	  of	  obese	  subjects	  failed	  to	  find	  
differences	   in	   skeletal	   muscle	   GPAT	   and	   DGAT1	   protein	   expression	   between	   lean	   and	  
obese	   subjects	   [43,	  101].	  On	   the	  other	  hand,	  acute	  exercise	   increased	  GPAT	  and	  DGAT1	  
protein	   expression	   while	   preventing	   lipid-­‐induced	   insulin	   resistance	   [102].	   GPAT	   and	  
DGAT1	  protein	  expression	  levels	  are	  dynamic,	  albeit	  only	  in	  the	  short-­‐term.	  Eight	  [103]	  or	  
sixteen	   weeks	   [49]	   of	   aerobic	   exercise	   or	   diet-­‐induced	   weight	   loss	   [49],	   conditions	  
associated	  with	  an	  increase	  and	  a	  decrease	  in	  intramyocellular	  TAG	  levels	  respectively,	  did	  
not	  alter	  DGAT1	  expression	   in	  obese	   subjects,	   indicating	   that	  at	   least	  DGAT1	  mRNA	  and	  
protein	   expression	   levels	   are	   not	   major	   determinants	   of	   IMCL	   levels	   in	   human	   skeletal	  
muscle.	  Moreover,	  DGAT1	  mRNA	  expression	   is	  similar	   in	  endurance-­‐trained	  athletes	  and	  
sedentary	   controls	   [104]	   and	   a	   lipid	   infusion	   following	   one	   exercise	   session	   increased	  
GPAT	   activity	  without	   affecting	   DGAT	   activity	   [105].	   In	   contrast	   to	   the	   limited	   evidence	  
from	  human	   studies,	   animal	   studies	   showed	  beneficial	   effects	   of	  DGAT1	  overexpression	  
on	  insulin	  sensitivity	  [25,	  26,	  106].	  We	  showed	  that	  a	  short-­‐term	  (1	  week)	  overexpression	  
of	   DGAT1	   in	   the	   tibialis	   anterior	   muscle	   of	   rats	   increased	   both	   TAG	   and	   DAG	   levels	  
indicating	   that	   increasing	   lipid	   turnover	   by	   means	   of	   DGAT1	   overexpression	   protects	  
against	  insulin	  resistance	  [26].	  
Another	  enzyme	  that	  has	  received	  interest	  in	  the	  synthesis	  of	  TAG	  in	  muscle	  is	  SCD1.	  
SCD1	  is	  a	  member	  of	  the	  family	  of	  stearoyl-­‐CoA	  desaturases	  (SCDs).	  Four	  isoforms	  exist	  in	  
mice	  (SCD1-­‐4)	  and	  two	  isoforms	  in	  humans	  (SCD1	  and	  SCD5)	  [107].	  Both	  SCD1	  and	  SCD5	  
localize	  to	  the	  ER	  [108].	  SCD1	  and	  SCD5	  desaturate	  fatty	  acids	  at	  the	  delta	  9	  position	  [108].	  
Little	   is	   known	   about	   the	   function	   of	   SCD5.	   SCD1	   is	   predominantly	   expressed	   in	   liver,	  
adipose	   tissue	   and	   skeletal	  muscle	   [107]	   and	   functions	   as	   a	   rate-­‐limiting	   enzyme	   in	   the	  
biosynthesis	   of	   monounsaturated	   fatty	   acids;	   it	   desaturates	   stearate	   and	   palmitate	   to	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generate	   the	   less	   toxic	  monounsaturated	   FAs	   oleate	   and	   palmitoleate.	   Unsaturated	   FAs	  
are	  the	  preferred	  substrates	  for	  TAG	  synthesis.	  SCD1	  is	  upregulated	  with	  exercise	  training	  
[23,	  49,	  109]	  and	  protects	  against	  saturated	  fat-­‐induced	  insulin	  resistance	  in	  myotubes	  in	  
vitro	  [110,	  111].	  On	  the	  other	  hand,	  SCD1	  protein	  expression	  was	  similar	  in	  obese	  and	  lean	  
subjects	  in	  the	  study	  of	  Thrush	  et	  al.	  [43]	  and	  was	  even	  shown	  to	  be	  increased	  in	  severely	  
obese	   subjects	   the	   study	   of	   Hulver	   et	   al.	   [112].	   Nevertheless,	   the	   beneficial	   effects	   of	  
DGAT1	  and	  SCD1	  overexpression	   further	   support	   the	  notion	   that	   channeling	  FAs	   to	  TAG	  
synthesis	   is	   beneficial	   for	   insulin	   sensitivity.	   Yet	   while	   increasing	   the	   TAG	   synthesis	  
capacity	  by,	   for	  example,	   training	  has	  been	  shown	  to	   improve	   insulin	  sensitivity,	   there	   is	  
no	  evidence	  for	  a	  causative	  role	  of	  impaired	  TAG	  synthesis	  capacity	  in	  the	  development	  of	  
obesity-­‐associated	  insulin	  resistance.	  
	  
TAG	  breakdown	  
Lipid	  turnover	  is	  not	  only	  determined	  by	  TAG	  synthesis	  but	  also	  by	  TAG	  lipolysis.	  In	  skeletal	  
muscle,	   two	  major	   lipases	   have	   been	   identified	   that	   are	   responsible	   for	   complete	   TAG	  
lipolysis:	   ATGL	   and	  HSL.	   Adipose	   triglyceride	   lipase	   (ATGL)	   hydrolyses	   TAG	   to	   form	  DAG	  
[113],	  whereas	  HSL	  mainly	  acts	  on	  DAG	   [114,	  115].	  When	   increased	  ATGL	  activity	   is	  not	  
counterbalanced	   by	   increased	   hormone-­‐sensitive	   lipase	   (HSL)	   or	   DGAT	   activity,	  
intermediates	  will	  accumulate.	   In	  vivo	  microdialysis	  studies	  have	  demonstrated	   impaired	  
lipolysis	   in	   skeletal	   muscle	   of	   obese	   subjects	   [116],	   suggesting	   that	   disturbances	   in	   the	  
regulation	   of	   lipolysis	   may	   contribute	   to	   the	   development	   of	   obesity-­‐associated	  
comorbidities.	   In	   addition,	   several	   observational	   studies	   have	   shown	   alterations	   in	   the	  
expression	  of	  proteins	  involved	  in	  lipolysis	  in	  skeletal	  muscle	  of	  obese	  and	  type	  2	  diabetic	  
subjects.	  Jocken	  et	  al.	  measured	  lipase	  expression	  levels	  in	  insulin-­‐resistant	  obese	  subjects	  
compared	   with	   lean	   controls	   and	   showed	   that	   HSL	   was	   decreased	   while	   ATGL	   was	  
increased	   without	   changes	   in	   CGI-­‐58,	   a	   cofactor	   for	   ATGL	   activity.	   These	   changes	  
concurrent	   with	   a	   lower	   DAG	   hydrolase	   activity	   may	   be	   a	   manifestation	   of	   incomplete	  
lipolysis	   [42].	   Surprisingly,	   the	   DAG	   level	   was	   decreased	   in	   the	   insulin-­‐resistant	   obese	  
subjects	   compared	  with	   the	   lean	   controls,	   indicating	   that	   the	   decreased	  DAG	   hydrolase	  
and	  normal	  TAG	  hydrolase	  activity	  in	  obese	  subjects	  did	  not	  result	  in	  increased	  DAG.	  This	  
absence	  of	  an	  effect	  on	  DAG	  accumulation	  raises	  the	  question	  whether	  the	  ratio	  of	  DAG	  to	  
TAG	  hydrolase	  activity	   is	  of	  physiological	   importance	   for	   lipid-­‐induced	   insulin	   resistance.	  
Moreover,	  compensation	  by	  TAG-­‐synthesis	  related	  proteins	   like	  DGAT	  might	  balance	  out	  
intracellular	   DAG	   and	   TAG	   levels,	   thus	   protecting	   from	   accumulation	   of	   lipotoxic	   DAG	  
species.	  Moro	  et	  al.	  determined	  DAG	  and	  TAG	  levels	  as	  well	  as	  lipase	  activities	  in	  skeletal	  
muscle	  biopsies	  from	  lean,	  obese	  and	  type	  2	  diabetic	  subjects.	  In	  contrast	  to	  the	  study	  of	  
Jocken	  et	   al.	   [42],	  DAG	   levels	  were	   increased.	  Additionally,	   a	  direct	   association	  with	   the	  
ratio	   of	  DAG	  hydrolase	   to	   TAG	  hydrolase	   activity	   (an	   index	   of	   incomplete	   triacylglycerol	  
hydrolysis)	  was	  observed,	  which	  explained	  54%	  of	  the	  variance	  in	  DAG	  [7].	  TAG	  hydrolase	  
activity	  was	  increased	  only	  in	  female	  obese	  and	  type	  2	  diabetic	  subjects	  compared	  to	  lean	  
controls	  [7].	  Although	  Jocken	  et	  al.	  [42]	  only	  used	  male	  subjects,	  gender	  differences	  most	  
likely	   do	   not	   explain	   the	   differences	   in	   DAG	   levels	   between	   the	   two	   studies,	   as	   no	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differences	   in	   DAG	   levels	   between	   males	   and	   females	   have	   been	   observed	   before	   [7].	  
Coen	   et	   al.	   showed	   decreased	   ATGL	   and	  HSL	   gene	   expression	   in	   obese	   insulin	   resistant	  
compared	  with	  BMI-­‐matched	  insulin	  sensitive	  controls,	  while	  DAG	  levels	  were	  similar	  [45].	  
In	   contrast	   to	   these	  studies,	   Li	  et	  al.	  showed	   that	  ATGL	  and	  HSL	  protein	   levels	  were	  not	  
altered	   in	   skeletal	  muscle	   of	   obese	  women	   compared	  with	   lean	  women	   and	   that	   there	  
were	  no	  differences	  in	  phosphorylation	  of	  specific	  sites	  known	  to	  affect	  HSL	  activity	  [101].	  	  
Recently,	  Badin	  et	  al.	  showed	  an	  imbalance	  between	  ATGL	  and	  HSL	  protein	  expression	  and	  
activity	  in	  obese	  diabetics	  versus	  lean	  controls	  [117],	  consistent	  with	  the	  studies	  of	  Moro	  
et	   al.	   [7]	   and	   Jocken	   et	   al.	   [42].	   Furthermore,	   it	   was	   shown	   that	   an	   imbalance	   of	   ATGL	  
relative	  to	  HSL	  promotes	  DAG	  accumulation	  and	  leads	  to	  insulin	  resistance	  at	  least	  in	  part	  
through	   the	   DAG-­‐induced	   PKC	   activity	   [117].	   However,	   in	   this	   study	   only	   obese	   type	   2	  
diabetics	   and	   not	  NGT	   obese	   subjects	   displayed	   alterations	   in	   lipase	   protein	   content,	   in	  
contrast	  with	  the	  data	  of	  Jocken	  et	  al	  [42].	  It	  was	  suggested	  that	  these	  differences	  in	  study	  
outcomes	  could	  be	  explained	  by	  age	  differences,	  since	  Badin	  et	  al.	  included	  younger	  obese	  
subjects	  [117].	  This	  age-­‐effect	  deserves	  further	  attention.	  
Thus,	  studies	  in	  which	  lipase	  levels	  and	  activity	  were	  measured	  in	  obese	  and/or	  type	  
2	  diabetic	  persons	  do	  not	  show	  consistent	  results.	  If	  the	  suggested	  importance	  of	  the	  ratio	  
of	  TAG	  to	  DAG	  hydrolysis	  would	  be	  true,	  one	  could	  reason	  that	  TAG	  hydrolase	  activity	   is	  
not	   as	   strictly	   regulated	   as	   DAG	   hydrolase	   activity,	   which	  may	   lead	   to	   a	  mismatch	   and	  
incomplete	   lipolysis	   in	   obese	   subjects	  with	   excess	   IMCL.	  However,	   intramyocellular	   TAG	  
and	  DAG	  hydrolysis	  capacity	  was	  measured	  in	  homogenates	  derived	  from	  frozen	  samples	  
[7,	   42]	   and	   therefore	   represents	   maximal	   capacity	   as	   opposed	   to	   physiological	   lipase	  
activity.	  Cell	  studies	  showed	  that	  ATGL	  and	  HSL	  activity	  is	  tightly	  regulated	  by	  coactivation	  
and	   repression	  by	   regulatory	   proteins.	   ATGL	   activity	   is	   dependent	   on	  CGI-­‐58	   (activator),	  
G0S2	  (suppressor)	  and	  perilipins	  for	  docking	  on	  the	  LD	  and	  the	  regulation	  of	  lipolysis	  upon	  
protein	  kinase	  A	  (PKA)	  stimulation	  [118-­‐121].	  Thus,	  endogenous	  intracellular	  lipase	  activity	  
is	   not	   only	   dependent	   on	   ATGL	   and	   HSL	   expression	   and	   enzyme	   activity,	   but	   is	   highly	  
dependent	  on	  subcellular	   localization	  and	  the	  presence	  and	  activation	  of	  other	  proteins.	  
Therefore,	   lipase	   protein	   expression	   and	   enzyme	   activity	   alone	   presumably	   do	   not	   give	  
enough	  information	  to	  draw	  conclusion	  about	  the	  importance	  of	  disturbances	   in	  skeletal	  
muscle	   lipolysis	   in	   lipid-­‐induced	   insulin	   resistance.	   Moreover,	   it	   is	   currently	   unknown	  
whether	  ATGL-­‐mediated	   lipolysis	  gives	   rise	   to	  1,2-­‐DAG,	  which	   is	  considered	  the	   lipotoxic	  
DAG	  intermediate	  capable	  of	  activity	  PKC	  [36].	  The	  stereospecificity	  of	  the	  ATGL	  reaction	  
needs	   to	  be	  elucidated.	  Taken	   together,	   it	   is	   still	  unclear	  whether	   the	   ratio	  of	  ATGL	  and	  
HSL	  activity	  is	  involved	  in	  the	  development	  of	  lipid-­‐induced	  insulin	  resistance.	  
	  
Lipid	  turnover	  and	  balances	  with	  oxidative	  capacity	  	  
The	  aim	  of	  intramyocellular	  lipid	  dynamics	  in	  normal	  physiology	  is	  to	  provide	  intracellular	  
fatty	   acids	   for	   oxidation	   when	   needed.	   In	   endurance-­‐trained	   athletes,	   elevated	   IMCL	  
storage	  serves	  as	  an	  important	  fuel	  store	  for	  prolonged	  exercise	  bouts	  and	  coincides	  with	  
a	   high	   capacity	   to	   oxidize	   these	   fatty	   acids	   [122,	   123].	   Interestingly,	   type	   2	   diabetic	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patients	   have	   impaired	   mitochondrial	   function	   compared	   to	   obese	   NGT	   while	   having	  
similar	   IMCL	   levels	   [19].	   Therefore,	   a	   proper	   balance	   between	   IMCL	   storage	   and	   the	  
myocellular	  oxidative	  capacity	  appears	   important	   to	  prevent	  detrimental	  effects	  of	   IMCL	  
accumulation.	   Indeed,	   studies	   using	   stable	   isotope	   tracer	   technology	   to	   study	   usage	   of	  
IMCL	  during	  exercise	  revealed	  that	  IMCL	  was	  an	  important	  substrate	  during	  exercise	  [122,	  
123].	   Moreover,	   the	   increased	   IMCL	   storage	   in	   endurance-­‐trained	   athletes	   [18,	   20]	  
indicates	  an	  increased	  IMCL	  resynthesis	  capacity.	   It	  could	  be	  reasoned	  that	   lipid	  droplets	  
in	  skeletal	  muscle	  of	  sedentary	  subjects	  have	  a	  low	  turnover	  rather	  than	  being	  frequently	  
degraded	   and	   resynthesized,	   which	   might	   affect	   the	   subcellular	   distribution,	   organelle	  
interactions	  and	  lipotoxic	  events.	  It	  is	  unclear	  to	  date	  whether	  IMCL	  usage	  and	  turnover	  is	  
indeed	   impaired	   in	  obese	  and	   type	  2	  diabetic	   subjects.	  While	  Standl	  et	  al.	   [124]	  did	  not	  
find	  any	  differences	  in	  IMCL	  use	  during	  exercise	  between	  type	  2	  diabetics	  and	  healthy	  lean	  
controls,	   IMCL	  usage	  was	  demonstrated	   to	  be	   low	   in	  obese	  and	  type	  2	  diabetic	   subjects	  
during	  exercise	  [122,	  125].	  The	  beneficial	  effects	  of	  exercise	  training	  for	  type	  2	  diabetics,	  
improved	  insulin	  sensitivity	  paralleled	  with	  increased	  IMCL	  storage	  [21,	  22],	  indicate	  that	  a	  
balance	   in	  FA	  uptake,	   IMCL	  storage	  and	  resynthesis,	  and	  oxidative	  metabolism	   improves	  
insulin	   sensitivity.	   Interestingly,	   FFA-­‐induced	   insulin	   resistance	   via	   lipid	   infusion	   was	  
completely	  reversed	  by	  a	  single	  exercise	  session	  [102],	  further	  supporting	  the	  importance	  
of	  exercise-­‐induced	  IMCL	  resynthesis	  in	  the	  prevention	  of	  lipid-­‐induced	  insulin	  resistance.	  
Increased	   lipid	  turnover	  on	  the	   long	  term,	   for	  example	  as	  a	  result	  of	  exercise	  training,	   is	  
usually	   paralleled	   by	   fiber	   type	   switches	   towards	   the	  more	   oxidative	   slow-­‐twitch	   type	   I	  
fibers	  [45,	  77,	  126,	  127],	  increased	  oxidative	  capacity	  and	  increased	  intramyocellular	  TAG	  
synthesis.	   Thus,	   elevated	   lipid	   turnover	   and	   IMCL	   resynthesis	   are	   components	   of	   the	  
physiological	   adaptation	   to	   training	   and	   increased	   metabolic	   capacity.	   Proper	   balance	  
between	   IMCL	   synthesis,	   lipolysis	   and	   oxidative	   metabolism	   is	   important	   for	   the	  
protection	   against	   lipotoxicity.	   The	   importance	   of	   the	   rate	   of	   lipid	   turnover	   per	   se	   on	  
subcellular	  distribution	  and	  buildup	  of	  lipotoxic	  intermediates	  requires	  further	  research.	  
	  
IMCL	  dynamics;	  concluding	  remarks	  
Skeletal	  muscle	  lipid	  turnover	  is	  disturbed	  in	  obese	  and	  type	  2	  diabetic	  subjects.	  However,	  
the	  mechanisms	   involved	  deserve	   further	   investigation.	   The	   regulation	  of	   lipid	   synthesis	  
and	   lipolysis	   in	   skeletal	  muscle	  and	   its	   role	   in	   lipid-­‐induced	   insulin	   resistance	   is	   complex	  
and	  dependent	  on	  the	  interplay	  of	  different	  proteins.	  Disturbing	  this	  balance	  might	  lead	  to	  
accumulation	   of	   lipid	   intermediates	   that	   have	   the	   potential	   to	   impair	   insulin	   signaling.	  
Measurements	   of	   enzyme	   levels	   in	   skeletal	   muscle	   biopsies,	   however,	   represent	   static	  
snap	  shots	  of	  the	  situation,	  while	  lipid	  metabolism	  is	  a	  highly	  dynamic	  process.	  Therefore,	  
further	  research	  is	  warranted.	  Tracer	  studies	  and	  primary	  myotube	  cultures	  could	  provide	  
valuable	  information	  on	  skeletal	  muscle	  lipid	  dynamics.	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LIPID	  DROPLETS	  &	  LIPID	  DROPLET	  COATING	  PROTEINS	  	  
As	   outlined	   above,	   lipid	   accumulation	   in	   the	   form	   of	   lipid	   droplets	   (LDs)	   in	  muscle	   is	   a	  
dynamic	   process	   that	   is	   heavily	   regulated	   by	   TAG	   synthetases	   and	   lipases.	   Since	   the	  
recognition	  of	  LDs	  as	  dynamic	  organelles	  as	  opposed	  to	  being	  merely	  silent	  components	  of	  
a	   cell,	   lipid	   droplet	   coat	   proteins	   have	   gained	   attention.	   LDs	   are	   composed	  of	   a	   neutral	  
lipid	   core	   surrounded	   by	   a	   phospholipid	  monolayer	   and	   a	   protein	   coat.	   Cells	   contain	   a	  
heterogeneous	   population	   of	   LDs	   with	   differences	   in	   lipid	   composition	   and	   protein	  
coating.	   The	   protein	   coat	   of	   LDs	   contains	   a	   variety	   of	   different	   proteins	   involved	   in	   LD	  
dynamics,	   including	   proteins	   involved	   in	   TAG	  metabolism,	   LD	   synthesis	   and	   breakdown,	  
fusion	  and	  fission	  of	  LDs,	  intracellular	  trafficking	  and	  interorganelle	  interactions	  [128-­‐131].	  
Research	   in	   this	   field	   is	   still	   in	   its	   infancy,	  but	  mounting	  evidence	  suggests	  a	   role	   for	  LD-­‐
coat	   proteins	   in	   protecting	   against	   lipotoxicity	   and	   insulin	   resistance.	   The	   lipid	   core	  
contains	   DAG,	   TAG,	   cholesterolesters	   and	   free	   FAs	   [132].	   One	   could	   hypothesize	   that	  
storage	  of	  lipids	  in	  the	  LD	  is	  not	  harmful	  as	  opposed	  to	  accumulation	  of	  lipids	  elsewhere	  in	  
the	   cell.	   High	   expression	   levels	   of	   LD-­‐coat	   proteins	  might	   therefore	   provide	   a	   depot	   for	  
intracellular	   lipids,	   thus	   sequestering	   (toxic)	   lipid	   species	   in	   LDs.	   Moreover,	   the	   lipid	  
droplet	   coat	   is	   an	   important	   interface	   for	   lipid	   metabolism	   determining	   rates	   of	   lipid	  
synthesis	  and	  lipolysis.	  	  
	  
Lipid	  droplet	  coat	  proteins:	  perilipins	  
The	   best-­‐characterized	   group	   of	   LD	   coat	   proteins	   is	   the	   perilipin	   (PLIN)	   protein	   family.	  
PLIN1	  (perilipin)	   is	  specific	  for	  adipose	  tissue,	  PLIN2	  (ADRP,	  adipophilin)	   [133-­‐135],	  PLIN3	  
(TIP47)	   [135],	   PLIN4	   (S3-­‐12)	   [136]	   and	   PLIN5	   (OXPAT,	  MLDP,	   LSDP5)	   [133,	   137-­‐139]	   are	  
expressed	   in	  muscle.	   Perilipins	   have	   been	   demonstrated	   to	   interact	  with	   key	   players	   in	  
lipid	  metabolism	  [119-­‐121],	   indicating	  that	  the	  protein	  coat	  of	  the	  LD	  is	  the	   interface	  for	  
intracellular	   lipid	  metabolism.	   Little	   is	   known	  about	   the	   specific	   roles	  of	   the	  perilipins	   in	  
skeletal	  muscle,	  but	  it	  could	  be	  suggested	  that	  the	  abundance	  of	  perilipin	  proteins	  might	  
facilitate	  the	  creation	  of	  a	  depot	  for	  intracellular	  lipids	  and	  might	  modulate	  TAG	  synthesis	  
and	  breakdown.	  Studies	  performed	   in	  vitro	  and	   in	  vivo	   in	  tissues	  other	  than	  muscle	  have	  
demonstrated	   that	   perilipins	   increase	   intracellular	   lipid	   levels	   by	   inhibiting	   lipolysis	   and	  
facilitating	   LD	   synthesis,	   while	   protecting	   against	   lipotoxic	   events	   [138,	   140,	   141],	  
providing	  additional	  support	  for	  the	  hypothesis	  that	  neutral	   lipid	  storage	  per	  se	  does	  not	  
induce	   lipotoxicity.	   Moreover,	   sequestering	   lipid	   intermediates	   towards	   storage	   in	   LDs	  
rather	  than	  accumulation	  in/near	  the	  membranes	  or	  at	  other	  intracellular	  locations	  could	  
prevent	   lipotoxicity	  without	  altering	   total	   intermediate	  storage.	  However,	   little	   is	  known	  
about	   the	   exact	   composition	   of	   lipid	   droplets	   and	   this,	   therefore,	   deserves	   further	  
attention.	  	  
Interestingly,	   in	   a	   human	   study	   in	   which	   no	   differences	   were	   found	   regarding	   the	  
protein	   expression	   of	   TAG	   synthesis	   or	   lipolysis-­‐related	   proteins,	   protein	   abundance	   of	  
PLIN3	   was	   lower	   in	   muscle	   of	   obese	   versus	   lean	   controls	   when	   expressed	   relative	   to	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intramyocellular	  TAG	  content	  [101].	  Moreover,	  PLIN2	  gene	  expression	  levels	  were	  lower	  in	  
insulin	  resistant	  obese	  subjects	  versus	  BMI-­‐matched	  insulin	  sensitive	  controls,	  with	  PLIN2	  
levels	   correlating	  positively	  with	   the	   rate	  of	  glucose	  disposal	   [45].	  Additionally,	  although	  
no	   differences	  were	   found	   in	   PLIN2	   protein	   expression	   in	   diabetic	   versus	   obese	   control	  
subjects,	   both	   weight	   loss	   and	   insulin-­‐sensitizing	   drugs	   (troglitazone	   or	   metformin)	  
resulted	  in	  increased	  protein	  expression	  of	  PLIN2	  [134].	  In	  a	  study	  performed	  in	  our	  group,	  
we	  found	  no	  differences	  in	  skeletal	  muscle	  PLIN2	  protein	  content	  when	  comparing	  type	  2	  
diabetes	   patients	   with	   BMI-­‐matched	   controls,	   two	   groups	   with	   similar	   IMCL	   levels.	   The	  
same	   was	   true	   for	   PLIN5.	   However,	   an	   8	   week	   treatment	   with	   the	   PPARγ	   agonist	  
rosiglitazone	  decreased	  PLIN2	  and	  PLIN5	  expression	  without	  changes	  in	  IMCL	  [133],	  which	  
might	  be	  explained	  by	  a	  starting	  shift	  towards	  less	  ectopic	  fat	  accumulation	  and	  does	  not	  
rule	  out	   a	  potential	   beneficial	   effect	  of	  perilipins.	  A	  16h	   lipid	   infusion	  after	   a	  90	  minute	  
exercise	   session	   did	   not	   affect	   expression	   of	   perilipins	   2-­‐5	   in	   skeletal	   muscle	   of	   lean	  
women,	  while	  IMCL	  was	  increased	  with	  30%	  [105],	  indicating	  that	  short-­‐term	  elevation	  of	  
IMCL	   storage	   is	   not	   necessarily	   accompanied	   by	   increased	   perilipin	   protein	   expression.	  
Information	   on	   the	   adaptations	   of	   PLIN	   activities	   upon	   long	   term	   increased	   fatty	   acid	  
availability	  in	  humans	  is	  lacking.	  
We	  and	  others	  [142,	  143]	  have	  recently	  shown	  that	  next	  to	  its	  presence	  in	  the	  lipid	  
droplet	  coat,	  PLIN5	  is	  present	  at	  the	  interface	  of	  LDs	  with	  mitochondria,	  as	  well	  as	  in	  the	  
mitochondria.	   Furthermore,	   PLIN5	   induces	   interactions	   of	   lipid	   droplets	   with	  
mitochondria.	   Besides,	   PLIN5	   regulates	   lipolysis	   by	   inhibiting	   ATGL	   activity	   under	   basal	  
conditions	   and	   stimulating	   lipolysis	   upon	   PKA	   stimulation	   [119-­‐121].	   Therefore,	   PLIN5	  
potentially	   is	   a	   very	   important	   regulator	   of	   oxidative	   metabolism	   in	   muscle	   matching	  
intracellular	   lipid	   load	   with	   downstream	   mitochondrial	   metabolism.	   Its	   exact	   role	   in	  
mitochondria	  and	  lipid	  droplet	  dynamics	  requires	  further	  study.	  
Reports	   describing	   phenotypes	   of	   animal	  models	   of	   overexpression,	   knockdown	   or	  
inhibition	   of	   perilipins	   are	   limited.	   PLIN2	   knockout	   or	   inhibition	   showed	   contradictory	  
results	   with	   respect	   to	   whole	   body	   or	   liver	   insulin	   sensitivity	   [140,	   144-­‐146].	   That	   is,	  
lowering	   of	   PLIN2	   activity	  was	   demonstrated	   to	   improve	   liver	   insulin	   sensitivity	   in	  mice	  
models	   of	   PLIN2	   inhibition	   [145,	   146],	   while	   siRNA-­‐mediated	   knockdown	   of	   PLIN2	   plus	  
PLIN3	   in	   liver	  cells	   impaired	   insulin	  sensitivity	   [140].	   It	  should	  be	  noted	  that	   in	  the	   latter	  
study,	  PLIN2	  knockdown	  coincided	  with	  compensatory	  increased	  PLIN3	  expression	  at	  the	  
LD	  surface.	  Therefore,	  effects	  of	  knockdown	  of	  both	  PLIN3	  and	  PLIN2	  on	  insulin	  signaling	  
was	   investigated	   [140].	   In	   the	   first	   two	   studies	   [145,	   146],	   potential	   compensation	   by	  
other	  PLIN	  members	  at	  the	  LD	  surface	  in	  combination	  with	  lower	  intracellular	  lipid	  storage	  
might	   have	   resulted	   in	   the	   beneficial	   effects	   of	   PLIN2	   knockdown.	   PLIN2	   knockouts	  
crossed	   with	   ob/ob	   mice	   showed	   improved	   insulin	   sensitivity	   in	   both	   liver	   and	   muscle	  
compared	   with	   ob/ob-­‐PLIN2+/+	   mice	   [144].	   We	   recently	   overexpressed	   PLIN2	   in	   tibialis	  
anterior	  of	  rats	  by	  means	  of	  gene-­‐electrotransfer.	  This	  intervention	  appeared	  to	  improve	  
skeletal	   muscle	   insulin	   sensitivity	   despite	   increased	   intramyocellular	   lipid	   storage	  
(unpublished	  data).	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Thus,	   based	   on	   present	   knowledge	   we	   cannot	   conclude	   whether	   perilipins	   might	  
have	   the	   potential	   to	   protect	   against	   lipid-­‐induced	   insulin	   resistance.	   Moreover,	  
expression	  levels	  of	  perilipins	  might	  reflect	  adaptations	  in	  the	  cellular	  adaptation	  towards	  
increased	  or	   decreased	   lipid	   load,	   thus	   following	   the	  pattern	  of	  myocellular	   fat	   storage.	  
Nevertheless,	  based	  on	   the	   information	   from	  transgenic	  animal	  models	  and	  cell	   studies,	  
genetic	  variation	  in	  LD-­‐coat	  proteins	  (single	  nucleotide	  polymorphisms),	  as	  was	  described	  
for	  PLIN1	  in	  human	  DNA	  [147-­‐149]	  and	  PLIN2	  in	  pig	  DNA	  [150],	  might	  be	  one	  of	  the	  factors	  
determining	   genetic	   predisposition	   for	   development	   of	   obesity	   and	   type	   2	   diabetes.	  
However,	   further	   human	   genetic	   characterization	   studies	   and	   gain-­‐	   and	   loss	   of	   function	  
animal	   and	   cell	   models	   are	   warranted	   to	   further	   characterize	   the	   role	   of	   PLIN	  
polymorphisms	  in	  (ectopic)	  fat	  storage	  and	  lipid-­‐induced	  insulin	  resistance.	  	  
	  
Lipid	  droplet	  dynamics;	  future	  perspectives	  
Lipid	  droplet	  coat	  proteins	  other	  than	  the	  perilipins	  
Other	  LD-­‐coat	  proteins	  shown	  to	  be	  present	  in	  muscle	  include	  members	  of	  the	  CIDE	  (cell	  
death-­‐inducing	  DFF45-­‐like	  effector)	  family,	  in	  particular	  Cidec/FSP27	  [151-­‐153],	  FIT1	  and	  -­‐
2	  [154,	  155],	  and	  SNARE	  proteins	  [156-­‐159],	  but	  not	  a	   lot	   is	  known	  about	  their	   function.	  
Interestingly,	  while	  total	  SNAP-­‐23	  protein	  levels	  were	  increased	  in	  T2D	  patients	  [160,	  161],	  
the	   amount	   of	   SNAP-­‐23	   in	   skeletal	   muscle	   plasma	   membranes	   was	   lower	   in	   type	   2	  
diabetes	  patients	  compared	  to	  controls	  and	  the	  amount	  of	  membrane	  SNAP-­‐23	  correlated	  
with	  systemic	   insulin	  sensitivity	   [160,	  161].	  Exocytosis	  of	  GLUT4	  vesicles	  with	  the	  plasma	  
membrane	  of	  insulin	  sensitive	  tissues	  as	  well	  as	  LD	  fusion	  are	  SNARE-­‐mediated	  processes	  
and	  high-­‐jacking	  of	   SNAP-­‐23	  by	   LDs	  has	  been	   suggested	   to	   limit	   SNAP-­‐23	  availability	   for	  
GLUT4	  translocation	  [160,	  162,	  163]	  but	  is	  beyond	  the	  scope	  of	  this	  review.	  Moreover,	  this	  
list	   of	   muscular	   LD	   coat	   proteins	   is	   expected	   to	   expand	   because	   this	   field	   is	   still	   in	   its	  
infancy.	  	  
	  
Lipid	  droplet	  size	  	  
LD	  size	  might	  be	  a	  parameter	  influencing	  IMCL-­‐storage	  induced	  lipotoxicity.	  An	  increased	  
surface	   to	   volume	   ratio,	   i.e.	   smaller	   lipid	   droplets,	   would	   result	   in	   a	   greater	   LD	   coating	  
area,	   potentially	   resulting	   in	   an	   increased	   capacity	   to	   mobilize	   lipids,	   which	   might	   be	  
beneficial.	  However,	  this	  would	  also	  result	  in	  an	  increased	  binding	  surface	  area	  for	  lipases,	  
perhaps	   resulting	   in	   increased	   lipid	   intermediates.	   Not	   a	   lot	   is	   known	   about	   the	  
importance	  of	   lipid	  droplet	   size	   regarding	   lipotoxic	  potential.	  A	  weight	   loss	  and	  exercise	  
program	  resulted	  in	  decreased	  LD	  size	  as	  determined	  by	  confocal	  microscopy	  paralleled	  by	  
changes	  in	  insulin	  sensitivity	  [164].	  Furthermore,	  rosiglitazone	  improved	  insulin	  sensitivity	  
in	  parallel	  with	  smaller	  LDs	  [165],	  and	  large	  LDs	  were	  demonstrated	  to	  be	  associated	  with	  
the	   development	   of	   diabetes	   in	   a	   study	   in	  which	   LD	   size	  was	   determined	  with	   electron	  
microscopy	  (EM)	  [166].	  On	  the	  other	  hand,	  no	  differences	  in	  LD	  size	  were	  observed	  after	  a	  
seven	  week	  endurance	  training	  period	  in	  lean	  untrained	  men	  and	  women	  using	  EM	  [167].	  
Furthermore,	   in	   the	   study	   of	   Van	   Loon	   et	   al.	   [18]	   no	   differences	   in	   LD	   size	  were	   found	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when	   comparing	   trained,	   obese	   sedentary	   and	   obese	   diabetics	   nor	   in	   another	   study	  
comparing	  obese	  subjects	  with	  lean	  controls	  [168].	  A	  limitation	  of	  these	  two	  studies	  is	  the	  
use	   of	   standard	   immunofluorescent	   microscopy,	   which	   is	   –	   in	   contrast	   to	   confocal	  
microscopy	   –	   suboptimal	   to	   determine	   true	   LD	   size	   as	   the	   2-­‐	   dimensional	   section	   plane	  
does	   not	   necessarily	   reflect	   the	  middle,	   largest	   diameter	   of	   all	   LDs.	   Basically,	   the	   same	  
limitation	   holds	   true	   for	   EM	   determinations	   of	   LD	   size.	   Further	   research	   is	   needed	   to	  
identify	  whether	  LD	  size	  is	  an	  important	  parameter	  in	  lipid-­‐induced	  insulin	  resistance.	  
	  
Intracellular	  localization	  and	  organelle	  interactions	  
Intramyocellular	  LDs	  are	  mainly	  localized	  in	  between	  the	  myofibers,	  in	  close	  contact	  with	  
mitochondria	   (Fig.	   2)	   and	   are	   less	   prominently	   present	   in	   the	   subsarcolemmal	   region.	  
Malenfant	   et	   al.	   described	   a	   more	   central	   localization	   of	   LDs	   (i.e.	   less	   LDs	   in	   the	  
subsarcolemmal	   region	   compared	  with	   the	  peripheral	   areas)	   in	  myofibers	  of	  NGT	  obese	  
subjects	   compared	   to	   lean	   individuals	   [168].	   Yet,	   in	   a	   study	   of	   Nielsen	   et	   al.,	   it	   was	  
concluded	   that	   subsarcolemmal	   LDs	   storage	   was	   increased	   in	   type	   2	   diabetics	   when	  
compared	   to	   BMI-­‐matched	   controls,	   using	   the	  more	   accurate	  method	   of	   ultrastructural	  
determinations	   with	   electron	  microscopy	   [169].	   Thus,	   LDs	   storage	  might	   shift	   from	   the	  
interior	  towards	  the	  subsarcolemma	  during	  the	  transition	  from	  obesity	  towards	  overt	  type	  
2	  diabetes.	  However,	  data	   is	   limited	  to	   firmly	  conclude	  on	  the	   importance	  of	  subcellular	  
LD	  localization	  in	  the	  development	  of	  insulin	  resistance.	  
	  
	  
Figure	   2.	   Transmission	   electron	   microscopy	   image	   of	   rat	   tibialis	   anterior	   muscle	   showing	  
intermyofibrillar	  lipid	  droplets	  and	  adjacent	  mitochondria.	  	  
	  
Re-­‐evaluating	  lipotoxic	  triggers	  in	  skeletal	  muscle	  	  
	  38	  
The	  effects	  of	   subcellular	   localization	  of	   LDs	  on	   insulin	   sensitivity	  might	  be	  mediated	  by	  
interactions	   of	   LDs	   with	   other	   subcellular	   compartments	   like	   mitochondria,	   the	   plasma	  
membrane,	  and	   the	   sarcoplasmic	   reticulum	   (SR,	   the	  muscle-­‐specific	   type	  of	   smooth	  ER).	  
An	  oversupply	  of	  lipids	  to	  organelles	  might	  impair	  organelle	  function.	  On	  the	  other	  hand,	  it	  
could	  be	   reasoned	   that	  a	  close	  apposition	   to	  SR	  or	  mitochondria	  might	  be	  beneficial	   for	  
lipid	  handling.	  Complexes	  of	  SR,	  mitochondria	  and	  LDs	  might	  be	  the	  intracellular	  interface	  
for	  lipid	  metabolism.	  The	  tubular	  invaginations	  of	  the	  sarcolemma	  ensure	  that	  the	  SR	  is	  in	  
direct	  contact	  with	  the	  extracellular	  space	  of	  the	  muscle.	  These	  tubular	  invaginations	  are	  
found	   on	   both	   sides	   of	   the	   z-­‐line.	   Intermyofibrillar	   lipid	   droplets	   and	  mitochondria	   are	  
usually	  found	  near	  these	  z-­‐lines.	  The	  close	  apposition	  of	  LDs	  and	  mitochondria	  was	  already	  
demonstrated	   in	   the	   early	   seventies	   by	   Hoppeler	   and	   colleagues	   [170].	   They	   suggested	  
that	  the	  contact	  surface	  area	  of	  LDs	  was	  the	  transfer	  site	  for	  fatty	  acids	  towards	  oxidative	  
metabolism	  and	  that	  a	  larger	  contact	  surface	  area	  would	  be	  beneficial	  for	  the	  efficiency	  of	  
lipid	  oxidative	  metabolism	  [171,	  172].	  Tarnapolsky	  et	  al.	  showed	  that	  a	  7-­‐week	  endurance-­‐
training	  period	   in	   lean	  untrained	  men	  and	  women	  significantly	   increased	   the	  number	  of	  
LDs	  in	  contact	  with	  mitochondria	  [167].	  One	  could	  hypothesize	  that	  lipid	  droplets	  that	  are	  
interacting	  with	  mitochondria	  are	  metabolically	  active	  LDs	  with	  a	  well-­‐regulated	  rate	  and	  
timing	   of	   lipolysis	   matched	   with	   downstream	   metabolism.	   That	   is,	   a	   close	   interaction	  
between	   LDs	   and	   mitochondria	   ensures	   efficient	   utilization	   of	   lipolysis-­‐derived	   FAs	   in	  
situations	   of	   increased	   energy	   demand,	   thereby	   preventing	   high	   intracellular	   FA	   levels.	  
Thus,	   interactions	   of	   LDs	   with	   SR	   and	   mitochondria	   might	   ensure	   controlled	   lipid	  
metabolism	   and	   loss	   of	   interactions	   or	   a	   higher	   ratio	   of	   LDs	   to	   mitochondria	   might	  
potentially	   be	   one	   of	   the	   intermediate	   steps	   in	   the	   development	   of	   lipotoxicity-­‐induced	  
insulin	   resistance.	   Moreover,	   proteins	   present	   on	   the	   mitochondrial	   outermembrane	  
and/or	  in	  the	  LD	  coat	  are	  presumably	  needed	  for	  interorganelle	  interactions.	  However,	  so	  
far	   no	   evidence	   is	   available	   for	   a	   role	   of	   LD-­‐mitochondria	   interactions	   in	   determining	  
insulin	  sensitivity	  of	  skeletal	  muscle	  and	  clearly	  further	  research	  in	  this	  area	  is	  warranted	  
to	  unravel	  the	  dynamics	  of	  interorganelle	  interactions.	  
	  
CONCLUSIONS	  AND	  PERSPECTIVES	  
The	   importance	   of	   intramyocellular	   lipid	   accumulation	   in	   the	   development	   of	   type	   2	  
diabetes	  is	  firmly	  established	  and	  can	  be	  attributed	  to	  a	  disbalance	  in	  skeletal	  muscle	  lipid	  
influx,	  lipid	  metabolism,	  and	  oxidative	  capacity.	  The	  mechanisms	  involved	  in	  lipid-­‐induced	  
insulin	   resistance,	   however,	   are	   still	   not	   fully	   unraveled.	   In	   animal	   and	   cell	   studies,	   lipid	  
intermediates	  like	  DAG,	  ceramides,	  LC-­‐FA-­‐CoA	  and	  acylcarnitines	  all	  have	  the	  potential	  to	  
induce	   insulin	   resistance.	   However,	   human	   studies	   show	   conflicting	   results,	   and	   are	   if	  
anything	   not	   pointing	   towards	   one	   mechanism	   that	   can	   be	   held	   responsible	   for	   the	  
muscular	  insulin	  resistance	  in	  type	  2	  diabetes.	  Rather,	  the	  strong	  interindividual	  variation	  
and	  the	  inconsistencies	  in	  the	  broad	  array	  of	  studies	  performed	  so	  far	  indicate	  that	  there	  
are	  several	  routes	  towards	  lipid-­‐induced	  insulin	  resistance.	  Furthermore,	  it	  should	  not	  be	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ignored	   that	   the	  available	  data	  are	  merely	  correlative,	  describe	  snap	  shots	  and	   focus	  on	  
one	  or	  a	  few	  parameters,	  while	  lipid	  metabolism	  is	  a	  highly	  complex	  and	  dynamic	  process.	  
Based	  on	  available	  evidence,	  we	  conclude	  that	  total	   levels	  of	  DAG,	  ceramides	  and	  LC-­‐FA-­‐
CoA	  are	  not	  appropriate	  predictors	  of	  obesity-­‐associated	  insulin	  resistance.	  	  
Nevertheless,	  given	  the	   fact	   that	   these	   lipid	  species	  have	  the	  potential	  of	   impairing	  
insulin	  signaling,	   it	  appears	  that	  the	  consequences	  of	   its	  accumulation	   in	  human	  skeletal	  
muscle	   are	   multifactorial	   and	   dependent	   on	   specific	   characteristics,	   the	   latter	   might	  
include	   the	   degree	   of	   saturation,	   chain	   length,	   stereo	   specificity	   and	   intracellular	  
localization.	  Recently,	  research	  in	  this	  field	  has	  shifted	  towards	  the	  packaging	  of	  lipids	  into	  
lipid	   droplets	   and	   the	   related	   lipid	   droplet	   dynamics.	   The	   heterogeneity	   and	   dynamic	  
nature	   of	   lipid	   droplets	   indicate	   that	   lipid	   droplet	   characteristics	   and	   expression	   of	   lipid	  
droplet-­‐coat	   proteins	   are	   determinants	   of	   intramyocellular	   lipotoxicity.	   Information	   on	  
this	  issue	  is	  still	  limited	  albeit	  promising,	  and	  definitely	  deserves	  further	  attention	  for	  our	  
understanding	  of	  obesity-­‐related	  diabetes	  and	  might	  provide	  targets	  for	  prevention.	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ABSTRACT	  
Obesity	   is	  associated	  with	  skeletal	  muscle	   insulin	  resistance,	  attributed	  to	   increased	   lipid	  
supply	  to	  the	  muscle.	  However,	  high	  intramyocellular	  lipid	  (IMCL)	  levels	  do	  not	  necessarily	  
result	  in	  impaired	  insulin	  signaling.	  Lipid	  droplet	  coat	  proteins	  modulate	  IMCL	  metabolism.	  
Here	  we	  aimed	  to	  investigate	  the	  relation	  between	  intramyocellular	  lipid	  droplet	  storage	  
capacity	  and	  lipid-­‐induced	  insulin	  resistance,	  and	  the	  role	  of	  skeletal	  muscle	  PLIN2,	  PLIN3,	  
PLIN5,	  ATGL	  and	  CGI-­‐58	  herein.	  Two	  human	  models	  of	  increased	  lipid	  supply	  were	  utilized;	  
a	   prolonged	   (60h)	   fast	   and	   consumption	   of	   a	   high	   fat	   diet	   for	   three	   weeks.	  
Intramyocellular	   lipid	   (IMCL)	   storage	   was	   assessed	   using	   Oil-­‐red-­‐O-­‐stainings.	   Insulin	  
sensitivity	  was	  determined	  with	  hyperinsulinemic-­‐euglycemic	  clamps.	  PLIN2,	  PLIN3,	  PLIN5,	  
ATGL	  and	  CGI-­‐58	  expression	  was	  investigated	  by	  qPCR	  and	  Western	  blotting.	  
PLIN3	  gene	  expression	  was	  downregulated	  after	  fasting	  (28%	  decrease,	  P=0.003),	  but	  this	  
did	  not	  result	  in	  decreased	  PLIN3	  protein	  content.	  Gene	  and	  protein	  expression	  of	  PLIN2,	  
PLIN5,	   ATGL	   and	   CGI-­‐58	   were	   not	   significantly	   different	   in	   the	   fasted	   versus	   the	   fed	  
condition.	  Interestingly,	  a	  larger	  increase	  in	  IMCL	  storage	  upon	  fasting	  was	  associated	  with	  
a	   lower	   reduction	   in	   insulin	   sensitivity	   (r=	   0.657,	   P=0.039).	  Moreover,	   PLIN2	   expression	  
correlated	  positively	  with	  changes	  in	  IMCL	  storage	  (r=0.732,	  P=0.01).	  In	  the	  second	  study,	  
a	   high	   fat	   diet	   resulted	   in	   increased	   IMCL	   but	   did	   not	   affect	   insulin	   sensitivity.	   PLIN5	  
protein	   levels	   showed	   a	   tendency	   for	   upregulation	   after	   the	   HFD	   intervention	   and	  
correlated	  negatively	  with	  insulin	  sensitivity.	  	  
In	   conclusion,	   in	   contrast	   to	   mouse	   studies,	   PLIN	   expression	   is	   not	   induced	   upon	  
prolonged	   fasting	   in	   human	   skeletal	   muscle.	   Subjects	   with	   a	   larger	   capacity	   to	   store	  
intramyocellular	  lipids	  in	  lipid	  droplets	  become	  less	  insulin	  resistant	  after	  a	  prolonged	  fast.	  
Contrastingly,	   this	   phenomenon	   was	   not	   apparent	   in	   the	   HFD	   intervention,	   indicating	  
differential	   effects	   of	   IMCL	   storage	   capacity	   upon	   short	   and	   long-­‐term	   increases	   in	   lipid	  
availability.	   The	   data	   suggest	   that	   under	   acute	   conditions	   of	   high	   lipid	   availability	   an	  
increased	  capacity	  to	  store	  IMCL	  protects	  against	  insulin	  resistance,	  and	  that	  PLIN2	  may	  be	  
an	  important	  determinant	  herein.	  
Chapter	  3	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INTRODUCTION	  
Obesity	   is	   associated	  with	   increased	   lipid	   supply	   to	   skeletal	  muscle	   [1].	   Intramyocellular	  
lipids	  (IMCL)	  are	  stored	   in	   lipid	  droplets	  (LDs),	  which	  are	  highly	  dynamic	  and	  consist	  of	  a	  
neutral	  lipid	  core	  enclosed	  by	  a	  phospholipid	  monolayer	  [2].	  This	  phospholipid	  monolayer	  
is	  decorated	  with	  a	  variety	  of	  different	  LD	  coat	  proteins,	  which	  modulate	  LD	  dynamics	  and	  
lipid	  metabolism	  (reviewed	  in	  [3-­‐5]).	  Two	  major	  proteins	  involved	  in	  regulating	  LD	  lipolysis	  
shuttle	  between	  the	  cytosol	  and	  the	  LD,	  namely	  ATGL	  (PNPLA2)	  and	  CGI-­‐58	  (ABHD5).	  ATGL	  
catalyzes	   the	   initial	   step	   in	   TAG	   hydrolysis	   and	   is	   a	   rate-­‐limiting	   enzyme	   in	   lipolysis	   [6].	  
Besides	  coactivation	  by	  CGI58	  [7]	  and	  repression	  by	  G0S2	  [8],	  ATGL	  activity	  is	  modulated	  
by	  various	   LD	   coat	  proteins,	   including	   those	  of	   the	  perilipin	   (PLIN)	  protein	   family	   [9-­‐14].	  
PLIN2	  (ADRP,	  adipophilin),	  PLIN3	  (TIP47),	  and	  PLIN5	  (OXPAT,	  MLDP,	  LSDP5)	  appear	  to	  be	  
the	   most	   prominent	   perilipins	   in	   skeletal	   muscle	   [15-­‐18].	   PLIN2	   is	   involved	   in	   both	   LD	  
synthesis	  and	   inhibition	  of	   LD	   lipolysis	   [13,	  19],	  PLIN3	   functions	   in	   the	  biogenesis	  of	   LDs	  
[20].	  PLIN5	  localizes	  to	  both	  LDs	  and	  mitochondria,	  modulates	  lipolysis	  by	  interacting	  with	  
ATGL	  and	  CGI-­‐58	  [10,	  11,	  14],	  and	  is	  considered	  to	  be	  involved	  in	  interactions	  of	  LDs	  with	  
mitochondria	  [15,	  21].	  	  
Increased	  IMCL	  content	  is	  associated	  with	  the	  development	  of	  insulin	  resistance	  [22,	  
23].	  However,	  increased	  IMCL	  levels	  do	  not	  necessarily	  result	  in	  impaired	  insulin	  signaling	  
(reviewed	   in	   [24]),	   indicating	   that	   not	   IMCL	  per	   se,	   but	   its	   characteristics	   and	   dynamics	  
determine	  lipid-­‐induced	  insulin	  resistance.	  In	  this	  context,	  one	  exercise	  session	  was	  shown	  
to	  prevent	  lipid-­‐induced	  insulin	  resistance	  by	  partitioning	  more	  fatty	  acids	  (FAs)	  into	  LD	  as	  
triacylglycerol	   (TAG)	   in	   human	   skeletal	   muscle	   [25].	   Furthermore,	   animal	   studies	   have	  
demonstrated	  that	  increased	  partitioning	  of	  lipids	  towards	  TAG	  storage	  by	  overexpression	  
of	  diacylglycerol	  acyltransferase	  (DGAT)	  protected	  against	   lipid-­‐induced	  insulin	  resistance	  
[26,	   27].	   Therefore	   we	   propose	   that	   interindividual	   variation	   in	   intramyocellular	   TAG	  
storage	   capacity	   –	   and	   the	   above-­‐mentioned	   proteins	   involved	   in	   this	   process	   –	   are	  
determinants	   of	   susceptibility	   to	   lipid-­‐induced	   insulin	   resistance.	   In	   line	   with	   our	  
hypothesis,	   animal	  models	   showed	   that	   feeding	   status	   and	   high	   fat	   intake	   affected	   the	  
expression	   levels	   of	   LD	   coat	   proteins	   in	   skeletal	   muscle.	   Skeletal	   muscle	   ATGL	   protein	  
content	   was	   increased	   upon	   fasting	   [28,	   29].	   Furthermore,	   both	   PLIN2	   and	   PLIN5	   are	  
upregulated	   upon	   fasting	   and	   high	   fat	   feeding	   in	   animal	   models	   [30-­‐34].	   In	   humans,	  
skeletal	  muscle	  ATGL	  protein	  expression	  was	  similar	   in	  obese	  compared	  to	  lean	  subjects,	  
but	  higher	   in	   type	  2	  diabetic	   subjects	   [35-­‐37].	  However,	   so	   far	   little	   is	   known	  about	   the	  
expression	  of	   lipolytic	  enzymes	  and	  perilipins	   in	  human	  skeletal	  muscle	  under	  conditions	  
with	   elevated	   skeletal	  muscle	   lipid	   supply	   and	   their	   role	   in	   human	   skeletal	  muscle	   lipid	  
metabolism.	  	  
Here	  we	  investigated	  the	  expression	  of	  ATGL,	  CGI-­‐58	  and	  PLINs	  2,	  3	  and	  5	  in	  human	  
skeletal	  muscle	  under	  conditions	  of	  acute	  and	  chronic	  elevation	  of	  fatty	  acid	  supply	  to	  the	  
muscle;	   fasting	   for	   60h	   and	   consumption	   of	   a	   high	   fat	   diet	   for	   three	   weeks.	   We	  
hypothesized	  that	  IMCL	  storage	  capacity	  and	  LD	  coat	  protein	  expression	  are	  determinants	  
of	  susceptibility	  to	  lipid-­‐induced	  insulin	  resistance.	  




Twelve	  young,	  healthy	   lean	  subjects	  without	  a	   family	  history	  of	  diabetes	  mellitus	  or	  any	  
other	   endocrine	  disorder	  were	   fasted	  or	   fed	   in	   energy	  balance	   for	   60h	   in	   a	   randomized	  
crossover	   design	   with	   a	   2-­‐week	   washout	   period	   in	   between.	   In	   the	   fasted	   condition,	  
subjects	  were	   fasted	   for	  60h	   (calorie-­‐free	  drinks	  only),	  whereas	   in	   the	  second	  condition,	  
subjects	   were	   fed	   in	   energy	   balance	   (50–35–15%	   of	   energy	   as	   carbohydrates,	   fat,	   and	  
protein,	   respectively).	   Before	   the	   start	   of	   each	   experimental	   period,	   a	   standardized	  
evening	  meal	  was	  provided.	  Subject	  stayed	  in	  a	  respiration	  chamber	  during	  the	  entire	  60h	  
to	   ensure	   compliance	   to	   the	   dietary	   regime	   and	   to	   allow	   the	   measurement	   of	   24h	  
substrate	   oxidation	   and	   energy	   expenditure	   [38].	   In	   the	   respiration	   chamber,	   subjects	  
followed	   an	   activity	   protocol	   as	   previously	   described	   [39].	   After	   leaving	   the	   respiration	  
chamber	   on	   the	   morning	   of	   the	   third	   day,	   a	   muscle	   biopsy	   was	   taken	   and	   a	  
hyperinsulinemic-­‐euglycemic	   clamp	   procedure	   was	   performed	   as	   described	   [38].	   A	  
detailed	   protocol	  was	   described	   previously	   [38].	   Subject	   characteristics	   can	   be	   found	   in	  
Supplemental	  Table	  1.	  None	  of	  the	  subjects	  was	  engaged	  in	  sports	  activities	  for	  more	  than	  
2h	  per	  week.	  The	  insulin	  sensitivity	  (Si	  index)	  was	  calculated	  by	  correcting	  the	  glucose	  rate	  
of	  disappearance	  (Rd)	  for	  the	  glucose	  and	  insulin	  values	  during	  the	  clamp.	  	  
	  
High	  fat	  diet	  intervention	  study	  	  
Ten	   sedentary,	   healthy	   overweight	   men	   participated	   (Supplemental	   Table	   2).	   Subjects	  
with	  a	  body	  weight	  gain	  or	  loss	  of	  more	  than	  3	  kg	  in	  past	  3	  months	  or	  more	  than	  20	  gram	  
alcohol	   intake	  per	  day	  were	  excluded.	  The	  subjects	  consumed	  a	   low-­‐fat	  run-­‐in	  diet	   for	  3	  
wk,	  after	  which	  baseline	  measurements	  were	  made	  (day	  21).	  Subsequently,	  to	  investigate	  
the	  effects	  of	   switching	   from	  a	   low-­‐	   to	  a	  high-­‐fat	  diet,	   subjects	   consumed	  a	  high-­‐fat	   for	  
three	  weeks,	  after	  which	  measurements	  were	  repeated	  (day	  42).	  A	  detailed	  protocol	  has	  
been	   described	   previously	   [40].	   Before	   and	   after	   the	   diet-­‐intervention,	   a	  muscle	   biopsy	  
was	   taken	   and	   subjects	   underwent	   a	   hyperinsulinemic-­‐euglycemic	   clamp	   as	   described	  
[40].	  The	  Si	   index	  was	  calculated	  by	  correcting	  the	  glucose	  rate	  of	  disappearance	  (Rd)	  for	  
the	  glucose	  and	  insulin	  values	  during	  the	  clamp.	  
Both	  study	  protocols	  were	  reviewed	  and	  approved	  by	  the	  Medical	  Ethical	  Committee	  
of	  Maastricht	  University	  Medical	   Centre	   and	   all	   subjects	   gave	  written	   informed	   consent	  
before	   participating	   in	   the	   study.	   Both	   studies	   have	   been	   registered	   at	  
www.trialregister.nl;	   registration	   numbers	  NTR	   2042	   (fasting	   study)	   and	  NTR	   2136	   (high	  
fat/low	   fat	   diet	   intervention	   study).	   Detailed	   study	   protocols	   and	   primary	   clinical	  
outcomes	  were	  published	  previously	  [38,	  40].	  
	  
Muscle	  biopsy	  
A	   percutaneous	   needle	   muscle	   biopsy	   was	   taken	   from	   the	   m.	   vastus	   lateralis	   in	   both	  
studies,	  directly	  frozen	  in	  melting	  isopentane,	  and	  stored	  at	  −80	  C.	  Muscle	  biopsies	  were	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available	  in	  eight	  and	  nine	  subjects	  from	  the	  low-­‐	  and	  high-­‐fat	  groups,	  respectively.	  Fresh	  
cryosections	  (5	  μm)	  were	  stained	  for	  IMCL	  by	  Oil-­‐Red-­‐O	  as	  described	  before	  [41].	  
	  
Quantitative	  Real-­‐Time	  PCRs	  
Total	   RNA	   was	   isolated	   from	   ~30mg	   of	   skeletal	   muscle	   tissue	   using	   Trizol	   reagent	  
(Invitrogen,	  Breda,	  The	  Netherlands).	  The	  quantity	  and	  integrity	  of	  the	  RNA	  was	  confirmed	  
with	   the	   Nanodrop	   Spectrophotometer	   (NanoDrop	   Technologies,	   Inc,	   Wilmington,	   DE,	  
USA).	  cDNA	  was	  synthesized	  using	   the	  high	  capacity	  RNA-­‐to-­‐cDNA	  kit	   (Life	  Technologies,	  
Bleiswijk,	   the	   Netherlands).	   Real	   Time	   qRT-­‐PCR	   reactions	   were	   performed	   using	   the	  
Taqman	  universal	  PCR	  master	  mix	  on	  a	  ABI	  PRISM	  7900	  (Applied	  Biosystems,	  Nieuwerkerk	  
aan	  den	   lJssel,	  Netherlands)	  using	  the	  following	  protocol:	  2	  min	  at	  50˚C,	  10	  min	  at	  95˚C,	  
followed	  by	  40	  cycli	  at	  95˚C	  of	  15	  sec	  and	  60˚C	  for	  1	  min.	  For	  all	  genes	  except	  for	  RPLP0,	  
Taqman	  probes	  were	  included	  to	  ensure	  specificity.	  RPLP0	  mRNA	  expression	  was	  detected	  
using	   SYBR	   green	   (Bio-­‐Rad,	   Veenendaal,	   The	  Netherlands).	  RPLP0,	  which	  was	   tested	   for	  
intra-­‐individual	   variability,	   was	   used	   as	   internal	   control.	   All	   expression	   data	   were	  
normalized	   by	   using	   the	   delta-­‐Ct	   method	   to	   normalize	   the	   relative	   abundance	   of	   the	  
target	  transcript	  against	  the	  internal	  reference.	  Primer-­‐	  and	  probesequences	  are	  given	  in	  
Supplemental	  Table	  3.	  
	  
Western	  blots	  
Western	   blots	   were	   performed	   in	   protein	   lysates	   from	   whole	   muscle	   homogenates.	  
Muscle	  samples	  were	  homogenized	  in	  RIPA	  lysis	  buffer	  containing	  1%	  NP40,	  0.5%	  SDS,	  and	  
phosphatase-­‐	  and	  protease	  inhibitors,	  lysates	  were	  mixed	  1:1	  with	  Laemmli	  sample	  buffer	  
and	   were	   further	   processed	   for	   standard	   SDS-­‐PAGE	   and	   Western	   blotting.	   Protein	  
concentration	  was	  determined	  and	  equal	  amounts	  of	  protein	  were	   loaded	  per	   lane.	  The	  
nitrocellulose	  membranes	   were	   incubated	  with	   antibodies	   against	   PLIN2	   (GP40;	   Progen	  
Biotechnik,	   Heidelberg,	   Germany),	   PLIN3	   (10694-­‐1-­‐AP;	   Acris	   Antibodies,	   Herford,	  
Germany),	   PLIN5	   (GP31;	   Progen	   Biotechnik,	   Heidelberg,	   Germany),	   ATGL	   (Cell	   Signalling	  
Technology,	   Bioké,	   Leiden,	   The	   Netherlands),	   CGI-­‐58	   (Novus	   Biologicals,	   Littleton,	  
Colorado,	   USA),	   and	   SR-­‐actin	   as	   the	   loading	   control	   (A-­‐2172;	   Sigma,	   St.	   Louis,	   USA).	  
Secondary	   antibodies	   for	   PLIN2,	   PLIN5,	   ATGL	   and	   SR-­‐actin	   contained	   a	   fluorescent	   tag	  
(IRDye800-­‐	   or	   IRDye700-­‐conjugated	   secondary	   antibodies	   (Rockland,	   Tebu-­‐bio,	  
Heerhugowaard,	   The	   Netherlands,	   and	   LICOR	   Biosciences,	   Westburg,	   Leusden,	   The	  
Netherlands)),	  Protein	  quantification	  was	  performed	  by	  scanning	  on	  an	  Odyssey	   Infrared	  
Imaging	   system	   (LI-­‐COR	   Biotechnology,	   Lincoln,	   Nebraska,	   USA).	   CGI-­‐58	   was	   detected	  
using	  an	  HRP-­‐conjugated	  antibody	  and	  ECL	  detection.	  Protein	   content	  was	  expressed	  as	  
arbitrary	  units	  (AU).	  
	  
Statistical	  analyses	  
Results	   are	   presented	   as	   mean	   ±	   SEM.	   Statistical	   analyses	   were	   performed	   using	   SPSS	  
version	   16.0	   for	   MacOS	   16.0	   (SPSS,	   Chicago,	   IL).	   Statistical	   comparisons	   between	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conditions	  and	  changes	  upon	  experimental	  interventions	  were	  performed	  using	  paired	  T-­‐
tests.	   Pearson’s	   correlation	   coefficients	   were	   used	   to	   describe	   the	   linear	   association	  
between	  variables.	  P<0.05	  was	  considered	  statistically	  significant.	  
	  
RESULTS	  
Effects	  of	  prolonged	  fasting	  on	  the	  expression	  of	  perilipins	  and	  lipolytic	  enzymes	  
We	   have	   published	   before	   that	   the	   prolonged	   fasting	   resulted	   in	   a	   2.7-­‐fold	   increase	   in	  
IMCL	   content	   and	   a	   45%	   reduction	   in	   the	   insulin	   sensitivity	   (Si)	   index	   [38].	   We	   here	  
measured	  gene	  and	  protein	  expression	  of	  PLIN2,	  PLIN3,	  PLIN5,	  ATGL	  and	  CGI-­‐58	  in	  human	  
skeletal	  muscle	  after	  the	  60	  hours	  fasting	  regimen.	  PLIN3	  gene	  expression	  was	  significantly	  
downregulated	  after	   fasting	  (P=0.003,	  28%	  decrease)	   (Fig.	  1B).	  Gene	  expression	   levels	  of	  
PLIN2	   (P=0.69),	   PLIN5	   (P=0.72),	  ATGL	   (P=0.15)	   and	   CGI-­‐58	   (P=0.73)	   did	   not	   significantly	  
change	  (Fig.	  1).	  Protein	  contents	  of	  PLIN2	  (P=0.92),	  PLIN3	  (P=0.95),	  PLIN5	  (P=0.99),	  ATGL	  
(=0.84)	  and	  CGI-­‐58	  (P=0.20)	  were	  unaltered	  after	  fasting	  (Fig.	  2).	  
	  
	  
Figure	  1.	  Gene	  expression	  levels	  of	  PLIN2	  (A),	  PLIN3	  (B),	  PLIN5	  (C),	  ATGL	  (D)	  and	  CGI-­‐58	  (E)	  in	  the	  fed	  
and	  the	  fasted	  state.	  Mean	  ±	  SEM,	  *P<0.05.	  
	  
We	   next	   investigated	   whether	   interindividual	   variation	   in	   the	   increase	   in	   IMCL	   upon	  
fasting	  was	  associated	  with	  insulin	  resistance.	  Very	  interestingly,	  the	  change	  in	  IMCL	  upon	  
fasting	   correlated	   positively	  with	   the	   change	   in	   insulin	   sensitivity	   (IS)	   (r=0.657,	   P=0.039)	  
(Fig.	   3A),	   indicating	   that	   increased	   intramyocellular	   lipid	   storage	   capacity	   is	   associated	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resistance	  may	   function	   to	   spare	   glucose	   for	   utilization	   by	   the	   brain.	   Interestingly,	   both	  
the	  change	   in	   IMCL	  and	   the	  change	   in	   IS	  upon	   fasting	  correlated	  negatively	  with	  plasma	  
glucose	   levels	   after	   the	   fasting	   period	   (r=-­‐0.720,	   P=0.012	   and	   r=-­‐0.654,	   P=0.029,	  
respectively)	   (Fig.	   3B-­‐C),	   implicating	   that	   a	   higher	   capacity	   for	   IMCL	   storage	   and	   the	  
associated	   lower	   fasting-­‐induced	   insulin	   resistance	  may	   in	   fact	   lead	   to	  a	  marked	  drop	   in	  
plasma	  glucose	  levels	  upon	  fasting.	  
	  
	  
Figure	   2.	  Protein	   content	  
of	   PLIN2	   (A),	   PLIN3	   (B),	  
PLIN5	   (C),	   ATGL	   (D)	   and	  
CGI-­‐58	   (E)	   in	   the	   fed	   and	  
the	   fasted	   state.	   Error	  
bars	  represent	  SEM.	  
	  
To	  explore	  potential	  explanations	  for	  interindividual	  variation	  in	  IMCL	  storage	  capacity	  and	  
the	  protection	   against	   fasting-­‐induced	   insulin	   resistance,	  we	   investigated	   correlations	  of	  
the	   protein	   content	   of	   PLIN2,	   PLIN5,	   ATGL	   and	   CGI-­‐58	   with	   IMCL	   content	   and	   IS.	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positive	  correlation	  with	  the	  change	  in	  IMCL	  (ΔIMCL)	  upon	  fasting	  (Table	  1)	  and	  the	  post-­‐
fasting	   IMCL	   level	   (r=0.564,	  P=0.071)	   (Table	  1	  and	  Fig.	  4A).	  Moreover,	   the	  PLIN2	  protein	  
content	   after	   fasting	   correlated	   positively	   with	   both	   the	   post-­‐fasting	   IMCL	   content	  
(r=0.732,	   P=0.01)	   (Table	   1)	   and	   the	   change	   in	   IMCL	   content	   upon	   fasting	   (r=0.628,	  
P=0.038)	  (Table	  1).	  There	  was	  a	  tendency	  (r=0.557,	  P=0.094)	  for	  a	  positive	  correlation	  of	  
the	  change	  in	  PLIN2	  protein	  content	  with	  the	  increase	  in	  IMCL	  upon	  fasting	  (Table	  1	  and	  
Fig.	  4B).	  Furthermore,	  the	  change	  in	  PLIN2	  protein	  content	  correlated	  positively	  with	  the	  
IMCL	  level	  after	  fasting	  (r=0.635,	  P=0.036)	  (Table	  1).	  	  
	  
	  
Figure	   3.	   Correlations	   fasting	   study.	   (A)	  
Correlation	  of	  the	  change	  in	  IMCL	  (fasting-­‐
fed)	   with	   the	   change	   in	   Si-­‐index	   upon	  
fasting	   (ΔSi-­‐index=fasted-­‐fed).	   (B)	  
Correlation	  of	  the	  change	  in	  IMCL	  with	  the	  
plasma	   glucose	   level	   after	   fasting.	   (C)	  
Correlation	   of	   the	   change	   in	   the	   Si-­‐index	  
with	  the	  plasma	  glucose	  level	  after	  fasting.	  
	  
PLIN5	   protein	   content	   after	   fasting	   correlated	   positively	   with	   post-­‐fasting	   IMCL	   levels	  
(r=0.710,	   P=0.022)	   (Table	   1	   and	   Fig.	   4C)	   and	   the	   change	   in	   IMCL	   upon	   fasting	   (r=0.798,	  
P=0.010).	  PLIN5	   (r=-­‐0.679,	  P=0.031)	   (Table	  1)	  and	  ATGL	   (r=-­‐0.689,	  P=0.019)	   (Table	  1	  and	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Fig.	   4D)	   protein	   content	   correlated	   negatively	   with	   IS	   in	   the	   fed	   state,	   whereas	   CGI-­‐58	  
protein	   content	   showed	  a	   tendency	   for	   a	   positive	   correlation	  with	   IS	   (r=0.595,	   P=0.054)	  
(Table	  1	  and	  Fig.	  4E).	  	  
	  
Table	  1.	  Correlations	  of	   the	  pre-­‐,	  post-­‐	   and	  delta	  protein	  expression	  of	  PLIN2,	  PLIN3,	  PLIN5,	  ATGL	  
and	   CGI-­‐58	  with	   the	   pre-­‐,	   post-­‐	   and	   delta	   Si-­‐index	   and	   IMCL	   upon	   fasting.	   r=	   Pearson	   correlation	  
coefficient,	  P=P-­‐value.	  The	  Si-­‐index	  is	  given	  in	  μmol	  min
-­‐1	  kg-­‐1/μU	  ml-­‐1.	  Correlations	  with	  P<0.10	  are	  
highlighted	  in	  bold.	  
	  













Fed	   PLIN2	   r	   0.126	   -­‐0.455	   0.564	   -­‐0.277	   0.545	   0.439	  
	   	   P	   0.713	   0.160	   0.071	   0.410	   0.100	   0.177	  
	   PLIN3	   r	   -­‐0.278	   -­‐0.181	   -­‐0.172	   -­‐0.395	   -­‐0.399	   -­‐0.004	  
	   	   P	   0.409	   0.573	   0.594	   0.204	   0.199	   0.990	  
	   PLIN5	   r	   0.237	   -­‐0.679	   0.294	   -­‐0.632	   0.206	   0.518	  
	   	   P	   0.511	   0.031	   0.410	   0.050	   0.568	   0.125	  
	   ATGL	   r	   -­‐0.059	   -­‐0.689	   0.105	   -­‐0.764	   0.17	   0.449	  
	   	   P	   0.863	   0.019	   0.758	   0.006	   0.64	   0.166	  
	   CGI-­‐58	   r	   -­‐0.021	   0.595	   -­‐0.105	   0.576	   -­‐0.102	   -­‐0.440	  
	   	  	   P	   0.951	   0.054	   0.759	   0.064	   0.778	   0.176	  
Fasted	   PLIN2	   r	   	   	   0.732	   -­‐0.157	   0.628	   0.376	  
	   	   P	   	   	   0.010	   0.645	   0.038	   0.255	  
	   PLIN3	   r	   	   	   -­‐0.447	   -­‐0.278	   -­‐0.248	   0.106	  
	   	   P	   	   	   0.168	   0.382	   0.489	   0.743	  
	   PLIN5	   r	   	   	   0.710	   -­‐0.373	   0.798	   0.557	  
	   	   P	   	   	   0.022	   0.289	   0.010	   0.094	  
	   ATGL	   r	   	   	   0.580	   0.000	   0.440	   0.267	  
	   	   P	   	   	   0.061	   0.999	   0.203	   0.427	  
	   CGI-­‐58	   r	   	   	   -­‐0.211	   0.333	   -­‐0.145	   -­‐0.287	  
	   	   P	   	   	   0.534	   0.317	   0.690	   0.392	  
Delta	  	   PLIN2	   r	   	   	   0.635	   -­‐0.024	   0.557	   0.226	  
	   	   P	   	   	   0.036	   0.944	   0.094	   0.504	  
	   PLIN3	   r	   	   	   -­‐0.154	   0.082	   -­‐0.014	   0.128	  
	   	   P	   	   	   0.650	   0.799	   0.969	   0.692	  
	   PLIN5	   r	   	   	   -­‐0.143	   0.332	   -­‐0.013	   -­‐0.125	  
	   	   P	   	   	   0.714	   0.383	   0.973	   0.748	  
	   ATGL	   r	   	   	   0.357	   0.498	   0.294	   -­‐0.096	  
	   	   P	   	   	   0.282	   0.119	   0.410	   0.778	  
	   CGI-­‐58	   r	   	   	   -­‐0.164	   -­‐0.131	   -­‐0.098	   0.059	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High	   fat	   diet-­‐induced	   changes	   in	   the	   expression	   of	   perilipins	   and	   proteins	  
involved	  in	  lipolysis	  
We	  next	  investigated	  the	  effect	  of	  another,	  more	  prolonged	  intervention	  characterized	  by	  
lipid	  oversupply	  on	  the	  expression	  of	  the	  PLINs,	  ATGL	  and	  CGI-­‐58.	  We	  previously	  published	  
that	  consumption	  of	  a	  high	   fat	  diet	   (HFD)	   for	  3	  weeks	  resulted	   in	  a	  1.55-­‐fold	   increase	   in	  
IMCL	   (P=0.043)	  without	  a	  significant	  effect	  on	   insulin	  sensitivity	   [40].	  Here	  we	  evaluated	  
the	   expression	   of	   several	   perilipins	   and	   lipolytic	   enzymes	   in	   the	   muscle	   biopsies	   from	  
those	  subjects.	  CGI-­‐58	  gene	  expression	  was	  significantly	  downregulated	  (P=0.03)	  (Fig.	  5E).	  
Gene	   expression	   levels	   of	   PLIN2	   (P=0.59),	   PLIN3	   (P=0.14),	   PLIN5	   (P=0.58)	   and	   ATGL	  
(P=0.34)	  were	  not	  significantly	  different	  after	  the	  diet	  intervention	  (Fig.	  5).	  PLIN5	  protein	  
levels	   showed	  a	   tendency	   for	  upregulation	  after	   the	  HFD	  diet	   (P=0.06).	  PLIN2,	  ATGL	  and	  
CGI-­‐58	   protein	   contents	   did	   not	   show	   any	   significant	   differences	   (P=0.74,	   P=0.48,	   and	  
P=0.21,	  respectively)	  (Supplemental	  Fig.	  1).	  
	  
	  
Figure	   4.	   Correlations	   PLINs,	  
ATGL	   and	   CGI-­‐58	   with	   IMCL	  
and	   insulin	   sensitivity	   in	   the	  
fasting	  study.	   (A)	  Correlation	  
of	  PLIN2	  in	  the	  fed	  state	  with	  
IMCL	   in	   the	   fasted	   state.	   (B)	  
Correlation	   of	   the	   change	   in	  
PLIN2	   with	   the	   change	   in	  
IMCL	   (fasting-­‐fed)	   upon	  
fasting.	   (C)	   Correlation	   of	  
PLIN5	  with	  IMCL	  in	  the	  fasted	  
state.	  (D)	  Correlation	  of	  ATGL	  
with	   insulin	   sensitivity	   (Si-­‐
index)	   in	   the	   fed	   state.	   (E)	  
Correlation	   of	   CGI-­‐58	   with	  
insulin	   sensitivity	   in	   the	   fed	  
state.	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Correlations	  were	  computed	  to	  investigate	  whether	  changes	  in	  IMCL	  content	  and	  IS	  upon	  
consumption	  of	  a	  HFD	  were	  associated	  with	  changes	   in	  protein	  expression	  of	  the	  above-­‐
mentioned	   proteins	   (Table	   2).	   PLIN2	   protein	   content	   upon	   consumption	   of	   the	   HFD	  
tended	   to	   correlate	   positively	  with	   the	   change	   in	   IMCL	   (r=0.629,	   P=0.069)	   (Table	   2	   and	  
Supplemental	  Fig.	  2).	  The	  change	  in	  PLIN5	  protein	  content	  correlated	  negatively	  with	  the	  
change	   in	   Si-­‐index	   (r=-­‐0.681,	   P=0.043)	   (Table	   2	   and	   Supplemental	   Fig.	   2).	   Moreover,	   in	  
contrast	   with	   the	   effects	   of	   60h	   fasting,	   the	   change	   in	   IMCL	   levels	   upon	   3	   weeks	  
consumption	  of	  a	  high	  fat	  did	  not	  correlate	  with	  changes	  in	  IS	  (r=-­‐0.229,	  P=0.554).	  
	  
	  
Figure	  5.	  Gene	  expression	  
levels	   of	   PLIN2	   (A),	   PLIN3	  
(B),	   PLIN5	   (C),	   ATGL	   (D)	  
and	  CGI-­‐58	  (E)	  before	  and	  
after	   consumption	   of	   a	  
HFD	  for	   three	  weeks	   (day	  
21=after	   the	   run-­‐in	   diet,	  
day	   42	   is	   after	   3	   weeks	  






Table	  2.	  Correlations	  of	  the	  change	   in	  protein	  expression	  (delta)	  of	  PLIN2,	  PLIN5,	  ATGL	  and	  CGI-­‐58	  
with	   the	   delta	   Si-­‐index	   and	   IMCL	   upon	   consumption	   of	   a	   high	   fat	   diet	   for	   3	   weeks.	   r=	   Pearson	  
correlation	  coefficient,	  P=P-­‐value.	  	  

































































Lipid	  content	  and	  PLIN	  expression	  upon	  fasting	  and	  high	  fat	  diet	  consumption	  
	  60	  




(μmol	  min-­‐1	  kg-­‐1/μU	  ml-­‐1)	  	  	  
ΔPLIN2	   r	   0.629	   -­‐0.028	  
	   P	   0.069	   0.943	  
ΔPLIN5	   r	   0.300	   -­‐0.681	  
	   P	   0.433	   0.043	  
ΔATGL	   r	   0.345	   -­‐0.179	  
	   P	   0.363	   0.644	  
ΔCGI-­‐58	   r	   0.348	   -­‐0.064	  
	  	   P	   0.359	   0.870	  
	  
DISCUSSION	  
Prolonged	   fasting	   is	   associated	   with	   increased	   plasma	   FFA	   levels	   and	   augmented	   IMCL	  
storage	   [38],	   and	   rapidly	   results	   in	   the	   development	   of	   insulin	   resistance	   [42].	  We	   here	  
show	   that	   subjects	  with	   a	   larger	   capacity	   to	   store	   lipids	   in	   intramyocellular	   LDs	   are	   less	  
insulin	  resistant	  after	  fasting.	  Such	  a	  relation	  was	  not	  observed	  after	  a	  more	  chronic	  high-­‐
fat	  diet	  intervention.	  Furthermore,	  we	  show	  that	  PLIN2	  is	  a	  determinant	  of	  IMCL	  storage	  
capacity.	  Our	  findings	  may	  indicate	  that	  especially	  under	  acute	  conditions,	  a	  high	  capacity	  
to	  store	  IMCL	  may	  be	  protective	  against	  lipid-­‐induced	  insulin	  resistance.	  
It	  has	  previously	  been	  shown	  that	  one	  bout	  of	  acute	  exercise	  protects	  against	   lipid-­‐
induced	  insulin	  resistance	  via	  an	  increased	  intramyocellular	  TAG	  storage	  capacity	  [25].	  Our	  
data	  are	  in	  harmony	  with	  those	  results.	  Jointly,	  these	  studies	  indicate	  that	  a	  high	  capacity	  
to	  store	  IMCL	  blunts	  the	  acute	  development	  of	  lipid-­‐induced	  insulin	  resistance	  upon	  acute	  
exposure	  to	  high	  circulatory	  FAs.	  While	  maintaining	   insulin	  sensitivity	   in	   the	   face	  of	  high	  
levels	   of	   fatty	   acids	   can	   be	   beneficial	   for	   post-­‐exercise	   glycogen	   sensitivity,	   the	  
physiological	   benefit	   upon	   fasting	   is	   less	   clear.	   During	   fasting,	  muscle	   insulin	   resistance	  
serves	  to	  direct	  glucose	  to	  the	  brain.	  Hence,	  a	  blunted	  induction	  of	  insulin	  resistance	  may	  
compromise	  glucose	  availability	  to	  the	  brain	  and	  is	  not	  necessarily	  considered	  beneficial.	  
Likewise,	   both	   the	   IMCL	   storage	   capacity	   and	   the	   change	   in	   IS	   upon	   fasting	   correlated	  
negatively	   with	   plasma	   glucose	   levels	   after	   fasting.	   Therefore,	   our	   results	   suggest	   that	  
subjects	  with	   a	   larger	   capacity	   for	   IMCL	   storage	   remain	   relatively	  more	   insulin	   sensitive	  
upon	  fasting	  and	  hence	  less	  effective	  in	  glucose	  sparing	  during	  fasting.	  	  
We	  next	   investigated	  whether	   the	  association	  of	   IMCL	   storage	   capacity	   and	   insulin	  
sensitivity	  also	  exists	  in	  a	  model	  of	  prolonged	  lipid	  oversupply;	  consumption	  of	  a	  high	  fat	  
diet	  for	  three	  weeks.	  However,	  in	  contrast	  to	  the	  fasting	  intervention,	  no	  correlation	  was	  
found	   between	   IMCL	   storage	   and	   insulin	   sensitivity	   after	   the	   diet	   intervention.	   A	   main	  
difference	   between	   the	   fasting	   intervention	   and	   the	   HFD	   intervention	   is	   the	   period	   of	  
investigation:	   60h	   versus	   3	  weeks.	   In	   that	   context,	   the	   protective	   effect	   of	   TAG	   storage	  
capacity	  on	  insulin	  sensitivity	  that	  was	  previously	  published	  was	  also	  found	  after	  a	  short-­‐
term	  intervention	  (90	  minutes	  of	  exercise)	  [25].	  It	  is	  well	  possible	  that	  on	  the	  longer	  term	  
increased	   lipid	   supply	   also	   leads	   to	   other	   adaptations,	   such	   as	   changes	   in	   fat	   oxidative	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capacity,	   that	   may	   mask	   the	   relation	   between	   TAG	   storage	   capacity	   and	   IS.	   Further	  
mechanistic	  studies	  are	  needed	  to	  understand	  what	  determines	  IMCL	  storage	  capacity	  of	  
skeletal	  muscle	  and	  how	  this	  is	  influenced	  by	  environmental	  conditions.	  
With	   respect	   to	   the	   determinants	   of	   IMCL	   storage	   capacity,	   LD	   coat	   proteins	   are	  
increasingly	   recognized	   as	   important	   modulators	   of	   intracellular	   lipid	   metabolism.	  
Interestingly,	  fasting	  downregulated	  gene	  expression	  of	  PLIN3,	  although	  this	  did	  not	  result	  
in	   lower	   PLIN3	   protein	   levels.	   In	   animal	   studies,	   PLIN3	   gene	   expression	   remained	  
unaltered	   upon	   fasting	   [31-­‐33].	   Furthermore,	   in	   contrast	   to	   the	   reported	   induction	   of	  
ATGL,	  PLIN2	  and	  PLIN5	  upon	  fasting	   in	  animal	  studies	  [28,	  29,	  31-­‐34],	  fasting	  for	  60h	  did	  
not	   induce	   expression	   of	   these	   lipid	   droplet	   coat	   proteins	   in	   human	   skeletal	   muscle,	  
indicating	   that	   increasing	   circulatory	   FAs	   when	   energy	   balance	   is	   negative	   is	   not	  
necessarily	  accompanied	  with	  induction	  of	  these	  genes/proteins.	  Our	  results	  demonstrate	  
that	  species	  differences	  exist	   regarding	  skeletal	  muscle	   responses	   to	   fasting.	   In	  addition,	  
our	  data	   indicate	  that	  even	  a	  substantial	   increase	   in	  muscle	   fat	  of	  2.7-­‐fold	   in	  the	  human	  
skeletal	  muscle	  can	  occur	  without	  the	  necessity	  of	   increasing	  PLIN	  content.	  Consistently,	  
also	   high-­‐fat	   feeding	   resulted	   in	   an	   increase	   in	   IMCL	   without	   induction	   of	   PLIN2.	  
Nevertheless,	   PLIN2	   did	   correlate	  with	   IMCL	   upon	   fasting	   and	   tended	   to	   correlate	  with	  
IMCL	   upon	   high	   fat	   feeding,	   indicating	   that	   a	   high	   PLIN2	   availability	   is	   associated	   with	  
increased	   IMCL	   content	   and	   that	   interindividual	   variation	   in	   PLIN2	  might	   be	   one	   of	   the	  
modulators	   of	   IMCL	   storage	   capacity.	   In	   accordance,	   we	   recently	   demonstrated	   that	  
knockdown	  of	  PLIN2	  prevented	  FA-­‐induced	   intramyocellular	  TAG	  storage,	   indicating	   that	  
the	   presence	   of	   PLIN2	   is	   essential	   for	   intramyocellular	   TAG	   storage	   [30].	   Interestingly,	  
PLIN2	   overexpression	   increased	   intramyocellular	   lipid	   accumulation	   while	   improving	  
insulin	   sensitivity,	   indicating	   that	   PLIN2	   facilitates	   neutral	   lipid	   storage	   which	   does	   not	  
impair	  skeletal	  muscle	  insulin	  sensitivity	  [30].	  	  
ATGL	  protein	  levels	  in	  the	  fed	  state	  negatively	  correlated	  with	  IS,	  consistent	  with	  the	  
paper	  of	  Badin	  et	  al.	  [36],	  in	  which	  a	  negative	  correlation	  of	  ATGL	  protein	  expression	  with	  
the	   glucose	   disposal	   rate	   was	   reported	   in	   a	   mixed	   population	   of	   lean,	   obese	   and	   T2D	  
subjects.	   This	   provides	   further	   support	   for	   the	   suggested	   importance	   of	   the	   lipolytic	  
balance	   for	   skeletal	   muscle	   IS	   [43,	   44].	   In	   contrast,	   CGI-­‐58	   in	   the	   fed	   state	   tended	   to	  
positively	   correlate	   with	   IS.	   PLIN5	   is	   also	   involved	   in	   the	   regulation	   of	   lipolysis	   and	  
modulates	   interactions	   of	   lipid	   droplets	   with	   mitochondria	   [11,	   12,	   14,	   15,	   21].	   While	  
PLIN5	   was	   demonstrated	   to	   be	   upregulated	   upon	   fasting	   in	   mouse	   models	   [31,	   33],	  
Kuramoto	   et	   al.	   recently	   showed	   that	   PLIN5	   is	   not	   required	   for	   fasting-­‐induced	   IMCL	  
storage	  in	  mice	  [45].	  However,	  translating	  this	  mechanistic	  insight	  to	  the	  human	  situation	  
should	   be	   done	  with	   care	   since	   species	   differences	  may	   exist	   regarding	   upregulation	   of	  
PLIN5	  upon	  fasting,	  as	  we	  show	  here.	  PLIN5	  did	  not	  correlate	  with	  IS	  in	  either	  the	  fed	  or	  
the	  fasted	  state.	  Moreover,	  PLIN5	  correlated	  negatively	  with	  IS	  upon	  the	  HFD	  intervention	  
in	  our	  group	  of	  obese	  sedentary	  subjects.	   In	  contrast,	  Amati	  et	  al.,	  previously	  reported	  a	  
positive	  correlation	  of	  PLIN5	  with	  IS	  in	  a	  population	  with	  a	  wide	  range	  in	  BMI	  and	  physical	  
fitness	  [35].	  Clearly,	  further	  research	  is	  necessary	  to	  investigate	  the	  importance	  of	  skeletal	  
muscle	  ATGL,	  CGI58	  and	  PLIN5	  expression	  levels	  for	  lipotoxicity	  and	  insulin	  sensitivity.	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In	  summary,	  we	  here	  show	  that	  in	  contrast	  to	  mouse	  studies,	  PLIN	  expression	  is	  not	  
induced	   upon	   prolonged	   fasting	   in	   human	   skeletal	   muscle.	   Furthermore,	   we	   show	   that	  
subjects	   with	   a	   larger	   capacity	   to	   store	   lipids	   in	   intramyocellular	   LDs	   are	   less	   insulin	  
resistant	  after	  fasting.	  This	  phenomenon	  was	  not	  apparent	  upon	  high	  lipid	  availability	  on	  
the	  longer	  term.	  Furthermore,	  PLIN2	  expression	  was	  associated	  with	  IMCL	  content.	  These	  
data	  suggest	  that	  under	  acute	  conditions	  of	  high	  lipid	  availability	  an	  increased	  capacity	  to	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SUPPLEMENTAL	  INFORMATION	  
Supplemental	  Table	  1.	  Subject	  characteristics	  fasting	  study.	  
Parameter	   Mean	  ±	  SEM	  
Age	  (years)	   23.6	  ±	  1.0	  
Body	  weight	  (kg)	   78.5	  ±	  2.5	  
Fat-­‐free	  mass	  (kg)	   65.9	  ±	  1.8	  
Height	  (m)	   1.86	  ±	  0.02	  
BMI	  (kg/m2)	   22.6	  ±	  0.5	  
VO2	  max	  (ml	  O2/kg	  FFM/min)	   57.5	  ±	  1.5	  
	  
	  
Supplemental	  Table	  2.	  Subject	  characteristics	  high	  fat	  diet	  intervention.	  
Parameter	   Mean	  ±	  SEM	  
Age	  (years)	   56.4	  ±	  2.5	  
Body	  weight	  (kg)	   91.3	  ±	  1.8	  
Fat-­‐free	  mass	  (kg)	   65.9	  	  ±	  1.9	  
Height	  (m)	   1.80	  ±	  0.02	  
BMI	  (kg/m2)	   28.3	  ±	  0.5	  
VO2	  max	  (ml	  O2/kg	  FFM/min)	   46.6	  ±	  2.4	  
	  
	  
Supplemental	  Table	  3.	  Primersequences.	  
Gene	   Forward	   Reverse	   Probe	  
PLIN2	  
(ADRP)	  
GCATTGGATATGATGATACTGATGAGTC	   GCGGGCAATTGCAAGAGT	   CCACTGTGCTGAGCACATTGAGTCACGT	  	  
PLIN3	  
(TIP47)	  
AGCACCCAGGTGACAGTGG	   CATGCTGGCCACACGGT	   CACACTGGGCTGCTGTACCGGTTCTT	  
PLIN5	  
(OXPAT)	  
GAGCCATGCTGTGGATGTTGTA	   CAGTGCCGCGAGCTCTTC	   TGGATCACTTCCTGCCCATGACGG	  	  	  
ABHD5	  	  
(CGI-­‐58)	  
GGAGAGAGGTCAGGATGGCTAA	  	  	   AACATCTTCTCTTCAGCTTCTTTAAGG	   CTCCCCACATGGTGCCCTACGTCTATATC	  	  
PNPLA2	  
(ATGL)	  
CCACGGCGCTGGTCA	   GGGCCTCTTTAGATACCTCAATGA	   TTGGCACCAGCCTCACCCAGG	  
RPLP0	   CCATTCTATCATCAACGGGTACAA	   AGCAAGTGGGAAGGTGTAATCC	   	  
	  
	  
Lipid	  content	  and	  PLIN	  expression	  upon	  fasting	  and	  high	  fat	  diet	  consumption	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Supplemental	   Figure	   1.	  
Protein	   content	   of	   PLIN2	  
(A),	   PLIN5	   (B),	   ATGL	   (C),	  
CGI-­‐58	  (D)	  before	  and	  after	  
3	  weeks	  HFD	   (day	   21=after	  
the	   run-­‐in	   diet,	   day	   42	   is	  
after	   3	   weeks	   HFD).	   Error	  
bars	  represent	  SEM.	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Supplemental	   Figure	   2.	   Correlations	   HFD	  
intervention.	  (A)	  Correlation	  of	  the	  change	  
in	   PLIN2	   protein	   content	   after	   the	   HFD	  
intervention	   with	   the	   change	   in	   IMCL.	   (B)	  
Correlation	  of	   the	  change	   in	  PLIN5	  protein	  
content	  upon	  consumption	  of	  the	  HFD	  with	  
the	  change	  in	  the	  Si-­‐index.	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Reduced	  incorporation	  of	  fatty	  acids	  into	  
triacylglycerol	  in	  myotubes	  established	  from	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ABSTRACT	  
Type	  2	  diabetes	  (T2D)	  is	  characterized	  by	  increased	  intramuscular	  lipid	  (IMCL)	  content	  and	  
disordered	   skeletal	  muscle	   lipid	  metabolism.	   Here	   we	   investigated	   skeletal	  muscle	   lipid	  
turnover	  in	  T2D	  versus	  BMI-­‐matched	  controls	  and	  examined	  if	  putative	  differences	  would	  
be	  preserved	  in	  myotubes	  of	  individuals	  with	  T2D.	  	  
Male	  obese	  T2D	  individuals	  (T2D)	  (n=6)	  and	  their	  age-­‐	  and	  BMI-­‐matched	  controls	  (C)	  (n=6)	  
underwent	   a	   hyperinsulinemic-­‐euglycemic	   clamp,	   VO2max	   test,	   DXA	   scan	   and	   muscle	  
biopsy	   of	   v.	   lateralis.	   Satellite	   cells	   were	   isolated.	   Myocytes	   were	   established	   and	  
differentiated	   towards	   myotubes.	   IMCL	   content,	   ex	   vivo	   and	   in	   vitro	   14C-­‐palmitate	  
oxidation	  (14CO2	  production)	  and	  incorporation	  of	  
14C-­‐palmitate	  into	  lipids	  were	  measured	  
in	  muscle	  biopsies	  and	  primary	  myotubes.	  
Intramuscular	  lipid	  content	  was	  similar	  between	  the	  two	  groups	  (4.0	  ±	  0.7%	  vs.	  3.9	  ±	  1.1%	  
for	   C	   vs.	   T2D,	   P=0.97).	   Palmitate	   oxidation	   (C:	   0.99	   ±	   0.17,	   T2D:	   0.53	   ±	   0.07	   nmol/mg	  
protein,	  P=0.03)	  and	   incorporation	   into	   triacylglycerol	   (TAG)	   (C:	  0.45	  ±	  0.13,	  T2D:	  0.11	  ±	  
0.02	   nmol/mg	   protein,	   P=0.047)	   in	   muscle	   homogenates	   were	   significantly	   reduced	   in	  
T2Ds	  vs.	  obese	  controls.	  Basal	   IMCL	  content	  (0.007	  ±	  0.001	  µg/mg	  protein	  for	  C,	  0.012	  ±	  
0.002	  µg/mg	  protein	   for	   T2Ds,	   P=0.076)	   tended	   to	   be	   higher	   in	   T2D	  myotubes	   and	  was	  
significantly	  associated	  with	  lower	  insulin	  sensitivity	  and	  higher	  fasting	  glucose;	  however,	  
there	  was	  no	  difference	   in	   14C-­‐palmitate	  uptake	   in	   the	  myotubes	   (3.15	  ±	  0.41	  vs.	  3.30	  ±	  
0.64,	   for	  C	  and	  T2D,	  respectively,	  P=0.85).	  Fatty	  acid	  oxidation	   in	  primary	  myotubes	  was	  
not	  different	  between	  the	  groups,	  but	   incorporation	  of	  palmitate	   into	  TAG	  tended	  to	  be	  
lower	   in	   the	   T2Ds	   and	   significantly	   corresponded	   with	   the	   ex	   vivo	   TAG	   incorporation	  
(r=0.848,	  P=0.008).	  Furthermore,	  incorporation	  of	  14C-­‐oleate	  into	  TAG	  after	  24	  hours	  was	  
significantly	   lower	   in	  myotubes	  from	  T2D	  patients	  compared	  with	  obese	  controls	   (2.24	  ±	  
0.47	   and	   0.94	   ±	   0.25	   nmol/mg	   protein	   for	   C	   and	   T2D,	   respectively,	   P=0.03).	   Our	   data	  
indicate	  that	  the	  ability	  to	  incorporate	  fatty	  acids	  into	  TAGs	  might	  be	  an	  inherent	  feature	  
of	  these	  muscle	  cells.	  Future	  studies	  should	   investigate	  the	   inherent	  pathways	   in	  muscle	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INTRODUCTION	  
Perturbations	   in	   lipid	   metabolism	   are	   associated	   with	   insulin	   resistance	   and	   type	   2	  
diabetes	  (T2D)	  [1].	  It	  has	  been	  proposed	  that	  an	  increased	  lipid	  supply,	  increased	  fatty	  acid	  
uptake,	  altered	  lipid	  partitioning	  and	  a	  reduced	  capacity	  for	  skeletal	  muscle	  fat	  oxidation	  
could	   contribute	   to	   intramyocellular	   lipid	   (IMCL)	   accumulation,	   lipotoxicity	   and	   insulin	  
resistance	   (reviewed	   in	   [2-­‐4]).	   However,	   whether	   these	   are	   inherited	   characteristics	   of	  
T2D,	   or	   simply	   the	   consequence	   of	   altered	   lifestyle	   and	   obesity,	   remains	   an	   ongoing	  
debate.	   In	   that	   context,	   studies	   in	   human	   primary	   myotubes	   are	   of	   interest,	   as	   cell	  
autonomous	   models	   are	   devoid	   of	   direct	   environmental	   influences.	   Hulver	   et	   al.	   [5]	  
demonstrated	   that	   myotubes	   of	   severely	   obese	   individuals	   retained	   an	   abnormal	   lipid	  
partitioning	   (i.e.	   elevated	   triacylglycerol	   to	   blunted	   fatty	   acid	   oxidation	   ratio;	   TAG/FAO)	  
[5].	  Furthermore,	  Aguer	  et	  al.	  [6]	  showed	  increased	  IMCL	  content	  in	  muscle	  tissue,	  as	  well	  
as	   in	   myotubes	   established	   from	   obese	   T2D	   subjects	   compared	   to	   obese	   nondiabetic	  
controls,	   indicating	   that	   increased	   IMCL	   content	   is	   preserved	   in	   vitro.	   Alternatively,	  
elevated	   fatty	   acid	   (FA)	  uptake	   could	   also	   contribute	   to	   the	   increased	   IMCL	  observed	   in	  
obesity	   and	   T2D.	   Some	   studies	   show	   no	   difference	   in	   uptake	   of	   FA	   [7,	   8],	   while	   others	  
show	   increased	  FA	  uptake	   in	   skeletal	  muscle	  of	  obese	  and	  T2D	   individuals	   [9].	   Likewise,	  
studies	   in	   primary	   human	  myotubes	   also	   showed	   inconsistent	   results	   [6,	   10,	   11].	   Taken	  
together,	   it	   is	   still	   unclear	  whether	  disturbances	   that	  exist	   in	   skeletal	  muscle	   tissue	   lipid	  
metabolism	  of	  T2D	  subjects	  are	  preserved	  in	  the	  myotubes.	  	  
As	  aberrant	  lipid	  metabolism	  is	  a	  central	  feature	  of	  obesity	  and	  T2D,	  the	  goal	  of	  the	  
present	   study	   was	   to	   investigate	   whether	   disturbances	   exist	   in	   intramyocellular	   FA	  
metabolism	   in	   skeletal	   muscle	   of	   obese	   T2D	   individuals	   compared	   to	   BMI-­‐	   and	   age-­‐
matched	   normoglycemic	   controls	   and	   to	   examine	   whether	   disturbances	   in	   lipid	  
metabolism	   are	   retained	   in	   vitro	   in	   the	   myotubes	   established	   from	   these	   donors.	   Our	  
study	  is	  a	  unique	  combination	  of	  ex	  vivo	  and	  in	  vitro	  analyses	  of	  lipid	  metabolism	  in	  human	  
skeletal	   muscle,	   coupled	   with	   detailed	   in	   vivo	   clinical	   phenotyping	   to	   assess	   insulin	  
sensitivity,	  aerobic	  capacity	  and	  substrate	  oxidation.	  We	  measured	  ex	  vivo	  FA	  metabolism	  
in	  skeletal	  muscle	  tissue	  and	  established	  primary	  myotubes	  from	  these	  donors	  for	  in	  vitro	  
studies.	  The	  myotubes	  were	  used	  to	   investigate	   lipid	  turnover	   (FA	  uptake,	  oxidation	  and	  
storage)	   using	   two	   different	   long	   chain	   FAs.	   The	   in	   vitro	   characteristics	  were	   correlated	  
with	   characteristics	   measured	   in	   vivo	   and	   ex	   vivo	   in	   the	   tissue.	   We	   show	   that	   FA	  
incorporation	   into	   triacylglycerol	   (TAG)	   is	   impaired	   in	   T2D	   muscle	   and	   in	   myotubes	  
established	  from	  these	  T2D	  donors,	  indicating	  that	  this	  perturbation	  is	  inherent	  to	  the	  T2D	  
muscle	  cell.	  




Six	   obese	   type	   2	   diabetic	   male	   subjects	   and	   six	   BMI-­‐	   and	   age-­‐matched	   male	   control	  
subjects	   participated.	   Clinical	   characteristics	   are	   presented	   in	   Table	   1.	   Subjects	   with	  
cardiovascular	  disease,	  (genetic)	  diseases	  that	  are	  associated	  with	  altered	  lipid	  profiles,	  or	  
subjects	  that	   lost	  >3	  kg	  body	  weight	  during	  the	  preceding	  6	  months	  were	  excluded	  from	  
participation.	   Subjects	   with	   type	   2	   diabetes	   were	   diagnosed	   at	   least	   1	   year	   prior	   to	  
beginning	   the	   study,	   were	   non-­‐insulin	   dependent,	   had	   well-­‐controlled	   diabetes	  
(HbA1c<7.8%)	   and	   no	   diabetes-­‐related	   co-­‐morbidities.	  Medication	   use	  was	   stable	   for	   at	  
least	  6	  months.	  All	   type	  2	  diabetic	  patients	  were	  on	  metformin,	   two	  diabetics	  were	  also	  
taking	   sulfonylurea.	   In	   addition,	   three	   diabetics	   were	   on	   statins	   and	   blood	   pressure-­‐
lowering	  medication.	  Obese	  control	  subjects	  had	  no	  family	  history	  of	  diabetes	  and	  did	  not	  
take	   any	   medication.	   The	   study	   was	   approved	   by	   the	   Medical	   Ethical	   Committee	   of	  
Maastricht	   University	   Medical	   Centre,	   and	   all	   subjects	   gave	   written	   informed	   consent	  
before	  participating	   in	   the	  study.	  All	   subjects	  performed	  a	  maximal	  aerobic	  capacity	   test	  
(VO2max)	   as	   described	   previously	   [12].	   Body	   composition	   was	   determined	   using	  
hydrostatic	  weighing	  [13].	  
	  
Hyperinsulinemic-­‐euglycemic	  clamp	  
To	  measure	  peripheral	   insulin	   sensitivity,	   a	   two-­‐step	  hyperinsulinemic-­‐euglycemic	   clamp	  
was	   performed.	   Patients	  were	   provided	  with	   a	   standardized	  meal,	   the	   day	   prior	   to	   the	  
clamp	   and	   muscle	   biopsy.	   Also	   patients	   were	   refrained	   from	   their	   oral	   anti-­‐diabetic	  
medication	   for	   at	   least	   1	   week.	   After	   an	   overnight	   fast,	   a	   blood	   sample	   was	   drawn	   to	  
measure	   glucose,	   insulin	   and	   free	   fatty	   acids	   (FFAs).	   Subsequently,	   step	   1	   was	   started;	  
insulin	  was	   infused	   at	   a	   rate	   of	   10	  mU/m2/min	   for	   4h	  with	   variable	   co-­‐infusion	   of	   20%	  
glucose	  (as	  a	  measure	  for	  liver	  insulin	  sensitivity).	  Subsequently,	  step	  2	  consisted	  of	  a	  2	  h	  
insulin	  infusion	  at	  a	  rate	  of	  40	  mU/m2/min	  (and	  20%	  variable	  glucose),	  this	  served	  as	  the	  
measure	   for	   skeletal	   muscle	   insulin	   sensitivity	   because	   hepatic	   glucose	   production	   is	  
almost	   totally	   inhibited.	   The	   M-­‐value	   was	   calculated	   as	   the	   glucose	   infusion	   rate	   and	  
corrected	  for	  lean	  body	  mass	  (μmol/kg/min).	  
	  
Muscle	  biopsy	  
Muscle	  biopsies	  were	  taken	  from	  the	  vastus	  lateralis	  under	  local	  anesthesia	  (2%	  lidocaine)	  
according	  to	  the	  Bergström	  technique	  [14]	  and	  processed	  for	  ex	  vivo	  assays	  performed	  the	  
same	  day.	  The	  remainder	  was	  snap-­‐frozen	  and	  stored	  at	  -­‐80°C	  for	  future	  analyses.	  
	  
Primary	  muscle	  cell	  cultures	  
Primary	  skeletal	  muscle	  cell	  cultures	  were	  established	  as	  previously	  described	  [15].	  Briefly,	  
satellite	   cells	   (quiescent	  mononuclear	  muscle	   cells)	  were	   isolated	  by	   trypsin-­‐collagenase	  
digestion,	  pre-­‐plated	  to	  remove	  fibroblasts	  and	  transferred	  to	  T-­‐25	  collagen-­‐coated	  flasks	  
in	  Dulbecco’s	  Minimum	  Essential	  Medium	   (DMEM)	   (Invitrogen,	   Breda,	   The	  Netherlands)	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supplemented	  with	  16%	  Fetal	  Bovine	  Serum	  (FBS)	  and	  human	  growth	  factors.	  Cells	  were	  
grown	   at	   37°C	   in	   a	   humidified	   atmosphere	   of	   5%	   CO2.	   Differentiation	   was	   initiated	   at	  
approximately	   90%	   confluence	   by	   switching	   to	   α-­‐MEM	  with	   2%	   FBS	   and	   antibiotics	   and	  
continued	  for	  7	  days.	  Media	  was	  changed	  every	  other	  day.	  	  	  
	  
Oil-­‐red-­‐O	  staining	  
Fresh	   muscle	   cryosections	   (5	   μm)	   were	   stained	   for	   IMCL	   by	   Oil-­‐Red-­‐O	   as	   described	  
previously	   [16]	   and	   expressed	   per	   cell	   surface	   area.	   Fully	   differentiated	  myotubes	  were	  
fixed	   with	   3.7%	   (vol/vol)	   formaldehyde	   in	   PBS	   for	   20	   min.	   Thereafter,	   slides	   were	  
incubated	   in	   0.3%	   (wt/vol)	   Oil	   Red	   O	   in	   60%	   (vol/vol)	   triethylphosphate	   for	   30	   min.	  
Subsequently,	  slides	  were	  mounted	  using	  mowiol.	  DAPI	  was	  included	  with	  the	  mowiol	  to	  
allow	   visualization	   of	   nuclei.	   Slides	   were	   examined	   using	   a	   Nikon	   E800	   fluorescence	  
microscope	   (Uvikon).	   Digital	   images	   were	   captured	   and	   processed	   using	   Lucia	   G/F	   5.49	  
image	  analysis	  software	  (Nikon).	  	  
	  
14C-­‐labeled	  ex	  vivo	  palmitate	  oxidation	  and	  lipid	  incorporation	  
Palmitate	   oxidation	   was	   determined	   by	   measuring	   production	   of	   14CO2	   (complete	  
oxidation)	  in	  skeletal	  muscle	  homogenates	  as	  previously	  described	  [17].	  Briefly,	  v.	  lateralis	  
muscle	   samples	   (~70	  mg)	  were	  placed	   in	   1.5mL	  of	   fresh	   ice-­‐cold	  homogenization	  buffer	  
containing	   (in	  mM)	   250	   sucrose,	   10	   Tris-­‐HCl,	   1	   EDTA	   and	   2	   ATP,	   pH	   7.4.	   Samples	   were	  
thoroughly	  minced	  with	   surgical	   scissors	  and	   transferred	   to	  a	  2mL	  glass	  homogenization	  
vessel.	  Muscle	   suspensions	  were	   homogenized	   on	   ice	  with	   a	   Teflon	   pestle	   at	   10	   passes	  
across	  30	   seconds	  at	  1200	   rpm.	  This	  method	  does	  not	   affect	  mitochondrial	  morphology	  
and	  function	  [18].	  Subsequently,	  the	  muscle	  homogenates	  were	  plated	  in	  triplicate	  into	  a	  
modified	  48-­‐well	   trapping	  device	  [19].	  A	  small	  groove	  was	  engineered	  between	  adjacent	  
wells	   so	   that	   CO2	   could	   freely	   diffuse	   between	   the	   incubation	   and	   trap	  wells.	   Reactions	  
were	  started	  with	  the	  addition	  of	  reaction	  media	  yielding	  final	  concentrations	  (in	  mM)	  of	  
0.2	  palmitate	  and	  0.0175	  [1-­‐14C]-­‐palmitate	  and	  125	  sucrose,	  20	  Tris-­‐HCL,	  25	  KH2PO4,	  200	  
KCL,	  2.5	  MgCl,	  0.25	  malate,	  4	  ATP,	  2.5	  DTT,	  2.5	  carnitine,	  0.125	  coenzyme	  A,	  0.25	  NAD+.	  
Trapping	  devices	  were	  sealed	  with	  a	  siliconized	  rubber	  gasket	  and	  incubated	  at	  37°C.	  After	  
two	  hours,	  reactions	  were	  terminated	  in	  the	  sealed	  reaction	  plates	  by	  the	  addition	  of	  70%	  
perchloric	   acid	   to	   the	   incubation	   wells.	   Perchloric	   acid	   also	   results	   in	   precipitation	   of	  
remaining	  FAs	  in	  the	  media.	  The	  trapping	  device	  was	  transferred	  to	  an	  orbital	  shaker,	  and	  
14CO2	  was	   trapped	   in	   the	   adjoining	  well	   in	   1N	  NaOH	   for	   1	  hour.	   Following	   trapping,	   the	  
muscle	   homogenates	   were	   spun	   for	   15	   minutes	   at	   15,000xg	   and	   measurement	   of	   14C-­‐
ASMs	   (acid-­‐soluble	   metabolites)	   were	   performed	   in	   the	   supernatants.	   The	   remaining	  
tissue	  homogenate	  was	  used	   for	   total	   lipid	   extraction	  with	  1ml	  of	   chloroform/methanol	  
(2v/1v).	   Lipids	   were	   dried	   under	   nitrogen	   gas,	   re-­‐dissolved	   in	   100ul	   of	  
chloroform/methanol	   (2v/1v)	   for	   thin	   layer	  chromatography	   (TLC)	   (Anal	  Tech	  TLC	  plates,	  
Whatman	   Ltd.,	   Kent,	   ME)	   and	   run	   in	   a	   mobile	   phase	   containing	   hexane/diethyl	  
ether/acetic	   acid,	   v/v/v,	   30:20:2).	   Bands	   corresponding	   to	   diacylglycerol	   (DAG)	   and	  
triacylglycerol	  (TAG)	  were	  scraped	  and	  quantified	  on	  a	  multipurpose	  scintillation	  counter	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(Wallac	  Winspectral	   1414	   liquid	   scintillation	   counter,	   Perkin	   Elmer,	   Boston,	  MA,	  USA)	   in	  
5mL	   of	   OptiFluor	   (Perkin	   Elmer,	   Boston,	   MA,	   USA).	   Data	   were	   normalized	   to	   protein	  
content	  of	  the	  muscle	  homogenate.	  
	  
In	  vitro	  14C-­‐palmitate	  oxidation	  and	  lipid	  incorporation	  
Cells	   were	   pre-­‐incubated	   for	   three	   hours	   with	   [1-­‐14C]-­‐palmitate	   (1μCi/ml;	   PerkinElmer,	  
Groningen,	  NL)	  and	  non-­‐labeled	  palmitate	  (100	  µM),	  L-­‐carnitine	  (1	  mM)	  and	  HEPES	  (12.5	  
mM)	   in	   α-­‐MEM	   (Invitrogen,	   Breda,	   The	  Netherlands).	   Palmitate	  was	   coupled	   to	   FA-­‐free	  
BSA	   in	   a	   molar	   ratio	   of	   5:1.	   Following	   incubation,	   14CO2	   and	  
14C-­‐ASMs	   (acid	   soluble	  
metabolites)	  were	  measured	   as	   previously	   described	   [15].	   All	   assays	  were	   performed	   in	  
triplicate,	  and	  data	  were	  normalized	  to	  protein	  content.	  The	  ratio	  of	  CO2:ASMs	  represents	  
the	  ratio	  of	  lipid	  completely	  oxidized	  to	  CO2	  relative	  to	  those	  metabolites	  of	  the	  lipid	  that	  
are	  not	  completely	  oxidized	  to	  CO2,	  in	  this	  case	  ASMs	  and	  which	  most	  likely	  represent	  TCA	  
cycle	  intermediates	  [20].	  At	  the	  end	  of	  the	  lipid	  oxidation	  assay,	  cells	  were	  washed	  twice	  
with	  PBS	  and	  harvested	  in	  0.05%	  SDS	  for	  subsequent	  protein	  measurement	  and	  total	  lipid	  
extraction	  with	  chloroform/methanol	  (2v/1v).	  Lipids	  were	  dried	  under	  liquid	  nitrogen,	  re-­‐
dissolved	  for	  thin	  layer	  chromatography	  (TLC)	  (Anal	  Tech	  TLC	  plates,	  Whatman	  Ltd.,	  Kent,	  
ME)	   and	   run	   in	   a	   mobile	   phase	   containing	   hexane/diethyl	   ether/acetic	   acid,	   v/v/v,	  
30:20:2).	   Bands	   corresponding	   to	   diacylglycerol	   (DAG),	   and	   triacylglycerol	   (TAG)	   were	  
scraped	   and	   quantified	   using	   a	   multi-­‐purpose	   scintillation	   counter	   (Wallac	   Winspectral	  
1414	  liquid	  scintillation	  counter,	  Perkin	  Elmer,	  Boston,	  MA,	  USA).	  
	  
In	  vitro	  pulse-­‐chase	  14C-­‐oleate	  experiments	  
Pulse	   chase	  experiments	  were	   adapted	   from	  Koves	   et	   al.	   [21].	  Muscle	   cells	  were	   grown	  
and	  differentiated	  in	  24-­‐well	  plates.	  αMEM	  supplemented	  with	  500	  μM	  oleate	  (2	  μCi	  per	  
ml	  [1-­‐14C]-­‐oleic	  acid,	  PerkinElmer,	  Boston,	  MA,	  USA)	  complexed	  to	  BSA	  (1.25%)	  was	  added	  
for	   24h	   on	   day	   6	   of	   differentiation	   (pulse).	   The	   chase	   media	   consisted	   of	   αMEM	  
supplemented	  with	  1	  mM	  carnitine	  and	  12.5	  mM	  HEPES.	  Cell	   samples	  were	  collected	   in	  
0.05%	  SDS	  at	  0	  and	  3h	  after	  the	  chase.	  Media	  was	  collected	  3h	  after	  the	  chase	  to	  measure	  
oxidation	   (14CO2	   and	  
14C-­‐ASMs)	   using	   a	   CO2	   trapping	   device	   followed	   by	   scintillation	  
counting	   as	   described	   previously	   [15].	   Lipids	  were	   extracted	   using	   chloroform:methanol	  
(2:1),	  and	  lipid	  species	  were	  separated	  of	  lipid	  species	  using	  thin	  layer	  chromatography	  as	  
described	   previously	   [15].	   Experiments	   were	   performed	   in	   triplicates	   per	   subject.	   Data	  
were	  normalized	  to	  protein	  content.	  
	  
In	  vitro	  fatty	  acid	  uptake	  
FA	   uptake	   was	   measured	   by	   incubating	   myotubes	   with	   FBS-­‐free	   DMEM	   containing	   0.2	  
µCi/mL	   [1-­‐14C]-­‐palmitate	   and	   20	   µM	   non-­‐labeled	   palmitate	   conjugated	   to	   FA-­‐free	   BSA	  
(ratio	  BSA	  to	  palmitate	  1:2.5).	  Cells	  were	  incubated	  at	  37°C	  for	  4	  min,	  washed	  three	  times	  
with	  PBS,	  and	  then	  lysed	  in	  0.1	  M	  NaOH.	  Cell	  lysates	  were	  added	  to	  5	  mL	  OptiFluor	  (Perkin	  
Elmer,	   Boston,	  MA,	   USA)	   and	   counted	   on	   a	  Wallac	  Winspectral	   1414	   liquid	   scintillation	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counter	   (Perkin	  Elmer,	  Boston,	  MA,	  USA).	  Experiments	  were	  performed	   in	   triplicates	  per	  
subject.	  Data	  were	  normalized	  to	  protein	  content.	  
	  
In	  vitro	  triacylglycerol	  levels	  
Intracellular	   TAG	   levels	   in	   differentiated	  myotubes	  were	  measured	  using	   the	  method	  of	  
Schwartz	  and	  Wolins	  [22].	  
	  
Statistics	  
Results	   are	   presented	   as	   mean	   ±	   SEM.	   Statistical	   analyses	   were	   performed	   using	   SPSS	  
version	   16.0	   for	   MacOS	   16.0	   (SPSS,	   Chicago,	   IL).	   Statistical	   comparisons	   between	  
conditions	  were	  performed	  using	  unpaired	  T-­‐tests.	  Pearson’s	  correlation	  coefficients	  were	  





Clinical	  characteristics	  of	  type	  2	  diabetic	  subjects	  and	  obese	  controls	  	  
By	  design,	   fasting	  plasma	  glucose	   levels	  were	  significantly	  higher	   in	  patients	  with	   type	  2	  
diabetes	   (T2D)	   compared	   with	   obese	   controls	   (C)	   (Table	   1).	   Circulating	   free	   fatty	   acids	  
(FFAs)	  were	  not	  different	  between	  the	  two	  groups.	  Skeletal	  muscle	  insulin	  sensitivity	  (the	  
M-­‐value	   at	   the	   insulin	   infusion	   rate	   of	   40	   mU/m2/min)	   tended	   to	   be	   lower	   in	   T2Ds	  
compared	   to	   obese	   controls	   (Table	   1).	   Aerobic	   capacity,	   as	   measured	   by	   VO2max,	   was	  
significantly	  lower	  in	  the	  T2D	  subjects	  compared	  with	  the	  controls	  (Table	  1).	  	  
	  
Table	  1.	  Subject	  characteristics.	  
	  	   C	   T2D	   P-­‐value	  
Age	  (y)	   54.7	  ±	  4.1	   58.3	  ±	  2.1	   0.44	  
BMI	  (kg/m2)	   31.2	  ±	  0.26	   30.8	  ±	  0.32	   0.33	  
%Fat	   32.8	  ±	  3.0	   33.0	  ±	  2.0	   0.96	  
VO2max	  (ml/min/kg)	   31.5	  ±	  0.8	   25.5	  ±	  1.83	   0.01	  
Glucose	  (mmol/L)	   5.22	  ±	  0.15	   7.13	  ±	  0.39	   <0.01	  
FFA	  (mmol/L)	   0.78	  ±	  0.39	   0.62	  ±	  0.17	   0.76	  
M-­‐value	  (μmol/kg/min)	   35.2	  ±	  5.6	   23.4	  ±	  3.6	   0.10	  
	  
Ex	  vivo	  
Intramuscular	  lipid	  content,	  fiber	  type	  and	  fatty	  acid	  metabolism	  
Intramuscular	  lipid	  content	  (IMCL)	  was	  similar	  between	  the	  two	  groups	  (5.2	  ±	  0.9%	  vs.	  5.3	  
±	  1.7%	   in	   type	  1	   fibers	   for	  C	   vs.	   T2D,	  P=0.97;	  2.7	  ±	  0.4%	  vs.	  2.5	  ±	  0.6%	   in	   type	  2	   fibers,	  
P=0.73;	  and	  4.0	  ±	  0.7%	  vs.	  3.9	  ±	  1.1%	  for	  total	  lipid	  content,	  P=0.96;	  Figure	  1).	  	  




Figure	   1.	   Intramyocellular	  
neutral	   lipid	   content	  
measured	   by	   Oil-­‐red-­‐O	  
staining	   in	   combination	  with	  
an	   immunofluorescence	  
staining	   against	   slow	  myosin	  
heavy	   chain	   to	   determine	  
fiber	  type.	  Mean	  ±	  SEM.	  
	  
We	   then	   investigated	   fat	   oxidative	   capacity	   in	   skeletal	   muscle	   homogenates	   using	   an	  
exogenously	   supplied	   long	   chain	   fatty	  acid	   (LCFA;	  palmitate).	  Palmitate	  oxidation	   to	  CO2	  
(“complete	  oxidation”)	  was	  significantly	  reduced	  in	  subjects	  with	  T2D	  (0.99	  ±	  0.17	  vs.	  0.53	  
±	  0.07	  nmol/mg	  protein	  for	  C	  vs.	  T2D,	  P=0.03;	  Figure	  2A).	  Acid-­‐soluble	  metabolites	  (ASMs;	  
“incomplete	  oxidation”)	  were	  not	  different	  between	  the	  two	  groups	  (P=0.86;	  Figure	  2B).	  
Thus,	  the	  ratio	  of	  complete	  to	  incomplete	  oxidation,	  which	  is	  indicative	  of	  a	  more	  efficient	  
FA	  metabolism,	  was	  also	  reduced	  in	  the	  T2Ds	  (0.12	  ±	  0.01	  vs.	  0.07	  ±	  0.01	  for	  C	  and	  T2D,	  
respectively,	  P<0.01;	  Figure	  2C).	  	  
Next,	  we	  measured	   the	   incorporation	  of	   14C-­‐palmitate	   into	   lipids	   in	   skeletal	  muscle	  
homogenates.	  While	   incorporation	   of	   14C-­‐palmitate	   into	   the	   total	   lipid	   pool	   was	   similar	  
between	   the	   two	   groups	   (Figure	   2D),	   we	   did	   observe	   decreased	   incorporation	   of	   14C-­‐
palmitate	  into	  triacylglycerols	  (TAGs)	  in	  T2D	  patients	  compared	  with	  obese	  controls	  (0.45	  
±	  0.13	  vs.	  0.11	  ±	  0.02	  nmol/mg	  protein,	   for	  C	  and	  T2D	  respectively,	  P=0.047;	  Figure	  2E),	  
with	   similar	   incorporation	   into	   diacylglycerols	   (DAGs)	   (Figure	   2F).	   This	   may	   indicate	   a	  
blunted	  ability	  of	  the	  skeletal	  muscle	  of	  T2Ds	  to	  efficiently	  store	  and	  retain	  the	  lipids	  in	  the	  
TAG	  pool.	  
	  
Relationships	  among	  in	  vivo	  and	  ex	  vivo	  characteristics	  
Correlations	  are	  shown	  in	  Supplemental	  Figure	  1.	  The	  ratio	  of	  palmitate	  CO2:ASMs	  tended	  
to	  correlate	  positively	  with	  VO2max	  (r=0.537,	  P=0.072)	  and	  negatively	  with	  fasting	  plasma	  
glucose	  levels	  (r=-­‐0.566,	  P=0.055).	  	  
	  

















	   77	  
	  
Figure	   2.	   Ex	   vivo	   14C-­‐
palmitate	   metabolism.	   (A)	  
14C-­‐palmitate	   oxidation	   to	  
CO2.	   (B)	  
14C-­‐palmitate	  
oxidation	   to	   ASMs.	   (C)	  
Ratio	   CO2:ASMs.	   (D)	   Total	  
14C-­‐palmitate	  incorporation	  
into	  lipids.	  (E)	  14C-­‐palmitate	  
incorporation	   into	  TAG.	   (F)	  
14C-­‐palmitate	  incorporation	  
into	   DAG.	   *P<0.05,	   error	  
bars	  represent	  SEM.	  
In	  vitro	  
Intramyocellular	  lipid	  content	  and	  metabolism	  
Intramyocellular	  lipid	  (IMCL)	  content,	  under	  standard	  culturing	  conditions	  (i.e.	  without	  FA	  
incubation)	  tended	  to	  be	  higher	  in	  the	  myotubes	  established	  from	  T2D	  patients	  compared	  
with	  obese	  controls	  (0.007	  ±	  0.001	  µg/mg	  protein	  for	  obese	  controls,	  0.012	  ±	  0.002	  µg/mg	  
protein	   for	   T2Ds,	   P=0.076;	   Figure	   3A	   and	   B).	   IMCL	   levels	   in	   primary	   myotubes	   were	  
positively	   related	  with	   fasting	   blood	   glucose	   (r=0.746,	   P=0.008,	   Figure	   3C)	   and	   inversely	  
related	   to	  M-­‐value	   (r=-­‐0.617,	   P=0.043,	   Figure	   3D),	   which	  may	   indicate	   that	   higher	   lipid	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Figure	   3.	   Intramyocellular	   lipid	   accumulation	   in	   primary	   human	  myotubes.	   (A)	   Oil-­‐red-­‐O	   staining.	  
Representative	   pictures	   are	   shown.	   (B)	   TAG	   content	   in	   the	   myotubes	   (in	   the	   absence	   of	   FA	  
treatment).	   (C-­‐D)	  Correlation	  of	  the	  TAG	  content	  of	  the	  myotubes	  with	  the	  fasting	  plasma	  glucose	  
level	  (C)	  and	  the	  M-­‐value	  (D).	  
	  
Exogenous	  fatty	  acid	  metabolism	  
In	  contrast	  to	  palmitate	  oxidation	  in	  muscle	  homogenates,	  in	  vitro	  14C-­‐palmitate	  oxidation	  
to	  CO2	  was	  not	  significantly	  lower	  in	  T2D	  patients	  compared	  with	  obese	  controls	  (0.039	  ±	  
0.021	  vs.	  0.020	  ±	  0.004	  nmol/mg	  protein,	   respectively,	  P=0.38;	  Figure	  4A).	  Furthermore,	  
oxidation	   to	   ASMs	  was	   not	   significantly	   different	   (P=0.59;	   Figure	   4B),	   and	   consequently	  
neither	  was	  the	  ratio	  of	  CO2	  to	  ASMs	  (P=0.38;	  Figure	  4C).	  Moreover,	  in	  vitro	  
14C-­‐palmitate	  
oxidation	  to	  CO2	  did	  not	  correlate	  with	  the	  ex	  vivo	  palmitate	  oxidation	  (r=-­‐0.115,	  P=0.721),	  
suggesting	  that	  the	  capacity	  to	  oxidize	  palmitate	  to	  CO2	  is	  not	  an	  inherent	  property	  of	  the	  
myotubes	  established	  from	  these	  T2D	  and	  obese	  individuals.	  
14C-­‐palmitate	   incorporation	   into	   total	   lipid	  pool	  was	   lower	   in	  myotubes	  established	  
from	   T2D	   patients	   compared	   with	   obese	   controls,	   but	   this	   difference	   did	   not	   reach	  
significance	   due	   to	   the	   high	   variation	   (5.84	   ±	   1.46	   vs.	   3.28	   ±	   0.27	   nmol/mg	   protein,	  
respectively,	  P=0.116;	  Figure	  4D).	  Similarly,	  palmitate	  incorporation	  into	  TAGs	  (0.39	  ±	  0.16	  
vs.	  0.15	  ±	  0.02	  vs.	  nmol/mg	  protein,	  for	  OB	  and	  T2D	  respectively,	  P=0.168,	  Figure	  4E)	  and	  
DAGs	   (0.063	   ±	   0.013	   vs.	   0.047	   ±	   0.007	   nmol/mg	   protein,	   P=0.290,	   for	   C	   and	   T2D,	  
respectively;	   Figure	   4F)	   were	   not	   statistically	   significant	   different	   between	   groups.	  
However,	   in	   vitro	   14C-­‐palmitate	   incorporation	   into	   TAGs	   strongly	   correlated	  with	  ex	   vivo	  
14C-­‐palmitate	   incorporation	   into	  TAGs	   (r=0.848,	  P=0.008).	  Similarly,	   in	  vitro	   14C-­‐palmitate	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incorporation	  into	  total	  neutral	  lipids	  also	  positively	  correlated	  with	  ex	  vivo	  14C-­‐palmitate	  
incorporation	  into	  TAGs	  (r=0.837,	  P=0.01).	  Thus,	  while	  we	  did	  not	  see	  the	  observed	  ex	  vivo	  
differences	   in	  TAG	   incorporation	   retained	   in	   vitro	  when	  comparing	   the	  T2Ds	  with	  obese	  
controls	  (Figure	  4E),	  we	  did	  find	  strong	  relationships	  between	  these	  two	  measures.	  Finally,	  
palmitate	  uptake	  was	  similar	  between	  the	  groups	   (3.15	  ±	  0.41	  vs.	  3.30	  ±	  0.64,	   for	  C	  and	  
T2D,	  respectively,	  P=0.85;	  Figure	  4G).	  	  	  
	  
	  
Figure	  4.	  In	  vitro	  exogenous	  
14C-­‐palmitate	   metabolism.	  
(A)	   14C-­‐palmitate	   oxidation	  
to	   CO2.	   (B)	  
14C-­‐palmitate	  
oxidation	  to	  ASMs.	  (C)	  Ratio	  
CO2:ASMs.	   (D)	   Total	  
14C-­‐
palmitate	  incorporation	  into	  
lipids.	   (E)	   14C-­‐palmitate	  
incorporation	   into	   TAG.	   (F)	  
14C-­‐palmitate	   incorporation	  
into	   DAG.	   (G)	   14C-­‐palmitate	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Endogenous	  fatty	  acid	  metabolism	  
The	   lack	   of	   difference	   in	   14C-­‐palmitate	   oxidation	   in	   primary	  myotubes	   from	  T2Ds	   versus	  
obese	  controls	  is	  consistent	  with	  work	  by	  Gaster	  et	  al.	  [23],	  who	  reported	  no	  reduction	  in	  
oxidation	   of	   exogenous	   lipid	   in	  myotubes	   from	   obese	   or	   obese	   T2D	   subjects	   compared	  
with	   lean	   subjects.	   However,	   they	   showed	   that	   complete	   oxidation	   of	   endogenous	   lipid	  
(IMCL	  oxidation)	  was	   reduced	   in	  obese	  and	  T2D	  myotubes	   compared	  with	   lean	   controls	  
[23].	  Therefore,	  we	  examined	  14C-­‐oleate	  oxidation	  after	  a	  24h	  pulse	  with	  500µM	  oleate	  in	  
the	  absence	  of	  carnitine	  to	  label	  the	  endogenous	  lipid	  pool.	  Oleate	  was	  chosen	  instead	  of	  
palmitate	   because	   of	   the	   lipotoxic	   effects	   of	   palmitate	   loading	   of	   myotubes	   [24,	   25].	  
Interestingly,	   incorporation	   of	   14C-­‐oleate	   into	   the	   total	   lipid	   pool	   after	   24	   hours	   was	  
significantly	  lower	  (1.7-­‐fold)	  in	  myotubes	  from	  T2D	  patients	  compared	  with	  obese	  controls	  
(16.3	  ±	  2.40	  vs.	  9.5	  ±	  0.78	  nmol/mg	  protein	  for	  C	  and	  T2D,	  respectively,	  P=0.02,	  Figure	  5A).	  
Furthermore,	   14C-­‐oleate	   incorporation	   into	   TAGs	  was	   significantly	   lower	   in	   T2D	   patients	  
(2.24	  ±	  0.47	  and	  0.94	  ±	  0.25	  nmol/mg	  protein	  for	  C	  and	  T2D,	  respectively,	  P=0.03,	  Figure	  
5B).	   DAG	   synthesis	  was	   not	   significantly	   different	   between	   the	   two	   groups	   (0.17	   ±	   0.05	  
and	  0.10	  ±	  0.02	  nmol/mg	  protein,	  respectively,	  P=0.31,	  Figure	  5C).	  	  
	  
	  
Figure	  5.	  Lipid	  synthesis	   in	  primary	  myotubes.	   Incorporation	  of	   14C-­‐oleate	  was	  measured	  after	  24h	  
incubation	   with	   400	   µM	   oleate	   in	   the	   absence	   of	   carnitine.	   (A)	   Total	   lipid	   synthesis.	   (B)	   TAG	  
synthesis.	  (C)	  DAG	  synthesis.	  *P<0.05.	  Error	  bars	  represent	  SEM.	  
	  
After	   24h	   incubation	   with	   oleate,	   oxidation	   was	   initiated	   by	   addition	   of	   carnitine	   and	  
measured	   after	   3	   hours.	   Interestingly,	   even	   despite	   reduced	   14C-­‐oleate	   incorporation	   in	  
TAG	   in	  T2D	  patients,	   the	  oxidation	  of	  endogenous	  14C-­‐oleate	  to	  CO2	  was	  not	  different	   in	  
obese	  controls	   versus	  T2D	  myotubes	   (0.009	  ±	  0.002	  vs.	  0.006	  ±	  0.002	  nmol/mg	  protein,	  
respectively,	   P=0.384;	   Figure	   6A).	   Likewise,	   oxidation	   to	   ASMs	  was	   similar	   between	   the	  
two	   groups	   (0.070	   ±	   0.012	   vs.	   0.058	   ±	   0.015	   nmol/mg	   protein,	   P=0.543;	   for	   C	   and	   T2D	  
respectively;	  Figure	  6B).	  Consequently,	  no	  differences	  were	  observed	  in	  the	  ratio	  of	  CO2	  to	  
ASMs	   (0.126	   ±	   0.032	   vs.	   0.093	   ±	   0.033,	   P=0.49;	   for	   C	   and	   T2D	   respectively;	   Figure	   6C).	  
Thus,	   in	   concert	   with	   the	   oxidation	   rates	   of	   exogenous	   14C-­‐palmitate,	   oxidation	   of	   the	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Figure	   6.	   In	   vitro	   endogenous	   14C-­‐oleate	   oxidation.	   Primary	  myotubes	   were	   loaded	   with	   400	  µM	  
oleate	   for	   24h	   and	   then	   pulsed	   in	   the	   presence	   of	   1	   mM	   carnitine	   for	   3h.	   Oxidation	   rates	   were	  
measured	   during	   this	   3h	   pulse	   period.	   (A)	   14C-­‐oleate	   oxidation	   to	   CO2.	   (B)	  
14C-­‐oleate	   oxidation	   to	  
ASMs.	  (C)	  Ratio	  CO2:ASMs.	  Error	  bars	  represent	  SEM.	  
	  
DISCUSSION	  
Obesity	  and	  type	  2	  diabetes	  (T2D)	  are	  associated	  with	  ectopic	  lipid	  accumulation	  in	  tissues	  
such	   as	   skeletal	   muscle	   [1,	   26-­‐29].	   IMCL	   content	   inversely	   correlates	   with	   peripheral	  
insulin	   sensitivity	   [30-­‐33],	   suggesting	   that	   fat	   accumulation	   leads	   to	   insulin	   resistance.	  
However,	   recent	   studies	   suggest	   that	   increasing	   the	   TAG	   storage	   capacity	   may	   be	  
beneficial	   [34-­‐36].	   Here,	   we	   investigated	   the	   oxidative	   and	   storage	   capacities	   of	   both	  
skeletal	  muscle	   tissue	  and	  myotubes	  established	   from	  satellite	   cells	  of	  obese	   individuals	  
with	   T2D	   and	   their	   BMI-­‐matched	   non-­‐diabetic	   controls.	   We	   show	   that	   oxidation	   and	  
incorporation	   of	   an	   exogenously	   supplied	   long-­‐chain	   FA	   (LCFA,	   palmitate)	   into	   TAGs	   are	  
significantly	  blunted	   in	  muscle	  tissue	  from	  T2D	   individuals.	   Importantly,	  we	  demonstrate	  
that	   this	   blunted	   FA	   oxidative	   capacity	   is	   not	   retained	   in	   the	   myotubes.	   However,	   the	  
myotubes	  of	  the	  T2D	  individuals	  did	  show	  reduced	  incorporation	  of	  exogenous	  palmitate	  
into	  TAG,	  and	   this	  was	   significantly	   related	   to	   the	   impaired	  palmitate	   incorporation	   into	  
TAG	  observed	  ex	  vivo.	  Moreover,	  incorporation	  of	  oleate	  into	  the	  total	  neutral	  lipid	  pool,	  
specifically	   the	   TAG	   pool,	   after	   prolonged	   FA	   incubation	   in	   the	   absence	   of	   carnitine	  
supplementation	  was	  significantly	  reduced	  in	  the	  myotubes	  from	  the	  T2D	  subjects.	  Since	  
the	   absence	   of	   carnitine	   prevents	   FA	   oxidation,	   this	   measurement	   mainly	   reflects	  
unidirectional	  TAG	  synthesis.	  Therefore,	  we	  conclude	  that	   lower	   lipid	   incorporation	   is	  an	  
inherent	   metabolic	   characteristic	   of	   myotubes	   of	   T2D	   individuals	   compared	   with	   BMI-­‐
matched	  obese	  controls.	  
	   We	  show	  a	  blunted	  complete	  oxidation	  of	  palmitate	  in	  the	  skeletal	  muscle	  tissue	  of	  
obese	  individuals	  with	  T2D	  compared	  with	  their	  BMI-­‐matched	  controls.	  As	  there	  were	  no	  
differences	   in	   the	   acid-­‐soluble	  metabolites	   (ASMs),	   the	   ratio	   of	   complete	   to	   incomplete	  
oxidation	  was	  also	  reduced	  in	  T2Ds.	  These	  findings	  extend	  those	  of	  Hulver	  et	  al.	  [37],	  who	  
demonstrated	   aberrant	   exogenous	   FA	   oxidation	   in	   the	   skeletal	   muscle	   of	   obese	   and	  
severely	  obese	  (BMI	  53.8	  ±	  3.5	  kg/m2)	  individuals	  compared	  with	  lean	  controls	  [37].	  In	  this	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independent	   of	   BMI.	   Interestingly	   though,	   we	   did	   not	   observe	   significant	   differences	   in	  
oxidation	  of	  exogenous	  palmitate	  to	  CO2	  and	  ASMs	  between	  myotubes	  of	  T2Ds	  and	  obese	  
controls.	   Additionally,	   we	   examined	   if	   FA	   oxidation	   from	   endogenous	   lipid	   pools	   was	  
compromised	  in	  T2D	  myotubes.	  After	  an	  overnight	  loading	  of	  the	  myocyte	  lipid	  pool	  with	  
oleate,	   no	   differences	   in	   endogenous	   FA	   oxidation	   rates	   between	   obese	   and	   T2D	  
myotubes	   were	   observed.	   This	   contrasts	   with	   the	   findings	   of	   Gaster	   et	   al.	   [23]	   who	  
demonstrated	   that	   complete	   oxidation	   of	   endogenous,	   but	   not	   exogenous,	   FAs	   was	  
reduced	   in	   T2D	  myotubes	   compared	   with	   obese	   controls.	   However,	   Gaster	   et	   al.	   show	  
reduced	  oxidation	  of	  palmitate	  in	  T2D	  myotubes	  after	  chronic	  incubation	  (four	  days)	  with	  
600μM	  palmitate	  [23],	  which	  presumably	  represents	  a	  combination	  of	  inherent	  oxidative	  
capacity	   and	   susceptibility	   to	   palmitate-­‐associated	   lipotoxicity.	   Our	   data	   suggest	   that	   a	  
reduced	  myocellular	  fat	  oxidative	  capacity	  in	  T2D	  patients	  may	  not	  be	  an	  inherent	  quality,	  
but	  rather	  a	  consequence	  of	  their	  environment.	  	  
It	  was	  recently	  shown	  that	  one	  bout	  of	  exercise	  improves	  the	  capacity	  to	  store	  TAG	  in	  
muscle	  and	  thereby	  prevents	  lipid-­‐induced	  insulin	  resistance	  [36].	  Moreover,	  by	  use	  of	  in	  
vivo	   infusion	   of	   13C-­‐palmitate,	   Bergman	   et	   al.	   [38]	   showed	   that	   palmitate	   incorporation	  
into	   skeletal	   muscle	   TAG	   was	   increased	   in	   endurance	   trained	   athletes	   compared	   with	  
sedentary	  controls.	  Here	  we	  found	  that	  incorporation	  of	  palmitate	  into	  TAGs,	  but	  not	  into	  
DAGs,	  was	  blunted	  in	  skeletal	  muscle	  of	  T2D	  patients.	  Collectively,	  these	  reports	  indicate	  
that	  increased	  channeling	  of	  FAs	  towards	  storage	  in	  the	  form	  of	  TAGs	  in	  skeletal	  muscle	  is	  
associated	  with	  an	  improved	  metabolic	  profile.	  In	  contrast	  to	  reduced	  oxidative	  capacity	  in	  
T2D,	  which	  was	  not	   retained	   in	   the	  myotubes,	   reduced	   incorporation	  of	  FAs	   into	  TAG	   in	  
T2D	  was	   retained	   in	   the	  myotubes.	   By	   reducing	   lipid	   intermediate	   accumulation,	   a	   high	  
capacity	  to	  channel	  FAs	  towards	  intramyocellular	  neutral	  lipid	  –TAGs–	  storage	  may	  protect	  
against	  lipid-­‐induced	  insulin	  resistance.	  Thus,	  a	  reduced	  rate	  of	  TAG	  storage	  in	  T2D	  may	  be	  
an	   important	   factor	   in	   the	   development	   of	   lipid-­‐induced	   insulin	   resistance	   in	   these	  
patients.	  	  
A	  possible	  explanation	  for	  the	  retained	  aberrant	  lipid	  incorporation	  capacity	  might	  be	  
that	  the	  relative	  abundance	  and	  capacities	  of	  enzymes	  involved	  in	  neutral	  lipid	  synthesis,	  
lipid	  droplet	   synthesis	   and	   stability	   are	   compromised.	   For	   example,	  we	  and	  others	  have	  
previously	  demonstrated	   that	   increasing	   the	  abundance	  of	  diacylglycerol	   acyltransferase	  
(DGAT)	  –	  the	  rate-­‐limiting	  enzyme	  for	  the	  final	  step	  in	  TAG	  synthesis	  -­‐	  or	  perilipin	  2	  (PLIN2)	  
or	  PLIN5	  –	  lipid	  droplet	  coat	  proteins	  –	  increases	  the	  intramyocellular	  TAG	  content	  [34,	  35,	  
39,	  40].	  Future	  studies	  should	  investigate	  the	  inherent	  pathways	  in	  muscle	  lipid	  turnover	  
in	  order	  to	  identify	  the	  critical	  regulation	  sites.	  	  
The	  finding	  that	  the	  capacity	  to	  incorporate	  FAs	  into	  TAGs	  is	  reduced	  in	  T2D	  patients,	  
combined	  with	  a	  similar	  fat	  oxidative	  capacity,	  seems	  incompatible	  with	  similar	  or	  higher	  
IMCL	  content	  in	  T2D	  muscle	  [6,	  41-­‐43].	  One	  explanation	  for	  this	  discrepancy	  could	  be	  an	  
altered	   FA	   uptake	   into	  muscle.	   Skeletal	  muscle	   FA	   uptake	   is	   a	   controversial	   topic,	   with	  
some	   investigators	   finding	   no	   difference	   in	   uptake	   of	   FAs	   [7,	   8],	   while	   others	   show	  
increased	  FA	  uptake	  in	  skeletal	  muscle	  of	  obese	  and	  T2D	  individuals	  [9].	  Here	  we	  could	  not	  
detect	  differences	  in	  FA	  uptake	  rates	  in	  cultured	  myotubes	  of	  T2D	  patients	  compared	  with	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obese	   controls.	  However,	   it	   should	  be	  noted	   that	   the	  measurement	  of	   FA	   incorporation	  
into	  TAG	  is	  a	  capacity	  measurement	  and	  illustrates	  the	  capacity	  to	  redirect	  FAs	  into	  TAG	  in	  
a	  given	  period	  of	  time.	  Alterations	  in	  lipolysis	  or	  increased	  24h	  FA	  flux	  into	  muscle	  in	  T2D	  
patients	  could	  explain	  why	  IMCL	  content	  may	  be	  higher	  in	  the	  long	  term	  situation.	  
It	  should	  be	  noticed	  that	  a	  potential	   limitation	  of	  this	  study	   is	   the	   lower	  VO2max	   in	  
the	  diabetics,	  which	  may	  affect	  the	  ex	  vivo	  findings.	  Hence,	  the	  lower	  palmitate	  oxidation	  
to	  CO2	  observed	  in	  the	  diabetics	  ex	  vivo	  may	  partly	  be	  explained	  by	  lower	  physical	  fitness.	  
Nevertheless,	   the	   strength	   of	   the	   present	   study	   is	   the	   incorporation	   of	   the	   in	   vitro	  
experiments,	  in	  which	  we	  show	  that	  -­‐	  in	  contrast	  to	  oxidative	  capacity	  -­‐	  FA	  incorporation	  
into	  TAG	  is	  inherently	  perturbed	  in	  obese	  individuals	  with	  type	  2	  diabetes	  compared	  with	  
their	  BMI-­‐matched	   controls.	  Our	   results	   are	   consistent	  with	   the	   view	   that	   IMCL	   content	  
and	  lipid	  turnover	  have	  a	  significant	  impact	  on	  insulin	  sensitivity	  and	  glucose	  homeostasis	  
since	   the	   ex	   vivo	   and	   in	   vitro	   findings	   corresponded	   with	   these	   markers	   of	   in	   vivo	  
metabolic	   health.	   Future	   studies	   using	   primary	   human	  muscle	   cell	  models	  with	  muscle-­‐
specific	   modulations	   of	   the	   lipid	   turnover	   pathways	   may	   help	   to	   unravel	   the	   specific	  
regulation	   sites	   of	   skeletal	   muscle	   and	   whole-­‐body	   energy	   metabolism	   in	   vivo.	   These	  
findings	  could	  have	  profound	  implications	  for	  how	  we	  utilize	  precision	  medicine	  to	  treat,	  
manage	  and	  prevent	  type	  2	  diabetes	  moving	  forward.	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Supplemental	   Figure	   1.	  Correlation	   of	   the	   ratio	   14C-­‐palmitate	   oxidation	   to	   CO2:ASMs	  with	   (A)	   the	  
VO2max	  and	  (B)	  the	  fasting	  plasma	  glucose	  level.	  
	  
















































	  	   87	  
	  
	  




Perilipin	  2	  improves	  insulin	  sensitivity	  in	  skeletal	  




Madeleen	  Bosma,	  Matthijs	  K.C.	  Hesselink,	  Lauren	  M.	  Sparks,	  	  
Silvie	  Timmers,	  Maria	  João	  Ferraz,	  Frits	  Mattijssen,	  Denis	  van	  Beurden,	  	  





Diabetes	  2012;	  61:	  2679-­‐2690	  
PLIN2	  improves	  insulin	  sensitivity	  
	  88	  
ABSTRACT	  
Type	   2	   diabetes	   is	   characterized	   by	   excessive	   lipid	   storage	   in	   skeletal	  muscle.	   Excessive	  
intramyocellular	   lipid	   storage	   exceeds	   intracellular	   needs	   and	   induces	   lipotoxic	   events	  
ultimately	  contributing	  to	  the	  development	  of	  insulin	  resistance.	  Lipid	  droplet	  (LD)-­‐coating	  
proteins	  may	   control	   proper	   lipid	   storage	   in	   skeletal	  muscle.	   Perilipin	   2	   (PLIN2/ADRP)	   is	  
one	   of	   the	  most	   abundantly	   expressed	   LD-­‐coating	   proteins	   in	   skeletal	  muscle.	   Here	  we	  
examined	   the	   role	   of	   PLIN2	   in	   myocellular	   lipid	   handling	   and	   insulin	   sensitivity	   by	  
investigating	   the	   effects	   of	   in	   vitro	   PLIN2	   knockdown	   and	   in	   vitro	   and	   in	   vivo	  
overexpression.	   PLIN2	   knockdown	   decreased	   LD	   formation	   and	   triacylglycerol	   storage,	  
marginally	   increased	   FA	   oxidation,	   and	   increased	   incorporation	   of	   palmitate	   into	  
diacylglycerols	   and	   phospholipids.	   PLIN2	   overexpression	   in	   vitro	   increased	  
intramyocellular	  TAG	  storage	  paralleled	  with	   improved	   insulin	  sensitivity.	   In	  vivo	  muscle-­‐
specific	  PLIN2	  overexpression	  resulted	  in	  increased	  LD	  accumulation	  and	  blunted	  the	  high-­‐
fat	   diet-­‐induced	   increase	   of	   OXPHOS	   protein	   content.	   Diacylglycerol	   levels	   were	  
unchanged,	  while	  ceramide	  levels	  were	  increased.	  Despite	  the	  increased	  intramyocellular	  
lipid	  accumulation,	  PLIN2	  overexpression	  improved	  skeletal	  muscle	  insulin	  sensitivity.	  We	  
conclude	   that	   PLIN2	   is	   essential	   for	   lipid	   storage	   in	   skeletal	   muscle	   by	   enhancing	   the	  
partitioning	   of	   excess	   FAs	   towards	   TAG	   storage	   in	   LDs	   thereby	   blunting	   lipotoxicity-­‐




Lipid	  droplets	  serve	  an	  essential	  function	  in	  eukaryotic	  cells.	  Accordingly	  intracellular	  lipid	  
levels	  need	  to	  be	  tightly	  controlled.	  Indeed,	  inappropriate	  intracellular	  lipid	  storage	  leads	  
to	  impaired	  cellular	  function.	  In	  obesity,	  lipids	  will	  overflow	  into	  the	  circulation	  as	  a	  result	  
of	  lack	  of	  storage	  capacity	  in	  adipose	  tissue	  and	  as	  a	  consequence	  lipids	  may	  accumulate	  
ectopically	  in	  tissues	  including	  skeletal	  muscle	  (intramyocellular	  lipids,	  IMCL).	  This	  ectopic	  
fat	  storage	  exceeds	  intracellular	  demand	  and	  may	  result	   in	   lipotoxic	  events	   including	  the	  
development	  of	   insulin	  resistance	  (reviewed	  in	  [1,	  2]).	  Paradoxically,	   IMCL	  is	   increased	  in	  
both	  endurance-­‐trained	  athletes	  and	  type	  2	  diabetic	  patients	  [3,	  4],	  indicating	  that	  ectopic	  
lipid	  accumulation	  per	  se	  does	  not	  induce	  insulin	  resistance.	  	  
Thus	   far,	   explanations	   for	   this	   athlete’s	   paradox	   have	   focused	   on	   lipid	   turnover,	  
oxidative	   capacity,	   and	   levels	   of	   lipid	   intermediates	   [5-­‐8].	   Interestingly,	   one	   exercise	  
session	  was	   shown	   to	  prevent	   lipid-­‐induced	   insulin	   resistance	  by	  partitioning	  more	   fatty	  
acids	   towards	   triacylglycerol	   (TAG)	  synthesis	   in	   skeletal	  muscle	   [9].	  Therefore,	   increasing	  
the	  depot	  for	  TAG	  storage	  might	  improve	  insulin	  sensitivity.	  Intracellular	  TAG	  is	  stored	  in	  
lipid	   droplets,	   which	   are	   increasingly	   recognized	   as	   dynamic	   organelles.	   They	   are	  
composed	  of	  a	  neutral	   lipid	  core	  containing	  TAG,	  diacylglycerol	   (DAG),	  cholesterolesters,	  
retinol	  esters,	  and	  free	  cholesterol	  [10]	  surrounded	  by	  a	  phospholipid	  monolayer	  [11]	  and	  
a	   protein	   coat,	   composed	   of	   a	   variety	   of	   LD-­‐coating	   proteins	   (reviewed	   in	   [12]).	  
Accumulating	  evidence	  suggests	   that	  LD-­‐coating	  proteins	  mediate	  LD	  dynamics	   including	  
LD	   synthesis,	   growth	   and	   fusion,	   intracellular	   transport,	   organelle	   interactions,	   and	   LD	  
breakdown	  and	  lipolysis	  (reviewed	  in	  [13,	  14].	  	  
	   The	   best	   characterized	   family	   of	   LD-­‐coating	   proteins	   is	   the	   PLIN	   protein	   family,	  
including	   perilipin	   (PLIN1),	   perilipin	   2	   (PLIN2,	   adipophilipin,	   ADRP),	   perilipin	   3	   (PLIN3,	  
TIP47),	   perilipin	   4	   (PLIN4,	   S3-­‐12),	   and	   perilipin	   5	   (PLIN5,	   OXPAT).	   Whereas	   PLIN1	  
expression	   is	   restricted	   to	   adipose	   tissue,	  where	   it	   plays	   a	   crucial	   role	   in	   the	   control	   of	  
storage	   and	   degradation	   of	   lipid	   droplets	   [15,	   16],	   PLIN2	   is	   expressed	   in	   several	   tissues	  
including	   liver,	  small	   intestine	  and	  skeletal	  muscle	   [17,	  18].	  PLIN2	   in	  skeletal	  muscle	  was	  
previously	   shown	   to	   colocalize	  with	   IMCL	   [19].	   Interestingly,	   skeletal	  muscle	  PLIN2	  gene	  
expression	   was	   shown	   to	   be	   lower	   in	   type	   2	   diabetics	   versus	   obese	   controls	   [20].	  
Furthermore,	  weight	   loss	   as	  well	   as	  metformin	   treatment,	   both	   resulting	   in	   lower	   IMCL	  
levels	  [21,	  22],	  were	  demonstrated	  to	  increase	  skeletal	  muscle	  PLIN2	  levels	  in	  parallel	  with	  
improved	   insulin	   sensitivity	   [23].	   PLIN2	   may	   be	   involved	   in	   the	   protection	   against	  
lipotoxicity	   by	   facilitating	   efficient	   IMCL	   storage	   in	   the	   form	  of	   TAG.	  However,	   loss-­‐	   and	  
gain	   of	   function	   studies	   to	   characterize	   PLIN2	   function	   in	   skeletal	   muscle,	   required	   to	  
obtain	  more	  functional	  insight	  into	  the	  role	  of	  PLIN2	  in	  muscle,	  have	  not	  been	  performed	  
to	   date.	   Here	   we	   aimed	   to	   examine	   the	   role	   of	   PLIN2	   in	  myocellular	   fat	   accumulation,	  
lipotoxicity	  and	  insulin	  sensitivity.	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MATERIALS	  AND	  METHODS	  
Cell	  culture	  experiments	  	  
C2C12	   cells	   (LGC	   standards,	   Teddington,	   USA)	   were	   maintained	   in	   DMEM	   (Invitrogen,	  
Breda,	   The	   Netherlands)	   containing	   antibiotics	   supplemented	   with	   10%	   FCS,	   grown	   on	  
ECM	  matrigel	   (Sigma,	  St.	   Louis,	  USA)	  coated	  cell	   culture	  plates	   (Greiner	  Bio-­‐One,	  Alphen	  
aan	   de	   Rijn,	   The	   Netherlands),	   and	   differentiated	   over	   the	   course	   of	   a	   week	   in	   DMEM	  
supplemented	  with	   2%	   FCS	   (differentiation	  media).	   Cells	  were	   treated	  with	   200–800µM	  
fatty	  acids	  (6-­‐24h)	  (octanoic	  acid,	  oleic	  acid	  or	  palmitic	  acid	  conjugated	  to	  BSA,	  ratio	  BSA	  
to	  FA	  1:2.5),	  or	  solely	  BSA	  as	  a	  control.	  For	  RNAi	  experiments,	  cells	  were	  transfected	  with	  
10	   nM	   Stealth	   RNAi	   oligos	   using	   Lipofectamine	   RNAiMAX	   (Invitrogen,	   Breda,	   The	  
Netherlands)	  as	  transfection	  reagent.	  PLIN2	  overexpression	  was	  achieved	  by	  transfections	  




In	   vitro	   14C-­‐palmitate	   metabolism	   was	   measured	   as	   described	   [24].	   Intracellular	  
triglyceride	  levels	  were	  measured	  using	  the	  method	  of	  Schwartz	  and	  Wolins	  [25].	  
	  
Glucose	  uptake	  assay	  
Glucose	  uptake	  was	  measured	  as	  described	  [26].	  
	  
Animal	  studies	  	  
C5Bl6	   mice	   were	   fed	   a	   low	   fat	   (10E%	   fat)	   or	   a	   high	   fat	   (45E%	   fat)	   diet	   (Research	   Diet	  
Services,	  Wijk	  bij	  Duurstede,	  The	  Netherlands)	  for	  8	  weeks.	  Tibialis	  anterior	  was	  dissected.	  
7-­‐week	   old	   male	   Wistar	   rats	   were	   purchased	   from	   Charles	   River	   (Wilmington,	  
Massachusetts,	  USA).	  Rats	  were	  fed	  either	  a	  chow	  diet	  (n=4)	  (SSNIFF®,	  Bio	  Services,	  Uden,	  
The	  Netherlands)	   or	   a	   high	   fat	   diet	   (n=12)	   (45%	   energy	   from	   fat,	   D01060502,	   Research	  
Diets,	   New	   Brunswick,	   NJ,	   USA).	   The	   Institutional	   Animal	   Care	   and	   Use	   Committee	   of	  
Maastricht	  University	   approved	   the	   experiments.	   The	   total	   intervention	   lasted	   3	  weeks.	  
One	   week	   after	   the	   start	   of	   the	   diets,	   rats	   were	   cannulated,	   followed	   by	   gene	  
electroporation	   and	   the	   hyperinsulinemic	   euglycemic	   clamp,	   with	   one-­‐week	   recovery	  
periods	  in-­‐between.	  	  
	  
Electroporation	  	  
Overexpression	   of	   mouse	   PLIN2	   in	   the	   left	   tibialis	   anterior	   (TA)	   muscle	   of	   the	   rat	   was	  
accomplished	   by	   an	   in	   vivo	   DNA	   electroporation	   technique	   under	   isoflurane	   anesthesia.	  
Left	  TA	  muscles	  were	  transcutaneously	  injected	  with	  75	  µg	  pENTR1A-­‐pUC	  Plin2-­‐construct,	  
right	  TA	  muscles	  were	  injected	  with	  empty	  vector	  as	  a	  control.	  Within	  15	  s	  after	  the	  last	  
injection	  one	  high	  voltage	  pulse	  of	  800	  V/cm	  and	   four	   low	  voltage	  pulses	  of	  80	  V/cm	  at	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1Hz	  were	  generated	  by	  an	  ECM	  830	  electroporator	  (BTX,	  San	  Diego,	  CA,	  USA)	  as	  described	  
before	  [27].	  	  
	  
Hyperinsulinemic	  euglycemic	  clamp	  
Clamps	  were	  performed	  as	  previously	  described	  [28].	  Briefly,	  after	  a	  6h	  fast,	  a	  continuous	  
infusion	  of	   insulin	  was	  administered	  at	  a	  rate	  of	  13	  mU/kg/min	  for	  120	  min.	  The	  glucose	  
infusion	   rate	  was	   adjusted	   to	  maintain	   blood	   glucose	   concentration	  within	   the	   range	  of	  
4.5-­‐5.5	  mM.	  Rats	  were	  conscious	  during	  the	  full	  procedure.	  45	  min	  before	  completion	  of	  
the	  clamp,	  a	  bolus	  of	  140	  µCi/kg	  of	  2-­‐[3H(N)]-­‐deoxy-­‐D-­‐glucose	  was	  administered.	  	  
	  
Lipid	  species	  
Skeletal	  muscle	  DAG,	  TAG	  and	  ceramide	  levels	  were	  measured	  as	  described	  [28].	  
	  
Western	  blots	  
Western	  blotting	  studies	  were	  performed	  using	  antibodies	  directed	  against	  PLIN2	  (Progen,	  
Heidelberg,	   Germany),	   PLIN3	   (Santa	   Cruz,	   Heidelberg,	   Germany),	   PLIN5	   (Progen,	  
Heidelberg,	   Germany),	   pAkt	   and	   Akt,	   ATGL	   (Cell	   Signalling	   Technology,	   Leiden,	   the	  
Netherlands),	  CGI-­‐58	  (Novus	  Biologicals,	  Littleton,	  USA),	  PGC1α	  (Calbiochem,	  Amsterdam,	  
The	   Netherlands),	   UCP3	   (kindly	   provided	   by	   L.J.	   Slieker,	   Eli	   Lilly),	   and	   OXPHOS	  
(Mitosciences,	  Eugene,	  Oregon,	  USA).	  Protein	  expression	  values	  were	  standardized	  against	  
actin	   protein	   expression	   (Sigma,	   St.	   Louis,	   USA).	   Secondary	   antibodies	   contained	   an	  
infrared	   dye	   (IRdye).	   Protein	   quantification	   was	   performed	   by	   scanning	   on	   an	   Odyssey	  
Infrared	  Imaging	  system	  (LI-­‐COR	  Biotechnology,	  Lincoln,	  Nebraska,	  USA).	  	  
	  
Statistical	  analysis	  
Differences	  between	  groups	  were	  evaluated	  with	  Univariate	  ANOVA	  followed	  by	  Tukey's	  
honestly	   significant	   difference	   post-­‐hoc	   tests	   (cell	   studies),	   unpaired	   (cell	   studies)	   or	  
paired	  T-­‐tests	  (animal	  experiments).	  P<0.05	  was	  considered	  statistically	  significant.	  	  
	  
RESULTS	  
PLIN2	  protein	  expression	  is	  induced	  upon	  lipid	  loading	  	  
We	   first	   examined	   if	   TAG	   accumulation	   in	   myotubes	   is	   indeed	   associated	   with	   altered	  
expression	  of	  PLIN2.	  To	   this	  end,	  C2C12	  mouse	  myotubes	  were	   incubated	  with	  different	  
types	   of	   fatty	   acids	   (FAs)	   (200	   µM)	   (Fig.	   1A).	   Octanoate,	   a	   short-­‐chain	   fatty	   acid	   that	   is	  
preferentially	  oxidized,	  did	  not	  increase	  TAG	  levels,	  whereas	  incubation	  with	  either	  oleate	  
or	  palmitate	  led	  to	  marked	  accumulation	  of	  myocellular	  TG	  as	  well	  as	  an	  increase	  in	  PLIN2	  
protein	   expression.	   The	   induction	   of	   PLIN2	   protein	   levels	   was	   dependent	   on	   FA	  
concentration,	   but	   reached	   the	   maximal	   induction	   at	   a	   FA	   concentration	   of	   200	   µM	  
(Supplementary	  Fig.	  1A),	  and	  on	  FA	  incubation	  time,	  when	  the	  FA	  concentration	  was	  held	  
constant	   at	   200	  µM	   (Supplementary	   Fig.	   1B).	  Next	  we	  determined	   the	   in	   vivo	   effects	  of	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lipid	  overload	  on	  PLIN2	  protein	  content.	  We	  found	  that	  both	  an	  8-­‐week	  HFD	  (Figure	  1B)	  
and	  6	  or	  24h	  hours	  of	  fasting	  (Supplementary	  Fig.	  1C)	  significantly	  increased	  PLIN2	  protein	  
levels	  in	  mouse	  skeletal	  muscle.	  
	  
Knockdown	  of	  PLIN2	  increases	  the	  cellular	  oxidative	  capacity	  	  
The	   lack	   of	   LD	   storage	   capacity	   in	   PLIN2	   knockdown	   cells	   may	   be	   compensated	   by	  
enhanced	   fat	   oxidative	   capacity	   or	   reduced	   fatty	   acid	   uptake.	   To	   investigate	   these	  
possibilities,	  we	  used	  an	  unbiased	  approach	  by	  implementing	  a	  whole	  genome	  expression	  
analysis	  in	  the	  PLIN2	  knockdown	  cells	  (Fig.	  2	  and	  Table	  1).	  Specifically,	  overrepresentation	  
analysis	  of	   functional	  Gene	  Ontology	  classes	  showed	  suppression	  of	  numerous	  pathways	  
related	   to	   fatty	   acid	   transport	   and	   lipid	   storage	   (Fig.	   2).	   Examples	   of	   genes	   that	   were	  
downregulated	  upon	  PLIN2	  knockdown	  include	  Fads2	  and	  Agpat9	  (Table	  1).	  Furthermore,	  
Gene	  Ontology	  classes	  corresponding	  to	  respiratory	  electron	  transport	  chain	  and	  glucose/	  
carbohydrate	   metabolism	   were	   increased	   upon	   PLIN2	   knockdown	   (Fig.	   2),	   indicating	   a	  
compensatory	  increase	  in	  expression	  of	  genes	  involved	  in	  mitochondrial	  function	  (average	  
PLIN2	   knockdown	   effect	   across	   treatment	   conditions:	   Pgc1α	   FC=3.2,	   Mterf	   FC=2.2,	  
Mrps33	  FC=1.5,	  Mfn1	  FC=1.3,	  Mtrf1l	  FC=1.8)	  (Table	  1).	  
	   Consistent	  with	   the	   gene	   expression	   levels,	   knockdown	   of	   PLIN2	   increased	   protein	  
expression	   of	  OXPHOS	   complexes	   (Fig.	   3A	   and	   Fig	   S3)	   (total	  OXPHOS	  Univariate	  ANOVA	  
PLIN2	   knockdown	   effect	   P<0.05,	   Complex	   I:	   P=0.095,	   II:	   P=0.052,	   III:	   P<0.05,	   and	   V:	  
P<0.01).	   Therefore,	   we	   next	   investigated	   whether	   PLIN2	   knockdown	   resulted	   in	   a	  
compensatory	  increased	  capacity	  to	  oxidize	  fat	  in	  order	  to	  deal	  with	  the	  lower	  capacity	  for	  
lipid	   storage	   by	   measuring	   14C-­‐palmitate	   oxidation.	   Knockdown	   of	   PLIN2	   tended	   to	  
increase	   total	   14C-­‐palmitate	   oxidation	   (P=0.055)	   (Fig.	   3B).	   However,	   complete	   14C-­‐
palmitate	  oxidation	  to	  CO2	  was	  not	  affected	  (Fig.	  3C).	   Instead,	  the	  tendency	  to	  increased	  
14C-­‐palmitate	  oxidation	   can	  probably	  be	  ascribed	   to	  an	   increase	   in	   incomplete	  oxidation	  
(acid	   soluble	   metabolites-­‐ASMs)	   (P=0.108,	   Fig.	   3D).	   Thus,	   PLIN2-­‐knockdown	   effects	   on	  
palmitate	  oxidation	  were	  modest,	  indicating	  that	  the	  increased	  mitochondrial	  density	  only	  





Figure	   1.	   PLIN2	   knockdown	   lowers	   intracellular	   neutral	   lipid	   accumulation.	   (A)	   C2C12	   myotubes	  
were	   incubated	   overnight	   with	   80µM	   BSA	   complexed	   to	   200µM	   oleate	   (OA),	   palmitate	   (PA),	  
octanoate	   (OctA),	   or	   solely	   BSA	   as	   a	   control.	   PLIN2	   and	   TAG	   levels	   are	   expressed	   as	   fold	   change	  
relative	  to	  the	  control	  treatment.	  *P<0.05	  compared	  with	  the	  control	  treatment.	  (B)	  PLIN2	  protein	  
expression	  in	  tibialis	  anterior	  muscle	  of	  C57Bl6	  mice	  fed	  a	  high	  fat	  or	  normal	  chow	  diet	  for	  8	  weeks.	  
(C-­‐F)	   C2C12	   myotubes	   were	   transfected	   with	   PLIN2	   siRNA	   (P2)	   or	   a	   scrambled	   control	   (S)	   and	  
incubated	  overnight	  with	  200µM	  BSA-­‐coupled	  oleate,	  palmitate	  or	  solely	  80µM	  BSA.	  Subsequently,	  
cells	   were	   harvested	   to	  measure	   PLIN2	   protein	   expression	   (C)	   and	   TAG	   levels	   (F).	   #P<0.05	   versus	  
control	  (FA	  effect),	  *P<0.05	  versus	  scrambled	  control	  with	  the	  corresponding	  FA	  treatment.	  Data	  are	  
expressed	  as	  mean	  ±	  SEM,	  n=3-­‐4.	  (D	  and	  E)	  Electron	  microscopy	  pictures;	  (E)	  highlights	  the	  oleate-­‐
treatment	  condition	  (increased	  LD	  size	  upon	  PLIN2	  knockdown).	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PLIN2	  is	  essential	  for	  intracellular	  LD	  storage	  	  
To	   obtain	   further	   insight	   into	   the	   importance	   of	   PLIN2	   for	   efficient	   TAG	   storage,	   we	  
knocked-­‐down	   PLIN2	   in	   myotubes	   using	   siRNA.	   Compared	   to	   PLIN2	   levels	   in	   cells	  
transfected	   with	   a	   scrambled	   control	   oligo,	   PLIN2	   mRNA	   levels	   were	   reduced	   by	   90%	  
(Supplementary	  Fig.	  2A)	  and	  protein	  levels	  decreased	  with	  85%	  on	  average	  (Fig.	  1C).	  The	  
knockdown	   of	   PLIN2	   prevented	   FA-­‐induced	   TAG	   accumulation	   and	   LD	   formation	   even	  
upon	   oleate	   or	   palmitate	   incubation,	   demonstrating	   that	   PLIN2	   is	   essential	   for	   TAG	  
storage	   in	   LDs	   (Fig.	   1D-­‐F).	   Protein	   expression	   of	   the	   LD-­‐coating	   protein	   PLIN3	   was	   not	  
affected	   by	   PLIN2	   knockdown,	   excluding	   a	   compensatory	   increase	   of	   this	   protein	  
(Supplementary	  Fig.	  2B).	  Please	  note	  that	  the	  LD-­‐coating	  proteins	  PLIN1,	  PLIN4	  and	  PLIN5	  
are	  not	  expressed	  in	  C2C12	  cells.	  Electron	  microscopic	  imaging	  confirmed	  that	  oleate	  and	  
palmitate	   led	   to	   massive	   lipid	   accumulation	   in	   control	   cells,	   whereas	   this	   lipid	  
accumulation	  was	  largely	  absent	  after	  FA	  loading	  in	  the	  PLIN2	  knockdown	  cells	  (Fig.	  1D-­‐E).	  
The	   few	   LDs	   that	   were	   present	   in	   PLIN2	   knockdown	   cells	   were	   markedly	   larger	   in	   size	  
compared	  to	  control	  cells.	  	  
	  
	  
Figure	  2.	  Gene-­‐expression	  profiles.	  Selected	  pathways	  identified	  by	  Gene	  Score	  Resampling	  (GSR)	  in	  
ErmineJ.	   Only	   pathways	   that	   were	   significantly	   up-­‐	   or	   downregulated	   (P<0.05)	   are	   shown.	   The	  
enrichment	   score	   reflects	   the	   degree	   to	   which	   a	   gene	   set	   is	   overrepresented	   at	   the	   top	  
(upregulated,	  positive	  score)	  or	  bottom	  (downregulated,	  negative	  score)	  of	  the	  ranked	  gene	  list	  and	  
is	  corrected	  for	  gene	  set	  size.	  Black	  bars:	  control	  condition,	  grey	  bars:	  oleate,	  white	  bars:	  palmitate	  
treatment.	  Microarray	  data	  have	  been	  submitted	  to	  Gene	  Expression	  Omnibus	  (GSE38590).	  
	  
Knockdown	   of	   PLIN2	   increases	   palmitate	   incorporation	   into	   DAG	   and	  
phospholipids	  	  
In	   the	   PLIN2	   knockdown	   situation,	   the	   lack	   of	   the	   capacity	   to	   store	   FAs	   as	   TAG	   in	   LDs	  
resulted	  in	  a	  trend	  towards	  increased	  total	  FA	  oxidation,	  with	  the	  majority	  of	  14C-­‐palmitate	  




deal	  with	  FAs	  in	  the	  absence	  of	  cellular	  TAG	  storage	  capacity	  would	  be	  to	  store	  FAs	  in	  lipid	  
species	   other	   than	   TAG.	   Therefore,	   14C-­‐palmitate	   incorporation	   into	   total	   neutral	   lipids,	  
TAG,	  DAG,	  and	  phospholipids	  was	  determined.	  Compared	  with	  the	  scrambled	  control,	  a	  3h	  
14C-­‐palmitate	   incubation	   of	   PLIN2	   knockdown	   cells	   resulted	   in	   a	   lower	   incorporation	   of	  
palmitate	   in	   the	   total	   neutral	   lipid	   pool	   (P<0.01)	   (Fig.	   3E).	   Besides	   decreased	   total	  
intracellular	   lipid	   storage,	   FA	   incorporation	   into	   neutral	   lipids	   shifted	   from	  TAG	   towards	  
DAG	   and	   phospholipids.	   14C-­‐palmitate	   incorporation	   into	   phospholipids	   and	   DAG	   was	  
increased	  in	  the	  PLIN2	  knockdown	  cells	  compared	  with	  the	  scrambled	  control	  cells	  (P<0.01	  
and	  P<0.05,	  respectively),	  balancing	  the	  lower	  incorporation	  into	  TAG	  (P<0.01)	  (Fig.	  3F-­‐H).	  
PLIN2	  knockdown	  did	  not	  compromise	  insulin	  signaling	  (Fig.	  3I-­‐J,	  P=0.0528	  for	  basal	  pAkt,	  
P=0.82	  for	  insulin	  stimulated	  pAkt,	  P=0.094	  for	  deoxyglucose	  uptake).	  	  
In	  summary,	  PLIN2	  is	  essential	  for	  LD	  formation	  and	  stability	  and	  intracellular	  TAG	  storage.	  
PLIN2	  knockdown	  increases	  FA	  oxidation	  only	  marginally.	  	  
	  
Table	   1:	   Expression	   patterns	   of	   a	   selection	   of	   genes	   in	   the	   6	   treatment	   conditions,	   derived	   from	  
pools	  of	  4	  samples	  per	  treatment	  condition.	  





Gene	   GeneID	   Gene	  name	   C	   OA	   PA	   C	   OA	   PA	  



















Dgke	   56077	   Diacylglycerol	  kinase,	  ε	   1	   1.23	   0.66	   1.81	   2.02	   1.97	  
Fads2	   56473	   Fatty	  acid	  desaturase	  2	   1	   0.51	   1.30	   0.53	   0.33	   0.73	  
Pltp	   18830	   Phospholipid	  transfer	  protein	   1	   1.31	   0.83	   0.41	   0.44	   0.37	  
Smpdl3b	   100340	   Sphingomyelin	  phosphodiesterase,	  acid-­‐like	  3B	   1	   1.01	   0.88	   0.42	   0.41	   0.55	  
Elovl4	   83603	   Elongation	  of	  very	  long	  chain	  fatty	  acids-­‐like	  4	   1	   0.99	   0.85	   0.65	   0.70	   0.53	  
Agpat4	   68262	   1-­‐Acylglycerol-­‐3-­‐phosphate	  O-­‐acyltransferase	  4	  	   1	   1.01	   0.91	   0.51	   0.57	   0.57	  
Agpat9	   231510	   1-­‐Acylglycerol-­‐3-­‐phosphate	  O-­‐acyltransferase	  9	   1	   1.33	   1.42	   0.50	   0.61	   0.59	  
Dgat2	   67800	   Diacylglycerol	  O-­‐acyltransferase	  2	   1	   0.84	   0.75	   0.60	   0.53	   0.58	  
Dhrs3	   20148	   Dehydrogenase/reductase	  member	  3	   1	   1.30	   1.95	   0.58	   0.74	   0.66	  
Erlin2	   244373	   ER	  lipid	  raft	  associated	  2	   1	   1.12	   1.07	   1.70	   1.53	   1.70	  
Erlin1	   226144	   ER	  lipid	  raft	  associated	  1	   1	   1.25	   1.13	   1.47	   1.68	   1.70	  



















Mterf	   545725	   Mitochondrial	  transcription	  termination	  factor	   1	   2.17	   1.09	   4.02	   1.85	   2.02	  
Mrps33	   14548	   Mitochondrial	  ribosomal	  protein	  S33	   1	   1.33	   1.38	   2.00	   2.18	   1.30	  
Car3	   12350	   Carbonic	  anhydrase	  3	   1	   1.25	   0.82	   12.4	   12.7	   11.5	  
Mfn1	   67414	   Mitofusin	  1	   1	   1.01	   0.95	   1.29	   1.37	   1.31	  
Cpt1b	   12895	   Carnitine	  palmitoyltransferase	  1b,	  muscle	   1	   2.36	   1.40	   0.69	   1.19	   0.89	  





ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F0	  













Pdk2	   18604	   Pyruvate	  dehydrogenase	  kinase,	  isoenzyme	  2	   1	   0.98	   0.84	   1.74	   1.94	   1.68	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Expression	  levels	  in	  scrambled	  control	  cells	  without	  FA	  treatment	  was	  set	  at	  1	  and	  expression	  levels	  
in	  other	  groups	  were	  related	  to	  this	  reference	  condition.	  qPCRs	  were	  performed	  for	  a	  selection	  of	  
genes	   to	   validate	   the	   microarray	   data	   (Supplementary	   Fig.	   3).	   C:	   Control	   (BSA);	   OA:	   oleate;	   PA:	  
palmitate	  condition.	  
	  
PLIN2	   overexpression	   protects	   against	   palmitate-­‐induced	   impairments	   in	  
insulin-­‐stimulated	  glucose	  uptake	  
Lipid	  intermediate	  accumulation	  other	  than	  TAG	  storage	  is	  considered	  to	  negatively	  affect	  
insulin	  signaling	  [29],	  while	  efficient	  TAG	  storage	  is	  considered	  harmless	  [28,	  30].	  Results	  
from	  the	  PLIN2	  knockdown	  studies	  illustrate	  that	  PLIN2	  is	  necessary	  for	  efficient	  storage	  of	  
FAs	   into	   inert	   TAG.	   Therefore,	   we	   next	   investigated	   whether	   overexpression	   of	   PLIN2	  
could	   facilitate	   efficient	   muscle	   TAG	   storage,	   and	   thereby	   prevent	   fat-­‐induced	  
impairments	   in	   insulin	   signaling.	   Hence,	   we	   overexpressed	   PLIN2	   in	   vitro	   in	   order	   to	  
investigate	   its	   potential	   beneficial	   effects	   on	   intramyocellular	   lipid	   handling.	   PLIN2	  
overexpression	   resulted	   in	   a	   two-­‐fold	   increase	   in	   PLIN2	   expression	   (Fig.	   4A),	   a	   6-­‐fold	  
increased	   intracellular	   TAG	   storage	   (P=0.04)	   (Fig.	   4B),	   and	   increased	   14C-­‐palmitate	  
incorporation	   into	   total	   neutral	   lipids	   (P=0.013),	   DAG	   and	   TAG	   (P=0.003	   and	   P=0.042,	  
respectively)	  while	   decreasing	   its	   incorporation	   into	   phospholipids	   (P=0.006)	   (Fig.	   4C-­‐F).	  
We	  next	  tested	  if	  PLIN2-­‐facilitated	  intramyocellular	  TAG	  storage	  could	  prevent	  palmitate-­‐
induced	  disruptions	  in	  insulin	  signaling.	  To	  this	  end,	  PLIN2-­‐	  and	  empty	  vector	  transfected	  
C2C12	   myotubes	   were	   incubated	   overnight	   with	   400	   µM	   palmitate,	   known	   to	   impair	  
insulin	  signaling	  [31].	  In	  line	  with	  the	  hypothesis,	  PLIN2	  overexpression	  rescued	  palmitate-­‐
mediated	  impairments	  in	  insulin-­‐stimulated	  glucose	  uptake	  (Fig.	  4G)	  (P<0.05).	  	  
	  
	  
Mlycd	   56690	   Malonyl-­‐CoA	  decarboxylase	   1	   1.82	   1.01	   1.19	   1.67	   1.57	  
Atp13a5	   268878	   ATPase	  type	  13A5	   1	   1.05	   0.72	   2.85	   2.68	   2.31	  
Gk5	   235533	   Glycerol	  kinase	  5	  	   1	   1.00	   0.79	   1.35	   1.55	   1.60	  
Lctl	   235435	   Lactase-­‐like	   1	   0.64	   0.95	   0.31	   0.25	   0.29	  



















Fgf21	   56636	   Fibroblast	  growth	  factor	  21	   1	   0.77	   0.84	   0.21	   0.23	   0.20	  
Pld1	   18805	   Phospholipase	  D1	   1	   1.18	   0.83	   1.62	   1.56	   1.63	  
Atf3	   11910	   Activating	  transcription	  factor	  3	   1	   1.05	   1.97	   0.40	   0.43	   0.42	  
Igfbp3	   16009	   Insulin-­‐like	  growth	  factor	  binding	  protein	  3	   1	   0.70	   0.78	   4.71	   4.22	   4.00	  





Golgi	  associated,	  γ	  adaptin	  ear	  containing,	  ARF	  













Gpr56	   14766	   G	  protein-­‐coupled	  receptor	  56	   1	   0.59	   0.88	   0.09	   0.08	   0.09	  






















Figure	   3.	   Altered	   lipid	   metabolism	   and	   oxidative	   capacity	   in	   PLIN2	   knockdown	   cells.	   (A)	   Protein	  
expression	   of	   the	  OXPHOS	   complexes	   I,	   II,	   III	   and	   V	   in	   cell	   cultures	   transfected	  with	   either	   PLIN2	  
siRNA	  [P2]	  or	  scrambled	  control	  siRNA	  [S],	  expressed	  as	  arbitrary	  units	  (AU),	  n=4	  for	  each	  treatment	  
condition.	   (B-­‐E)	   Analysis	   of	   3h	   14C-­‐palmitate	   oxidation	   rates	   in	   PLIN2	   knockdown	   and	   negative	  
control	   cells;	   total	   oxidation	   (sum	   of	   14C-­‐CO2	   and	  
14C-­‐ASMs)	   (B),	   complete	   oxidation	   to	   CO2	   (C),	  
incomplete	  oxidation	  to	  acid	  soluble	  metabolites	  (ASMs)	  (D),	  n=6	  per	  treatment	  condition.	  (E-­‐H)	  14C-­‐
Palmitate	  incorporation	  into	  total	  neutral	  lipids	  (E),	  TAG	  (F),	  phospholipids	  (G),	  and	  DAG	  (H).	  Values	  
were	   normalized	   to	   protein	   levels.	   Incorporation	   into	   TAG,	   DAG	   and	   phospholipids	   is	   expressed	  
relative	   to	   the	   control	   condition.	   (I)	   Insulin-­‐stimulated	   Akt	   phosphorylation	   (ratio	   pAkt/Akt).	   (J)	  
Insulin-­‐stimulated	  3H-­‐deoxyglucose	  uptake.	  *P<0.05,	  error	  bars	  represent	  SEM.	  
	  
In	  vivo,	  unilateral	  overexpression	  of	  PLIN2	  
To	   investigate	   if	   PLIN2	  overexpression	  also	  has	  beneficial	   effects	  on	   insulin	   sensitivity	   in	  
vivo,	  we	  overexpressed	  PLIN2	  unilaterally	  in	  muscle	  of	  rats	  fed	  chow	  or	  high	  fat	  diet	  (HFD).	  
We	  used	  an	   in	  vivo	  gene	  electroporation	  method	  to	  achieve	  ectopic	  PLIN2	  expression	   in	  
rat	   tibialis	   anterior	  muscle	   in	   one	   leg,	   using	   the	   contralateral	   leg	   of	   the	   same	  animal	   as	  
control.	  Marked	  overexpression	  of	  PLIN2	   in	   rat	   tibialis	   anterior	  muscle	  was	  obtained,	   as	  



































































































































































































































siRNA S      S     S     P2   P2   P2
 OA     -       +      -       -      +      -
 PA      -        -      +       -       -       +
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as	  well	  as	  immunofluorescence	  showing	  numerous	  LDs	  coated	  by	  PLIN2	  (Figure	  5B).	  Lipid	  
droplets	   in	   PLIN2	   overexpressing	   muscle	   were	   larger	   and	   more	   numerous	   (Fig.	   5B-­‐C),	  
indicating	  increased	  IMCL	  levels	  upon	  PLIN2	  overexpression.	  
	  
	  
Figure	   4.	   PLIN2	   over-­‐
expression	  protects	  against	  
palmitate-­‐induced	   insulin	  
resistance	   in	   C2C12	  
myotubes.	   (A)	   Western	  
blot	   demonstrating	  
efficiency	   of	   PLIN2	  
overexpression.	   (B)	   TAG	  
levels.	   (C-­‐F)	   Incorpora-­‐tion	  
into	   (C)	   neutral	   lipids,	   (D)	  
TAG,	   (E)	   DAG,	   and	   (F)	  
phospholipids	   (PL).	   Incor-­‐
poration	   into	   TAG,	   DAG	  
and	  PL	  is	  expressed	  relative	  
to	   the	   control	   condition.	  
(G)	   Insulin-­‐stimulated	  
deoxy-­‐glucose	   uptake.	   EV:	  
empty	   vector,	   PA:	  
palmitate	   (400	   µM),	   C:	  
control.	  *P<0.05,	  error	  bars	  
represent	  SEM.	  
	  
An	   unbiased	   whole	   genome	   expression	   analysis	   revealed	   that	   genes	   related	   to	   lipid	  
metabolism	  and	  mitochondrial	  fatty	  acid	  oxidation	  were	  differentially	  regulated	  in	  PLIN2-­‐
electroporated	   versus	   control	   muscle	   in	   rats	   on	   the	   high	   fat	   diet	   (Table	   2	   and	  
Supplementary	   Fig.	   4).	   More	   specifically,	   examples	   of	   genes	   that	   were	   downregulated	  
upon	   PLIN2	   overexpression	   included	   PGC1α	   (FC=-­‐1.92),	   CPT2	   (FC=-­‐1.74)	   and	   the	  
mitofusins	   (MFN1-­‐	   FC=-­‐1.53;	   MFN2-­‐	   FC=-­‐1.53)	   (Table	   2).	   This	   group	   of	   downregulated	  
genes	  was	  overrepresented	  in	  gene	  sets	  linked	  with	  oxidative	  phosphorylation,	  fatty	  acid	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genes	   (Supplementary	   Fig.	   S5).	   Upregulated	   genes	   included	   SCD1	   (FC=1.62)	   and	   PPARγ	  
(FC=1.57)	   and	  were	   associated	  with	   gene	   sets	   related	   to	   lipid	   storage	   and	   carbohydrate	  
metabolism	  (Table	  2).	  Thus,	  PLIN2	  overexpression	  was	  associated	  with	  a	  metabolic	  profile	  
consistent	  with	  a	  shift	  from	  FA	  oxidation	  towards	  lipid	  storage.	  
	  
	  
Figure	  5.	  Gene-­‐electrotransfer-­‐mediated	  
over-­‐expression	   of	   PLIN2	   in	   rat	   tibialis	  
anterior	   muscle.	   (A)	   Representative	  
Western	   blot	   demonstrating	  
overexpression	   of	   PLIN2	   in	   the	   left	  
tibialis	   anterior	   muscle.	   EV:	   empty	  
vector.	   (B)	   Lipid	   accumulation	   (red;	   Oil-­‐
red-­‐O)	   and	   PLIN2	   expression	   (green)	  
(overlap	   of	   PLIN2	   and	   lipids	   appears	  
yellow,	  but	  depends	  on	  the	  place	  of	  the	  
cross-­‐cut	   through	   the	   intracellular	   lipid	  
droplets)	   in	   tibialis	   anterior	   muscle	  
sections	   of	   the	   right	   (control;	   empty	  
vector)	  and	  left	  (PLIN2-­‐vector)	  leg	  of	  rats	  
fed	   a	   high	   fat	   diet.	   Cell	  membranes	   are	  
stained	   in	   blue.	   Representative	   pictures	  
are	  shown.	  The	  image	  on	  the	  right	  lower	  
panel	  is	  a	  magnification	  of	  a	  selection	  of	  
the	   picture	   above.	   (C)	   Ultrastructure	  
(TEM)	   of	   muscle	   samples	   from	   sham	  
electroporated	   and	   PLIN2	   electropo-­‐
rated	  muscle.	  
PLIN2	  overexpression	  induces	  changes	  in	  the	  expression	  of	  proteins	  involved	  in	  
lipid	  metabolism	  
Western	  blottings	  were	  performed	  to	  extend	  the	  PLIN2	  overexpression-­‐mediated	  changes	  
in	  gene	  expression	  to	  proteins	  involved	  in	  mitochondrial	  function	  (OXPHOS,	  PGC1α,	  UCP3)	  
and	   lipolysis	   (ATGL,	   CGI-­‐58,	   PLIN5).	   In	   the	   chow-­‐fed	   group	   of	   animals,	   no	   significant	  
changes	  in	  protein	  expression	  were	  observed	  upon	  PLIN2	  overexpression.	  However,	  in	  rats	  
fed	  the	  HFD	  for	  four	  weeks,	  protein	  levels	  of	  OXPHOS	  complexes	  I,	  III	  and	  V	  tended	  to	  be	  
decreased	   by	   PLIN2	   overexpression	   (P=0.075	   for	   complex	   II)	   (Supplementary	   Fig.	   6A),	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suggesting	  that	  the	  HFD-­‐induced	  upregulation	  of	  OXPHOS	  protein	  expression	  was	  blunted	  
by	   PLIN2	   overexpression.	   These	   results	   corresponded	   with	   the	   observed	   lower	   gene	  
expression	   levels	   of	   genes	   related	   with	  mitochondrial	   function	   and	   fatty	   acid	   oxidation	  
(Table	  2	  and	  Supplementary	  Fig.	  4).	  PGC1α	  protein	  expression	  as	  well	  as	  PLIN5,	  another	  
LD-­‐coating	  protein,	  which	   is	  supposed	  to	  be	   involved	   in	  oxidative	  processes	  [32],	   tended	  
to	   be	   decreased	   upon	   PLIN2	   overexpression	   (P=0.062	   and	   P=0.078,	   respectively)	  
(Supplementary	   Fig.	   6B-­‐C).	   Protein	   expression	   of	   ATGL,	   CGI-­‐58,	   and	   UCP3	   were	   not	  
significantly	  changed	  (Supplementary	  Fig.	  6D-­‐F).	  	  
	  
Table	   2:	   Heat	  map.	   Fold	   changes	   in	   gene	   expression	   for	   a	   selection	   of	   genes	   are	   given	   for	   PLIN2	  
versus	   empty-­‐vector	   electroporated	   muscles.	   qPCRs	   were	   performed	   for	   a	   selection	   of	   genes	   to	  
validate	  the	  microarray	  data	  (Supplementary	  Fig.	  4).	  
ID	   Fold	  change	   Gene	   Unigene	   Description	  
308100	   2.63	   Acat3	   Rn.203063	   Acetyl-­‐Coenzyme	  A	  acetyltransferase	  3	  
100359680	   2.43	   LOC1003596
80	  
Rn.81758	   Lysophosphatidylcholine	  acyltransferase	  2-­‐like	  
313220	   2.39	   Acnat2	   Rn.162815	   Acyl-­‐coenzyme	  A	  amino	  acid	  N-­‐acyltransferase	  2	  
29347	   2.23	   Faah	   Rn.89119	   Fatty	  acid	  amide	  hydrolase	  
499210	   2.18	   Acer3	   Rn.19122	   Alkaline	  ceramidase	  3	  
500973	   2.12	   Slc37a2	   Rn.224149	   Solute	  carrier	  family	  37	  (glycerol-­‐3-­‐phosphate	  transporter),	  
member	  2	  
64035	   2.09	   Pygl	   Rn.21399	   Phosphorylase,	  glycogen	  
360622	   2.05	   Igfbp4	   Rn.160666	   Insulin-­‐like	  growth	  factor	  binding	  protein	  4	  
361401	   1.99	   Pla2g15	   Rn.93631	   Phospholipase	  A2,	  group	  XV	  
83730	   1.94	   Vamp8	   Rn.82672	   Vesicle-­‐associated	  membrane	  protein	  8	  
296474	   1.93	   Pric285	   Rn.47450	   Peroxisomal	  proliferator-­‐activated	  receptor	  A	  interacting	  
complex	  285	  
24377	   1.91	   G6pd	   Rn.11040	   Glucose-­‐6-­‐phosphate	  dehydrogenase	  
29411	   1.9	   Ppt1	   Rn.1574	   Palmitoyl-­‐protein	  thioesterase	  1	  
361527	   1.9	   Pld3	   Rn.128036	   Phospholipase	  D	  family,	  member	  3	  
286896	   1.83	   Sgpl1	   Rn.26953	   Sphingosine-­‐1-­‐phosphate	  lyase	  1	  
298199	   1.76	   Adfp	   Rn.101967	   Adipose	  differentiation	  related	  protein	  
296371	   1.7	   Pltp	   Rn.117434	   Phospholipid	  transfer	  protein	  
288707	   1.7	   Gltp	   Rn.4111	   Glycolipid	  transfer	  protein	  
29560	   1.7	   Hif1a	   Rn.10852	   Hypoxia-­‐inducible	  factor	  1,	  α	  subunit	  
314649	   1.69	   S1pr4	   Rn.225785	   Sphingosine-­‐1-­‐phosphate	  receptor	  4	  
294422	   1.68	   Smpdl3a	   Rn.8142	   Sphingomyelin	  phosphodiesterase,	  acid-­‐like	  3A	  
361076	   1.65	   RGD1561955	   Rn.200706	   Similar	  to	  diacylglycerol	  kinase	  η	  
246074	   1.64	   Scd1	   Rn.1023	   Stearoyl-­‐CoA	  desaturase	  1	  
25096	   1.63	   Pld1	   Rn.11130	   Phospholipase	  D1	  
314360	   1.6	   Galc	   Rn.30608	   Galactosylceramidase	  
54315	   1.59	   Ucp2	   Rn.13333	   Uncoupling	  protein	  2	  (mitochondrial,	  proton	  carrier)	  
24334	   1.58	   Eno2	   Rn.10828	   Enolase	  2,	  γ,	  neuronal	  
25664	   1.57	   Pparg	   Rn.23443	   Peroxisome	  proliferator-­‐activated	  receptor	  γ	  
24654	   1.53	   Plcb1	   Rn.45523	   Phospholipase	  C,	  beta	  1	  (phosphoinositide-­‐specific)	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25595	   1.5	   Map2	   Rn.10484	   Microtubule-­‐associated	  protein	  2	  
301265	   -­‐3.19	   Adhfe1	   Rn.90768	   Phospholipase	  A2,	  group	  VII	  	  
291437	   -­‐2.61	   St3gal6	   Rn.199051	   Lipase,	  endothelial	  
81782	   -­‐2.42	   Cxcl14	   Rn.59	   Sterol	  O-­‐acyltransferase	  1	  
308100	   -­‐2.38	   Serhl2	   Rn.203063	   Acetyl-­‐CoA	  acetyltransferase	  3	  
117243	   -­‐3.31	   Acsl6	   Rn.33697	   Acyl-­‐CoA	  synthetase	  long-­‐chain	  family	  member	  6	  
114508	   -­‐3.17	   Fbp2	   Rn.15319	   Fructose-­‐1,6-­‐bisphosphatase	  2	  
25747	   -­‐3.04	   Ppara	   Rn.9753	   Peroxisome	  proliferator	  activated	  receptor	  α	  
291135	   -­‐2.71	   Acot13	   Rn.1730	   Acyl-­‐CoA	  thioesterase	  13	  
79131	   -­‐2.28	   Fabp3	   Rn.32566	   Fatty	  acid	  binding	  protein	  3,	  muscle	  and	  heart	  
311617	   -­‐2.26	   Fitm2	   Rn.107822	   Fat	  storage-­‐inducing	  transmembrane	  protein	  2	  
361637	   -­‐2.24	   Acsm5	   Rn.35367	   Acyl-­‐CoA	  synthetase	  medium-­‐chain	  family	  member	  5	  
117035	   -­‐2.05	   Slc25a20	   Rn.3289	   Solute	  carrier	  family	  25	  (carnitine/acylcarnitine	  
translocase),	  member	  20	  
252898	   -­‐1.95	   Acox2	   Rn.10622	   Acyl-­‐CoA	  oxidase	  2,	  branched	  chain	  
171142	   -­‐1.93	   Ehhadh	   Rn.3671	   Enoyl-­‐Coenzyme	  A,	  hydratase/3-­‐hydroxyacyl	  CoA	  
dehydrogenase	  
83516	   -­‐1.92	   Ppargc1a	   Rn.19172	   Peroxisome	  proliferator-­‐activated	  receptor	  γ,	  coactivator	  
1α	  
64304	   -­‐1.87	   Acads	   Rn.1167	   Acyl-­‐CoA	  dehydrogenase,	  C-­‐2	  to	  C-­‐3	  short	  chain	  
29470	   -­‐1.84	   Mecr	   Rn.15375	   Mitochondrial	  trans-­‐2-­‐enoyl-­‐CoA	  reductase	  
25413	   -­‐1.74	   Cpt2	   Rn.11389	   Carnitine	  palmitoyltransferase	  2	  
305166	   -­‐1.72	   Agpat9	   Rn.214521	   1-­‐Acylglycerol-­‐3-­‐phosphate	  O-­‐acyltransferase	  9	  
25062	   -­‐1.7	   Gpd2	   Rn.89705	   Glycerol-­‐3-­‐phosphate	  dehydrogenase	  2,	  mitochondrial	  
305606	   -­‐1.69	   Mtif2	   Rn.160632	   Mitochondrial	  translational	  initiation	  factor	  2	  
25288	   -­‐1.68	   Acsl1	   Rn.6215	   Acyl-­‐CoA	  synthetase	  long-­‐chain	  family	  member	  1	  
25624	   -­‐1.68	   Vamp1	   Rn.31977	   Vesicle-­‐associated	  membrane	  protein	  1	  
252900	   -­‐1.66	   Dgat2	   Rn.9523	   Diacylglycerol	  O-­‐acyltransferase	  homolog	  2	  (mouse)	  
171155	   -­‐1.66	   Hadhb	   Rn.11253	   Hydroxyacyl-­‐CoA	  dehydrogenase/3-­‐ketoacyl-­‐CoA	  
thiolase/enoyl-­‐CoA	  hydratase,	  β	  subunit	  
29653	   -­‐1.65	   Gpam	   Rn.44456	   Glycerol-­‐3-­‐phosphate	  acyltransferase,	  mitochondrial	  
25708	   -­‐1.57	   Ucp3	   Rn.9902	   Uncoupling	  protein	  3	  (mitochondrial,	  proton	  carrier)	  
64476	   -­‐1.56	   Mfn2	   Rn.8570	   Mitofusin	  2	  
192647	   -­‐1.53	   Mfn1	   Rn.160939	   Mitofusin	  1	  
313510	   -­‐1.52	   Atpaf1	   Rn.18579	   ATP	  synthase	  mitochondrial	  F1	  complex	  assembly	  factor	  1	  
353229	   -­‐1.52	   Sgms1	   Rn.55975	   Sphingomyelin	  synthase	  1	  
291567	   -­‐1.52	   Ppargc1b	   Rn.163382	   Peroxisome	  proliferator-­‐activated	  receptor	  gamma,	  
coactivator	  1	  β	  
	  
PLIN2	  overexpression	  augments	  myocellular	   fat	  storage	  while	  blunting	  high	  fat	  
diet	  induced	  insulin	  resistance	  	  
We	   next	   investigated	   if	   the	   enhanced	   TAG	   storage	   capacity	   was	   associated	   with	   a	  
reduction	   in	   the	   lipotoxic	   FA	   intermediates	   DAG	   and	   ceramides.	   Interestingly,	   despite	  
increased	  IMCL	  accumulation,	  PLIN2	  overexpression	  did	  not	  increase	  DAG	  levels	  (Fig.	  6A),	  
nor	  was	   the	  FA-­‐composition	   (saturation	  and	   fatty	  acid	  chain	   length)	  of	   the	  DAG	   fraction	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affected	   by	   PLIN2	   overexpression	   (Supplementary	   Fig.	   7).	   Thus,	   increased	   total	  
intramyocellular	   lipid	   levels	   in	   PLIN2-­‐overexpressing	   muscle	   were	   not	   paralleled	   by	  
increased	  DAG	  levels,	  indicating	  that	  FAs	  were	  stored	  as	  TAG.	  Intriguingly,	  ceramide	  levels	  
were	  increased	  by	  23%	  (Fig.	  6B)	  upon	  PLIN2	  overexpression.	  	  
	  
	  
Figure	   6.	  Overexpression	   of	   PLIN2	   in	   tibialis	   anterior	   muscle	   of	   rats	   on	   a	   high	   fat	   diet	   improves	  
insulin	  sensitivity	  of	  the	  muscle.	  (A)	  Skeletal	  muscle	  DAG	  and	  (B)	  ceramide	  levels	  in	  PLIN2-­‐	  or	  empty	  
vector	  (EV)	  electroporated	  muscle	  of	  rats	  on	  a	  high	  fat	  diet.	  (C)	  3H-­‐labeled	  deoxyglucose	  uptake	   in	  
control	  and	  PLIN2-­‐electroporated	  tibialis	  anterior	  muscle	  of	  rats	  on	  a	  high	  fat	  diet	  (n=11).	  Error	  bars	  
represent	  SEM.	  
	  
PLIN2	   overexpression	   thus	   increased	   IMCL	   levels	   concurrent	   with	   an	   altered	   gene	  
expression	   profile	   favoring	   efficient	   fat	   storage	   rather	   than	   oxidation.	   Therefore,	   we	  
investigated	   whether	   these	   consequences	   of	   PLIN2	   overexpression	   would	   affect	   insulin	  
sensitivity.	   To	   this	   end,	   a	   hyperinsulinemic	   euglycemic	   clamp	   was	   implemented.	   As	  
anticipated,	  rats	  on	  the	  HFD	  gained	  significantly	  more	  weight	  compared	  with	  the	  rats	  on	  a	  
control	  (chow)	  diet	  (chow	  +1.91±0.41	  vs.	  HFD	  +2.94±0.20	  g/d,	  P=0.01)	  and	  a	  HFD	  feeding	  
period	  of	  3	  weeks	  sufficed	  to	  impede	  whole-­‐body	  insulin	  sensitivity	  as	  indicated	  by	  a	  lower	  
glucose	   infusion	   rate	   during	   the	   stable	   phase	   of	   the	   clamp	   (chow	   31.8±1.0	   vs.	   HFD	  
26.6±1.6	   mg/min/kg,	   P=0.05).	   PLIN2-­‐overexpression	   effects	   on	   insulin	   sensitivity	   were	  
investigated	   in	   rats	   fed	   the	   HFD.	   During	   the	   stable	   phase	   of	   the	   clamp,	   3H-­‐labeled	  
deoxyglucose	  was	  administered	  intravenously	  to	  investigate	  muscle-­‐specific	  deoxyglucose	  
uptake,	   comparing	   the	   PLIN2-­‐overexpressing	   tibialis	   anterior	   muscle	   with	   the	   control	  
sham-­‐electroporated	   muscle	   of	   the	   same	   rat.	   Interestingly,	   despite	   the	   profoundly	  
increased	  total	  intramyocellular	  lipid	  accumulation	  (Fig.	  5B-­‐C)	  and	  the	  increased	  ceramide	  
levels	   (Fig.	   6B),	   insulin	   sensitivity	   was	   not	   impaired	   in	   the	   PLIN2	   overexpressing	   leg.	  
Rather,	  deoxyglucose	  uptake	  significantly	  increased	  by	  11.1%	  in	  the	  PLIN2	  overexpressing	  
leg	  compared	  with	  the	  control	  leg	  (P=0.045)	  (Fig.	  6C).	  	  
	  
DISCUSSION	  
The	   protein	   coat	   of	   lipid	   droplets	   is	   an	   important	   interface	   for	   the	   regulation	   of	  








































































non-­‐adipose	  tissue.	  In	  the	  present	  study	  we	  demonstrate	  that	  PLIN2	  plays	  an	  essential	  role	  
in	   skeletal	  muscle	   IMCL	   storage.	   First	   of	   all	   we	   showed	   that	   PLIN2	   is	   upregulated	   upon	  
loading	  myotubes	  with	  long	  chain	  FAs	  and	  after	  prolonged	  consumption	  of	  a	  high	  fat	  diet	  
or	  fasting	   in	  skeletal	  muscle	  of	  mice.	  These	  findings	  served	  as	  a	  first	   indication	  for	  a	  role	  
for	  PLIN2	  in	  skeletal	  muscle	  lipid	  metabolism.	  In	  subsequent	  loss	  of	  function	  experiments	  
we	  demonstrate	  that	  PLIN2	  plays	  an	  essential	  role	  in	  skeletal	  muscle	  lipid	  handling.	  siRNA-­‐
mediated	   knockdown	   of	   PLIN2	   prevented	   intramyocellular	   TAG	   storage.	   Moreover,	  
palmitate	  incorporation	  into	  DAG	  and	  phospholipids	  was	  increased,	   indicating	  that	  PLIN2	  
is	  necessary	  for	  FA	  channeling	  to	  TAG	  in	  LDs	  and	  that	  in	  the	  absence	  of	  PLIN2,	  part	  of	  the	  
FAs	  are	  channeled	  to	  storage	  in	  the	  form	  of	  lipid	  intermediates	  other	  than	  TAG.	  Moreover,	  
LD	   accumulation	   was	   restricted	   to	   a	   few	   lipid	   droplets	   per	   myotube	   upon	   PLIN2	  
knockdown,	   indicating	   that	   PLIN2	   is	   essential	   for	   the	   formation	   and/or	   stability	   of	   LDs.	  
Studies	   towards	  subcellular	   localization	  of	   LDs	   indicated	   that	  PLIN2	  might	  be	   involved	   in	  
budding	  of	  LDs	   from	  ER	  or	  cell	  membrane	  structures	  [33,	  34].	  Functional	   involvement	  of	  
PLIN2	  in	  LD	  synthesis	  has	  been	  shown	  in	  studies	  in	  fibroblasts	  and	  liver	  [35-­‐37].	  Our	  results	  
support	  a	  role	  for	  PLIN2	  in	  skeletal	  muscle	  LD	  synthesis,	  LD	  stability	  and	  TAG	  storage.	  
	   Next	   to	   a	   lowering	   in	   intramyocellular	   TAG	   content	   after	   PLIN2	   knockdown,	   we	  
observed	   less	  LDs,	  but	   the	   few	  existing	  LDs	  per	  cell	  had	  a	   larger	  size,	   indicating	   that	   the	  
cell	  copes	  with	  the	  flux	  of	  FAs	  entering	  the	  cells	  by	  maximizing	  the	  volume-­‐to-­‐surface	  ratio	  
in	   the	   few	  available	   lipid	  droplets.	  The	   latter	   is	  consistent	  with	   the	  study	  of	  Bell	  et	  al.	   in	  
which	  PLIN2	  knockdown	  was	  shown	  to	  decrease	  LD	  number	  while	  increasing	  LD	  size	  [38].	  	  
	   Enhancing	   the	   partitioning	   of	   excess	   FAs	   towards	   TAG	   storage	   is	   considered	   to	   be	  
beneficial	   in	   preventing	   insulin	   resistance	   by	   limiting	   the	   accumulation	   of	   lipotoxic	   lipid	  
species	   like	   ceramides,	   DAG	   and	   fatty	   acyl-­‐CoA	   [28,	   30].	   As	   our	   knockdown	   studies	  
demonstrated	   that	   PLIN2	   is	   essential	   for	   intramyocellular	   TAG	   storage,	   we	   investigated	  
whether	  PLIN2	  overexpression	  would	  influence	  lipid	  metabolism	  and	  lipid-­‐induced	  insulin	  
resistance.	  Therefore,	  we	  determined	  the	  effects	  of	  in	  vitro	  PLIN2	  overexpression	  in	  C2C12	  
myotubes	   and	   in	   vivo	   unilateral	   muscle-­‐specific	   ectopic	   PLIN2	   expression	   in	   rat	   tibialis	  
anterior	  muscle.	  PLIN2	  overexpression	  markedly	  augmented	   the	  accumulation	  of	  TAG	   in	  
lipid	   droplets,	   which	   were	   both	   greater	   in	   number	   and	   larger	   in	   size,	   consistent	   with	  
previous	  studies	  [36].	  Short-­‐term	  incorporation	  of	  palmitate	  into	  both	  TAG	  and	  DAG	  was	  
increased	  upon	  PLIN2	  overexpression	  in	  myotubes,	  indicating	  increased	  channeling	  of	  FAs	  
towards	   storage.	   Increased	   total	   intramyocellular	   lipid	   levels	   upon	   prolonged	   PLIN2	  
overexpression	   in	   tibialis	   anterior	   muscle	   (7	   days)	   were	   not	   paralleled	   by	   increased	  
intramyocellular	   DAG	   levels,	   indicating	   that	   FAs	   were	   efficiently	   stored	   as	   neutral	   TAG.	  
Moreover,	  the	  gene	  expression	  profiles	  show	  a	  shift	  towards	  increased	  gene	  expression	  of	  
genes	   involved	   in	   lipid	   storage,	   further	   supporting	   the	   notion	   that	   PLIN2	   facilitates	  
intramyocellular	  TAG	  storage.	  
	   The	   increase	   in	   TAG	   accumulation	   was	   not	   paralleled	   with	   an	   increased	   oxidative	  
capacity.	  In	  contrast,	  the	  HFD-­‐induced	  increase	  in	  mitochondrial	  density	  was	  blunted	  upon	  
PLIN2	  overexpression	  and	  genes	  involved	  in	  FA	  oxidation	  and	  mitochondrial	  function	  were	  
downregulated.	  One	  could	  hypothesize	  that	  an	  increased	  capacity	  to	  efficiently	  store	  TAG	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in	   muscle	   would	   diminish	   the	   need	   for	   an	   increased	   fat	   oxidative	   capacity.	   Decreased	  
expression	   of	   genes	   and	   proteins	   involved	   in	   fatty	   acid	   oxidation	   has	   been	   described	  
previously	   in	   conditions	   of	   inhibited	   lipolysis	   [39,	   40].	   Recent	   studies	   show	   that	   the	  
regulation	  of	  mitochondrial	  genes	  by	  their	  transcription	  factors	  PPARα	  and	  PGC1	  require	  
fatty	   acids	   that	   are	   liberated	   by	   lipolysis	   from	   LD.	   Thus,	   ATGL	   deficient	   mice	   are	  
characterized	  by	  a	  marked	  reduction	   in	  mitochondrial	   function,	  which	  can	  be	  rescued	  by	  
administration	   of	   the	   PPAR	   agonist	   Wy14,643	   [41].	   Likewise,	   PLIN2	   overexpression	  
decreased	  gene	  expression	  of	  several	  PPARα	   target	  genes.	   It	  could	  be	  hypothesized	  that	  
PLIN2-­‐facilitated	   LD	   storage	   reduces	   lipid	   turnover,	   leading	   to	   a	   reduced	   transcriptional	  
activity	  of	  mitochondrial	  genes,	  consistent	  with	  the	  results	  of	  our	  micro-­‐array	  analysis.	  In	  
that	   respect,	   studies	   in	   hepatocytes	   and	   embryonic	   kidney	   cells	   reported	   an	   increased	  
lipolysis	  after	  PLIN2	  knockdown	  [37,	  38,	  40],	  indicating	  that	  PLIN2	  shields	  the	  droplet	  from	  
lipolysis.	   A	   proper	   balance	   between	   IMCL	   synthesis,	   lipolysis	   and	   oxidative	   metabolism	  
ensures	  low	  local	  intracellular	  FA	  levels	  thereby	  preventing	  against	  lipotoxicity.	  
	   Our	   study	   is	   the	   first	   to	   examine	   the	   effects	   of	   overexpression	   of	   PLIN2	   on	   insulin	  
sensitivity.	  PLIN2	  loss	  of	  function	  studies	  in	  tissues	  other	  than	  muscle	  showed	  inconsistent	  
results	  on	   insulin	  sensitivity	   [38,	  42-­‐44].	  Lowering	  of	  PLIN2	  activity	  was	  demonstrated	  to	  
improve	   liver	   insulin	  sensitivity	   in	  mice	  models	  of	  PLIN2	   inhibition	   [43,	  44],	  while	   siRNA-­‐
mediated	  knockdown	  of	  PLIN2	  plus	  PLIN3	  in	  liver	  cells	  impaired	  insulin	  sensitivity	  [38].	  In	  
our	   study	  we	   hypothesized	   that	   overexpression	   of	   PLIN2	   –	   by	   enhancing	   partitioning	   of	  
excess	  fat	  towards	  TAG	  storage	  –	  would	  improve	  insulin	  sensitivity.	  Whereas	  in	  vitro	  PLIN2	  
knockdown	   in	  our	  hands	  did	  not	  affect	   insulin	   sensitivity,	  we	  did	   indeed	   find	   that	  PLIN2	  
overexpression	  completely	  rescued	  palmitate-­‐induced	  impairments	  in	  insulin	  signaling,	  in	  
parallel	   with	   increased	   intracellular	   TAG	   accumulation.	   We	   were	   able	   to	   extend	   this	  
observation	   to	   the	   in	   vivo	   situation	   by	   showing	   improved	   insulin	   sensitivity	   in	   skeletal	  
muscle	  of	  PLIN2-­‐electroporated	  muscle	  of	  rats	  on	  a	  high	  fat	  diet,	  despite	  increased	  IMCL	  
storage.	  While	  IMCL	  levels	  were	  increased,	  DAG	  levels	  were	  unaffected	  and	  unexpectedly,	  
ceramide	   levels	  were	   increased	  upon	  PLIN2	  overexpression.	  The	   latter	   is	  consistent	  with	  
the	  study	  of	  Brown	  et	  al.	   [45],	  describing	  that	   increased	  ceramide	   levels	  associated	  with	  
lowered	  lipase	  activity	  in	  liver	  did	  not	  impair	  insulin	  sensitivity	  [45],	  this	  leaves	  the	  option	  
open	  that	   the	  subcellular	   localization	  of	  ceramide	  (rather	  than	  simply	  ceramide	  content)	  
may	  be	  a	  determinant	  of	  the	  lipotoxic	  potential	  of	  ceramides.	  	  
One	  limitation	  of	  our	  in	  vivo	  study	  is	  that	  our	  results	  only	  apply	  to	  overexpression	  of	  
PLIN2	   in	   tibialis	   anterior	  muscle,	  which	   is	  mainly	   composed	  of	   type	   IIb	   fibers.	  Glycolytic	  
muscles	  are	  prone	  to	  lipid-­‐induced	  insulin	  resistance	  [46].	  Therefore,	  the	  observation	  that	  
overexpression	  of	  PLIN2	  resulted	  in	  excessive	  lipid	  storage	  in	  the	  predominantly	  glycolytic	  
tibialis	   anterior	   muscle	   while	   at	   the	   same	   time	   improving	   insulin-­‐stimulated	   glucose	  
uptake	  indicates	  that	  PLIN2-­‐mediated	  improved	  partitioning	  of	  FAs	  in	  LDs	  is	  a	  potent	  way	  
to	  blunt	  lipid-­‐induced	  insulin	  resistance.	  	  
We	   conclude	   that	   high	   levels	   of	   PLIN2	   are	   beneficial	   for	   proper	   storage	   of	   TAG	   in	  
skeletal	   muscle	   and	   thereby	   prevent	   the	   development	   of	   insulin	   resistance.	   In	   that	  
respect,	  we	   recently	  observed	   increased	  PLIN2	   levels	   in	   skeletal	  muscle	  after	   training	  as	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well	   as	   in	   trained	   compared	   with	   untrained	   subjects	   (unpublished	   data),	   providing	  
additional	  evidence	  that	  high	  PLIN2	  levels	  –	  even	  with	  high	  IMCL	  content	  –	  are	  associated	  
with	   improved	   insulin	   sensitivity.	   Likewise,	   Coen	   et	   al.	   showed	   lower	   PLIN2	   gene	  
expression	  levels	  in	  skeletal	  muscle	  of	  insulin	  resistant	  obese	  subjects	  versus	  BMI-­‐matched	  
insulin	  sensitive	  controls	  [20]	  and	  both	  weight	  loss	  and	  pharmacological	  insulin	  sensitizing	  
strategies	  (troglitazone	  or	  metformin)	  resulted	  in	  increased	  PLIN2	  protein	  levels	  in	  skeletal	  
muscle	  [23].	  	  
	   In	   summary,	   using	   in	   vitro	   and	   in	   vivo	   methods	   we	   establish	   that	   PLIN2	   is	   an	  
important	  facilitator	  of	  IMCL	  storage.	  PLIN2	  is	  essential	  for	  myocellular	  TAG	  storage	  in	  lipid	  
droplets.	   By	   improving	   IMCL	   storage,	   PLIN2	   protects	   from	   lipotoxicity	   resulting	   in	  
enhanced	  insulin	  sensitivity.	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Figure	  S1.	  (A	  and	  B)	  C2C12	  myotubes	  were	  
incubated	  with	   BSA-­‐complexed	   oleate.	   (A)	  
Concentration	   range	   (oleate).	   (B)	   Time	  
range	   (0	   to	   24h	   following	   incubation	  with	  
200	   µM	   oleate).	   (C)	   PLIN2	   protein	  
expression	  was	  measured	  in	  gastrocnemius	  
muscle	   of	   male	   Sv129	   mice	   (2-­‐3-­‐month-­‐
old)	  after	  0,	  6	  or	  24h	  of	  fasting	  (fasting	  was	  
started	  at	  the	  onset	  of	  the	  light	  cycle)	  (n=4-­‐
5	  per	  group).	  *P<0.05.	  
	  













































Figure	   S2.	   (A)	   Efficacy	   of	   siRNA-­‐
mediated	   knockdown	   of	   PLIN2.	  
C2C12	   myotubes	   were	   transfected	  
with	   PLIN2	   siRNA	   or	   a	   scrambled	  
control.	   RNA	   was	   isolated,	   reverse	  
transcribed,	   and	   PLIN2	   mRNA	  
expression	   was	   measured	   by	   qPCR.	  
(B)	  TIP47	  protein	  expression	  was	  not	  
affected	  by	  PLIN2	  knockdown.	  C2C12	  
myotubes	   were	   transfected	   with	  
PLIN2	   siRNA	   or	   a	   scrambled	   control	  
and	  incubated	  overnight	  with	  200µM	  
BSA-­‐coupled	   oleate,	   palmitate	   or	  
solely	  80µM	  BSA.	  Subsequently,	  cells	  
were	   harvested	   to	   measure	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Figure	  S3.	  (A)	  Protein	  expression	  of	  the	  OXPHOS	  complexes	  I,	  II,	  III	  and	  V	  in	  cell	  cultures	  transfected	  
with	  either	  PLIN2	  siRNA	  [P2]	  or	  S-­‐scrambled	  control	  siRNA	  [S],	  expressed	  as	  arbitrary	  units	  (AU),	  n=4	  
for	   each	   treatment	   condition.	   (B)	  Microarray	   validation:	   qPCRs	  were	   performed	   for	   a	   selection	   of	  
genes.	  *P<0.05.	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Figure	  S4.	  (A)	  Gene	  expression	  profile	  for	  PLIN2-­‐	  or	  empty	  vector-­‐electroporated	  muscles.	  Selected	  
pathways	   identified	   by	   Gene	   Score	   Resampling	   (GSR)	   in	   ErmineJ.	   Only	   pathways	   that	   were	  
significantly	  up-­‐	  or	  downregulated	  (P<0.05)	  are	  shown.	  The	  enrichment	  score	  reflects	  the	  degree	  to	  
which	   a	   gene	   set	   is	   overrepresented	   at	   the	   top	   (upregulated,	   positive	   score)	   or	   bottom	  
(downregulated,	  negative	  score)	  of	  the	  ranked	  gene	  list	  and	  is	  corrected	  for	  gene	  set	  size.	  (B)	  qPCRs	  
were	  performed	  for	  a	  selection	  of	  genes	  to	  confirm	  the	  microarray	  data.	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Figure	   S5.	   (A)	   Overrepresentation	  
of	  PPARα	  target	  genes	  in	  the	  group	  
of	   genes	   that	  were	  downregulated	  
upon	   PLIN2	   electroporation.	   (A)	  
Enrichment	   plot	   (GSEA	   gene	   set	  
enrichment	   analysis).	   (B)	   Genes	  
included	   in	   this	   gene	   set.	   These	  
genes	  have	  the	  promoter	  regions	  [-­‐
2kb,2kb]	  around	  transcription	  start	  
site	   that	   contain	   the	   motif	  
CARAACTAGGNCAAAGGTCA	   which	  




Figure	  S6.	  Protein	  expression	  of	  OXPHOS	  complexes,	  PGC1,	  PLIN5,	  ATGL,	  CGI-­‐58	  and	  UCP3	  in	  PLIN2	  
or	  empty	  vector	  electroporated	  muscle.	  Muscle	  homogenates	   from	  tibialis	  anterior	  electroporated	  
muscles	  from	  chow-­‐	  and	  HFD-­‐fed	  animals	  were	  blotted	  for	  protein	  expression	  of	  OXPHOS	  complexes	  
(A),	  PGC1	  (B),	  PLIN5/OXPAT	  (C),	  ATGL	  (D),	  CGI-­‐58	  (E),	  and	  UCP3	  (F),	  *P<0.05	  (ANOVA-­‐Tukey’s	  post-­‐
hoc	  analyses).	  EV:	  empty	  vector.	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Figure	  S7.	  Fatty	  acid	  composition	  of	  the	  DAG	  fraction.	   (A)	  The	  FA	  composition	  of	  the	  DAG	  fraction	  
depicted	   in	  percentage	  of	   the	   total	  DAG	   fraction	   for	   rats	  on	  high	   fat	   diet	   in	   the	  empty	   vector-­‐	   or	  
PLIN2	   electroporated	   legs.	   (B)	   Saturation	   of	   the	   FAs	   in	   the	   DAG	   fraction	   in	   the	   empty	   vector-­‐	   or	  






































































































Figure	  S8.	  Lactosylceramide	  (A)	  and	  glycosylated	  
ceramide	   (B)	   levels	   in	   PLIN2	   or	   empty	   vector	  
(EV)	   electroporated	   tibialis	   anterior	   muscle	   of	  
rats	  fed	  a	  HFD.	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ABSTRACT	  
Perilipin	  5	  (PLIN5/OXPAT)	  is	  a	  lipid	  droplet	  (LD)	  coat	  protein	  mainly	  present	  in	  tissues	  with	  
a	  high	  fat-­‐oxidative	  capacity,	  suggesting	  a	  role	  for	  PLIN5	  in	  facilitating	  fatty	  acid	  oxidation.	  
Here,	  we	  investigated	  the	  role	  of	  PLIN5	  in	  fat	  oxidation	  in	  skeletal	  muscle.	  	  
In	   human	   skeletal	   muscle	   we	   observed	   that	   PLIN5	   (but	   not	   PLIN2)	   protein	   content	  
correlated	  tightly	  with	  OXPHOS	  content	  and	   in	  rat	  muscle	  PLIN5	  content	  correlated	  with	  
mitochondrial	  respiration	  rates	  on	  a	  lipid-­‐derived	  substrate.	  This	  prompted	  us	  to	  examine	  
PLIN5	   protein	   expression	   in	   skeletal	   muscle	   mitochondria	   by	   means	   of	   immunogold	  
electron	  microscopy	   and	  Western	   blots	   in	   isolated	  mitochondria.	   These	   data	   show	   that	  
PLIN5,	   in	   contrast	   to	   PLIN2,	   not	   only	   localizes	   to	   LD	   but	   also	   to	  mitochondria,	   possibly	  
facilitating	   fatty	   acid	  oxidation.	  Unilateral	  overexpression	  of	  PLIN5	   in	   rat	   tibialis	   anterior	  
muscle	   augmented	   myocellular	   fat	   storage	   without	   increasing	   mitochondrial	   density	   as	  
indicated	   by	   the	   lack	   of	   change	   in	   protein	   content	   of	   five	   components	   of	   the	   OXPHOS	  
system.	   Mitochondria	   isolated	   from	   PLIN5	   overexpressing	   muscles	   did	   not	   possess	  
increased	   fatty-­‐acid	   respiration.	   Interestingly	   though,	   14C-­‐palmitate	   oxidation	   assays	   in	  
muscle	   homogenates	   from	   PLIN5	   overexpressing	   muscles	   revealed	   a	   44.8%	   (p=0.05)	  
increase	   in	  complete	   fatty	  acid	  oxidation.	  Thus,	   in	  mitochondrial	   isolations	  devoid	  of	  LD,	  
PLIN5	  does	  not	  augment	  fat	  oxidation,	  while	  in	  homogenates	  containing	  PLIN5-­‐coated	  LD,	  
fat	  oxidation	  is	  higher	  upon	  PLIN5	  overexpression.	  	  
The	   presence	   of	   PLIN5	   in	   mitochondria	   helps	   to	   understand	   why	   PLIN5,	   in	   contrast	   to	  
PLIN2,	  is	  of	  specific	  importance	  in	  fat	  oxidative	  tissues.	  Our	  data	  suggests	  involvement	  of	  







Perilipin	  5	  (aliases	  include	  OXPAT,	  lipid	  storage	  droplet	  protein	  5,	  myocardial	  lipid	  droplet	  
protein	  and	  PAT-­‐1)	  is	  a	  lipid	  droplet	  (LD)	  coat	  protein	  that	  belongs	  to	  the	  perilipin	  family	  of	  
proteins.	   Although	   the	   tissue	   distribution	   of	   this	   protein	   family	   differs	   considerably	  
between	  members,	  all	  perilipin	  proteins	  are	  involved	  in	  accumulation	  and	  metabolism	  of	  
lipids	   in	   LDs	   [1,	   2].	   Perilipin	   5	   (PLIN5)	   expression	   is	   highest	   in	   tissues	   with	   a	   high	   fat-­‐
oxidative	   capacity,	   such	   as	   heart,	   oxidative	   (type	   I)	   skeletal	  muscles	   and	   brown	   adipose	  
tissue	   [3-­‐5].	   Recently,	  we	   showed	   that	   in	   rat	   and	   human	   skeletal	  muscle,	   PLIN5	   protein	  
content	  paralleled	   the	   LD	   content,	  with	  most	   abundant	  expression	   in	  muscle	   fibres	   that	  
have	  highest	  fat	  content	  (type	  1	  fibres	  in	  humans,	  type	  2a	  in	  rodents)	  [6].	  	  
PLIN5	  has	  been	  found	  covering	  the	  lipid	  droplet	  and	  to	  be	  present	  in	  the	  cytosol	  [3,	  
4].	   PLIN5	   overexpression	   in	   vitro	   in	   OP-­‐9	   and	   COS-­‐7	   cells	   increased	   cellular	   triglyceride	  
storage	   in	   parallel	   with	   increases	   in	   fatty	   acid	   (FA)	   oxidation	   and	   induction	   of	   gene	  
expression	  of	  mitochondrial	  enzymes	   involved	   in	  oxidative	  metabolism	  [4].	  These	  results	  
suggest	   involvement	   of	   PLIN5	   in	   triglyceride	   storage	   as	  well	   as	   oxidative	   degradation	   of	  
FAs	   released	   from	   the	   droplet,	   and	   suggest	   involvement	   of	   PLIN5	   in	   lipid	   turnover.	  
Recently,	   it	   has	   been	   shown	   that	   PLIN5	   indeed	   has	   the	   potential	   to	   modulate	   the	  
interaction	  of	  the	  major	  triacylglycerol	  lipase	  ATGL	  with	  the	  LD	  as	  well	  as	  with	  its	  co-­‐factor	  
CGI-­‐58	  [7]	  in	  a	  well	  orchestrated	  manner	  to	  modulate	  LD	  lipolysis	  [8-­‐10].	  
To	  maintain	   cellular	   concentrations	   of	   cytotoxic	   FAs	   low,	   effective	   shuttling	   of	   FAs	  
towards	  mitochondrial	   oxidation	   should	  be	   facilitated.	   In	   oxidative	   tissues	   this	   is	   in	   part	  
facilitated	   by	   the	   close	   vicinity,	   and	   sometimes	   even	   physical	   interaction	   of	   LD	   with	  
mitochondria.	   Functional	   interactions	   between	   LDs	   and	   mitochondria	   have	   long	   been	  
reported	   [11-­‐14],	   and	   evidence	   is	   emerging	   that	   mitochondria	   are	   not	   only	   actively	  
controlling	   FA	   levels	   in	   their	   vicinity	   by	   directing	   FAs	   towards	   β-­‐oxidation,	   but	   the	  
presence	   of	   the	   enzymatic	   machinery	   to	   re-­‐esterify	   FA	   in	   mitochondria	   indicates	   that	  
mitochondria	  may	  also	  have	  the	  option	  to	  redirect	  the	  fatty	  acids	  towards	  triacylglycerol	  
synthesis	   in	  LD.	  Likewise,	   isoforms	  of	  acyl	  CoA:diacylglycerol	  acyltransferase	  (DGAT)	  [15],	  
glycerol	   3-­‐phosphate	   acyl	   transferases	   (GPAT)	   [16,	   17]	   and	   long-­‐chain	   acyl-­‐CoA	  
synthetases	   [18]	   have	   been	   identified	   in	   mitochondria.	   Orchestrated	   interaction	   of	  
processes	   at	   the	   LD	   and	   the	  mitochondria	   is	   hence	   of	   pivotal	   importance	   in	   tissues	   like	  
cardiac	  and	  skeletal	  muscle	  and	  brown	  adipose	  tissue	  where	  large	  fluctuations	  in	  fatty	  acid	  
oxidation	  are	  prominent.	  These	  tissues	  also	  typically	  express	  PLIN5	  as	  a	  LD	  coat	  protein.	  	  
Imaging	   the	   LDs	   and	   PLIN5	   by	   immunofluorescence	   revealed	   that	   the	   majority	   of	  
PLIN5	   is	   localized	   to	   the	   lipid	  droplet	  but	  also	   that	   -­‐mainly	   in	   fat	  oxidative	   type	   I	  muscle	  
fibres-­‐	   PLIN5	   could	   be	   readily	   detected	   in	   a	   staining	   pattern	   similar	   to	   recognised	  
mitochondrial	  proteins	  [6].	  This	  staining	  pattern,	  along	  with	  the	  high	  expression	  of	  PLIN5	  
in	   tissues	  with	  high	   FA	  oxidation	   capacity	   [3-­‐5]	   and	   the	  observation	   that	  overexpressing	  
PLIN5	   increased	   both	   palmitate	   oxidation	   and	   the	   expression	   of	   genes	   encoding	  
mitochondrial	   proteins	   [4]	   hints	   towards	   involvement	   of	   PLIN5	   in	   mitochondrial	   fat	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oxidation.	   Likewise,	   it	   has	   recently	   been	   suggested	   that	   PLIN5	   at	   the	   LD	   surface	   may	  
recruit	  LD	  to	  the	  mitochondria	  [19].	  	  	  
We	  here	  show	  that	  PLIN5	  is	  present	  within	  the	  mitochondria	  in	  cardiac	  and	  skeletal	  
muscle.	   PLIN5	   overexpression	   in	   skeletal	   muscle	   indicates	   that	   lipid	   droplets	   and	  
mitochondria	   need	   interaction	   before	   PLIN5	   possesses	   its	   facilitating	   role	   to	   augment	  
mitochondrial	  fat	  oxidation.	  
	  
MATERIALS	  AND	  METHODS	  
PLIN5	  antibody	  	  
The	  PLIN5	  antibody	  used	   in	   this	   study	   is	  directed	  against	   amino	  acids	  451-­‐463	  of	   the	  C-­‐
terminus	  and	  was	  derived	  from	  Progen	  (#GP31;	  guinea	  pig	  polyclonal;	  Progen,	  Heidelberg,	  
Germany).	  This	  antibody,	  as	  well	  as	  other	  available	  antibodies	  against	  PLIN5,	  was	  tested	  in	  
pilot	  experiments	  (Western	  blots	  and	  immunogold	  labelling	  for	  electron	  microscopy)	  in	  a	  
variety	  of	   cells	   and	   tissues	   known	   to	   vary	   in	  endogenous	  PLIN5	  protein	  expression	   (HEK	  
and	   C2C12	   cells,	   white	   adipose	   tissue,	   cardiac	   muscle,	   glycolytic	   skeletal	   muscle	   (EDL),	  
oxidative	  skeletal	  muscle	  (soleus),	  liver	  and	  testis).	  Thus,	  PLIN5	  expression	  was	  highest	  in	  
oxidative	   tissues	   (heart	   and	   oxidative	   skeletal	   muscle).	   The	   antibody	   used	   in	   this	   study	  
showed	   the	  expected	   tissue	  distribution,	  a	  double	  band	  of	   the	  expected	   size,	   and	  a	   low	  
background	  and	  specific	  PLIN5	  labelling	  on	  the	  transmission	  electron	  microscopy	  pictures.	  
Negative	  controls	  using	  non-­‐immune	  serum	  did	  not	  show	  any	  bands	  in	  Westerns	  nor	  did	  it	  
result	  in	  immunogold	  or	  immunofluorescence	  staining.	  	  
	  
Cell	  culture	  and	  treatments	  
HEK293	  cells	  (LGC	  standards,	  Teddington,	  Middlesex,	  United	  Kingdom)	  were	  maintained	  in	  
DMEM	   (GlutaMAX	   low	   glucose	   DMEM,	   Invitrogen,	   Breda,	   The	   Netherlands)	   containing	  
antibiotics	   (50	   U/ml	   penicillin	   and	   50	   µg/ml	   streptomycin;	   Gibco-­‐Invitrogen,	   Rockville,	  
USA)	   supplemented	  with	  10%	  FCS.	  Cells	  were	   grown	   in	  12-­‐well	   plates	   (Greiner	  Bio-­‐One,	  
Alphen	   aan	   de	   Rijn,	   The	   Netherlands)	   and	   transfected	   with	   Plin5	   plasmid	   construct	  
(pcDNA3.1-­‐CMV;	  2	  µg	  per	  well)	  using	  10	  µL/ml	  Lipofectamine2000	  as	  transfection	  reagent	  
(Invitrogen,	  Breda,	  The	  Netherlands).	  Cells	  were	  harvested	  24h	  posttransfection.	  
	  
Human	  study	  	  
Eleven	   healthy,	   lean,	  male	   volunteers	  without	   a	   family	   history	   of	   diabetes	   or	   any	   other	  
endocrine	  disorder	  participated	  in	  this	  study.	  The	  mean	  age	  of	  the	  subjects	  was	  23.6	  ±	  1.0	  
years;	  mean	  BMI	  was	  22.6	  ±	  0.5	  kg/m2.	  Subjects	  were	  fed	  in	  energy	  balance	  for	  60h	  (50–
35–15%	  of	   energy	   as	   carbohydrates,	   fat,	   and	   protein,	   respectively).	   After	   60h,	   a	  muscle	  
biopsy	   of	   the	   vastus	   lateralis	   was	   taken	   using	   the	   Bergstrom	   technique	   [20].	   Muscle	  
samples	  were	  immediately	  frozen	  in	  melting	  isopentane	  and	  stored	  at	  80°C	  until	  assayed.	  
The	   study	   protocol	   was	   reviewed	   and	   approved	   by	   the	   Medical	   Ethical	   Committee	   of	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Maastricht	  University	  Medical	  Centre	  and	  all	  subjects	  gave	  their	  written	  informed	  consent	  
before	  participating	  in	  the	  study.	  
	  
ZDF	  rat	  study	  design	  
Twenty-­‐six	  male,	  ZDF	  rats	  (ZDF/Gmi,	  fa/fa)	  were	  purchased	  from	  Charles	  River	  (Chatillon-­‐
sur-­‐Chalaronne,	  France).	  The	  rats	  arrived	  at	  the	  age	  of	  5	  or	  11	  weeks	  and	  were	  housed	  in	  
pairs	  with	  ad	   libitum	  access	  to	  tap	  water	  and	  chow.	  At	  6,	  12,	  and	  19	  weeks	  of	  age	  (n=8,	  
n=8,	  and	  n=10,	  respectively),	  rats	  were	  killed	  by	  cervical	  dislocation,	  and	  hind	  leg	  muscles	  
were	   rapidly	   dissected.	   The	   tibialis	   anterior	   muscle	   was	   processed	   for	   mitochondrial	  
isolation	   [21]	   and	   soleus	   and	   EDL	   muscles	   were	   processed	   for	   electron	   microscopy	   or	  
rapidly	  frozen	  in	  melting	  isopentane	  (Fluka,	  Zwijndrecht,	  The	  Netherlands),	  and	  stored	  at	  -­‐
80°C.	   All	   experiments	   were	   approved	   by	   the	   The	   Animal	   Care	   and	   Use	   Committee	   of	  
Maastricht	   University	   (approval	   number	   2005-­‐058)	   and	   the	   study	   complied	   with	   the	  
principles	  of	  laboratory	  animal	  care.	  	  
	  
Electroporation	  study	  design	  	  
A	   total	   of	   eighteen	   8-­‐week	   old	   male	   Wistar	   rats	   were	   purchased	   from	   Charles	   River	  
(Wilmington,	  Massachusetts,	  USA).	  Rats	  were	  housed	  individually	  on	  a	  12:12	  h	   light-­‐dark	  
cycle	   (light	   from	  7:00	   am	   to	   7:00	   pm),	   at	   room	   temperature	   (21–22	   °C)	  with	  ad	   libitum	  
access	   to	   tap	   water.	   Rats	   were	   fed	   a	   high	   fat	   diet	   (45%	   energy	   from	   fat,	   D01060502,	  
Research	  Diets,	  New	  Brunswick,	  NJ,	  USA)	  for	  the	  duration	  of	  the	  3-­‐week	  intervention.	  The	  
Animal	   Care	   and	   Use	   Committee	   of	   Maastricht	   University	   approved	   the	   experiments	  
(approval	   number	   2010-­‐036)	   and	   the	   study	   complied	   with	   the	   principles	   of	   laboratory	  




Two	  weeks	   after	   the	   start	   of	   the	   diet,	   overexpression	  of	  Plin5	   in	   either	   the	   right	   or	   left	  
tibialis	  anterior	  (TA)	  muscle	  of	  the	  rat	  was	  accomplished	  by	  an	  in	  vivo	  DNA	  electrotransfer	  
technique	   to	  obtain	  overexpression	  of	  mouse	  perilipin	  5	   in	  one	   leg;	   the	  contralateral	  TA	  
served	   as	   a	   sham-­‐electroporated	   internal	   control.	  Plin5	  was	   electroporated	   randomly	   in	  
the	  left	  or	  the	  right	  TA.	  DNA	  electroporation	  was	  performed	  under	  isoflurane	  anaesthesia.	  
TA	  muscles	  were	  transcutaneously	   injected	  with	  either	  150	  µg	  (2	  µg/µl)	  pcDNA3.1-­‐CMV-­‐
Plin5	   or	   pcDNA3.1-­‐empty	   vector	   in	   0.9%	   sterile	   NaCl.	   Within	   15	   seconds	   after	   the	   last	  
injection	  5	  electric	  pulses	  were	  applied	  by	   two	   stainless	   steel	  plate	  electrodes	  placed	  at	  
the	  ventral	  and	  dorsal	   side	  of	   the	   leg.	  One	  high	  voltage	  pulse	  of	  800	  V/cm	  and	   four	   low	  
voltage	  pulses	  of	  80	  V/cm	  at	  1	  Hz	  were	  generated	  by	  an	  ECM	  830	  electroporator	  (BTX,	  San	  
Diego,	   CA,	   USA)	   as	   described	   previously	   [22,	   23].	   Rats	   were	   sacrificed	   8	   days	  
postelectroporation.	  TA	  muscles	  were	  excised	  and	  processed	  for	  mitochondrial	   isolations	  
and	   electron	   microscopy.	   The	   remainder	   of	   the	   TA	   was	   rapidly	   frozen	   in	   melting	  
isopentane	  for	  histology	  and	  protein	  isolations.	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Mitochondrial	  isolations	  
After	  excision,	  the	  right	  and	  left	  TA	  muscles	  were	  placed	  into	  ice-­‐cold	  medium	  containing	  
100	  mM	   sucrose,	   100	  mM	   KCl,	   50	  mM	   Tris-­‐HCl,	   1mM	   KH2PO4,	   0.1mM	   EGTA,	   and	   0.2%	  
(wt/vol)	   FA-­‐free	  bovine	   serum	  albumin	   (pH	  7.4).	   The	   TA	  was	   immediately	   processed	   for	  
mitochondrial	   isolation,	   essentially	   according	   to	   Tonkonogi	   and	   Sahlin	   [24].	   The	   protein	  
concentration	   in	   the	   mitochondrial	   pellet	   was	   measured	   using	   fluorescamine	   (Fluram;	  
Fluka,	   Zwijndrecht,	   the	   Netherlands)	   with	   bovine	   serum	   albumin	   as	   a	   standard	   [25].	  
Freshly	   isolated	   mitochondria	   were	   used	   immediately	   for	   mitochondrial	   respirometry.	  
Remaining	  mitochondria	  were	  stored	  at	  −80°C	  for	  further	  analysis.	  
	  
High-­‐resolution	  respirometry	  in	  isolated	  mitochondria	  	  
Mitochondrial	   oxygen	   consumption	   was	  measured	   essentially	   according	   to	   Hoeks	   et	   al.	  
[26]	  at	  37°C	  using	  a	  two-­‐chamber	  oxygraph	  (OROBOROS	  Instruments,	   Innsbruck,	  Austria)	  
and	   expressed	   as	   pmol	   O2/mg	   mitochondrial	   protein	   per	   second.	   Mitochondria	   were	  
characterized	  using	  a	  carbohydrate-­‐derived	  substrate	   (5	  mM	  pyruvate)	  and	  a	  FA-­‐derived	  
substrate	  (50	  µM	  palmitoyl-­‐CoA	  plus	  2	  mM	  carnitine).	  For	  this	  purpose,	  mitochondria	  (0.1	  
mg	  for	  pyruvate	  and	  0.2	  mg	  for	  palmitoyl-­‐CoA	  plus	  carnitine)	  were	  incubated	  in	  a	  medium	  
consisting	  of	   100	  mM	  sucrose,	   20	  mM	  K+-­‐Tes	   (pH	  7.2),	   50	  mM	  KCl,	   2	  mM	  MgCl2,	   1	  mM	  
EDTA,	  4	  mM	  KH2PO4,	  3	  mM	  malate	  and	  0.1%	  of	  FA-­‐free	  BSA.	  Maximal	   coupled	   (state	  3)	  
respiration	  was	  initiated	  by	  addition	  of	  450	  µM	  of	  adenosine	  diphosphate	  (ADP).	  State	  4o	  
respiration,	   reflecting	   proton	   leak,	   was	   measured	   as	   the	   residual	   respiration	   following	  
addition	   of	   1	   µg/ml	   oligomycin	   (an	   F1-­‐F0	   ATPase	   inhibitor).	   Maximal	   oxygen	   flux	   rates	  
(state	  uncoupled,	  state	  U)	  were	  obtained	  by	  titration	  of	  the	  chemical	  uncoupler	  carbonyl	  
cyanide	   p-­‐trifluoromethoxyphenylhydrazone	   (FCCP).	   Addition	   of	   excess	   cytochrome	  C	   to	  
the	  chamber	   in	  the	  presence	  of	  pyruvate	  and	  ADP	  did	  not	   increase	  respiration	  (data	  not	  
shown);	   indicating	   that	   during	   isolation	   outer	   mitochondrial	   membrane	   integrity	   was	  
retained.	  	  
	  
14C-­‐palmitate	  oxidation	  assay	  
Ex	  vivo	  fat	  oxidation	  was	  measured	  as	  described	  [27].	  Briefly,	  muscle	  was	  homogenized	  in	  
a	  buffer	  (pH	  7.4)	  containing	  250	  mM	  sucrose,	  10	  mM	  Tris-­‐HCL,	  2	  mM	  ATP	  and	  1	  mM	  EDTA	  
(Sigma,	  St.	  Louis,	  USA).	  Subsequently,	  muscle	  homogenates	  were	  incubated	  for	  2h	  with	  [1-­‐
14C]-­‐labelled	   palmitate	   (1	   µCi/ml,	   Perkin	   Elmer,	   Boston,	   USA)	   and	   200	   µM	   non-­‐labelled	  
(cold)	  palmitate	   in	   reaction	  media	   containing	   L-­‐carnitine,	  ATP	  and	   coenzyme	  A	   (all	   from	  
Sigma,	  St.	   Louis,	  USA)	  at	  37°C.	  Palmitate	  was	  coupled	   to	  FA-­‐free	  BSA	   in	  a	  molar	   ratio	  of	  
5:1.	  After	   incubation,	   reactions	  were	   terminated	  by	  adding	  40	  μl	  of	  70%	  perchloric	  acid,	  
and	   the	   CO2	   produced	   during	   the	   incubation	   was	   trapped	   in	   200	   μl	   of	   1	   N	   sodium	  
hydroxide	  that	  had	  been	  added	  to	  adjacent	  wells	  [28].	  The	  acidified	  medium	  was	  stored	  at	  
4°C	  overnight,	  and	  then	  acid	  soluble	  metabolites	  (ASMs)	  were	  assayed	  in	  supernatants	  of	  
the	  acid	  precipitate.	  Radioactivity	  of	  CO2	  and	  ASMs	  was	  determined	  by	  liquid	  scintillation	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counting	  by	  use	  of	  5	  ml	  of	  Hionic	  Fluor	  (Perkin	  Elmer,	  Boston,	  USA).	  Data	  were	  normalized	  
to	  protein	  content.	  
	  
Electron	  microscopy	  procedures	  
Ultrastructural	   morphology	   and	   PLIN5	   localization	   were	   examined	   using	   transmission	  
electron	   microscopy.	   For	   determinations	   of	   ultrastructural	   morphology,	   muscle	   tissue	  
sections	   were	   fixed	   in	   2.5%	   glutaraldehyde	   in	   0.1	   M	   phosphate	   buffer	   (pH	   7.4).	  
Postfixation	  was	  performed	   in	  1%	  osmium	  tetroxide	   in	  0.1	  M	  cacodylate	  buffer	   (pH	  7.4)	  
supplemented	  with	  1.5%	  potassium	  ferrocyanide.	  The	  samples	  were	  then	  dehydrated	  and	  
embedded	   in	   epon.	   Ultrathin	   sections	   were	   examined	   using	   a	   Philips	   CM100	   electron	  
microscope.	  	  	  
For	  determinations	  of	  subcellular	  localization	  of	  PLIN5,	  soleus,	  extensor	  digitorum	  longus	  
(EDL)	   and	   heart	  muscle	   tissues	   14-­‐wk	   old	   ZDF	   rats	   (ZDF/Gmi,	   fa/fa)	   and	   tibialis	   anterior	  
muscle	  tissues	  from	  electroporated	  Wistar	  rats	  were	  cut	  into	  pieces	  with	  a	  maximum	  size	  
of	  1	  mm3,	  fixed	  for	  1	  h	  at	  room	  temperature	   in	  a	  mixture	  of	  2%	  formaldehyde	  and	  0.2%	  
glutaraldehyde	  in	  0.1	  M	  phosphate	  buffer	  (pH	  7.4),	  and	  stored	  in	  1%	  formaldehyde	  in	  0.1	  
M	  phosphate	  buffer	   (pH	  7.4).	  Tissue	  pieces	  were	   immersed	   in	  a	  2.3	  M	  sucrose	   solution,	  
frozen	   in	   liquid	   nitrogen	   and	   ultrathin	   cryo-­‐sections	   were	   cut	   under	   liquid	   nitrogen,	  
sections	  were	  transferred	  from	  the	  knife	  edge	  to	  a	  formvar	  and	  carbon-­‐coated	  grid	  in	  2.3	  
M	  sucrose/	  1.8%	  methylcellulose	   (1:1),	   as	  described	  by	  Tokuyasu	   [29-­‐31].	   Sections	  were	  
immunogold	   labelled	   as	   described	   by	   Tokuyasu	   [31]	   using	   a	   PLIN5	   antibody	   (#GP31;	  
Guinea	   pig	   polyclonal;	   Progen	   Biotechnik,	   Heidelberg,	   Germany)	   in	   a	   1:100	   dilution	   and	  
protein	  A-­‐gold	  (20	  nm	  particles)	  [32].	  Guinea	  pig	  normal	  serum	  (Santa	  Cruz	  Biotechnology,	  
Tebu-­‐bio,	  Heerhugowaard,	  The	  Netherlands)	  was	  used	  as	  a	  negative	  control.	  
	  
Oil-­‐red-­‐O	  stainings	  and	  immunofluorescence	  
Neutral	   lipids,	  mitochondria	   and	  PLIN5	   in	  muscle	   sections	  were	   stained	  with	   a	  modified	  
Oil-­‐red-­‐O	   staining	   for	   fluorescence	   microscopy	   as	   previously	   described	   [33]	   using	  
antibodies	   against	   PLIN5	   (#GP31;	   Progen	   Biotechnik,	   Heidelberg,	   Germany),	   laminin	   (L-­‐
9393;	  Sigma,	  St.	   Louis,	  USA),	   and	  OXPHOS	   (MS601;	  MitoSciences,	  Eugene,	  OR,	  USA)	  and	  
the	  appropriate	  secondary	  Alexa-­‐fluor	  conjugated	  antibodies	  (Invitrogen,	  Groningen,	  The	  
Netherlands).	   Fluorescent	   images	   of	   Alexa-­‐350	   (laminin),	   Alexa-­‐488	   (PLIN5),	   Alexa-­‐647	  
(OXPHOS),	  and	  Oil-­‐red-­‐O	  (visible	  in	  the	  red	  -­‐594-­‐	  channel)	  were	  acquired	  using	  an	  imaging	  
system	   consisting	   of	   an	   IX81	   inverted	  microscope	   (Olympus,	   Hamburg,	   Germany),	   an	   X-­‐
cite	   fluorescent	   light	   source	   (Lumen	   Dynamics	   group,	  Mississauga,	   Ontario,	   Canada),	   F-­‐
view	   II	   CCD	   camera	   (OSIS,	   Münster,	   Germany)	   and	   the	   Cell^F	   imaging	   software	   (OSIS).	  
Fluorescent	  photomicrographs	  were	  made	  from	  Z-­‐stacks	  consisting	  of	  30-­‐40	  images	  with	  a	  
distance	   of	   0.28	   µm	   using	   the	   maximum	   intensity	   projection	   method	   in	   the	   ImageJ	  
software	  (Rasband,	  W.S.,	  ImageJ,	  U.	  S.	  National	  Institutes	  of	  Health,	  Bethesda,	  Maryland,	  
USA,	  http://rsb.info.nih.gov/ij/,	  1997-­‐2009).	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Western	  blots	  	  
Western	   blots	   were	   performed	   in	   protein	   lysates	   from	   whole	   muscle	   homogenates	   or	  
mitochondrial	   fractions.	  Muscle	   samples	   and	  mitochondrial	   fractions	  were	  homogenized	  
in	   ice-­‐cold	   PBS	   containing	   1%	   Nonidet-­‐P40,	   0.5%	   sodium	   dodecyl	   sulfate,	   0.1	   mM	  
phenylmethylsulfonyl	   fluoride,	   complete	   inhibitor	   (Roche,	  Almere,	   The	  Netherlands)	   and	  
processed	   for	   standard	   SDS-­‐PAGE	   and	   Western	   blotting.	   Protein	   concentration	   was	  
determined	   and	   equal	   amounts	   of	   protein	   were	   loaded	   per	   lane.	   The	   nitrocellulose	  
membranes	   were	   incubated	   with	   antibodies	   against	   PLIN5	   (GP31;	   Progen	   Biotechnik,	  
Heidelberg,	   Germany),	   PLIN2	   (GP40;	   Progen	   Biotechnik,	   Heidelberg,	   Germany),	   OXPHOS	  
(MS601;	  MitoSciences,	  Eugene,	  OR,	  USA),	  PGC1α	  (516557;	  Calbiochem;	  VWR	  International	  
BV,	   Amsterdam,	   The	  Netherlands),	   VDAC	   (SC-­‐8828;	   Santa	   Cruz	   Biotechnology,	   Tebu-­‐bio,	  
Heerhugowaard,	  The	  Netherlands),	  and	  SR-­‐actin	  (A-­‐2172;	  Sigma,	  St.	  Louis,	  USA).	  
Blots	  incubated	  with	  PLIN5,	  PLIN2,	  OXPHOS,	  PGC1α,	  VDAC	  and	  sr-­‐actin	  were	  probed	  with	  
appropriate	   IRDye800-­‐conjugated	   or	   IRDye700-­‐conjugated	   secondary	   antibodies	  
(Rockland,	  Tebu-­‐bio,	  Heerhugowaard,	  The	  Netherlands,	  and	  LICOR	  Biosciences,	  Westburg,	  
Leusden,	  The	  Netherlands),	  and	  bands	  at	  a	  molecular	  weight	  corresponding	  to	  the	  control	  
samples	  were	  quantified	  using	   the	  Odyssey	   infrared	   imaging	   system	   (LICOR	  Biosciences,	  
Westburg,	  Leusden,	  The	  Netherlands).	  
	  
Statistical	  analysis	  
Results	   are	   presented	   as	   mean	   ±	   SE.	   Differences	   between	   groups	   were	   evaluated	   with	  
paired	   T-­‐tests.	   Outcomes	   were	   considered	   statistically	   significant	   when	   P<0.05	   (two-­‐
tailed).	   Pearson’s	   correlation	   coefficients	   were	   used	   to	   describe	   the	   linear	   association	  
between	  variables.	  All	  analyses	  were	  performed	  using	  the	  Statistical	  Package	  for	  the	  Social	  
Sciences	  (SPSS	  16.0,	  Nieuwegein,	  The	  Netherlands)	  software	  for	  Mac	  16.0.	  
	  
RESULTS	  
Skeletal	  muscle	  PLIN5	  protein	  content	  correlates	  with	  oxidative	  capacity	  
In	   order	   to	   explore	   the	   role	   of	   PLIN5	   in	   skeletal	   muscle,	   we	   measured	   PLIN5	   protein	  
content	  in	  muscle	  biopsies	  of	  vastus	  lateralis	  muscle	  of	  young	  healthy	  male	  subjects.	  PLIN5	  
protein	  content	  correlated	  strongly	  with	  the	  protein	  content	  of	  structural	  components	  of	  
the	   individual	   complexes	  of	   the	  electron	   transport	   chain;	  OXPHOS	  complexes	   I	   (r=0.721,	  
P=0.012),	   III	   (r=0.810,	   P=0.003),	   IV	   (r=0.704,	   P=0.016)	   and	   V	   (r=0.606,	   P=0.048)	   but	   not	  
with	   protein	   content	   of	   VDAC,	   an	   outermitochondrial	   membrane	   protein	   without	   a	  
recognized	  role	  in	  (fat)	  oxidation	  (r=0.148,	  P=0.664)	  (n=11)	  (Table	  1).	  	  
These	  observations	   indirectly	   suggest	  a	   role	  of	  PLIN5	   in	  mitochondrial	   fat	  oxidative	  
metabolism.	  This	   led	  us	  to	  investigate	  the	  relationship	  between	  PLIN5	  protein	  content	   in	  
whole	  muscle	  homogenates	  with	   respiration	   rates	  of	   isolated	  muscle	  mitochondria	  on	  a	  
fat-­‐derived	   substrate	   (palmitoyl-­‐CoA).	   Thus,	  we	   analyzed	   correlations	   of	   skeletal	  muscle	  
PLIN5	   protein	   expression	   with	   mitochondrial	   function	   in	   a	   model	   of	   progressive	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myocellular	   fat	   deposition,	   the	   maturing	   Zucker	   diabetic	   fatty	   (ZDF)	   rats	   (fa/fa).	   In	   this	  
model,	  PLIN5	  protein	  content	  tracks	  with	  intramyocellular	  lipid	  content	  [6].	  	  
	  
Table	  1.	  Correlation	  of	  PLIN5	  protein	  expression	  with	  OXPHOS	  complexes	  in	  human	  vastus	  lateralis	  
muscle.	  
	   VDAC	   OXPHOS	  
I	  
OXPHOS	  II	   OXPHOS	  III	   OXPHOS	  IV	   OXPHOS	  V	  
Pearson	  Correlation	   -­‐0.148	   .721*	   0.455	   .810*	   .704*	   .606*	  
P	   0.664	   0.012	   0.159	   0.003	   0.016	   0.048	  
	  
We	  examined	  the	  correlation	  between	  PLIN5	  content	  in	  whole	  muscle	  homogenates	  and	  
intrinsic	  mitochondrial	   function	   in	  mitochondria	   isolated	   from	   these	  muscles	  by	   classical	  
mitochondrial	   respirometry	  using	  palmitoyl-­‐CoA	  as	  a	  FA-­‐derived	  substrate.	   In	   these	   rats,	  
PLIN5	   protein	   content,	   but	   importantly	   not	   PLIN2	   protein	   content,	   positively	   correlated	  
with	   ADP-­‐driven	   state	   3	   respiration	   (r=0.713,	   P<0.001)	   as	   well	   as	   respiration	   under	  
maximal	  FCCP-­‐mediated	  uncoupled	  conditions	  (state	  U,	  r=0.663,	  P=0.001)	  (Table	  2).	  These	  
observations	  may	   indicate	  that	   in	  muscles	   in	  which	  PLIN5	  protein	  content	  scales	  with	  LD	  
content,	  PLIN5	  is	  involved	  in	  facilitating	  increased	  mitochondrial	  fat	  oxidation.	  
	  
Table	   2.	   Correlation	   of	   PLIN5	   protein	   expression	   with	   respiration	   of	   mitochondria	   isolated	   from	  
skeletal	  muscle	  of	  fatty	  ZDF	  rats.	  	  
	  	  
	   	  	  
Palmitoyl-­‐CoA	  
	  State	  3	   State	  U	  
PLIN5	   Pearson	  Correlation	   .713*	   .663*	  
	   P	   <0.001	   0.001	  
	   n	   23	   23	  
PLIN2	   Pearson	  Correlation	   0.343	   0.182	  
	   P	   0.1	   0.396	  
	  	   n	   24	   24	  
	  
Perilipin	   5	   localizes	   to	   lipid	   droplets	   as	  well	   as	   to	  mitochondria	   in	   cardiac	   and	  
skeletal	  muscle	  	  
The	   strong	   correlation	   of	   PLIN5	   protein	   content	   with	   OXPHOS	   complexes	   and	  
mitochondrial	   respiration	   on	   a	   FA-­‐derived	   substrate	   led	   us	   to	   examine	   whether	   PLIN5,	  
next	   to	   its	   recognized	   localisation	   to	   LD,	   is	   also	   present	   in	   mitochondria.	   Thus,	   we	  
measured	  PLIN5	  protein	  content	  in	  total	  muscle	  protein	  lysates	  as	  well	  as	  in	  mitochondrial	  
fractions	   from	   rat	   skeletal	   muscle	   (Fig.	   1A).	   A	   double	   band	   representing	   PLIN5	   was	  
observed	   in	  whole	  muscle	   lysates	   and	  more	   strikingly	   also	   in	   isolated	  mitochondria.	   To	  
exclude	   the	   ability	   that	   the	   PLIN5	   signal	   detected	   in	   the	   mitochondria	   originated	   from	  
contamination	  of	  the	  mitochondrial	  fraction	  with	  ER	  or	  LD	  derived	  membrane	  fractions	  we	  
examined	  protein	  expression	  of	  ADRP/PLIN2	   in	  our	  mitochondrial	   fractions	  (Fig.	  1B).	  The	  
absence	   of	   an	   ADRP/PLIN2	   band	   indicates	   that	   the	   mitochondrial	   fractions	   used	   were	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devoid	   of	   ER	   or	   LD	   membrane	   structures,	   substantiating	   our	   notion	   that	   PLIN5	   indeed	  
localizes	  to	  mitochondria.	  	  
We	   further	   substantiated	   mitochondrial	   localisation	   of	   PLIN5	   using	   immunogold	  
electron	  microscopy,	  the	  gold	  standard	  methodology	  for	  subcellular	  localisation	  studies	  of	  
single	   proteins.	   In	   all	   muscles	   examined	   (soleus,	   EDL	   and	   cardiac	   muscle)	   PLIN5	   was	  
present	   on	   the	   LDs,	   at	   the	   interface	   of	   LDs	   with	   mitochondria,	   as	   well	   as	   in	   the	  
mitochondria	   (Fig.	  1C	  and	  1D),	  whereas	  other	  structures	  were	  almost	  completely	  devoid	  
of	  gold	  particles.	  Negative	  controls	  by	  omission	  of	  the	  primary	  antibody	  or	  by	  using	  non-­‐
immune	   serum	   did	   not	   show	   any	   immunogold	   staining.	   Immunogold	   staining	   using	   the	  
ADRP/PLIN2	  antibody	  only	  revealed	  staining	  associated	  with	  LD	  (data	  not	  shown).	  
	  
	  
Figure	  1.	  Perilipin	  5	  protein	  expression	   in	  whole	  muscle	  homogenates,	   isolated	  mitochondria	  and	  
muscle	   sections.	   (A)	  Western	   blotting	   of	   perilipin	   5	   in	   whole	   skeletal	   muscle	   lysates	   from	   heart	  
muscle,	   extensor	   digitorum	   longus	   (EDL)	   and	   tibialis	   anterior	  muscles	   and	  mitochondria	   isolated	  
from	   tibialis	   anterior	  muscle.	   (B)	  Western	  blots	   incubated	  with	   the	  PLIN2	  antibody	  did	  not	   show	  
any	  bands	   in	   isolated	  mitochondria,	   indicating	  that	   the	  mitochondrial	   fraction	  was	  devoid	  of	   lipid	  
droplets	   and	  was	   not	   contaminated	  with	   fragments	   of	   the	   ER.	   HEK	   cells	   transfected	   with	   PLIN2	  
plasmid	  were	  used	  as	  positive	  control.	   (C)	  PLIN5	   immunogold	   labeling	   in	  rat	  soleus	  muscle.	  PLIN5	  
coats	  the	  lipid	  droplets	  and	  is	  present	  at	  mitochondria	  but	  not	  at	  myofibrils.	  (D)	  PLIN5	  immunogold	  
labeling	  in	  rat	  left	  ventricle	  showing	  mitochondrial	  localization	  of	  PLIN5.	  	  




PLIN5	  overexpression	  in	  rat	  tibialis	  anterior	  muscle	  
To	  examine	   the	  effect	  of	  overexpression	  of	  PLIN5	  on	   its	   subcellular	   localisation,	   a	  CMV-­‐
driven	   full-­‐length	  PLIN5	   construct	  was	  used	   for	  unilateral	  overexpression	  of	  PLIN5	   in	   rat	  
tibialis	   anterior	   muscle	   by	   gene	   electroporation	   using	   the	   contralateral	   empty	   vector-­‐
electroporated	   leg	   as	   an	   internal	   control.	   Upon	   transfection	   in	   HEK	   cells	   the	   construct	  
used	   resulted	   in	   the	   anticipated	   double	   band	   on	   the	  Western,	   representing	   two	   PLIN5	  
isoforms	  (Fig.	  2A).	  	  
	  
	  
Figure	   2.	   PLIN5	   overexpression	   (gene	   electroporation)	   in	   rat	   muscle	   using	   an	   empty	   vector	   as	  
internal	   control.	   (A)	   Specificity	   of	   the	   PLIN5	   antibody	   (Progen).	   A	   full	   length	   PLIN5	   vector	   was	  
transfected	   in	   cells	   without	   endogenous	   PLIN5	   expression	   (HEK	   cells),	   this	   resulted	   in	   ectopic	  
expression	  of	  PLIN5.	  (B)	  PLIN5	  protein	  content	  in	  protein	  lysates	  from	  electroporated	  tibialis	  anterior	  
muscle	   (n=16).	   Error	   bars	   represent	   SEM,	   *P<0.01.	   The	   samples	   were	   derived	   from	   the	   same	  
experiment	   and	   were	   simultaneously	   processed	   in	   random	   order	   on	   two	   gels/blots.	   EV:	   empty	  
vector.	   (C)	  Shows	  the	  effect	  of	  PLIN5	  overexpression	  on	   lipid	  storage	  (upper	  right	  hand	  panel)	  and	  
PLIN5	  content	  (lower	  right	  hand	  panel)	  compared	  to	  the	  empty	  vector	  control	  (upper	  and	  lower	  left	  
hand	  panels).	  LDs	  are	  stained	  in	  red),	  PLIN5	  in	  green	  and	  cell	  membranes	  in	  blue.	  Bars	  represent	  100	  
µm.	   (D)	   Overlay	   of	   PLIN5	   and	   mitochondrial	   proteins	   upon	   PLIN5	   overexpression.	   PLIN5	  
overexpression	  increases	  LD	  (in	  red)	  and	  PLIN5	  (in	  green)	  content	  (upper	  right	  hand	  and	  middle	  left	  
hand	  panel,	  respectively).	  Mitochondria	  are	  shown	  in	  magenta	  (middle	  left	  hand	  panel).	  The	  lower	  
left	   hand	   panel	   shows	   LD	   decorated	   with	   PLIN5	   while	   the	   lower	   right	   hand	   panel	   shows	   PLIN5	  
interaction	  with	  mitochondria.	  The	  bar	  represents	  20	  µm.	  Representative	  image	  are	  shown.	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In	   rat	   tibialis	   anterior	   muscle,	   PLIN5	   overexpression	   doubled	   PLIN5	   protein	   content	   in	  
whole	   muscle	   homogenates	   (P=0.0006,	   n=14,	   paired	   T-­‐test)	   (Fig.	   2B).	   Consistent	   with	  
results	   obtained	   in	   vitro	   [4,	   5],	   PLIN5	   overexpression	   profoundly	   augmented	  
intramyocellular	   lipid	   storage	   in	   the	   transfected	  muscle	   (Fig.	  2C).	   Immunohistochemistry	  
revealed	  that	  PLIN5	  was	  present	  on	  LDs	  and	  showed	  punctuate	  mitochondrial	  localisation.	  
Double	  immunofluorescence	  using	  an	  antibody	  cocktail	  against	  structural	  components	  of	  
all	   5	  OXPHOS	   complexes	   confirmed	   co-­‐localisation	  of	  PLIN5	  with	  mitochondria	   (Fig.	   2D).	  
Ultrastructural	   analysis	   by	   electron	   microscopy	   confirmed	   the	   light	   microscopy	   based	  
observation	   of	   augmented	   lipid	   storage	   upon	   PLIN5	   overexpression	   and	   clearly	   showed	  
increased	   LD	   size	   (Fig.	   3).	   In	   addition,	   almost	   all	   LD	   appear	   to	   interact	   tightly	   with	  
mitochondria	  in	  the	  PLIN5-­‐overexpressing	  muscle	  and	  sometimes	  even	  appear	  to	  envelop	  
the	   lipid	   droplets	   (Fig.	   3).	   Immunogold	   labelling	   of	   PLIN5	   in	   electroporated	   muscle	  
confirmed	  the	  localization	  of	  PLIN5	  in	  mitochondria,	  on	  LDs	  and	  on	  the	  LD-­‐mitochondrial	  
interface	  (Fig.	  4).	  	  
	  
PLIN5	  overexpression	  does	  not	  affect	  mitochondrial	  density	  	  
To	   examine	   the	   putative	   effect	   of	   PLIN5	   overexpression	   on	   mitochondrial	   density,	   we	  
measured	   in	  whole	  muscle	   homogenates	   the	   protein	   content	   of	   PGC1α	   (Fig.	   5A),	   VDAC	  
(Fig.	   5B)	   and	   5	   distinct	   structural	   components	   of	   subunits	   of	   the	   individual	   OXPHOS	  
complexes	  (complex	  I	  subunit	  NDUFB8,	  complex	  II	  subunit	  30kDa,	  complex	  III	  subunit	  Core	  
2,	  complex	   IV	  subunit	   I	  and	  complex	  V	  ATP	  sythase	  subunit	  alpha	   (Fig.	  5C).	  Although	  we	  
observed	   a	   non-­‐significant	   (p=0.14)	   increase	   in	   PGC1α,	   a	   key	   co-­‐activator	   for	  
mitochondrial	   biogenesis,	   protein	   content	   of	   VDAC	   and	   OXPHOS	   complexes	   remained	  




Figure	   3.	  PLIN5	   overexpression	  
results	   in	   large	   LDs.	   Left	   hand	  
panels	   (A	   and	   C)	   show	   empty	  
vector	   control	   data,	   right	   hand	  
panels	   (B	   and	   D)	   show	   PLIN5	  
overexpression	   data.	   Note	   the	  
apparent	   larger	   LD	   size	   upon	  
PLIN5	   overexpression.	   Bar	  
represents	   10	  µm	   in	   the	  upper	  





PLIN5	  overexpression	  does	  not	  improve	  respiration	  of	  isolated	  mitochondria	  	  
Mitochondrial	   respirometry	   assays	   in	   the	   mitochondria	   isolated	   from	   PLIN5	  
overexpressing	   muscles	   relative	   to	   muscles	   isolated	   from	   empty	   vector	   electroporated	  
muscles	  did	  not	   reveal	   significant	  differences	   in	   respiration,	  neither	  on	  pyruvate	   (empty	  
vector	   vs.	   PLIN5	  15.98	  ±	   1.17	   vs.	   15.48	  ±	   1.18	   state	  3/	   state	  2,	   P=0.83;	   22.53	  ±	   0.88	   vs.	  
22.29	  ±	  1.44	  state	  U/	  state	  2,	  P=0.68),	  nor	  on	  palmitoyl-­‐CoA	  (empty	  vector	  vs.	  PLIN5	  6.76	  ±	  
0.38	  vs.	  7.36	  ±	  0.30	  state	  3/	  state	  2,	  P=0.23;	  8.56	  ±	  0.63	  vs.	  9.14	  ±	  0.49	  state	  U/	  state	  2,	  
P=0.37)	  (Fig.	  6A	  and	  6B).	  Thus,	  in	  a	  system	  in	  which	  PLIN5-­‐coated	  LDs	  are	  dissociated	  from	  




Figure	  4.	  PLIN5	  labeling	   in	  
mitochondria	   and	   on	   the	  
LDs.	   Immunogold	   staining	  
of	  PLIN5	  in	  tibialis	  anterior	  
muscle	   of	   empty	   vector	  
(control)	   (A)	   or	   PLIN5-­‐
electroporated	  muscle	  (B).	  
PLIN5	  overexpression	  (B,	  C	  
and	   D)	   resulted	   in	   larger	  
LDs	   and	   intimate	  
interaction	   of	   LDs	   with	  
mitochondria	   at	   PLIN5	  
positive	   sites	   (see	  
arrowheads	   in	   C	   and	   D).	  
Bars	   represent	   1	   µm.	   (E)	  
Intramitochondrial	   PLIN5	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Figure	   5.	   Abundance	   of	   mitochondrial	   proteins	   upon	   PLIN5	   overexpression.	  Western	   blots	   were	  
performed	   for	   expression	   of	   PGC1α	   (A),	   VDAC	   (B)	   and	   5	   distinct	   structural	   components	   of	   the	  
OXPHOS	   complexes	   (C)	   in	   lysates	   from	   whole	   muscle	   homogenates	   (n=14).	   Error	   bars	   represent	  
SEM,	   *=P<0.01.	   The	   samples	   were	   derived	   from	   the	   same	   experiment	   and	   were	   simultaneously	  
processed	  in	  random	  order.	  	  
	  
PLIN5	  overexpression	  improved	  14C-­‐palmitate-­‐oxidation	  
Given	   the	   intimate	   association	   of	   LDs	  with	  mitochondria	  we	   performed	   complementary	  
measurements	   of	   fat	   oxidation	  using	   14C-­‐palmitate	   in	  whole	  muscle	   homogenates	  when	  
LDs	   and	   mitochondria	   were	   not	   dissociated.	   Total	   14C-­‐palmitate-­‐oxidation	   was	   not	  
changed	   (empty	  vector	  0.71	  ±	  0.06	  nmol/2h/mg	  protein,	  PLIN5	  0.71	  ±	  0.03	  nmol/2h/mg	  
protein,	  P=0.99)	  (Fig.	  6C).	  However,	  oxidation	  of	  14C-­‐palmitate	  to	  14CO2	  increased	  by	  44.8%	  
(empty	   vector	   0.05	   ±	   0.008,	   PLIN5	   0.07	   ±	   0.012	   14CO2/total	  
14C-­‐palmitate	   oxidation,	  
P=0.05)	   (Fig.	   6D).	   The	   respiration	   data	   in	   isolated	   mitochondria	   and	   in	   muscle	  
homogenates	   jointly	   indicate	   that	   overexpression	   of	   PLIN5	   does	   not	   augment	  
mitochondrial	  fat	  oxidative	  capacity	  per	  se	  but	  rather	  creates	  a	  situation	  in	  which	  shuttling	  
of	   FAs	   towards	  mitochondria	   becomes	  more	   efficient,	   thereby	   protecting	  mitochondria	  









































Figure	  6.	  Effects	  of	  PLIN5	  overexpression	  on	  mitochondrial	  respiration	  and	  FA	  oxidation.	   (A	  and	  B)	  
State	  3	   (coupled)	  and	  state	  U	  (uncoupled)	  respiration	  on	  palmitoyl-­‐CoA	  (A)	  or	  pyruvate	  (B),	  values	  
are	   standardized	   to	   state	   2	   respiration	   (background	   respiration	   in	   the	   absence	   of	   ADP)	   (n=9).	   (C)	  
Total	   14C-­‐palmitate	   oxidation	   in	   muscle	   homogenates	   (CO2	   plus	   ASMs).	   (D)	   The	   ratio	   of	   CO2	  
production	  (complete	  oxidation)	  to	  total	  palmitate	  (PA)	  oxidation	  (CO2	  plus	  acid	  soluble	  metabolites)	  
(n=7).	  Error	  bars	  represent	  SEM,	  P-­‐values	  were	  derived	  from	  paired	  T-­‐tests.	  	  
DISCUSSION	  
PLIN5	  was	  recently	   identified	  as	  a	  member	  of	  the	  perilipin	  family	  of	   lipid	  droplet	  coating	  
proteins	   and	  was	   considered	   to	   be	   an	   exchangeable	   LD	   coat	   protein;	   unlike	   perilipins	   1	  
and	   2,	   PLIN5	   is	   not	   exclusively	   found	   in	   the	   LD-­‐coat	   but	   also	   cytosolically	   [3-­‐5].	   Using	   a	  
variety	  of	  validated	  techniques,	  however,	  we	  here	  show	  that	  PLIN5	  in	  muscle	  is	  found	  at	  
the	   LDs	   as	   well	   as	   in	   mitochondria,	   this	   in	   contrast	   to	   PLIN2,	   the	   other	   major	   LD	   coat	  
protein	  found	  in	  muscle.	  PLIN5	  positive	  mitochondria	  were	  detected	  in	  oxidative	  (soleus),	  
glycolytic	  (EDL),	  and	  mixed	  (TA)	  muscles	  as	  well	  as	  in	  cardiac	  muscle.	  Both	  subsarcolemmal	  
mitochondria	   and	   intramyofibrillar	  mitochondria	   contained	   PLIN5.	   Gene	   electroporation	  
mediated	   overexpression	   of	   PLIN5	   doubled	   PLIN5	   protein	   content	   and	   resulted	   in	  more	  
numerous	  and	  apparently	  larger	  LDs	  in	  intimate	  interaction	  with	  mitochondria.	  Functional	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in	   isolated	  mitochondria	  was	  not	  affected	  by	  PLIN5	  overexpression.	   Interestingly	  though,	  
fatty	   acid	   oxidation	   rates	   were	   higher	   in	   whole	   muscle	   homogenates	   of	   PLIN5	  
overexpressing	  muscles,	  suggesting	  a	  facilitating	  role	  of	  PLIN5	  in	  augmenting	  fat	  oxidation	  
situations	  when	  LDs	  are	  physically	  interconnected	  to	  the	  mitochondrial	  reticulum,	  possibly	  
by	  shuttling	  or	  chaperoning	  of	  LD-­‐derived	  FAs	  towards	  mitochondria	  for	  oxidation.	  	  
Recent	  reports	  have	  shown	  that	  PLIN5	  localised	  to	  LDs	  in	  tissues	  rich	  in	  mitochondria	  
[3-­‐5],	   that	  overexpressing	  PLIN5	   in	  OP-­‐9	  and	  COS-­‐7	  cells	  promoted	   fat	  oxidation	   [4]	  and	  
that	   the	   proteome	   of	   LDs	   contained	   multiple	   mitochondrial	   proteins	   [34].	   In	   addition,	  
PLIN5	   interaction	   with	   ATGL	   on	   LDs	   and	   on	   undefined	   intracellular	   structures	   lacking	  
neutral	  lipids	  [8]	  has	  been	  reported.	  This	  has	  led	  us	  to	  investigate	  the	  possibility	  that	  PLIN5	  
also	  localizes	  to	  mitochondria.	  	  	  
	   Thus,	  we	  observed	   that	  PLIN5	  protein	   content	   in	   vastus	   lateralis	  muscle	  of	   healthy	  
young	  male	  subjects	  correlated	  positively	  and	  tightly	  with	  structural	  components	  of	  all	  five	  
complexes	  of	  the	  electron	  transport	  chain,	  but	  not	  with	  mitochondrial	  proteins	  without	  a	  
recognised	   role	   in	   fat	   oxidation.	   The	   lack	   of	   associations	   of	   PLIN5	   with	   VDAC,	   a	  
mitochondrial	   protein	   not	   involved	   in	   (fat)	   oxidation,	   narrows	   the	   interpretation	   of	  
previous	  observations	  of	  PLIN5	  being	  abundant	  in	  mitochondria	  rich	  tissues	  [3-­‐5]	  and	  may	  
hint	  towards	  a	  more	  direct	  involvement	  of	  PLIN5	  in	  mitochondrial	  fat	  oxidation.	  Hence,	  we	  
studied	   ADP-­‐driven	   respiration	   rates	   on	   palmitoyl-­‐CoA	   in	   mitochondria	   isolated	   from	  
tibialis	  anterior	  muscles	  of	  ZDF	  rats	  with	  a	  range	  in	  myocellular	  fat	  content.	  We	  previously	  
observed	   that	   muscles	   of	   these	   rats	   have	   increased	   PLIN5	   and	   PLIN2	   protein	   content	  
which	  tracked	  with	  intramyocellular	  fat	  content	  [6].	  Fascinatingly,	  coupled	  respiration	  and	  
maximal	   respiration	   on	   palmitoyl-­‐CoA	   correlated	   tightly	   with	  muscle	   PLIN5	   content	   but	  
interestingly	  not	  with	  PLIN2	  content.	  Thus,	  only	  PLIN5	  paralleled	  changes	  in	  mitochondrial	  
fat	  oxidative	  capacity.	  Upon	  Western	  blotting	  isolated	  mitochondria	  with	  a	  specific	  PLIN5	  
antibody,	  we	  were	  able	   to	  unmask	  PLIN5	  as	   a	  mitochondrial	   protein.	   The	  mitochondrial	  
isolation	   protocol	   used	   results	   in	   a	   very	   clean	   mitochondrial	   homogenate	   without	  
contamination	   of	   other	   membrane	   structures	   of	   remnants	   of	   LD	   membranes.	   This	   was	  
substantiated	  by	  the	  observation	  that	  the	  mitochondrial	  isolation	  was	  negative	  for	  PLIN2,	  
while	   showing	  clear	  PLIN5	  bands	   in	  mitochondria	   isolated	   from	  a	  variety	  of	   skeletal	   and	  
cardiac	   muscles.	   To	   further	   substantiate	   these	   findings	   we	   performed	   double	  
immunofluorescence	   microscopy	   with	   PLIN5	   along	   with	   an	   antibody	   against	   structural	  
components	   of	   the	   electron	   transport	   chain	   in	   rat	   tibialis	   anterior	   muscles.	   Confocal	  
analysis	  of	  tissue	  sections	  indeed	  localised	  PLIN5	  to	  the	  LD,	  but	  also	  to	  the	  mitochondria.	  
For	   a	  more	   detailed	   confirmation	   of	   PLIN5	   being	   expressed	   in	  mitochondria	  we	   applied	  
post-­‐embedding	   immunogold	  electron	  microscopy,	   the	  gold	   standard	   for	  high-­‐resolution	  
subcellular	   localisation	   studies	   of	   proteins	   [35].	   Thus,	   we	   identified	   PLIN5	   to	   the	   LD	  
membrane	   as	   well	   as	   in	   mitochondria	   in	   sections	   from	   rat	   glycolytic	   (EDL),	   oxidative	  
(soleus)	  and	  cardiac	  muscle.	  PLIN5	  was	  consistently	  present	  in	  subsarcolemmal	  as	  well	  as	  
in	   intermyofibrillar	   mitochondria	   of	   all	   muscle	   types	   examined.	   Again,	   no	   such	  
observations	  were	  made	  for	  PLIN2,	  the	  other	  major	  LD	  coat	  protein	  in	  muscle.	  Except	  for	  
LDs,	  other	  organelles	  and	  myofibrillar	  structures	  were	  almost	  devoid	  of	  any	  PLIN5	  signal.	  	  
Chapter	  6	  
	  133	  
Having	  identified	  PLIN5	  in	  mitochondria	  we	  set	  out	  to	  investigate	  the	  effect	  of	  PLIN5	  
overexpression	   on	   PLIN5	   subcellular	   distribution	   and	   myocellular	   ultrastructure.	   We	  
deliberately	  choose	  unilateral	  gene	  electroporation	  as	  the	  in	  vivo	  approach	  to	  overexpress	  
PLIN5	  in	  the	  tibialis	  anterior	  muscle	  of	  a	  rat.	  Thus,	  we	  were	  able	  to	  avoid	  lifelong	  adaptive	  
responses	  while	  creating	  the	  ability	  to	  use	  the	  contralateral	  leg	  as	  an	  internal	  control.	  This	  
resulted	   in	   a	   two-­‐fold	   overexpression	   of	   PLIN5.	   Immunofluorescence	   microscopy	   and	  
immunogold	   electron	   microscopy	   in	   tibialis	   anterior	   samples	   of	   the	   control	   and	   the	  
overexpressing	  muscle	  confirmed	  specific	   localisation	  of	  PLIN5	   to	  mitochondria	  and	   lipid	  
droplets.	  No	  apparent	  changes	  in	  the	  subcellular	  distribution	  of	  PLIN5	  were	  observed,	  i.e.,	  
subsarcolemmal	   and	   intermyofibrillar	  mitochondria	   pools	   both	   remained	   PLIN5	   positive	  
and	   qualitative	   examination	   of	   electron	  microscopical	   images	   did	   not	   indicate	   selective	  
upregulation	  of	  PLIN5	  at	  the	  LD	  site	  or	  at	  mitochondria.	  Using	  a	  variety	  of	  mitochondrial	  
proteins	  we	   did	   not	   obverse	   indications	   of	   increased	  mitochondrial	   density	   upon	   PLIN5	  
overexpression	  during	  the	  8	  day	  time	  span	  of	  PLIN5	  overexpression.	  	  
Moreover,	   PLIN5	   overexpression	   augmented	   intramyocellular	   lipid	   storage	   and	   LD	  
size,	  possibly	   reflecting	   the	   involvement	  of	  PLIN5	   in	  ATGL-­‐mediated	   lipolysis	   [8,	  10].	  The	  
localization	  of	  PLIN5	  on	  the	  LDs	  and	  in	  mitochondria	  suggests	  a	  role	  for	  PLIN5	  in	  directing	  
or	   binding	   fatty	   acids	   -­‐or	   fatty	   acid	   derivatives-­‐	   for	   mitochondrial	   oxidation.	  
Measurements	   of	   respiration	   in	   isolated	   mitochondria	   did	   not	   reveal	   any	   differences	  
between	   mitochondria	   derived	   from	   the	   sham-­‐	   and	   the	   PLIN5-­‐electroporated	   muscle,	  
which	  does	  not	  support	  a	  direct	  role	  for	  PLIN5	   in	  mitochondrial	  respiration.	   Interestingly	  
though,	   when	   examining	   14C-­‐palmitate	   oxidation	   in	   muscle	   homogenates	   -­‐when	  
mitochondria	   are	   not	   examined	   in	   isolation	   but	   in	   context	   of	   their	   native	   subcellular	  
milieu-­‐	  we	  observed	  increased	  complete	  oxidation	  of	  14C-­‐palmitate	  to	  CO2.	  This	  occurred	  
in	  the	  absence	  of	  an	  increase	  in	  accumulation	  of	  acid	  soluble	  metabolites,	  indicating	  that	  
the	   supply	   of	   fatty	   acids	   and/or	   the	   rate	   of	   ß-­‐oxidation	   were	   better	   matched	   with	   the	  
capacity	  for	  downstream	  FA	  oxidative	  metabolism.	  It	  should	  be	  noted	  that,	  albeit	  unlikely,	  
we	  cannot	  exclude	  the	  possibility	  that,	  during	  the	  isolation	  of	  mitochondria,	  the	  stronger	  
physical	   interaction	  between	  mitochondria	  and	   lipid	  droplets	  upon	  PLIN5	  overexpression	  
resulted	   in	   a	   loss	   of	  mitochondria	   intimately	   connected	   to	   the	   large	   lipid	   droplets.	   This	  
could	   explain	   the	   discrepancy	   in	   the	   results	   of	   the	   experiments	   in	  muscle	   homogenates	  
and	  isolated	  mitochondria.	  Nevertheless,	  the	  increase	  14C-­‐palmitate	  to	  CO2	  points	  towards	  
a	  beneficial	  effect	  of	  PLIN5	  overexpression	  on	  mitochondrial	  fatty	  acid	  oxidation.	  
Thus,	   given	   the	   dual	   localization	   of	   PLIN5	   to	   the	   LD	   and	   to	   mitochondria,	   it	   is	  
tempting	  to	  speculate	  that	  next	  to	  a	  role	  for	  PLIN5	  in	  releasing	  fatty	  acids	  from	  the	  LD	  by	  
co-­‐regulating	   lipolysis,	  PLIN5	   is	  also	   involved	   in	  shuttling/chaperoning/binding	  fatty	  acids	  
or	   fatty	  acid	  derivatives	   from	  LD	  origin	   to	  mitochondria	   for	  sake	  of	  oxidation.	  While	   this	  
suggestion	   clearly	   needs	   further	   experimental	   substantiation,	   it	   is	   well	   in	   line	   with	  
previous	  observations	  by	  others	  that	  overexpressing	  PLIN5	  augmented	  fat	  oxidation	  [4].	  In	  
the	   process	   of	   finalizing	   this	   manuscript,	   Wang	   et	   al.	   [36]	   showed	   that	   PLIN5	   is	   an	  
important	  mediator	  of	  the	  release	  of	  fatty	  acids	  for	  mitochondrial	  β-­‐oxidation	  in	  liver	  cells.	  
Upon	  PKA	  stimulation,	  PLIN5	  increases	  LD	  hydrolysis	  thus	  making	  fatty	  acids	  available	  for	  
PLIN5	  localizes	  to	  muscle	  mitochondria	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downstream	   mitochondrial	   metabolism	   [36].	   Whether	   the	   same	   holds	   true	   for	   muscle	  
deserves	  further	  investigation.	  
	   Although	  our	  data	  clearly	  support	  mitochondrial	  localization	  of	  PLIN5	  it	  remains	  to	  be	  
solved	   how	   PLIN5	   gets	   into	   mitochondria.	   We	   were	   unable	   to	   find	   evidence	   for	   an	   N-­‐
terminal	   mitochondrial	   targeting	   pre-­‐sequence	   following	   targeted	   database	   searches	  
using	   PSORT	   [37]	   and	   SignalP	   [38].	   Although	   such	   a	   pre-­‐sequence	   is	   common	   for	  many	  
mitochondrial	   proteins	   [39],	   it	   should	   be	   noted	   that	   a	   variety	   of	   other	   mitochondrial	  
proteins	   do	   not	   contain	   such	   a	   pre-­‐sequence	   either	   [40].	   Rather,	   the	   mitochondrial	  
localization	  of	  these	  proteins	  is	  determined	  by	  structural	  characteristics	  of	  the	  protein.	  It	  
has	   been	   postulated	   that	   protein	   localization	   to	   LDs	   is	   determined	   by	   basic	   and	  
hydrophobic	   domains,	  with	   remarkable	   similarities	   to	   the	   signals	   that	   target	   proteins	   to	  
mitochondria	  [41].	  Interestingly,	  we	  did	  find	  structural	  homology	  of	  PLIN5	  with	  the	  alpha	  
and	   beta	   chains	   of	   the	  mitochondrial	   protein	  ATP	   synthase	   (PropSearch)	   [42],	   providing	  
additional	   support	   for	   structural	   characteristics	   in	   the	   PLIN5	   sequence	   that	   could	  
determine	   mitochondrial	   localization.	   Proteome	   analysis	   of	   the	   LD	   coat	   interestingly	  
revealed	   that	   the	   mitochondrial	   protein	   ATP	   synthase	   was	   present	   in	   LD	   fractions	   of	  
lipolytically	  stimulated	  adipocytes	  [34].	  Thus,	  PLIN5	  would	  not	  be	  the	  first	  protein	  localised	  
to	  mitochondria	  and	   lipid	  droplets	  while	   lacking	  a	  mitochondrial	   targeting	  pre-­‐sequence.	  
Moreover,	  recent	  work	  revealed	  that	  the	  last	  20	  amino	  acids	  of	  the	  C-­‐terminal	  end	  of	  the	  
protein	  were	  identified	  to	  be	  essential	  for	  recruitment	  of	  mitochondria	  to	  the	  lipid	  droplet	  
surface	  [36].	   	  
	   In	   conclusion,	   we	   provide	   evidence	   that	   PLIN5	   is	   abundantly	   expressed	   in	  
subsarcolemmal	   and	   intermyofibrillar	   mitochondria	   of	   glycolytic,	   oxidative	   and	   cardiac	  
muscle	   as	   well	   as	   on	   the	   interface	   of	   mitochondria	   and	   lipid	   droplets.	   PLIN5	  
overexpression	  augmented	  fat	  oxidation	  in	  muscle	  homogenates	  containing	  both	  LDs	  and	  
mitochondria	  but	  not	  in	  isolated	  mitochondria.	  These	  findings	  unmask	  PLIN5	  as	  a	  protein	  
localised	  to	  LD	  and	  mitochondria	  with	  a	  putative	  role	  in	  channelling	  LD	  derived	  fatty	  acids	  
towards	   mitochondrial	   oxidation.	   Interaction	   of	   PLIN5	   coated	   LD	   with	   mitochondria	  
appears	  more	  frequent	  and	  more	  intimate	  upon	  skeletal	  muscle	  PLIN5	  overexpression.	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ABSTRACT	  
While	  lipid	  deposition	  in	  skeletal	  muscle	  is	  considered	  to	  be	  involved	  in	  obesity-­‐associated	  
insulin	   resistance,	   neutral	   intramyocellular	   lipid	   (IMCL)	   accumulation	   per	   se	   does	   not	  
necessarily	  induce	  insulin	  resistance.	  We	  previously	  demonstrated	  that	  overexpression	  of	  
the	   lipid	   droplet	   coat	   protein	   perilipin	   2	   augments	   intramyocellular	   lipid	   content	   while	  
improving	  insulin	  sensitivity.	  Another	  member	  of	  the	  perilipin	  family,	  perilipin	  5	  (PLIN5),	  is	  
predominantly	   expressed	   in	   oxidative	   tissues	   like	   skeletal	  muscle.	   Here	  we	   investigated	  
the	   effects	   of	   PLIN5	   overexpression	   –	   in	   comparison	  with	   effects	   of	   PLIN2	   –	   on	   skeletal	  
muscle	  lipid	  levels,	  gene	  expression	  profiles	  and	  insulin	  sensitivity.	  	  
Gene	  electroporation	  was	  used	  to	  overexpress	  PLIN5	  in	  tibialis	  anterior	  muscle	  of	  rats	  fed	  
a	   high	   fat	   diet.	   Eight	   days	   after	   electroporation,	   insulin-­‐mediated	   glucose	   uptake	   in	  
skeletal	  muscle	  was	  measured	  by	  means	  of	  a	  hyperinsulinemic	  euglycemic	  clamp.	  Electron	  
microscopy,	  fluorescence	  microscopy	  and	  lipid	  extractions	  were	  performed	  to	  investigate	  
IMCL	  accumulation.	  Gene	  expression	  profiles	  were	  obtained	  using	  microarrays.	  	  
TAG	   storage	   and	   lipid	   droplet	   size	   increased	   upon	   PLIN5	   overexpression.	   Despite	   the	  
higher	  IMCL	  content,	  insulin	  sensitivity	  was	  not	  impaired	  and	  DAG	  and	  acylcarnitine	  levels	  
were	   unaffected.	   In	   contrast	   to	   the	   effects	   of	   PLIN2	   overexpression,	   microarray	   data	  
analysis	   revealed	   a	   gene	   expression	   profile	   favoring	   FA	   oxidation	   and	   improved	  
mitochondrial	   function.	   In	   conclusion,	   both	   PLIN2	   and	   PLIN5	   increase	   neutral	   IMCL	  
content	  without	   impeding	   insulin-­‐mediated	  glucose	  uptake.	  As	  opposed	  to	  the	  effects	  of	  
PLIN2	  overexpression,	  overexpression	  of	  PLIN5	  in	  skeletal	  muscle	  promoted	  expression	  of	  
a	   cluster	   of	   genes	   under	   control	   of	   PPARα	   and	   PGC1α	   involved	   in	   FA	   catabolism	   and	  




Obesity	   is	  associated	  with	   increased	  lipid	  supply	  to	  skeletal	  muscle	  resulting	   in	   increased	  
intramyocellular	   lipid	   (IMCL)	   storage.	   Accumulation	   of	   IMCL	   is	   associated	   with	   the	  
development	   of	   insulin	   resistance.	   However,	   IMCL	   accumulation	   per	   se	   does	   not	  
necessarily	   induce	   insulin	   resistance	   (reviewed	   in	   [1]).	   Recent	   studies	   suggest	   that	  
increasing	   the	   capacity	   for	   triacylglycerol	   (TAG)	   storage	   in	   lipid	   droplets	   (LDs)	   creates	   a	  
sink	  for	  storage	  of	  fatty	  acids	  (FAs)	  in	  the	  form	  of	  neutral	  lipids	  thereby	  sequestering	  FAs	  
and	  protecting	  against	  lipotoxicity	  [2-­‐5].	  
By	   regulating	  processes	   like	  LD	  synthesis,	  breakdown,	   fusion,	   intracellular	   transport	  
and	   interorganelle	   interactions,	  LD	  coat	  proteins	  are	  determinants	  of	  the	  highly	  dynamic	  
nature	   of	   LDs	   (reviewed	   in	   [6,	   7]).	   One	   of	   the	  major	   lipid	   droplet	   coat	   protein	   families	  
characterized	   to	   date	   is	   the	   perilipin	   family.	   Perilipin	   2	   (PLIN2),	   PLIN3	   and	   PLIN5	   are	  
considered	   the	  major	  perilipins	   in	   skeletal	  muscle.	   Indeed,	  we	  have	   recently	   shown	   that	  
PLIN2	   overexpression	   in	   muscle	   results	   in	   massive	   fat	   accumulation	   in	   muscle,	   while	  
insulin-­‐mediated	   glucose	   uptake	   was	   only	   modestly	   increased	   [2].	   Furthermore,	   PLIN2	  
overexpression	   also	   blunted	   high	   fat	   diet-­‐induced	   induction	   of	   expression	   of	   OXPHOS	  
protein	  complexes	  [2],	  which	  may	   indicate	  that	   in	  the	   long	  run	  oxidative	  capacity	  will	  no	  
longer	  keep	  track	  with	  intramyocellular	  lipid	  content	  in	  this	  situation.	  
Why	  skeletal	  muscle	  expresses	  both	  PLIN2	  and	  PLIN5	  is	  still	  unknown.	  We	  and	  others	  
[8,	  9]	  recently	  found	  that	  PLIN5	  not	  only	  localizes	  to	  LDs,	  but	  also	  to	  mitochondria.	  Thus,	  
the	   putative	   role	   of	   PLIN5	   is	   most	   likely	   not	   limited	   to	   the	   regulation	   of	   lipolysis.	  
Putatively,	  PLIN5	  may	  also	  be	  involved	  in	  shuttling	  of	  FAs	  to	  mitochondria	  for	  oxidation.	  In	  
line	  with	  this	  we	  observed	  that	  PLIN5	  overexpression	  also	  augmented	  intramyocellular	  LD	  
content	   in	   parallel	   with	   improved	   oxidation	   of	   palmitate	   to	   CO2	   [8].	   Here,	  we	   aimed	   to	  
further	   investigate	   the	   effects	   of	   PLIN5	   overexpression	   -­‐	   in	   comparison	   with	   effects	   of	  
PLIN2	  -­‐	  on	  lipid	  storage,	  transcriptomic	  oxidative	  gene	  profiles,	  and	  insulin	  sensitivity.	  	  
	  
METHODS	  
Study	  design	  	  
8-­‐week	  old	  male	  Wistar	  rats	  were	  purchased	  from	  Harlan	  (Horst,	  The	  Netherlands).	  Rats	  
were	  housed	  individually	  on	  a	  12:12	  h	  light-­‐dark	  cycle	  (light	  from	  7:00	  am	  to	  7:00	  pm),	  at	  
room	  temperature	  (21–22	  °C)	  with	  ad	  libitum	  access	  to	  tap	  water.	  Rats	  were	  fed	  a	  high	  fat	  
diet	   (45%	  energy	   from	  fat,	  D01060502,	  Research	  Diets,	  New	  Brunswick,	  NJ,	  USA)	   for	   the	  
duration	  of	  the	  3-­‐week	  intervention.	  The	  Institutional	  Animal	  Care	  and	  Use	  Committee	  of	  
Maastricht	  University	  approved	  the	  experiments.	  During	  the	  experiments	  all	  efforts	  were	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Electroporation	  
Two	  weeks	   after	   the	   start	   of	   the	   diet,	   overexpression	  of	   Plin5	   in	   either	   the	   right	   or	   left	  
tibialis	  anterior	  (TA)	  muscle	  of	  the	  rat	  was	  accomplished	  by	  an	  in	  vivo	  DNA	  electrotransfer	  
technique	  to	  achieve	  overexpression	  of	  PLIN5	  in	  one	  leg;	  the	  contralateral	  TA	  served	  as	  a	  
sham-­‐electroporated	  internal	  control.	  Plin5	  was	  electroporated	  randomly	  in	  the	  left	  or	  the	  
right	   TA.	   DNA	   electroporation	  was	   performed	   under	   isoflurane	   anaesthesia.	   TA	  muscles	  
were	   transcutaneously	   injected	   with	   either	   150	   µg	   (2	   µg/µl)	   pcDNA3.1-­‐CMV-­‐Plin5	   or	  
pcDNA3.1-­‐empty	  vector	  in	  0.9%	  sterile	  saline.	  Within	  15	  seconds	  after	  the	  last	  injection	  5	  
electric	  pulses	  were	  applied	  by	   two	  stainless	  steel	  plate	  electrodes	  placed	  at	   the	  ventral	  
and	  dorsal	  side	  of	  the	  leg.	  One	  high	  voltage	  pulse	  of	  800	  V/cm	  and	  four	  low	  voltage	  pulses	  
of	  80	  V/cm	  at	  1	  Hz	  were	  generated	  by	  an	  ECM	  830	  electroporator	   (BTX,	   San	  Diego,	  CA,	  
USA)	   as	   described	   previously	   [10,	   11].	   Rats	   were	   killed	   8	   days	   post-­‐electroporation.	   TA	  
muscles	   were	   quickly	   dissected	   and	   processed	   for	   mitochondrial	   isolations	   and	  
morphological	  analysis.	  The	  remainder	  of	  the	  TA	  was	  rapidly	  frozen	  in	  melting	  isopentane	  
for	  further	  analyses.	  
	  
Cannulation	  and	  hyperinsulinemic	  euglycemic	  clamps	  
Throughout	   the	   entire	   study,	   rats	   were	   handled	   daily	   for	   familiarisation.	   Indwelling	  
catheters	  were	   placed	   in	   the	   right	   jugular	   vein	   (for	   the	   sampling	   of	   blood)	   and	   the	   left	  
carotid	   artery	   (for	   the	   infusion	  of	   insulin	   and	   glucose)	   under	   isoflurane	   anaesthesia	   and	  
aseptic	   conditions,	   two	   weeks	   before	   the	   hyperinsulinemic	   euglycemic	   clamp	   was	  
performed.	   The	   venous	   catheter	  was	   extended	   to	   the	   level	   of	   the	   right	   atrium	   and	   the	  
arterial	  catheter	  within	  the	  aortic	  arch.	  Both	  catheters	  were	  tunnelled	  subcutaneously	  and	  
exteriorized	  at	  the	  top	  of	  the	  head,	  where	  they	  were	  attached	  in	  dentist	  cement	  between	  
2-­‐3	   screws	   onto	   a	   90º-­‐bend	   needle.	   The	   catheters	   were	   filled	   with	   a	   mixture	   of	   85%	  
glycerol	  (Merck,	  Darmstadt,	  Germany)	  and	  500	  U/ml	  heparin	  (Leo	  Pharma	  BV,	  Breda,	  The	  
Netherlands)	  to	  maintain	  patency.	  All	  rats	  regained	  pre-­‐surgery	  body	  mass	  within	  3	  days.	  
Hyperinsulinemic	   euglycemic	   clamps	   of	   conscious	   rats	   were	   performed	   after	   a	   6h	  
fast.	   Insulin	   stimulated	   glucose	   disposal	   in	   vivo	   within	   the	   individual	   tibialis	   anterior	  
muscles	   was	   studied	   according	   to	   a	   previously	   described	   method	   [12].	   A	   primed	  
continuous	   infusion	   of	   insulin	   (Actrapid	  HM;	  Novo	  Nordisk,	   Copenhagen,	   Denmark)	  was	  
administered	   at	   a	   rate	   of	   13	   mU/kg/min	   for	   120	   min.	   Blood	   glucose	   values	   were	  
monitored	  at	  10-­‐min	  intervals	  throughout	  the	  clamp.	  The	  glucose	  infusion	  rate	  (GIR)	  was	  
adjusted	   to	  maintain	   blood	   glucose	   concentration	  within	   the	   range	  of	   3.5-­‐4.5	  mM.	  Rats	  
were	  conscious	  during	  the	  entire	  clamp.	  45	  min	  before	  completion	  of	  the	  clamp,	  a	  bolus	  of	  
140	  µCi/kg	  of	  the	  non-­‐metabolizable	  glucose	  analogue	  2-­‐[3H(N)]-­‐deoxy-­‐D-­‐glucose	  (Perkin	  
Elmer,	   Waltham,	   Massachusetts,	   USA)	   was	   administered	   to	   measure	   insulin-­‐stimulated	  
glucose	   disposal	   in	   the	   individual	   TA	   muscles.	   Upon	   completion	   of	   the	   clamp,	   the	   rats	  
were	   sacrificed	   with	   an	   overdose	   of	   sodium	   pentobarbital	   and	   tibialis	   anterior	   muscles	  
were	  quickly	  dissected	  and	  frozen	  in	  liquid	  nitrogen-­‐cooled	  isopentane	  and	  stored	  at	  -­‐80ºC	  





Frozen	  TA	  muscle	  sections	  were	  ground	  to	  powder	  under	  liquid	  nitrogen,	  homogenized	  in	  
MilliQ	   water,	   and	   eluted	   on	   columns	   filled	   with	   DOWEX	   ion-­‐exchange	   resin	   (Sigma,	   St.	  
Louis,	  Missouri,	   USA)	   using	   elution	   buffer	   (0.3	  M	   ammonium	   acetate	   and	   1.25%	   formic	  
acid	  in	  H2O,	  pH	  4.9).	  Ionizing	  radiation	  counts	  were	  determined	  by	  scintillation	  counting.	  
	  
Electron	  microscopy	  procedures	  
Ultrastructural	  morphology	  was	  examined	  using	  transmission	  electron	  microscopy.	  Muscle	  
tissue	   sections	   were	   fixed	   in	   2.5%	   glutaraldehyde	   in	   0.1	   M	   phosphate	   buffer	   (pH	   7.4).	  
Postfixation	  was	  performed	   in	  1%	  osmium	  tetroxide	   in	  0.1	  M	  cacodylate	  buffer	   (pH	  7.4)	  
supplemented	  with	  1.5%	  potassium	  ferrocyanide.	  The	  samples	  were	  then	  dehydrated	  and	  
embedded	   in	   epon.	   Ultrathin	   sections	   were	   examined	   using	   a	   Philips	   CM100	   electron	  
microscope.	   Electron	   microscopy	   pictures	   were	   available	   from	   4	   rats.	   5-­‐10	   images	   per	  
muscle	  sample	  were	  taken	  randomly.	  LD	  size	  was	  measured	  using	  the	  freehand	  selection	  
tool	  of	  ImageJ	  [13].	  
	  
Oil-­‐red-­‐O	  staining	  and	  immunofluorescence	  
Neutral	   lipids	   were	   stained	   in	  muscle	   sections	   with	   a	  modified	   Oil-­‐red-­‐O	   staining	   along	  
with	   immunofluorescence	   to	   study	   PLIN5	   and	   laminin	   using	   antibodies	   against	   PLIN5	  
(#GP31;	   Progen	  Biotechnik,	  Heidelberg,	  Germany)	   and	   laminin	   (L-­‐9393;	   Sigma,	   St.	   Louis,	  
USA)	   as	   previously	   described	   [14]	   and	   visualised	  with	   appropriate	   secondary	  Alexa-­‐fluor	  
conjugated	  antibodies	  (Invitrogen,	  Groningen,	  The	  Netherlands).	  	  
	  
Lipid	  profiles	  	  
Intramyocellular	   TAG	   levels	   were	   measured	   using	   the	   method	   of	   Schwartz	   and	   Wolins	  
[15].	  DAG	  [2]	  and	  acylcarnitine	  [16]	  levels	  were	  measured	  as	  described	  previously.	  
	  
Western	  blots	  	  
Western	  blots	  were	  performed	  with	  muscle	  homogenates	   in	  RIPA-­‐lysis	   buffer	  mixed	  1:1	  
with	   Laemmli	   sample	   buffer	   (Bio-­‐Rad,	   Mississauga,	   Ontario,	   Canada)	   using	   antibodies	  
directed	  against	  PLIN2	  (GP40;	  Progen,	  Heidelberg,	  Germany),	  PLIN3	  (SC-­‐14726,	  Santa	  Cruz	  
Biotechnology,	  Heidelberg,	  Germany),	  PLIN5	  (GP31;	  Progen,	  Heidelberg,	  Germany),	  ATGL	  
(2138,	   Cell	   Signaling,	   Boston,	   USA),	   CGI-­‐58	   (NB110-­‐41576,	   Novus	   Biologicals,	   Littleton,	  
USA),	  and	  HSL	  (4107,	  Cell	  Signalling,	  Boston,	  USA).	  Secondary	  antibodies	  for	  PLIN2,	  PLIN3	  
PLIN5,	  ATGL	  and	  SR-­‐actin	  contained	  a	  fluorescent	  tag	  (IRDye800-­‐	  or	  IRDye700-­‐conjugated	  
secondary	   antibodies	   (Rockland,	   Tebu-­‐bio,	  Heerhugowaard,	   The	  Netherlands,	   and	   LICOR	  
Biosciences,	  Westburg,	  Leusden,	  The	  Netherlands).	  Protein	  quantification	  was	  performed	  
by	   scanning	   on	   an	   Odyssey	   Infrared	   Imaging	   system	   (LI-­‐COR	   Biotechnology,	   Lincoln,	  
Nebraska,	  USA).	  CGI-­‐58	  and	  HSL	  were	  detected	  using	  an	  HRP-­‐conjugated	  antibody	  and	  ECL	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detection.	  Protein	  expression	  values	  were	  standardized	  against	  sr-­‐actin	  protein	  expression	  
(Sigma,	  St.	  Louis,	  USA)	  and	  expressed	  in	  arbitrary	  units	  (AU).	  
	  
RNA	  isolation	  and	  microarray	  gene	  expression	  analysis	  
Total	  RNA	  from	  rat	  tibialis	  anterior	  muscle	  was	  extracted	  and	  purified	  with	  the	  RNeasy	  kit	  
for	   fibrous	   tissue	   (Qiagen,	   Venlo,	   The	   Netherlands).	   RNA	   quality	   was	   assessed	   on	   an	  
Agilent	  2100	  bioanalyzer	   (Agilent	  Technologies,	  Amsterdam,	  The	  Netherlands)	  with	  6000	  
Nano	   Chips	   using	   the	   Eukaryote	   Total	   RNA	  Nano	   assay.	   RNA	  was	   judged	   as	   suitable	   for	  
array	  hybridization	  only	  if	  samples	  showed	  intact	  bands	  corresponding	  to	  the	  28S	  and	  18S	  
rRNA	  subunits,	  displayed	  no	  chromosomal	  peaks	  or	  RNA	  degradation	  products,	  and	  had	  a	  
RIN	   (RNA	   integrity	   number)	   above	   8.0.	   RNA	   samples	   from	   6	   rats	   were	   pooled.	   Five	  
micrograms	  of	  RNA	  were	  used	  for	  one	  cycle	  cRNA	  synthesis	  (Affymetrix,	  Santa	  Clara,	  CA).	  
Hybridization,	  washing	  and	  scanning	  of	  Affymetrix	  rat	  arrays	  was	  carried	  out	  according	  to	  
standard	  Affymetrix	  protocols.	  To	  adjust	   for	  non-­‐specific	  hybridization	  and	  optical	  noise,	  
the	  array	  expression	  data	  were	  normalized	  with	  RMA	  (robust	  multichip	  analysis,	  a	  package	  
of	   the	   Bioconductor	   project	   [17]	   in	   the	   R	   environment.	   Functional	   analysis	   of	   the	   array	  
data	  was	  performed	  by	  a	  method	  based	  on	  enrichment	  of	  gene	  sets	  (Gene	  Ontology	  (GO)	  
classes	  using	   the	  application	  GSEA	   [18]	   and	  gene	   set	   clustering	  analysis	  using	  Cytoscape	  




Results	  are	  presented	  as	  mean	  ±	  SEM.	  Differences	  between	  groups	  were	  evaluated	  with	  
paired	   T-­‐tests.	   Outcomes	   were	   considered	   statistically	   significant	   when	   P<0.05	   (two-­‐
tailed).	  Analyses	  were	  performed	  using	  the	  Statistical	  Package	  for	  the	  Social	  Sciences	  (SPSS	  
16.0,	   Nieuwegein,	   The	   Netherlands)	   software	   for	   Mac	   16.0.	   For	   microarray	   data,	  
normalized	  enrichment	  scores	  (NES)	  and	  false	  discovery	  rates	  (q-­‐values),	  calculated	  by	  the	  
application	  GSEA,	  were	   reported.	  Q-­‐values<0.05	  were	   considered	   statistically	   significant.	  
In	  Cytoscape,	  cut-­‐off	  values	  were	  set	  at	  P<0.005	  and	  q<0.1.	  
	  
RESULTS	  
PLIN5	  overexpression	  increases	  intramyocellular	  lipid	  storage	  
PLIN5	  electroporation	  resulted	  in	  a	  2.8-­‐fold	  overexpression	  of	  PLIN5	  (empty	  vector	  muscle	  
lysates	  0.81	  ±	  0.19,	  PLIN5	  muscle	  2.28	  ±	  0.42	  AU,	  P<0.05,	  n=9)	  (Fig	  1A).	  The	  overexpression	  
of	  PLIN5	  gave	   rise	   to	  a	  pronounced	   increase	   in	   IMCL	   levels	   (Fig.	  1B-­‐C).	   Lipid	  droplet	   size	  
was	   increased;	   the	   LD	   size	   distribution	   shifted	   from	   LDs	   of	   up	   to	   1.2	   μm2	   in	   size	   in	   the	  
empty	   vector-­‐electroporated	   muscle	   fibers	   to	   LDs	   of	   up	   to	   5.8	   μm2	   in	   the	   PLIN5	  
overexpressing	  fibers	  (Fig.	  1D).	  The	  average	  LD	  size	  increased	  more	  than	  five-­‐fold	  (P<0.01)	  
(Fig.	   1D).	   The	   increase	   in	   LD	   size	   occurred	   in	   parallel	   with	   a	   3-­‐fold	   increase	   in	  
intramyocellular	  triacylglycerol	   (TAG)	   levels	   (Fig.	  2A).	  Diacylglycerol	   (DAG)	   levels	   (Fig.	  2B)	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were	   unchanged.	   Acylcarnitines	   are	   formed	   in	   mitochondria	   when	   β-­‐oxidation	   rates	  
outpace	  the	  capacity	  of	  the	  TCA	  cycle	  [20]	  and	  have	  been	  implemented	  in	  development	  of	  
insulin	   resistance.	   Free	   carnitine	   (Fig.	   2C)	   and	   acylcarnitine	   levels	   (Fig.	   2D)	   were	   not	  
different	   in	   the	   PLIN5-­‐electroporated	   muscle	   versus	   the	   empty	   vector	   control.	  
Additionally,	   the	   FA-­‐composition	   of	   the	   DAG	   fraction	  was	   not	   significantly	   changed	   and	  
the	  individual	  acylcarnitine	  species	  did	  not	  show	  a	  different	  profile	  in	  empty-­‐vector	  versus	  




Figure	  1.	  PLIN5	  overexpression	  increases	   intramyocellular	   lipid	  accumulation	  and	  lipid	  droplet	  size.	  
(A)	  PLIN5	  protein	  content	  in	  protein	  lysates	  from	  electroporated	  tibialis	  anterior	  muscle.	  (B)	  Shows	  
the	   effect	   of	   PLIN5	   overexpression	   on	   PLIN5	   content	   (lower	   right	   hand	   panel)	   and	   lipid	   storage	  
(upper	  right	  hand	  panel)	  compared	  to	  the	  empty	  vector	  control	  (upper	  and	  lower	  left	  hand	  panels).	  
LDs	   are	   stained	   in	   red,	   PLIN5	   in	   green	   and	   cell	   membranes	   in	   blue.	   Bars	   represent	   100	   µm.	   (C)	  
Electron	  microscopy	   showing	   skeletal	  muscle	  ultrastructure.	   (D)	   Lipid	  droplet	   size	  distribution	  and	  
average	  LD	  size.	  EV:	  empty	  vector,	  *P<0.05,	  error	  bars	  represent	  SEM.	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Figure	   2.	   PLIN5	   over-­‐
expression	   results	   in	  
increased	  TAG	  accumulation.	  
(A)	   Skeletal	   muscle	   TAG	  
levels	   (ug/	   mg	   protein).	   (B)	  
DAG	   content	   (µmol/mg	   dry	  
weight).	   (C)	   Free	   carnitine	  
(ρmol/mg	   protein).	   (D)	  
Acylcarnitine	   levels	  
(ρmol/mg	   protein).	   EV:	  
empty	  vector.	  *P<0.05,	  error	  
bars	  represent	  SEM.	  
	  
	  
Increased	  ATGL	  protein	  content	  in	  PLIN5	  overexpressing	  muscle	  
PLIN5	   overexpression	   was	   not	   paralleled	   by	   compensatory	   changes	   in	   PLIN2	   and	   PLIN3	  
protein	  content	  (Fig.	  3A	  and	  B).	  ATGL	  protein	  content	  was	  significantly	   increased	  by	  16%	  
(P=0.047)	  (Fig.	  3C),	  while	  CGI-­‐58	  protein	  content	  showed	  a	  trend	  towards	  downregulation	  
(P=0.10)	   (Fig.	   3D).	   HSL	   protein	   content	   was	   similar	   in	   empty	   vector	   and	   PLIN5-­‐






Figure	   3.	   PLIN5	   overexpression	  
increased	   ATGL	   protein	   content.	   (A-­‐
D)	  Western	  blots	  for	  PLIN2	  (A),	  PLIN3	  
(B),	  ATGL	  (C),	  CGI-­‐58	  (D)	  and	  HSL	  (E)	  
in	   whole	   muscle	   protein	   lysates	  
(n=17).	  	  
	  
PLIN5	  overexpression	  results	  in	  a	  gene	  expression	  pattern	  favoring	  FA	  oxidative	  
metabolism	  	  
Upon	   PLIN5	   overexpression,	   775	   genes	   were	   upregulated,	   1042	   genes	   were	  
downregulated	  (fold	  change	  cut-­‐off	  value	  1.3).	  Table	  1	  gives	  the	  gene	  expression	  profiles	  
for	   a	   selection	   of	   genes,	   the	   complete	   microarray	   dataset	   can	   be	   found	   as	   supporting	  
document	  online	  (Supplemental	  Table	  S3).	  Gene	  class	  enrichment	  analyses	  revealed	  that	  
PLIN5	  overexpression	  resulted	  in	  increased	  expression	  of	  genes	  involved	  in	  FA	  β-­‐oxidation,	  
the	   TCA	   cycle,	   the	   electron	   transport	   chain	   and	   mitochondrion	   organization	   (Table	   2).	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Table	   1.	  Heat	  map.	   Fold	   changes	   in	   gene	   expression	   for	   a	   selection	   of	   genes	   are	   given	   for	   PLIN5	  
versus	  empty-­‐vector	  (EV)	  electroporated	  muscles.	  	  
Gene	  name	   Entrez	  ID	   Description	   Fold	  change	  
Pla2g4c	   691810	   Phospholipase	  A2,	  group	  IVC	  (cytosolic,	  calcium-­‐independent)	   2.94	  
Acsm5	   361637	   Acyl-­‐CoA	  synthetase	  medium-­‐chain	  family	  member	  5	   2.17	  
Scand3	   288622	   SCAN	  domain	  containing	  3	   2.17	  
LOC679586	   679586	   Similar	  to	  ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F0	  complex,	  subunit	  G	   1.89	  
Atp5hl1	   306478	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F0	  complex,	  subunit	  d-­‐like	  1	   1.78	  
Dync2li1	   298767	   Dynein	  cytoplasmic	  2	  light	  intermediate	  chain	  1	   1.77	  
Acat3	   308100	   Acetyl-­‐Coenzyme	  A	  acetyltransferase	  3	   1.70	  
Rfk	   499328	   Riboflavin	  kinase	   1.70	  
Angptl4	   362850	   Angiopoietin-­‐like	  4	   1.68	  
Atp6v1a	   685232	   ATPase,	  H+	  transporting,	  lysosomal	  V1	  subunit	  A	   1.63	  
Hsd3b	   682974	   3β-­‐hydroxysteroid	  dehydrogenase/Δ5-­‐4	  isomerase	  type	  II	   1.59	  
Fabp4	   79451	   Fatty	  acid	  binding	  protein	  4	   1.58	  

















Cd36	   29184	   Cd36	  molecule	   1.49	  
RGD1559672	   500650	   Similar	  to	  translocase	  of	  inner	  mitochondrial	  membrane	  23	  homolog	   1.48	  
Nkain3	   689576	   Na+/K+	  transporting	  ATPase	  interacting	  3	   1.47	  
Ehhadh	   171142	   Enoyl-­‐CoA,	  hydratase/3-­‐hydroxyacyl	  CoA	  dehydrogenase	   1.45	  
Atp6v1b1	   312488	   ATPase,	  H+	  transporting,	  lysosomal	  V1	  subunit	  B1	   1.41	  
Atp6v1g3	   289407	   ATPase,	  H+	  transporting,	  lysosomal	  V1	  subunit	  G3	   1.38	  
Fads6	   303671	   Fatty	  acid	  desaturase	  domain	  family,	  member	  6	   1.35	  
Mrps27	   361883	   Mitochondrial	  ribosomal	  protein	  S27	   1.34	  
Acox2	   252898	   Acyl-­‐CoA	  oxidase	  2,	  branched	  chain	   1.33	  
RGD1561341	   502769	   Similar	  to	  translocase	  of	  outer	  mitochondrial	  membrane	  20	  homolog	   1.33	  
Pld6	   287366	   Phospholipase	  D	  family,	  member	  6	   1.33	  
Atp5s	   362749	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F0	  complex,	  subunit	  s	  (factor	  B)	   1.32	  
Slc27a3	   295219	   Solute	  carrier	  family	  27	  (fatty	  acid	  transporter),	  member	  3	   -­‐2.98	  
Pparg	   25664	   Peroxisome	  proliferator-­‐activated	  receptor	  γ	   -­‐1.89	  
Gk5	   367146	   Glycerol	  kinase	  5	  (putative)	   -­‐1.79	  
Ppt1	   29411	   Palmitoyl-­‐protein	  thioesterase	  1	   -­‐1.70	  
Sln	   367086	   Sarcolipin	   -­‐1.68	  
Pla2g2a	   29692	   Phospholipase	  A2,	  group	  IIA	   -­‐1.66	  
Smpd3	   94338	   Sphingomyelin	  phosphodiesterase	  3,	  neutral	  membrane	   -­‐1.56	  
Pltp	   296371	   Phospholipid	  transfer	  protein	   -­‐1.45	  
Slc37a2	   500973	   Solute	  carrier	  family	  37	  (glycerol-­‐3-­‐phosphate	  transporter),	  member	  2	   -­‐1.38	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Chn2	   84031	   Chimerin	  2	   -­‐1.38	  
Prkcd	   170538	   Protein	  kinase	  C,	  δ	   -­‐1.35	  
Ldhal6b	   369018	   Lactate	  dehydrogenase	  A-­‐like	  6B	   -­‐1.35	  
Scd	   83792	   Stearoyl-­‐CoA	  desaturase	  (Δ9-­‐desaturase)	   -­‐1.31	  
	  
To	   investigate	   if	   these	   gene	   expression	   profiles	   were	   specific	   for	   PLIN5-­‐induced	   lipid	  
accumulation,	   we	   compared	   these	   results	   with	   overexpression	   of	   PLIN2.	   As	   described	  
previously	   [2],	   PLIN2	   overexpression	   increased	   IMCL	   levels	   concurrent	   with	   a	   gene	  
expression	  profile	  favoring	  lipid	  storage	  rather	  than	  oxidation.	  Figure	  4	  displays	  the	  effects	  
of	  PLIN5	  and	  PLIN2	  electroporation	  (versus	  the	  corresponding	  empty	  vector	  controls)	  on	  
gene	  sets	  involved	  in	  fatty	  acid	  oxidation	  and	  mitochondrial	  function.	  Interestingly,	  PLIN5	  
has	  opposite	  effects	  on	  transcription	  levels	  of	  genes	  involved	  in	  FA	  oxidation	  compared	  to	  
PLIN2.	   Our	   data	   indicate	   that	   –	   as	   opposed	   to	   PLIN2	   overexpression	   –	   PLIN5	  
overexpression	   is	   associated	   with	   induction	   of	   a	   transcriptional	   program	   favoring	   FA	  
catabolism	   and	   subsequent	   mitochondrial	   oxidation.	   These	   changes	   in	   gene	   expression	  
were	   functionally	   reflected	   in	   increased	   14C-­‐palmitate	   oxidation	   to	   CO2	   after	   PLIN5	  
overexpression	  which	  we	  observed	  previously	   (empty	   vector	   0.05	   ±	   0.008,	   PLIN5	  0.07	   ±	  
0.012	  14CO2/total	  
14C-­‐palmitate	  oxidation,	  P	  =	  0.05)	  [8].	  
	  
Table	  2.	  PLIN5	  overexpression	  increased	  expression	  of	  genes	  involved	  in	  mitochondrial	  function	  and	  
fatty	  acid	  oxidation.	  Microarray	  gene	  expression	  profiles	  for	  PLIN5	  overexpression	  were	  clustered	  in	  
Gene	  Ontology	   (GO)	   classes	   using	  GSEA	   (Gene	   Set	   Enrichment	  Analysis).	   This	   table	   shows	   the	  GO	  
classes	  that	  were	  enriched	  in	  the	  set	  of	  upregulated	  genes.	  All	  upregulated	  GO	  classes	  with	  a	  false	  
discovery	  rate	  (FDR)	  q-­‐value<0.05	  are	  shown.	  NES:	  normalized	  enrichment	  score.	  
GO	   Name	   NES	   FDR	  q-­‐value	  
GO:0005759	   Mitochondrial	  matrix	   4.01	   <1.00E-­‐06	  
GO:0044455	   Mitochondrial	  membrane	  part	   3.60	   <1.00E-­‐06	  
GO:0045333	   Cellular	  respiration	   3.59	   <1.00E-­‐06	  
GO:0005743	   Mitochondrial	  inner	  membrane	   3.50	   <1.00E-­‐06	  
GO:0019866	   Organelle	  inner	  membrane	   3.30	   <1.00E-­‐06	  
GO:0030964	   NADH	  dehydrogenase	  complex	   3.29	   <1.00E-­‐06	  
GO:0045271	   Respiratory	  chain	  complex	  I	   3.28	   <1.00E-­‐06	  
GO:0005747	   Mitochondrial	  respiratory	  chain	  complex	  I	   3.26	   <1.00E-­‐06	  
GO:0005746	   Mitochondrial	  respiratory	  chain	   3.01	   <1.00E-­‐06	  
GO:0022900	   Electron	  transport	  chain	   2.98	   <1.00E-­‐06	  
GO:0070469	   Respiratory	  chain	   2.90	   4.52E-­‐05	  
GO:0006084	   Acetyl-­‐CoA	  metabolic	  process	   2.88	   1.29E-­‐04	  
GO:0072329	   Monocarboxylic	  acid	  catabolic	  process	   2.79	   2.74E-­‐04	  
GO:0006091	   Generation	  of	  precursor	  metabolites	  and	  energy	   2.76	   4.48E-­‐04	  
GO:0009060	   Aerobic	  respiration	   2.74	   5.01E-­‐04	  
GO:0015980	   Energy	  derivation	  by	  oxidation	  of	  organic	  compounds	   2.71	   6.28E-­‐04	  
GO:0022904	   Respiratory	  electron	  transport	  chain	   2.67	   1.04E-­‐03	  
GO:0009062	   Fatty	  acid	  catabolic	  process	   2.58	   2.97E-­‐03	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GO:0046356	   Acetyl-­‐CoA	  catabolic	  process	   2.55	   3.86E-­‐03	  
GO:0006119	   Oxidative	  phosphorylation	   2.48	   7.09E-­‐03	  
GO:0046395	   Carboxylic	  acid	  catabolic	  process	   2.46	   7.23E-­‐03	  
GO:0003954	   NADH	  dehydrogenase	  activity	   2.43	   8.80E-­‐03	  
GO:0016054	   Organic	  acid	  catabolic	  process	   2.42	   9.12E-­‐03	  
GO:0048037	   Cofactor	  binding	   2.42	   9.01E-­‐03	  
GO:0007005	   Mitochondrion	  organization	  and	  biogenesis	   2.40	   1.01E-­‐02	  
GO:0050662	   Coenzyme	  binding	   2.39	   1.08E-­‐02	  
GO:0006099	   Tricarboxylic	  acid	  cycle	   2.39	   1.08E-­‐02	  
GO:0051187	   Cofactor	  catabolic	  process	   2.38	   1.10E-­‐02	  
GO:0051186	   Cofactor	  metabolic	  process	   2.37	   1.20E-­‐02	  
GO:0006732	   Coenzyme	  metabolic	  process	   2.37	   1.18E-­‐02	  
GO:0006637	   Acyl-­‐CoA	  metabolic	  process	   2.37	   1.16E-­‐02	  
GO:0009109	  
	  








Oxidoreductase	  activity,	  acting	  on	  NADH	  or	  NADPH,	  quinone	  or	  similar	  





GO:0051262	   Protein	  tetramerization	   2.32	   1.77E-­‐02	  
GO:0035383	   Thioester	  metabolic	  process	   2.32	   1.76E-­‐02	  
GO:0008137	   NADH	  dehydrogenase	  (ubiquinone)	  activity	   2.31	   1.76E-­‐02	  
GO:0042773	   ATP	  synthesis	  coupled	  electron	  transport	   2.29	   2.11E-­‐02	  
GO:0050136	   NADH	  dehydrogenase	  (quinone)	  activity	   2.29	   2.11E-­‐02	  
GO:0016651	   Oxidoreductase	  activity	   2.27	   2.27E-­‐02	  
GO:0051087	   Chaperone	  binding	   2.27	   2.23E-­‐02	  
GO:0019395	   Fatty	  acid	  oxidation	   2.24	   2.84E-­‐02	  
GO:0006635	   Fatty	  acid	  beta-­‐oxidation	   2.23	   3.02E-­‐02	  
GO:0034440	   Lipid	  oxidation	   2.23	   3.09E-­‐02	  
GO:0016469	   Proton-­‐transporting	  two-­‐sector	  ATPase	  complex	   2.22	   3.16E-­‐02	  
GO:0005777	   Peroxisome	   2.21	   3.39E-­‐02	  
GO:0042579	   Microbody	   2.19	   3.74E-­‐02	  
GO:0015985	   Energy	  coupled	  proton	  transport,	  down	  electrochemical	  gradient	  	   2.19	   3.96E-­‐02	  
GO:0015986	   ATP	  synthesis	  coupled	  proton	  transport	   2.18	   4.24E-­‐02	  
GO:0006818	   Hydrogen	  transport	   2.17	   4.52E-­‐02	  
GO:0000062	   Fatty-­‐acyl-­‐CoA	  binding	   2.16	   4.49E-­‐02	  












Table	  3.	  PLIN5	  overexpression	  lowers	  expression	  of	  genes	  involved	  in	  immune	  processes.	  Microarray	  
gene	   expression	   profiles	   for	   PLIN5	   overexpression	   were	   clustered	   in	   Gene	   Ontology	   (GO)	   classes	  
using	  GSEA	  (Gene	  Set	  Enrichment	  Analysis).	  This	  table	  shows	  the	  GO	  classes	  that	  were	  enriched	  in	  
the	  set	  of	  downregulated	  genes.	  All	  downregulated	  GO	  classes	  with	  a	  false	  discovery	  rate	  (FDR)	  q-­‐
value<0.05	  are	  shown.	  NES:	  normalized	  enrichment	  score.	  
GO	   Name	  
No.	  of	  genes	  	  
in	  the	  set	   NES	   FDR	  q-­‐val	  
GO:0002252	   Immune	  effector	  process	   249	   -­‐2.99	   1.60E-­‐03	  
GO:0004428	   Inositol	  or	  phosphatidylinositol	  kinase	  activity	   31	   -­‐2.97	   1.15E-­‐03	  
GO:0002768	  
	  


















GO:0002274	   Myeloid	  leukocyte	  activation	  	   78	   -­‐2.83	   2.03E-­‐03	  
GO:0005765	   Lysosomal	  membrane	   61	   -­‐2.82	   1.99E-­‐03	  
GO:0016050	   Vesicle	  organization	   74	   -­‐2.80	   2.03E-­‐03	  
GO:0009897	   External	  side	  of	  plasma	  membrane	  	   177	   -­‐2.68	   5.10E-­‐03	  
GO:0000323	   Lytic	  vacuole	  	   189	   -­‐2.61	   7.09E-­‐03	  
GO:0002443	   Leukocyte	  mediated	  immunity	  	   146	   -­‐2.52	   1.18E-­‐02	  
GO:0005096	   GTPase	  activator	  activity	  	   138	   -­‐2.51	   1.25E-­‐02	  
GO:0050776	   Regulation	  of	  immune	  response	   297	   -­‐2.49	   1.34E-­‐02	  
GO:0046488	   Phosphatidylinositol	  metabolic	  process	  	   72	   -­‐2.49	   1.29E-­‐02	  
GO:0005100	   Rho	  GTPase	  activator	  activity	  	   22	   -­‐2.47	   1.41E-­‐02	  
GO:0002449	   Lymphocyte	  mediated	  immunity	  	   118	   -­‐2.47	   1.36E-­‐02	  
GO:0046649	   Lymphocyte	  activation	  	   310	   -­‐2.47	   1.32E-­‐02	  
GO:0042110	   T	  cell	  activation	  	   212	   -­‐2.46	   1.32E-­‐02	  
GO:0005764	   Lysosome	  	   188	   -­‐2.44	   1.44E-­‐02	  
GO:0001727	   Lipid	  kinase	  activity	  	   26	   -­‐2.39	   1.91E-­‐02	  
GO:0035586	   Purinergic	  receptor	  activity	  	   31	   -­‐2.39	   1.93E-­‐02	  
GO:0050852	   T	  cell	  receptor	  signaling	  pathway	  	   34	   -­‐2.32	   2.43E-­‐02	  
GO:0046854	   Phosphatidylinositol	  phosphorylation	  	   15	   -­‐2.32	   2.38E-­‐02	  
GO:0006909	   Phagocytosis	  	   64	   -­‐2.32	   2.36E-­‐02	  
GO:0050851	   Antigen	  receptor-­‐mediated	  signaling	  pathway	  	   54	   -­‐2.32	   2.35E-­‐02	  
GO:0006044	   N-­‐acetylglucosamine	  metabolic	  process	   16	   -­‐2.28	   2.68E-­‐02	  
GO:0044420	   Extracellular	  matrix	  part	  	   103	   -­‐2.27	   2.70E-­‐02	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GO:0019724	   B	  cell	  mediated	  immunity	  	   68	   -­‐2.23	   3.17E-­‐02	  
GO:0001614	   Purinergic	  nucleotide	  receptor	  activity	  	   27	   -­‐2.22	   3.13E-­‐02	  
GO:0046633	   Alpha-­‐beta	  T	  cell	  proliferation	  	   20	   -­‐2.21	   3.23E-­‐02	  
GO:0006041	   Glucosamine	  metabolic	  process	  	   16	   -­‐2.20	   3.28E-­‐02	  
GO:0016502	   Nucleotide	  receptor	  activity	  	   27	   -­‐2.19	   3.48E-­‐02	  
GO:0010717	   Regulation	  of	  epithelial	  to	  mesenchymal	  transition	  	   24	   -­‐2.17	   3.85E-­‐02	  
GO:0002250	   Adaptive	  immune	  response	  	   124	   -­‐2.16	   3.85E-­‐02	  
GO:0007173	   Epidermal	  growth	  factor	  receptor	  signaling	  pathway	  	   39	   -­‐2.15	   4.24E-­‐02	  
GO:0005581	   Collagen	  	   24	   -­‐2.14	   4.24E-­‐02	  
GO:0000139	   Golgi	  membrane	   265	   -­‐2.14	   4.19E-­‐02	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GO:0050778	   Positive	  regulation	  of	  immune	  response	  	   228	   -­‐2.14	   4.29E-­‐02	  
GO:0002062	   Chondrocyte	  differentiation	  	   45	   -­‐2.12	   4.70E-­‐02	  
GO:0006040	   Amino	  sugar	  metabolic	  process	  	   21	   -­‐2.11	   4.87E-­‐02	  
GO:0045061	   Thymic	  T	  cell	  selection	  	   16	   -­‐2.10	   4.99E-­‐02	  
GO:0007229	   Integrin-­‐mediated	  signaling	  pathway	  	   46	   -­‐2.10	   4.95E-­‐02	  
GO:0045309	   Protein	  phosphorylated	  amino	  acid	  binding	  	   21	   -­‐2.10	   4.89E-­‐02	  
	  
	  
Figure	   4.	   Gene	   expression	   profiles	   of	   PLIN5	   overexpression	   were	   markedly	   different	   from	   those	  
obtained	   after	   overexpression	   of	   PLIN2.	   Cytoscape	   gene	   set	   clustering	   (two	   selected	   clusters	   are	  
shown).	  The	  cluster	  on	  the	  left	  shows	  gene	  sets	  involving	  mitochondrial	  function	  including	  the	  TCA	  
cycle	  and	  the	  electron	  transport	  chain.	  The	  cluster	  on	  the	  right	  hand	  side	  shows	  gene	  sets	  linked	  to	  
FA	  oxidative	  metabolism.	  Gene	  expression	   levels	   in	   the	  PLIN2	  and	  PLIN5	  electroporated	   legs	  were	  
both	  compared	   to	   the	  corresponding	  empty	  vector	   legs.	  The	   inner	   circle	   color	   corresponds	   to	   the	  
effect	   of	   PLIN2	   overexpression,	   the	   circle	   border	   represents	   the	   effects	   of	   PLIN5	   overexpression.	  
Blue:	  downregulation,	  red:	  upregulation,	  white:	  no	  change.	  The	  lines	  indicate	  overlap	  between	  gene	  
sets.	  The	  gene	  sets	  included	  the	  GO	  classes,	  KEGG	  pathways,	  REACT,	  and	  WiP	  gene	  sets.	  
	  
Despite	   increased	   IMCL	   content,	   PLIN5	   overexpression	   did	   not	   impair	   insulin	  
sensitivity	  	  
Skeletal	   muscle	   insulin	   sensitivity	   was	   measured	   under	   stable	   clamp	   conditions	  
(Supplemental	   Figure	   1).	   Despite	   the	   pronounced	   effect	   of	   PLIN5	   overexpression	   on	  
intramyocellular	   lipid	   storage	   and	   LD	   size,	   3H-­‐deoxyglucose	  uptake	  was	   similar	   in	   empty	  
vector	   and	   PLIN5-­‐electroporated	   muscle	   (Fig.	   5),	   indicating	   that	   PLIN5-­‐induced	  





Figure	   5.	   PLIN5	   overexpression-­‐	   induced	  
intramyocellular	   lipid	   accumulation	   did	   not	   affect	  
insulin	   sensitivity.	   3H-­‐labeled	   deoxyglucose	   uptake	  	  
(ρmol/g	   wet	   weight/h)	   in	   empty	   vector	   (EV)	   and	  
PLIN5-­‐electroporated	   tibialis	   anterior	  muscle	   (n=9).	  
Error	  bars	  represent	  SEM.	  
	  
DISCUSSION	  
Elevated	  IMCL	  levels	  have	  been	  associated	  with	  the	  development	  of	  insulin	  resistance	  [21-­‐
23],	   however	   data	   from	   the	   last	   decade	   indicates	   that	   the	   relation	   between	   IMCL	   and	  
insulin	  sensitivity	  may	  be	  less	  straightforward	  than	  originally	  proposed	  [3,	  4,	  24].	  In	  recent	  
years,	   PLINs	   have	   been	   identified	   as	   important	   regulators	   of	   skeletal	   muscle	   lipid	  
metabolism.	   Skeletal	   muscle-­‐specific	   PLIN2	   overexpression	   improved	   insulin	   sensitivity	  
despite	   increased	   IMCL	   levels	   [2].	  Here	  we	   show	   that	   the	  augmented	   IMCL	   storage	  as	  a	  
result	   of	   PLIN5	   electroporation	   did	   not	   impair	   insulin-­‐stimulated	   glucose	   uptake,	  
consistent	  with	  effects	  of	  PLIN2	  overexpression.	  Yet,	   in	  striking	  contrast	  to	  the	  effects	  of	  
PLIN2	   overexpression	   [2],	   PLIN5	   electroporation	   resulted	   in	   a	   gene	   expression	   profile	  
favoring	  fatty	  acid	  catabolism	  and	  mitochondrial	  function.	  This	  profile	  of	  high	  PLIN5	  levels,	  
augmented	   IMCL	  storage,	   increased	  oxidative	  gene	  expression	  and	  fat	  oxidative	  capacity	  
without	   a	   negative	   impact	   on	   skeletal	   muscle	   insulin-­‐mediated	   glucose	   uptake	   mimics	  
observations	  in	  master	  athletes	  [25].	  	  
Both	  PLIN2	  and	  PLIN5	  overexpression	  resulted	  in	  increased	  LD	  size,	  consistent	  with	  in	  
vitro	  studies	  [9,	  26,	  27].	  When	  compared	  to	  PLIN2-­‐induced	  LD	  expansion	  [2],	  LDs	  in	  PLIN5-­‐
overexpressing	  muscle	  were	   approximately	   1.3-­‐fold	   larger	   in	   size.	  While	   large	   LDs	   have	  
previously	  been	  suggested	  to	  be	  more	  detrimental	  with	  respect	  to	  insulin	  sensitivity	  than	  
small	  LDs	  [28-­‐30],	  we	  here	  demonstrate	  that	  augmenting	  LD	  size	  by	  overexpressing	  PLIN5	  
did	  not	   impede	  insulin-­‐mediated	  glucose	  uptake	  	   	  or	  compromise	  mitochondrial	  function	  
measured	  as	  fat	  oxidative	  capacity	  within	  the	  time	  frame	  of	  our	  studies.	  	  
One	  mechanism	  by	  which	  PLINs	  and	  an	  increase	  in	  LD	  size	  may	  prevent	  lipid-­‐induced	  
insulin	   resistance	   is	   by	   sequestering	   bioactive	   lipids.	   Indeed,	   PLIN5	   overexpression	  
increased	   intramyocellular	   TAG	   storage	   without	   affecting	   the	   accumulation	   of	   the	  
potentially	  insulin	  desensitizing	  and	  mitotoxic	  lipid	  intermediates	  DAG	  and	  acylcarnitines.	  
These	   effects	   parallel	   observations	   upon	   PLIN2	   overexpression	   [2],	   when	   IMCL	   content	  
was	   also	   augmented	   while	   fatty	   acid	   intermediates	   remained	   unchanged.	   Thus,	   both	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PLIN2	  and	  PLIN5	  overexpression	  augmented	  neutral	  TAG	  accumulation	   in	  a	  manner	   that	  
did	  not	  impede	  insulin-­‐mediated	  glucose	  uptake.	  
While	  the	  effects	  of	  PLIN2	  and	  PLIN5	  on	  IMCL	  content	  and	  insulin	  sensitivity	  appear	  
alike,	  marked	  differences	  were	  observed	  in	  gene	  expression	  profiles.	  In	  striking	  contrast	  to	  
the	   effects	   of	   PLIN2	   overexpression,	   which	   results	   in	   lowered	   expression	   of	   genes	   and	  
proteins	   involved	   in	   oxidative	   metabolism	   [2],	   PLIN5	   overexpression	   resulted	   in	   a	  
transcriptomic	  profile	  representing	  improved	  oxidative	  capacity.	  Our	  unbiased	  microarray	  
approach	   raised	   the	   opportunity	   to	   study	   gene	   expression	   patterns	   across	   the	   whole	  
genome.	  Gene	  set	  enrichment	  analysis	  revealed	  overrepresentation	  of	  upregulated	  genes	  
in	  a	  multiple	  gene	   sets	   involved	   in	   FA	  β-­‐oxidation,	   the	  TCA	  cycle,	   the	  electron	   transport	  
chain	   and	   mitochondrion	   organization.	   Consistent	   with	   our	   data,	   ectopic	   expression	   of	  
PLIN5	   in	   COS	   cells	   increased	   expression	   of	   genes	   involved	   in	   FA	   oxidation	   [31].	   Whilst	  
short-­‐term	  (one	  week)	  PLIN2	  overexpression	  was	  beneficial	   to	   insulin	   sensitivity	   [2],	   it	   is	  
anticipated	  that	  in	  the	  long	  run,	  PLIN2	  overexpression	  may	  result	  in	  a	  mismatch	  between	  
lipid	  storage	  and	  oxidative	  capacity.	  In	  contrast,	  PLIN5	  overexpression	  results	  in	  increased	  
IMCL	   storage	   paralleled	   with	   increased	   oxidative	   capacity,	   observations	   similar	   to	  
endurance	  trained	  athletes	  who	  have	  high	  PLIN5	  and	  IMCL	  levels,	  are	  insulin	  sensitive	  [25]	  
and	  are	  protected	  against	  lipid-­‐induced	  insulin	  resistance	  [32].	  	  
Since	   acylcarnitine	   accumulation	   has	   been	   suggested	   to	   reflect	   an	   imbalance	  
between	  β-­‐oxidation	  and	  TCA	  cycle	  activity	  [33],	  the	   lack	  of	  an	   induction	  of	  acylcarnitine	  
accumulation	   further	  confirms	  that	  PLIN5	  overexpression	  results	   in	  neutral	   IMCL	  storage	  
matched	  with	  downstream	  catabolic	  metabolism.	  Moreover,	   genes	   involved	   in	   immune-­‐
processes	   associated	   with	   insulin	   resistance	   were	   downregulated	   upon	   PLIN5	  
overexpression.	   Though,	   whether	   increased	   PLIN5	   expression	   is	   beneficial	   in	   the	   long	  
term,	  remains	  to	  be	  investigated.	  
How	   PLIN5	   overexpression	   promotes	   oxidative	   gene	   expression	   is	   currently	  
unknown.	  It	   is	  however	  of	  interest	  to	  note	  that	  the	  vast	  majority	  of	  the	  genes	  induced	  is	  
under	   control	   of	   the	   PPAR-­‐PGC1α	   complex.	   PPAR-­‐PGC1α	   mediated	   gene	   expression	  
requires	  fatty	  acids	  as	  ligands.	  Recent	  studies	  in	  mice	  lacking	  the	  ATGL	  gene	  revealed	  that	  
fatty	   acids	  which	   serve	   as	   ligands	   for	   PPARs	   have	   to	   originate	   from	   LD	   lipolysis;	   lack	   of	  
ATGL	   leads	   to	   severe	   reduction	   of	   oxidative	   gene	   expression	   [34-­‐36].	   Consistently,	   we	  
showed	   that	   ectopic	   overexpression	   of	   PLIN1	   in	   cultured	   myotubes	   abolished	   AGTL	  
mediated	  lipolysis	  and	  downregulated	  oxidative	  gene	  expression	  [37],	  which	  could	  not	  be	  
rescued	   by	   adding	   exogenous	   fatty	   acids	   to	   the	   medium.	   This	   indicates	   that	   reduced	  
intramyocellular	   LD	   lipolysis	  modulates	  gene	  expression	  by	  affecting	   ligand	   release	   from	  
the	  LD.	  Along	  the	  same	   lines,	  one	  may	  speculate	  that	  overexpression	  of	  PLIN5	   induces	  a	  
reversed	   process.	   In	   contrast	   to	   overexpressing	   PLIN1	   in	   muscle,	   overexpressing	   PLIN5	  
may	  promote	   liberation	  of	   fatty	  acids	   from	  the	  LD	  as	   ligands	   to	  promote	  oxidative	  gene	  
expression	  and	  fat	  oxidative	  capacity.	  	  
Interestingly,	   PLIN5	   appears	   to	   have	   a	   dual	   effect	   on	   LD	   lipolysis.	   Under	   basal	  
conditions	   PLIN5	   inhibits	   lipolysis	   while	   under	   stimulated	   conditions	   PLIN5	   appears	   to	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facilitate	  lipolysis	  [38-­‐41].	  In	  the	  present	  study	  PLIN5	  overexpression	  resulted	  in	  increased	  
ATGL	   protein	   content.	   Thus,	   a	   higher	   availability	   of	   both	   PLIN5	   and	  ATGL	  may	   translate	  
into	   increased	   lipolytic	   capacity	   under	   stimulated	   conditions	   and	   promotes	   liberation	   of	  
fatty	  acids	  as	  ligands	  for	  the	  PPAR-­‐PGC1α	  complex	  [34].	  With	  that,	  PLIN5	  overexpression	  
might	   induce	   a	   feed-­‐forward	   loop,	   since	   skeletal	   muscle	   PGC1α	   activation	   is	   known	   to	  
affect	  both	  oxidative	   capacity	   and	   intracellular	   lipid	   storage	   [42-­‐44].	  On	   the	  other	  hand,	  
we	  also	  observed	  that	  overexpression	  of	  PLIN5	  resulted	  in	  a	  profound	  increase	  in	  LD	  size	  
and	   TAG	   content.	  Which	   could	   reflect	   a	   state	  of	   decreased	  ATGL-­‐mediated	   lipolysis	   and	  
hence	  blunted	  availability	  of	  fatty	  acids	  as	  ligands.	  Therefore,	  it	  can	  not	  be	  excluded	  that	  
PLIN5	  may	  activate	  PPAR/PGC1	  via	  other	  mechanisms.	  Based	  upon	  subcellular	  distribution	  
of	  PLIN5	  and	  its	  interaction	  with	  mitochondria	  we	  previously	  hypothesized	  a	  role	  for	  PLIN5	  
as	   a	   chaperone	   protein	   shuttling	   fatty	   acids	   towards	   mitochondria	   for	   oxidation	   [8].	  
Similarly,	  PLIN5	  may	  also	  be	  involved	  in	  shuttling	  LD-­‐derived	  fatty	  acids	  towards	  nuclei	  to	  
serve	  as	   ligands	  for	  PPAR/PGC1.	   In	  that	  respect	   it	   is	  of	  relevance	  to	  note	  that	  PLIN5	  was	  
shown	  to	  localize	  to	  small,	  high	  dense	  lipid	  droplets	  and	  to	  be	  involved	  in	  lipid	  trafficking	  
[26].	  
	   Based	   on	   previous	   reports	   and	   our	   current	   data	   of	   improved	   gene	   expression	   of	  
oxidative	   genes,	   we	   propose	   that	   PLIN5	   is	   an	   important	   player	   in	   matching	  
intramyocellular	   lipid	   storage	   capacity	   with	   the	   ability	   to	   regulate	   oxidative	   gene	  
expression	  on	  the	  one	  hand	  and	  facilitating	  release	  of	  fatty	  acids	  from	  the	  LD	  as	  substrates	  
for	  mitochondrial	  oxidation	  on	  the	  other	  hand.	  	  
	   In	  summary,	  PLIN2	  and	  PLIN5	  both	  increase	  neutral	  IMCL	  content	  without	  negatively	  
impacting	   on	   insulin	   sensitivity.	   Interestingly,	   as	   opposed	   to	   the	   transcriptomic	   profile	  
upon	   PLIN2	   overexpression,	   we	   here	   report	   that	   overexpression	   of	   PLIN5	   in	   skeletal	  
muscle	   promoted	   expression	   of	   a	   cluster	   of	   genes	   under	   control	   of	   PPARα	   and	   PGC1α	  
involved	   in	   fatty	   acid	   catabolism	   and	   mitochondrial	   oxidation.	   This	   suggests	   a	   role	   of	  
PLIN5,	  either	  directly	  or	  indirectly,	  in	  mediating	  skeletal	  muscle	  oxidative	  gene	  expression.	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Supplemental	  Table	  1.	  Content	  of	  the	  individual	  FA-­‐species	  in	  the	  DAG	  fraction	  (µmol/g).	  Data	  are	  
mean	  ±	  SEM.	  	  
FA	   EV	   PLIN5	   P-­‐value	  
14:0	  	  	  	  	  	   	  	  0.49	  ±	  0.13	   	  	  0.46	  ±	  0.09	   0.81	  
15:0	  	  	  	  	  	   	  	  0.19	  ±	  0.07	   	  	  0.10	  ±	  0.04	   0.34	  
16:0	  	  	  	  	  	   12.73	  ±	  1.58	   11.99	  ±	  1.95	   0.72	  
16:1n-­‐7tr	  	  	  	   	  	  0.20	  ±	  0.07	   	  	  0.21	  ±	  0.06	   0.94	  
16:1n-­‐7	  	  	  	  	   	  	  0.80	  ±	  0.36	   	  	  0.43	  ±	  0.10	   0.31	  
18:0	  	  	  	  	  	   	  	  5.05	  ±	  0.87	   	  	  4.46	  ±	  0.68	   0.53	  
18:1tr	  	  	  	  	  	   	  	  0.23	  ±	  0.08	   	  	  0.20	  ±	  0.07	   0.60	  
18:1n-­‐9	  	  	  	  	   11.72	  ±	  3.07	   	  	  8.87	  ±	  1.64	   0.38	  
18:1n-­‐7	  	  	  	  	   	  	  0.27	  ±	  0.14	   	  	  0.45	  ±	  0.19	   0.47	  
18:2n-­‐6tr	  	  	  	   	  	  0.16	  ±	  0.07	   	  	  0.08	  ±	  0.04	   0.34	  
18:2n-­‐6	  	  	  	  	   	  	  7.14	  ±	  2.38	   	  	  4.84	  ±	  1.09	   0.38	  
20:0	  	  	  	  	  	   	  	  0.11	  ±	  0.02	   	  	  0.07	  ±	  0.02	   0.29	  
18:3n-­‐6	  	  	  	  	   	  	  0.22	  ±	  0.12	   	  	  0.07	  ±	  0.05	   0.32	  
20:1n-­‐9	  	  	  	  	   	  	  0.17	  ±	  0.05	   	  	  0.14	  ±	  0.03	   0.55	  
18:3n-­‐3	  	  	  	  	   	  	  0.26	  ±	  0.15	   	  	  0.13	  ±	  0.04	   0.41	  
18:4n-­‐3	  	  	  	  	   	  	  0.11	  ±	  0.04	   	  	  0.04	  ±	  0.03	   0.25	  
20:2n-­‐6	  	  	  	  	   	  	  0.28	  ±	  0.07	   	  	  0.30	  ±	  0.08	   0.82	  
20:3n-­‐6	  	  	  	  	   	  	  0.02	  ±	  0.01	   	  	  0.09	  ±	  0.03	   0.06	  
20:4n-­‐6	  	  	  	  	   	  	  1.14	  ±	  0.19	   	  	  0.98	  ±	  0.23	   0.52	  
23:0	  	  	  	  	  	   	  	  0.10	  ±	  0.05	   	  	  0.00	  ±	  0.00	   0.07	  
22:2n-­‐6	  	  	  	  	   	  	  0.23	  ±	  0.07	   	  	  0.16	  ±	  0.06	   0.39	  
24:1n-­‐9	  	  	  	  	   	  	  0.25	  ±	  0.09	   	  	  0.26	  ±	  0.08	   0.91	  
22:4n-­‐6	  	  	  	  	   	  	  0.21	  ±	  0.05	   	  	  0.15	  ±	  0.04	   0.38	  
22:5n-­‐3	  	  	  	  	   	  	  0.18	  ±	  0.10	   	  	  0.22	  ±	  0.21	   0.88	  
22:6n-­‐3	  	  	  	  	   	  	  0.41	  ±	  0.08	   	  	  0.42	  ±	  0.12	   0.94	  
Sum	  Saturated	   18.67	  ±	  2.18	   17.09	  ±	  2.68	   0.56	  
Sum	  Unsaturated	   23.99	  ±	  6.06	   18.05	  ±	  3.31	   0.35	  
Total	  DAG	   42.66	  ±	  7.85	   35.13	  ±	  5.87	   0.37	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Supplemental	  Table	  2.	  Skeletal	  muscle	  content	  of	  the	  individual	  acylcarnitine	  species	  (ρmol/mg).	  
Data	  are	  mean	  ±	  SEM.	  
Species	   EV	   PLIN5	   P-­‐value	  
C2	   391.6	  ±	  19.3	   374.3	  ±	  19.4	   0.52	  
C3	   4.53	  ±	  0.35	   4.58	  ±	  0.44	   0.90	  
C4	   12.0	  ±	  1.41	   12.8	  ±	  1.92	   0.59	  
C5:1	   0.40	  ±	  0.07	   0.43	  ±	  0.06	   0.82	  
C5	   2.65	  ±	  0.41	   2.37	  ±	  0.39	   0.41	  
C4-­‐3OH	   8.61	  ±	  0.77	   8.81	  ±	  0.99	   0.79	  
C6	   3.50	  ±	  0.47	   3.56	  ±	  0.54	   0.87	  
C5-­‐OH	   2.11	  ±	  0.11	   2.15	  ±	  0.16	   0.81	  
C8:1	   0.24	  ±0.03	   0.32	  ±	  0.06	   0.15	  
C16:1	   8.98	  ±	  1.66	   8.63	  ±	  1.50	   0.83	  
C16	   47.3	  ±	  10.3	   41.1	  ±	  7.69	   0.45	  
C16:2-­‐OH	   0.57	  ±	  0.13	   0.52	  ±	  0.09	   0.57	  
C16:1-­‐OH	   1.02	  ±	  0.16	   1.05	  ±	  0.16	   0.83	  
C16-­‐OH	   0.71	  ±	  0.11	   0.73	  ±	  0.13	   0.88	  
C18:3	   1.62	  ±	  0.36	   1.36	  ±	  0.26	   0.34	  
C18:2	   25.0	  ±	  5.87	   21.3	  ±	  4.14	   0.44	  
C18:1	   48.1	  ±	  10.5	   42.6	  ±	  8.41	   0.50	  
C18	   16.7	  ±	  3.22	   14.9	  ±	  2.64	   0.53	  
C18:2-­‐OH	   0.57	  ±	  0.08	   0.57	  ±	  0.13	   0.97	  
C18:1-­‐OH	   0.71	  ±	  0.10	   0.85	  ±	  0.19	   0.44	  
C18-­‐OH	   0.35	  ±	  0.05	   0.35	  ±	  0.07	   0.97	  
C20:4	   1.51	  ±	  0.39	   1.34	  ±	  0.28	   0.57	  
C20:2	   1.86	  ±	  0.35	   1.84	  ±	  0.42	   0.95	  
C20:1	   2.07	  ±	  0.35	   2.27	  ±	  0.51	   0.65	  
C20	   0.46	  ±	  0.07	   0.47	  ±	  0.09	   0.90	  
C20:2-­‐OH	   0.09	  ±	  0.02	   0.09	  ±	  0.03	   0.89	  
C20:1-­‐OH	   0.10	  ±	  0.03	   0.06	  ±	  0.02	   0.23	  
C20-­‐OH	   0.22	  ±	  0.06	   0.21	  ±	  0.05	   0.92	  
C22:2	   0.08	  ±	  0.02	   0.09	  ±	  0.03	   0.83	  
C22:1	   0.12	  ±	  0.02	   0.15	  ±	  0.03	   0.24	  
C22	   0.07	  ±	  0.02	   0.06	  ±	  0.02	   0.68	  
C22:1-­‐OH	   0.03	  ±	  0.01	   0.05	  ±	  0.02	   0.37	  
C22-­‐OH	   0.03	  ±	  0.01	   0.07	  ±	  0.03	   0.25	  
C24:2	   0.01	  ±	  0.01	   0.02	  ±	  0.01	   0.16	  
C24:1	   0.09	  ±	  0.02	   0.09	  ±	  0.03	   0.82	  
Total	   634.3	  ±	  44.3	   596.9	  ±	  47.0	   0.44	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Supplemental	   Figure	   1.	  
(A)	   Plasma	   glucose	   levels	  
and	  glucose	  infusion	  rates	  
(GIR)	   15	  min.	   before	   and	  
during	   the	  45-­‐min	   clamp.	  
Mean	   ±	   SEM	   (n=9).	   (B)	  
Representative	   graph	   of	  
the	   complete	   clamp	  
procedure	   for	   1	   rat	   (run	  
in	  phase	  and	   the	  45	  min.	  
stable	   phase	   after	   the	  
injection	   of	   the	   3H-­‐
deoxyglucose	   bolus).	   The	  
dotted	   line	   indicates	   the	  
timepoint	  of	  the	  injection	  
of	   the	   3H-­‐deoxyglucose	  
bolus.	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ABSTRACT	  
We	   studied	   the	   hypothesis	   that	   proteins	   involved	   in	   lipid	   droplet	   (LD)	   assembly,	  
maturation	   and	   localization,	   and	   mobilization	   contribute	   to	   exercise	   mediated	  
improvements	   in	   insulin	   sensitivity	   and	   concomitant	  metabolic	   flexibility.	   Eighteen	  male	  
type	  2	  diabetics	  (T2D)	  and	  twenty	  BMI-­‐	  and	  age-­‐matched	  normoglycemic	  control	  subjects	  
(C)	  exercise-­‐trained	  for	  12	  weeks.	  Myocellular	  LDs,	  LD	  coating	  proteins,	  indices	  of	  muscle	  
lipolysis	  and	  the	  putative	  LD	  mitochondria	  anchoring	  protein	  OPA1	  were	  measured	  before	  
and	  after	  training,	  and	  evaluated	  in	  the	  light	  of	  changes	  in	  insulin	  sensitivity	  and	  substrate	  
selection.	  	  
Pre-­‐training,	   protein	   contents	   of	   PLIN3	   and	  OPA1	  were	   significantly	   lower	   in	   T2D,	   along	  
with	   similar	   LD	  content,	  PLIN2,	  PLIN5,	  TAG-­‐hydrolysis	  and	  ATGL.	  Training	   restored	  PLIN3	  
and	   OPA1	   in	   T2D	   towards	   C	   levels.	   Post-­‐training	   LD	   content	   only	   modestly	   (P=0.10)	  
increased,	  while	  PLIN2	  and	  PLIN5	  protein	  content	  increased	  ~2-­‐fold	  in	  C	  and	  T2D	  (P<0.05).	  
Pre-­‐training	  PLIN5	  content	  correlated	  with	  OPA1,	  and	  ectopically	  overexpressing	  PLIN5	  in	  
rat	   muscle	   increased	   OPA1	   and	   blunted	   lipotoxicity.	   Changes	   in	   LD	   coating	   proteins	  
correlated	   with	   changes	   in	   substrate	   selection	   under	   basal	   and	   insulin-­‐stimulated	  
conditions.	  
In	  conclusion,	  T2D	  subjects	  restored	  their	  capacity	  to	  mature	  nascent	  LD	  by	  restoration	  of	  
PLIN3.	  Restoration	  of	  OPA1	  upon	  training	  may	  promote	  LD	  mitochondrial	  interaction	  and	  
reduce	   lipotoxicity.	   Exercise-­‐training	   increased	  PLIN2	  and	  PLIN5	  and	  hence	   reduced	  TAG	  
hydrolase	  activity	  despite	  increased	  ATGL	  content.	  Correlative	  analysis	  revealed	  that	  these	  
changes	   may	   be	   implicated	   in	   regulating	   exercise-­‐	   and	   insulin-­‐mediated	   changes	   in	  




Lipid	  droplets	  (LDs)	  are	  lipid	  dense	  organelles	  present	  in	  virtually	  all	  eukaryotic	  cells.	  While	  
originally	   viewed	  as	   relatively	   inert	  organelles	   sequestering	   fatty	   acids	   for	   triacylglycerol	  
(TAG)	   storage,	   research	   over	   the	   past	   two	   decades	   unveiled	   LDs	   as	   highly	   dynamic	  
organelles	  with	   a	   key	   role	   in	   orchestrated	   uptake	   and	   release	   of	   fatty	   acids.	   Fatty	   acids	  
released	   from	   the	   LD	   serve	   as	   substrates	   for	   (mitochondrial)	   oxidation,	   as	   signalling	  
molecules	   or	   as	   precursors	   for	   phospholipid	   synthesis	   [1].	   Dysregulation	   of	   storage	   and	  
hydrolysis	   of	   lipids	   in	   the	   LD	   is	   associated	  with	  multiple	   disease	   states,	   including	   insulin	  
resistance	  and	  type	  2	  diabetes	  (T2D)	  (reviewed	  in	  [2-­‐5]).	  	  
The	  identification	  of	  a	  family	  of	  LD	  associated	  proteins	  -­‐the	  PLIN	  proteins-­‐	  has	  been	  
pivotal	  to	  our	  understanding	  of	  the	  regulation	  of	  LD	  turnover.	  At	  present	  the	  PLIN	  protein	  
family	  comprises	  five	  members	  with	  shared	  homology	  in	  the	  N-­‐terminal	  domain	  [6]:	  PLIN1	  
(perilipin),	   PLIN2	   (ADRP),	   PLIN3	   (TIP47),	   PLIN4	   (S3-­‐12)	   and	   PLIN5	   (OXPAT)	   [7].	   PLIN	  
proteins	   are	   scaffolding	   proteins	   with	   a	   regulatory	   role	   in	   adipose	   triglyceride	   lipase	  
(ATGL)	  mediated	  TAG	  hydrolysis	  [8-­‐10]	  and	  may	  hence	  give	  rise	  to	  bioactive	  lipid	  species	  
with	   insulin	   desensitizing	   properties.	   Of	   these	   PAT	   proteins,	   PLIN2,	   3	   and	   5	   are	   most	  
abundant	   in	   skeletal	   muscle,	   the	   organ	   responsible	   for	   ~80%	   of	   post-­‐prandial	   glucose	  
uptake	  [11].	  The	  observation	  that	  LD	  content	  negatively	  associates	  with	  insulin-­‐stimulated	  
glucose	   uptake	   [12,	   13]	   and	   the	   ability	   of	   PLIN	   proteins	   to	   affect	   lipolysis	   has	   put	  
myocellular	   LD	   central	   stage	   in	   studies	   towards	   muscle	   insulin	   resistance	   and	   type	   2	  
diabetes.	  	  
We	   previously	   studied	   the	   role	   of	   PLIN2	   and	   PLIN5	   in	   insulin-­‐mediated	   glucose	  
uptake,	   in	   rat	   skeletal	   muscle	   upon	   gene	   electroporation	   mediated	   overexpression	   of	  
PLIN2	   or	   PLIN5.	   Despite	   a	   massive	   increase	   in	   LD	   content	   upon	   PLIN2	   and	   PLIN5	  
overexpression,	   insulin-­‐mediated	   glucose	   uptake	   in	   the	   overexpressing	   muscles	   was	  
maintained,	  or	  even	  modestly	   improved	   [14,	  15].	   Intriguingly,	   trained	  athletes	  also	  have	  
lots	  of	  myocellular	   LD,	  whilst	  being	  very	   insulin	   sensitive	   [12,	  16].	   In	   line	  with	  our	  PLIN5	  
overexpression	  study	  in	  rats,	  a	  cross-­‐sectional	  human	  study	  revealed	  that,	  despite	  having	  
significantly	   higher	   LD	   content	   than	   controls,	   older	   (65	   years),	   trained	   athletes	   were	  
significantly	  more	   insulin	  sensitive	   than	  controls	  of	   the	  same	  age	   [17].	   In	   these	  athletes,	  
PLIN5	   protein	   content	   correlated	   positively	   with	   insulin	   sensitivity	   [17].	   Likewise,	   we	  
recently	  observed	  that	  in	  young	  lean	  trained	  athletes	  protein	  content	  of	  PLIN2	  and	  PLIN5	  
in	   muscle	   was	   up	   and	   stepwise	   regression	   analysis	   identified	   PLIN5	   as	   a	   dominant	  
predictor	   of	   insulin-­‐mediated	   glucose	   uptake	   [18].	   Moreover,	   we	   observed	   that	   acute	  
exercise	   in	   rats	   promotes	   gene	   expression	   of	   PLIN2	   and	   PLIN5.	   This	   indicates	   that	   the	  
cross-­‐sectional	   observation	   of	   trained	   humans	   having	   higher	  myocellular	   PLIN5	   content	  
may	  originate	  from	  sustained	  exercise	  training	  and	  unmasks	  PLIN5	  as	  a	  putative	  player	  in	  
the	  insulin	  sensitizing	  effect	  of	  exercise	  training.	  
Another	   characteristic	   of	   insulin	   resistant	   muscle	   is	   metabolic	   inflexibility,	   i.e.	   a	  
reduced	  ability	   to	  adjust	  substrate	  selection	  to	  substrate	  availability	   [19,	  20].	  During	   low	  
intensity	   physical	   exercise	   and	   in	   the	   fasted	   state,	   fatty	   acid	   oxidation	  normally	   prevails	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over	   glucose	   oxidation	   while	   in	   the	   post-­‐prandial	   state	   and	   upon	   increasing	   exercise	  
intensity,	  glucose	  oxidation	  becomes	  more	  prominent.	  The	  transition	  between	  fasting	  and	  
feeding	  can	  experimentally	  be	  mimicked	  during	  a	  hyperinsulinemic	  euglycemic	  clamp.	   In	  
trained	   humans,	   muscle	   ATGL	   content	   was	   identified	   as	   a	   significant	   predictor	   of	  
metabolic	   flexibility	   under	   clamp	   conditions	   [18].	   In	   addition,	   it	   has	   been	   shown	   that	  
during	   exercise	   fatty	   acids	   required	   to	   fuel	   muscle	   contraction	   at	   least	   partly	   originate	  
from	  myocellular	   LD	   [21]	   and	   that	  mainly	   droplets	   coated	  with	   PLIN2	   become	   depleted	  
post-­‐exercise	  [22].	  	  
At	  present,	  however,	  it	  is	  not	  known	  if,	  and	  to	  what	  extent,	  adaptive	  responses	  of	  proteins	  
involved	  in	  LD	  assembly,	  maturation	  and	  localization,	  and	  mobilization	  are	  involved	  in	  the	  
insulin	   sensitizing	   effect	   of	   exercise	   training	   in	   type	   2	   diabetic	   patients.	   Therefore	   we	  
studied	  the	  hypothesis	  that	  proteins	  involved	  in	  LD	  degradation	  and	  synthesis	  contribute	  
to	   exercise-­‐mediated	   improvements	   in	   insulin	   sensitivity	   and	   concomitant	   metabolic	  
flexibility.	  
	  
RESEARCH	  DESIGN	  AND	  METHODS	  
Subjects	  
Male	   type	  2	  diabetic	   subjects	   (T2D,	  n=18)	  and	  normoglycemic	  control	   subjects	   (C,	  n=20)	  
matched	   for	   body	   weight,	   body	   mass	   index	   (BMI)	   and	   age	   were	   included.	   All	   diabetic	  
patients	  had	  well-­‐controlled	  diabetes	  (HbA1c=7.2	  ±	  0.2%)	  diagnosed	  for	  at	  least	  one	  year.	  
Drug	   use	   to	   promote	   glycemic	   control	   was	   restricted	   to	   oral	   anti-­‐diabetic	   agents	  
(metformin	  only,	  or	  in	  combination	  with	  SU	  derivatives).	  Body	  composition	  was	  measured	  
by	  hydrostatic	  weighing	  and	  maximal	  work	  load	  and	  oxygen	  uptake	  was	  assessed	  during	  a	  
graded	   cycling	   test	  until	   exhaustion.	   The	  ethical	   committee	  of	   the	  Maastricht	  University	  
Medical	   Centre	   approved	   the	   study.	   All	   subjects	   gave	   written	   informed	   consent	   before	  
participation.	  	  
	  
Exercise	  training	  protocol	  
Subjects	   adhered	   to	   a	   12-­‐week	   individually	   supervised	   progressive	   exercise	   training	  
program	  in	  small	  groups	  (n=3-­‐4).	  Prior	  to	  the	  training	  protocol	  maximal	  workload	  capacity	  
was	  determined	  twice,	  the	  first	  test	  served	  as	  a	  familiarisation	  trial,	  while	  the	  second	  test	  
was	   used	   to	   determine	   the	   workload	   during	   the	   training	   program	   [23].	   All	   tests	   were	  
performed	   under	   standardized	   conditions	   and	   substrate	   oxidation	   measurements	   were	  
performed	  (indirect	  calorimetry)	  during	  the	  steady-­‐state	  phase	  of	  submaximal	  stages	  at	  75	  
and	   125	   Watt.	   To	   ensure	   the	   progressive	   nature	   of	   the	   training	   program,	   maximal	  
workload	   (Wmax)	   was	   determined	   again	   after	   6	   weeks	   of	   training	   and	   workload	   was	  
adjusted	  accordingly.	  	  
During	  the	  12	  weeks	  of	  training,	  cycling	  ergometer	  exercise	  was	  performed	  twice	  a	  week	  
for	   30	   minutes	   at	   55%	   Wmax.	   Resistance	   exercise	   was	   performed	   once	   a	   week	   and	  
comprised	   1	   series	   of	   8	   repetitions	   at	   55%	  of	   previously	   determined	  maximal	   voluntary	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contraction	   (MVC)	   [23]	   and	   2	   series	   of	   8	   repetitions	   at	   75%	  MVC	   and	   focused	   on	   large	  
muscle	   groups.	   The	   MVC	   test	   to	   assess	   maximal	   work	   load	   was	   preceded	   by	   a	  
familiarization	  trial.	  Every	  4	  weeks,	  MVC	  was	  reassessed	  and	  training	  loads	  was	  readjusted	  
accordingly.	   Training	   sessions	   were	   preceded	   and	   ended	   with	   5	   minutes	   of	   warming	  
up/cooling	  down	  on	  the	  cycling	  ergometer	  at	  45%	  Wmax.	  
	  
Hyperinsulinemic-­‐euglycemic	  clamp	  
A	  6h	  hyperinsulinemic-­‐euglycemic	   insulin	   clamp	   (40	  mU/m2/min)	  was	   performed	  before	  
and	   after	   the	   training	   period	   after	   an	   overnight	   fast	   as	   described	   previously	   [23].	  
Antidiabetic	  medication	  was	   discontinued	   7	   days	   prior	   to	   the	   clamp.	   Subjects	   refrained	  
from	  any	  physical	  exercise	  at	  least	  48	  hours	  prior	  to	  the	  clamp.	  Rates	  of	  glucose	  disposal	  
(Rd)	  was	  determined	  using	   [6,6-­‐2H2]	   glucose	  and	  used	   to	   calculate	   the	   insulin	   sensitivity	  
index	   (Si).	   In	   the	   final	   30	  minutes	   of	   the	   non-­‐insulin	   stimulated	   period	   (t=150-­‐180)	   and	  
under	   steady	   hyperinsulinemic	   conditions	   (t=330-­‐360),	   substrate	   selection	  was	   assessed	  
by	   indirect	   calorimetry.	  Needle	  muscle	   biopsies	  were	   obtained	   from	   the	   vastus	   lateralis	  
before	  and	  after	  the	  training	  program	  30	  minutes	  before	  the	  onset	  of	  the	  clamp.	  Biopsies	  
were	   freed	   from	  visible	  detectable	   fat	   and	   connective	   tissue	  and	   snap	   frozen	   in	  melting	  
isopentane	  and	  stored	  at	  -­‐80°C	  for	  further	  analyses.	  	  	  
	  
Blood	  sample	  analysis	  
Arterialised	  blood	   samples	  were	   collected	   in	  EDTA	  coated	   tubes,	   from	  a	  hot-­‐box	  heated	  
hand	   vein.	   Plasma	   free	   fatty	   acids	   (FFAs)	   and	   glucose	   were	   measured	   with	   enzymatic	  
assays	   automated	   on	   a	   Cobas	   Fara/Mira	   (FFA:	   Wako	   Nefa	   C	   test	   kit;	   Wako	   Chemicals,	  
Neuss,	   Germany)	   (glucose:	   hexokinase	   method;	   LaRoche,	   Basel,	   Switzerland).	   Plasma	  
insulin	  levels	  were	  measured	  by	  a	  radioimmunoassay	  (Linco	  Research,	  St.	  Charles,	  MO).	  
	  
Lipid	  droplet	  content	  
Intramyocellular	  lipid	  content	  was	  assessed	  histochemically	  in	  muscle	  cross-­‐sections	  using	  
a	  modified	  oil-­‐red-­‐O	  staining	  for	  fluorescence	  microscopy	  [24].	  Lipid	  droplets	  were	  binned	  
and	   the	   area	   fraction	   of	   the	   LD	   relative	   to	   muscle	   cell	   area	   was	   computed.	   Thus,	   LD	  
content	   can	   be	   measured	   accurately.	   Due	   to	   limitations	   in	   the	   optical	   resolution,	   this	  
method	   does	   not	   allow	   valid	   statements	   on	   the	   change	   in	   LD	   size.	   For	   each	   subject	   a	  
minimum	   of	   150	   muscle	   fibers	   were	   examined	   pre-­‐	   and	   post-­‐training.	   Representative	  
histological	  slides	  are	  presented	  in	  Figure	  1.	  
	  
Western	  blotting	  	  
Muscle	   samples	   were	   homogenized	   in	   ice-­‐cold	   PBS	   containing	   1%	   Nonidet-­‐P40,	   0.5%	  
sodium	   dodecyl	   sulfate,	   0.1	   mM	   phenylmethylsulfonyl	   fluoride,	   and	   complete	   inhibitor	  
(Roche,	   Almere,	   The	   Netherlands)	   and	   processed	   for	   standard	   SDS-­‐PAGE	   and	   Western	  
blotting.	  Gels	  were	  loaded	  with	  equal	  amounts	  of	  protein	  of	  pre-­‐	  and	  posttraining	  lysates	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of	  2	  control	  and	  2	  type	  diabetic	  subjects	  per	  gel	  to	  allow	  valid	  comparison	  between	  pre-­‐	  
and	  posttraining	  samples.	  	  
Membranes	  were	  incubated	  with	  antibodies	  against	  FIT1	  and	  FIT2	  (kindly	  provided	  by	  Dr.	  
David	  Silver,	  Duke	   -­‐	  National	  University	  of	  Singapore,	  Singapore);	  FSP27	   (kindly	  provided	  
by	   dr.	   Vishu	   Puri,	   Boston	   University	   School	   of	   Medicine,	   USA);	   PLIN2	   (GP40,	   Progen,	  
Heidelberg,	   Germany);	   PLIN3	   (GP30,	   Progen);	   PLIN5	   (GP31,	   Progen);	   ATGL	   (2138,	   Cell	  
Signalling	  Technology,	  Leiden,	  The	  Netherlands);	  CGI58	  (NB110-­‐41576,	  Novus	  Biologicals,	  
Littleton,	  CO,	  USA);	  OPA1	  (612606,	  BD	  Biosciences,	  Breda,	  The	  Netherlands);	  and	  SR-­‐actin	  
as	  the	  loading	  control,	  A-­‐2172;	  Sigma,	  St.	  Louis,	  USA.	  	  
Blots	   incubated	   with	   FITs,	   FSP27,	   PLINs,	   and	   OPA1	   were	   probed	   with	   appropriate	  
IRDye800-­‐conjugated	   secondary	   antibodies	   (Rockland,	   Gilbertsville,	   PA,	   USA	   and	   LICOR	  
Biosciences,	   Westburg,	   Leusden,	   The	   Netherlands),	   and	   bands	   at	   a	   molecular	   weight	  
corresponding	  to	  the	  control	  samples	  were	  quantified	  using	  the	  Odyssey	  infrared	  imaging	  
system	  (LICOR	  Biosciences,	  Westburg,	   the	  Netherlands).	  Blots	  detecting	  ATGL	  and	  CGI58	  
were	  probed	  with	  the	  appropriate	  horseradish-­‐conjugated	  antibodies	  and	  after	  incubation	  
specific	  protein	  bands	  were	  visualized	  by	  chemiluminescence	  and	  analyzed	  by	  Chemidoc	  
XRS	   system	   (Bio-­‐Rad,	   Veenendaal,	   the	   Netherlands).	   Protein	   content	   was	   expressed	   as	  
arbitrary	  units	  (AU).	  
	  
TAG	  and	  DAG	  hydrolase	  activity	  
TAG	   and	   DAG	   hydrolase	   activities	   were	   measured	   in	   muscle	   tissue	   homogenates	   as	  
previously	   described	   [25].	   Briefly,	   triolein	   and	   1(3)-­‐mono-­‐oleyl-­‐2-­‐O-­‐mono-­‐oleylglycerol	  
were	   emulsified	   with	   phospholipids	   by	   sonication.	   Triolein	   is	   a	   triglyceride	   containing	  
three	  oleic	  acid	  specifically	  used	  to	  determine	  TAG	  hydrolase	  activity.	  1(3)-­‐Mono-­‐oleyl-­‐2-­‐
O-­‐mono-­‐oleylglycerol	   is	   a	   DAG	   analog	   used	   to	   measure	   specifically	   the	   DAG	   hydrolase	  
activity,	   since	   it	   is	   not	   a	   substrate	   for	  monoacylglycerol	   lipase.	   Lipase	  activity	  data	  were	  
normalized	   to	   total	   protein	   content	   determined	   in	   each	   sample	   and	   expressed	   in	  
nmol/min/mg.	  
	  
Electroporation	  study	  	  
A	  total	  of	  18	  8-­‐week	  old	  male	  Wistar	  rats	  were	  purchased	  from	  Charles	  River	  (Wilmington,	  
Massachusetts,	   USA).	   Rats	   were	   housed	   individually	   on	   a	   12:12	   h	   light-­‐dark	   cycle	   (light	  
from	  7:00	  am	  to	  7:00	  pm),	  at	  room	  temperature	  (21–22	  °C)	  with	  ad	  libitum	  access	  to	  tap	  
water.	   Rats	  were	   fed	   a	   high	   fat	   diet	   (45%	   energy	   from	   fat,	   D01060502,	   Research	  Diets,	  
New	  Brunswick,	  NJ,	  USA)	  for	  the	  duration	  of	  the	  3-­‐week	  intervention.	  The	  Animal	  Care	  and	  
Use	  Committee	  of	  Maastricht	  University	  approved	  the	  experiments.	  	  
Two	  weeks	  after	  the	  start	  of	  the	  diet,	  overexpression	  of	  mouse	  Plin5	  in	  either	  the	  right	  or	  
left	   tibialis	   anterior	   (TA)	   muscle	   of	   the	   rat	   was	   accomplished	   by	   an	   in	   vivo	   DNA	  
electrotransfer	   technique	   to	   obtain	   overexpression	   of	  mouse	   perilipin	   5	   in	   one	   leg;	   the	  
contralateral	   TA	   served	   as	   a	   sham-­‐electroporated	   internal	   control.	   Plin5	   was	  
electroporated	   in	   the	   left	   or	   the	   right	   TA	   on	   a	   random	   basis	   to	   eliminate	   bias.	   DNA	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electroporation	   was	   performed	   under	   isoflurane	   anaesthesia.	   TA	   muscles	   were	  
transcutaneously	  injected	  with	  either	  150	  µg	  (2	  µg/µl)	  pcDNA3.1-­‐CMV-­‐Plin5	  or	  pcDNA3.1-­‐
empty	   vector	   in	   0.9%	   sterile	   NaCl.	  Within	   15	   seconds	   after	   the	   last	   injection	   5	   electric	  
pulses	  were	  applied	  by	  two	  stainless	  steel	  plate	  electrodes	  placed	  at	  the	  ventral	  and	  dorsal	  
side	  of	  the	  leg.	  One	  high	  voltage	  pulse	  of	  800	  V/cm	  and	  four	  low	  voltage	  pulses	  of	  80	  V/cm	  
at	   1	   Hz	   were	   generated	   by	   an	   ECM	   830	   electroporator	   (BTX,	   San	   Diego,	   CA,	   USA)	   as	  
described	  previously	  [26,	  27].	  Rats	  were	  sacrificed	  8	  days	  postelectroporation.	  	  
	  
Oxygen	  consumption	  in	  isolated	  mitochondria	  
After	  excision,	  the	  right	  and	  left	  TA	  muscles	  were	  placed	  into	  ice-­‐cold	  medium	  containing	  
100	  mM	   sucrose,	   100	  mM	   KCl,	   50	  mM	   Tris-­‐HCl,	   1mM	   KH2PO4,	   0.1mM	   EGTA,	   and	   0.2%	  
(wt/vol)	   FA-­‐free	  bovine	   serum	  albumin	   (pH	  7.4).	   The	   TA	  was	   immediately	   processed	   for	  
mitochondrial	   isolation,	   essentially	   according	   to	   Tonkonogi	   and	   Sahlin	   [28].	   The	   protein	  
concentration	   in	   the	   mitochondrial	   pellet	   was	   measured	   using	   fluorescamine	   (Fluram;	  
Fluka,	   Zwijndrecht,	   the	   Netherlands)	   with	   bovine	   serum	   albumin	   as	   a	   standard	   [29].	  
Freshly	  isolated	  mitochondria	  were	  used	  immediately	  for	  mitochondrial	  respirometry.	  	  
FA-­‐induced	  respiration	  uncoupled	  from	  ATP	  synthesis	  was	  determined	  as	  a	  marker	  for	  FA-­‐
induced	  uncoupling.	   Thus,	   0.2	  mg	  mitochondria	   in	   the	  presence	  of	   5	  mM	  pyruvate	   as	   a	  
substrate	   and	   oligomycin	   (1	   µg/ml)	   to	   block	   ATP	   synthesis	   (state	   4o	   respiration),	   were	  
automatically	  titrated	  with	  increasing	  levels	  of	  palmitate	  by	  a	  titration	  pump	  (OROBOROS®	  
Instruments,	  Innsbruck,	  Austria)	  while	  respiration	  was	  monitored.	  The	  free	  concentrations	  
of	   palmitate	   were	   calculated	   using	   the	   equation	   described	   [30]	   for	   the	   binding	   of	  
palmitate	  to	  BSA	  at	  37°C.	  Data	  for	  FA	  concentration-­‐response	  curves	  were	  analyzed	  with	  
the	   four	   parameter	   logistic	   curve	   fit	   option	   of	   the	   Sigmaplot	   8.0	   application	   (Systat	  
Software,	   Erkrath,	   Germany).	   All	   substrates	   were	   dissolved	   in	   double	   distilled	   water	  




Results	  are	  presented	  as	  mean	  ±	  SEM.	  Statistical	  analyses	  were	  performed	  using	  SPSS	  for	  
Windows	   15.0	   software	   (SPSS,	   Chicago,	   IL).	   Statistical	   comparisons	   between	   conditions	  
(pre-­‐	  and	  posttraining)	  were	  performed	  using	  paired	  T-­‐tests.	  Correlations	   reported	  were	  
computed	  as	  Spearman	  correlation	  coefficients.	  The	  level	  of	  statistical	  significance	  was	  set	  




Control	   subjects	   (C)	   and	   type	  2	  diabetic	  patients	   (T2D)	  were	   carefully	  matched	   for	  body	  
weight,	  BMI	  and	  age	  (Table	  1).	  Body	  composition	  was	  similar	  between	  T2D	  and	  C	  and	  was	  
unaffected	   by	   training	   (Table	   1).	   Maximal	   workload	   capacity	   and	   concomitant	   oxygen	  
Perilipins	  in	  type	  2	  diabetic	  muscle	  before	  and	  after	  exercise	  training	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uptake	   before	   training	   was	   comparable	   prior	   to	   training	   and	   increased	   similarly	   upon	  
training	  in	  both	  groups	  (+6.4	  ±	  2.6%;	  P=0.04	  in	  C	  and	  +11.3	  ±	  2.2%;	  P<0.01	  in	  T2D).	  Fasting	  
plasma	   free	   fatty	   acid	   (FFA)	   levels	   were	   similar	   across	   groups	   and	   were	   unaffected	   by	  
training	  (Table	  1).	  	  
	  
Insulin	  sensitivity	  index	  
The	   insulin	   sensitivity	   index	   (Si,	   μmol/kg/min/mU)	   was	   considerably	   lower	   in	   T2D	  
compared	   with	   C	   (Table	   2).	   Exercise	   training	   significantly	   (P<0.01)	   improved	   insulin	  
sensitivity	  in	  T2D	  and	  C	  (Table	  2).	  	  
	  
Lipid	  oxidation	  
Under	  insulin	  stimulation,	  suppression	  of	  lipid	  oxidation	  was	  less	  pronounced	  in	  T2D	  than	  
in	  C	  before	  training	  (metabolic	  inflexibility).	  After	  training,	  suppression	  of	  lipid	  oxidation	  in	  
T2D	   restored	   to	   levels	   similar	   to	   age-­‐	   and	   BMI	   matched	   control	   subjects	   (Table	   2),	  
reflecting	   restoration	  of	  metabolic	   flexibility.	   Lipid	  oxidation	  during	   submaximal	  exercise	  
(at	  75	  and	  125	  W)	  was	  comparable	   in	  C	  and	  T2D	  before	  training	  (2.06	  ±	  0.49	  and	  2.26	  ±	  
0.47	   mmol/kg/min	   at	   75	   watt	   in	   C	   and	   T2D,	   respectively;	   1.76	   ±	   0.39	   and	   1.63	   ±	   0.57	  
mmol/kg/min	  at	  125	  watt	  in	  C	  and	  T2D,	  respectively).	  Training	  improved	  lipid	  oxidation	  in	  
C	  and	  T2D	  at	  75	  Watts	  (3.25	  ±	  0.34	  in	  C;	  P<0.01	  and	  3.99	  ±	  0.43	  in	  T2D;	  P<0.01)	  as	  well	  as	  
at	  125	  Watts	  (2.86	  ±	  0.57	  in	  C;	  P<0.05	  and	  3.13	  ±	  0.42	  in	  T2D;	  P<0.01).	  	  
	  
Table	  1.	  Subject	  characteristics.	  
	   C	  	   T2D	  
	   Pre-­‐training	   Post-­‐training	   Pre-­‐training	   Post-­‐training	  
Age	  (years)	   59.0	  ±	  0.8	   /	   	  	  59.4	  ±	  1.1	   /	  
Years	  since	  diagnosis	   /	   /	   	  	  	  	  3.9	  ±	  0.9	   /	  
Weight	  (kg)	   94.7	  ±	  2.7	   	  93.6	  ±	  2.7	   	  	  93.8	  ±	  2.9	   92.8	  ±	  3.1	  
Height	  (cm)	   179	  	  ±	  1.3	   /	   	  	  	  177	  ±	  1.3	   /	  
BMI	  (kg/m2)	   29.7	  ±	  0.8	   	  29.4	  ±	  0.8	   	  	  30.0	  ±	  0.8	   29.8	  ±	  0.9	  
Body	  fat	  (%)	   31.5	  ±	  1.4	   	  30.6	  ±	  1.6	   	  	  31.1	  ±	  1.4	   	  	  29.9	  ±	  1.3*	  
FM	  (kg)	   30.0	  ±	  1.8	   	  29.2	  ±	  2.0	   	  	  29.4	  ±	  1.9	   	  	  28.0	  ±	  1.8*	  
FFM	  (kg)	   64.6	  ±	  2.0	   	  65.4	  ±	  2.0	   	  	  64.3	  ±	  1.7	   64.8	  ±	  1.8	  
VO2max	  (ml/min/kg)	   28.8	  ±	  1.0	   	  	  	  30.2	  ±	  1.2*	   	  	  27.5	  ±	  1.2	   	  	  31.1	  ±	  1.2*	  
Wmax	  (Watt)	   207	  ±	  10	   	  236	  ±	  9*	   202	  ±	  9	   233	  ±	  9*	  
Average	  strength	  (kg)	   85.8	  ±	  3.2	   	  104.0	  ±	  3.5*	   	  	  83.7	  ±	  3.5	   102.4	  ±	  4.2*	  
Fasting	  glucose	  (mmol/l)	   	  	  5.9	  ±	  0.1	   	  	  	  	  	  5.5	  ±	  0.1*	   	  	  	  	  	  	  9.0	  ±	  0.4#	   	  	  	  	  	  9.0	  ±	  0.4#	  
HbA1c	  (%)	   	  	  5.8	  ±	  0.1	   	  	  	  	  	  5.7	  ±	  0.1*	   	  	  	  	  	  	  7.2	  ±	  	  0.2#	   	  	  	  	  7.2	  	  ±	  0.2#	  
Triacylglycerol	  (mmol/l)	   	  	  1.52	  ±	  0.13	   	  	  	  1.49	  ±	  0.15	   	  	  	  	  1.77	  ±	  0.16	   	  	  	  1.68	  ±	  0.14	  
Type	  1	  muscle	  fibers	  (%)	   40.0	  ±	  2.3	   	  39.5	  ±	  2.8	   	  	  40.0	  ±	  3.9	   	  36.5	  ±	  2.5	  
Type	  2	  muscle	  fibers	  (%)	   60.0	  ±	  2.3	   	  60.5	  ±	  2.8	   	  	  60.0	  ±	  3.9	   	  63.5	  ±	  2.5	  
Data	  are	  expressed	  as	  mean	  ±	  SEM,	   #T2D	  significantly	  different	   from	  control	  group,	  *post-­‐training	  





Table	  2.	  Substrate	  kinetics	  pre-­‐	  and	  post	  training.	  
	   C	  	   T2D	  
	   Pre-­‐training	   Post	  training	   Pre-­‐training	   Post	  training	  
Plasma	  insulin	  (mU/l)	   	   	   	   	  
	  	  	  	  	  	  	  	  	  	  	  Basal	   	  	  18.1	  ±	  2.4	   	  	  	  	  16.1	  ±	  2.1*	   	  	  16.4	  ±	  1.2	   	  	  	  	  14.6	  ±	  0.8*	  
	  	  	  	  	  	  	  	  	  	  	  Clamp	   112.5	  ±	  5.4	   112.1	  ±	  5.5	   107.6	  ±	  4.8	   103.1	  ±	  2.7	  
Plasma	  FFA	  (μmol/l)	   	   	   	   	  
	  	  	  	  	  	  	  	  	  	  	  Basal	   	  	  479.0	  ±	  22.9	   	  	  454.9	  ±	  28.3	   	  	  519.4	  ±	  25.3	   	  500.1	  ±	  34.1	  
	  	  	  	  	  	  	  	  	  	  	  Clamp	   	  	  84.7	  ±	  7.2	   	  	  	  	  67.5	  ±	  6.9*	   107.1	  ±	  8.7	   	  	  	  87.6	  ±	  8.7*	  




	   	   	   	  
	  	  	  	  	  	  	  	  	  	  	  Basal	   	  	  	  1.08	  ±	  0.05	   	  	  	  1.03	  ±	  0.05	   	  	  	  1.08	  ±	  0.05	   	  1.09	  ±	  0.05	  
	  	  	  	  	  	  	  	  	  	  	  Clamp	   	  	  	  0.63	  ±	  0.04	   	  	  	  0.55	  ±	  0.04	  	   	  	  	  	  	  0.75	  ±	  0.04#	   	  	  	  0.59	  ±	  0.05*	  
	  	  	  	  	  	  	  	  	  	  	  Delta	   	  -­‐0.46	  ±	  0.05	   	  	  -­‐0.48	  ±	  0.06	   	  	  -­‐0.32	  ±	  0.06	   	  	  -­‐0.49	  ±	  0.06*	  
Si	  =	   insulin	   sensitivity	   index.	  Data	  are	  expressed	  as	  mean	  ±	  SEM.,	   #T2D	  significantly	  different	   from	  
control	  group,	  *post-­‐training	  significantly	  different	  from	  pre-­‐training.	  
	  
Muscle	  LD	  content	  and	  contents	  of	  LD-­‐coat	  proteins	  
Immunohistochemical	  analyses	  of	  percentage	  MHCI	  and	  MHCII	  positive	  muscle	  fibers	  was	  
similar	  at	  baseline	  and	  did	  not	  change	  significantly	  upon	   training	   (Table	  1	  and	  Figure	  1).	  
Pre-­‐training,	  LD	  content	  was	  comparable	   in	  both	  (BMI	  matched)	  groups	  (1.36	  ±	  0.20	  and	  
1.49	  ±	  0.20	   in	  C	  and	  T2D,	   respectively;	  P=0.65)	  and	  was	  unaffected	   in	  C	   (1.36	  ±	  0.20	  vs.	  
1.33	  ±	  0.23	  pre-­‐	  and	  post-­‐training;	  P=0.89),	  whereas	  in	  T2D	  a	  near	  significant	  and	  modest	  
increase	   in	   LD	   content	   was	   observed	   (from	   1.49	   ±	   0.20	   to	   1.91	   ±	   0.34;	   P=0.10).	  
Representative	  images	  of	  the	  combined	  LD	  and	  fiber	  typing	  are	  shown	  in	  Figure	  1.	  Content	  
of	  LD	  coat	  proteins	  involved	  in	  LD	  assembly	  were	  not	  different	  between	  groups	  nor	  were	  
significantly	  affected	  by	  exercise	  training	  (FIT1	  1.24	  ±	  0.17	  in	  C	  vs.	  0.89	  ±	  0.16	  in	  T2D	  pre-­‐	  
training	  and	  0.86	  ±	  0.17	  in	  C	  vs.	  1.01	  ±	  0.12	  in	  T2D	  post-­‐training,	  FIT2	  1.14	  ±	  0.16	  in	  C	  vs.	  
0.99	  ±	  0.18	  in	  T2D	  pre-­‐	  training	  and	  0.97	  ±	  0.23	  in	  C	  vs.	  0.91	  ±	  0.11	  in	  T2D	  post-­‐training,	  
FSP27	  1.00	  ±	  0.08	  in	  C	  vs.	  1.02	  ±	  0.12	  in	  T2D	  pre-­‐	  training	  and	  0.88	  ±	  0.10	  in	  C	  vs.	  1.10	  ±	  
0.13in	  T2D	  post-­‐training).	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Figure	   1.	   (A-­‐D)	   Representative	   images	   of	  
lipid	   droplet	   content	   (red)	   with	   type	   1	  
muscle	   fibers	   (green)	   in	   control	   subjects	  
pre-­‐	   and	   post	   training	   (A	   and	   B)	   and	   in	  
type	   2	   diabetic	   (T2D)	   subjects	   pre-­‐	   and	  
post	  training	  (C	  and	  D).	  	  	  
	  
Of	   the	   myocellular	   members	   of	   the	   perilipin	   family	   (PLIN2,	   PLIN3	   and	   PLIN5),	   protein	  
content	  of	  PLIN2	  and	  PLIN5	  were	  similar	  in	  C	  and	  T2D	  pre-­‐training	  (PLIN2:	  0.59	  ±	  0.06	  and	  
0.71	  ±	   0.09	   in	  C	   and	  T2D	   respectively;	   PLIN5:	   0.70	   ±	   0.14	   and	  0.70	   ±	   0.10	   in	  C	   and	  T2D	  
respectively,	  Figure	  2A	  and	  B)	  while	  pre-­‐training	  PLIN3	  was	  significantly	  down	  in	  T2D	  (1.10	  
±	   0.11	   and	   0.81	   ±	   0.08	   in	   C	   and	   T2D	   respectively;	   P=0.04,	   Figure	   2C).	   The	   training	  
intervention	  augmented	  protein	  content	  of	  all	  members	  of	  the	  perilipin	  family,	  indicative	  
of	  active	  remodelling	  of	  the	  LD.	  Thus,	  protein	  content	  of	  PLIN2	  and	  PLIN5	  approximately	  
doubled	   after	   exercise	   training	   in	   C	   and	   T2D	   (PLIN2:	   from	   0.59	   ±	   0.06	   to	   1.17	   ±	   0.14;	  
P<0.01	  in	  C	  and	  from	  0.71	  ±	  0.09	  to	  1.55	  ±	  0.20;	  P<0.01	  in	  T2D,	  PLIN5:	  from	  0.70	  ±	  0.14	  to	  
1.29	  ±	  0.19;	  P=0.03	  in	  C	  and	  from	  0.70	  ±	  0.10	  to	  1.27	  ±	  0.20;	  P=0.01	  in	  T2D,	  Figure	  2A	  and	  
B),	  while	  in	  T2D	  patients	  protein	  content	  of	  PLIN3	  restored	  to	  pre-­‐training	  levels	  observed	  
in	  C	   (1.09	  ±	  0.09	  and	  1.00	  ±	  0.08	   in	  C	  and	  T2D	  respectively,	  Figure	  2C).	  Training-­‐induced	  
changes	   in	   PLIN2	   and	   PLIN5	   protein	   abundance	   correlated	   (r=0.476,	   P=0.007)	   and	   the	  
change	   in	   PLIN2	   post-­‐training	   correlated	   positively	   with	   the	   training-­‐induced	   change	   in	  







Figure	  2.	  Protein	  expression	  of	  PLIN2	  (A),	  PLIN3	  (B)	  and	  PLIN5	  (C)	   in	  vastus	  lateralis	  muscle,	  before	  
(white	  bars)	   and	   after	   training	   (black	   bars).	  Data	   are	   expressed	   as	  mean	   (in	   arbitrary	  units,	  AU)	   ±	  
SEM.	  *P<0.05.	  	  
A	   series	   of	   recent	   papers	   prompted	   us	   to	   zoom	   deeper	   into	   the	   role	   of	   PLIN5	   in	   the	  
exercise-­‐mediated	   adaptations	   in	   LD	   assembly	   and	   mobilization.	   Thus,	   trained	   athletes	  
have	   very	   high	   levels	   of	   PLIN5	   [17,	   18]	   and	   myocellular	   overexpression	   of	   PGC1α,	   a	  
promiscuous	   transcriptional	   co-­‐activator	   with	   a	   prominent	   role	   in	   driving	   the	   adaptive	  
response	   to	   exercise	   profoundly	   induces	   PLIN5	   [18].	   Furthermore,	   PLIN5	   has	   also	   been	  
observed	   in	  mitochondria	  [31,	  32]	  and	  overexpression	  of	  PLIN5	  promotes	  oxidative	  gene	  
expression	   [15]	   and	   interactions	   of	   mitochondria	   with	   LDs	   [32].	   Thus,	   we	   examined	   if	  
PLIN5	   content	   pre-­‐training	   correlated	   with	   abundance	   of	   proteins	   of	   the	   oxidative	  
phosphorylation	   system	   (OXPHOS).	   Indeed,	   we	   observed	   that	   post-­‐training	   content	   of	  
complex	   I	   subunit	   NDUFB8,	   complex	   II	   subunit	   30	   kDa	   and	   complex	   V	   ATP	   synthase	  
subunit	  alpha	  correlated	  significantly	  with	  PLIN5	  (r=0.391,	  P=0.029;	  r=0.379,	  P=0.035	  and	  
r=0.447,	  P=0.012,	  respectively).	  	  
Moreover,	   it	  has	  recently	  been	  shown	  that	  a	  mitochondrial	   innermembrane	  protein	  
optic	  atrophy	  1	   (OPA1)	   involved	   in	  mitochondrial	   fusion,	   interacts	  with	  PLIN1	   in	  adipose	  
tissue	   to	   regulate	   adipocyte	   lipolysis	   [33].	   If	   extrapolation	   to	  muscle	   is	   valid,	  OPA1	  may	  
interact	  with	  PLIN5	  to	  regulate	  lipolysis	  of	  myocellular	  LD.	  Therefore,	  we	  examined	  OPA1	  
in	  muscle	   biopsies	   of	   C	   and	   T2D	   pre-­‐	   and	   post-­‐training.	   Interestingly,	  we	   observed	   that	  
OPA1	  was	  significantly	  down	  in	  patients	  with	  T2D	  	  (1.40	  ±	  0.15	  and	  1.04	  ±	  0.12	  pre-­‐training	  
in	  C	  and	  T2D	  respectively;	  P=0.04,	  Figure	  3A)	  and	  that	  training	  restored	  values	   in	  T2D	  to	  
control	   levels	  1.27	  ±	  0.14	  and	  1.51	  ±	  0.10	  post-­‐training	   in	  C	  and	  T2D	  respectively,	  Figure	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Figure	   3.	   (A)	   OPA1	  
protein	   content	   before	  
(white	   bars)	   and	   after	  
training	   (black	   bars).	  
(B)	   OPA1	   protein	  
content	   in	   empty	  
vector	   and	   PLIN5-­‐
electroporated	   tibialis	  
anterior	  muscle	   of	   rats	  
(n=18).	   (C)	   Palmitate-­‐
induced	   uncoupling.	  
Oxygen	  consumption	  in	  
isolated	   mitochondria	  
from	  empty	  vector	  (EV)	  
or	   PLIN5-­‐
electroporated	   muscle	  
upon	   titration	   with	  
palmitate	   (n=10).	   (D-­‐E)	  
EC50	   (D)	   and	   Vmax	   (E)	  
for	   palmitate	   titration-­‐
induced	   oxygen	  
consumption	   (n=10).	  
Data	   are	   expressed	   as	  
mean	  ±	  SEM.	  *P<0.05.	  
	  
To	   shed	   more	   light	   on	   this	   issue,	   we	   overexpressed	   PLIN5	   using	   unilateral	   gene	  
electroporation	  in	  rats	  in	  vivo	  [31].	  Thus,	  we	  showed	  that	  doubling	  the	  protein	  content	  of	  
PLIN5	  upon	  electroporation	  coincided	  with	  a	  significant	  increase	  in	  OPA1	  content	  (Figure	  
3B).	   Titration	   of	   fatty-­‐acids	   to	   mitochondria	   isolated	   from	   the	   PLIN5	   overexpressing	  
muscles	   with	   simultaneous	   measurement	   of	   mitochondrial	   respiration	   suggest	   a	  
protective	  effect	  of	  PLIN5	  overexpression	  and	  concomitant	  increase	  of	  OPA1	  to	  fatty-­‐acid	  
induced	  uncoupling	  and	  lipotoxicity	  (Figure	  3C	  and	  D).	  
	  
Lipase	  activities	  and	  contents	  of	  ATGL	  and	  CGI-­‐58	  
Contents	  of	  the	  major	  triacylglycerol	  lipase	  ATGL	  and	  its	  indispensable	  co-­‐activator	  CGI58	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T2D,	  CGI58:	  1.09	  ±	  0.11	  and	  0.81	  ±	  0.10	  in	  C	  and	  T2D,	  Figure	  4A	  and	  B).	  Training	  tended	  to	  
increase	  ATGL	  content	  in	  T2D	  (towards	  1.70	  ±	  0.34,	  P=0.06,	  Figure	  4A),	  while	  this	  increase	  
was	   absent	   in	   C	   (0.73	   ±	   0.14	   vs.	   0.77	   ±	   0.20;	   P=0.85	   Figure	   4A,	   pre-­‐	   and	   post-­‐training,	  
respectively),	  hence	  ATGL	  content	  post-­‐training	  was	  significantly	  higher	  in	  T2D	  compared	  
to	  C	   (P=0.02).	  While	   content	  of	  CGI-­‐58	  was	  not	   significantly	   affected	  by	   training,	  CGI-­‐58	  
protein	  content	  post-­‐training	  was	  significantly	  lower	  in	  T2D	  than	  in	  C	  (P=0.03,	  Figure	  4B).	  
Moreover,	  the	  training-­‐induced	   increase	   in	  ATGL	  and	  PLIN5	  content	  correlated	  positively	  
with	  improvement	  in	  insulin	  mediated	  suppression	  in	  fat	  oxidation	  (r=0.364,	  P=0.048	  and	  
r=0.438,	   P=0.022,	   respectively)	   and	   negatively	   with	   the	   change	   in	   insulin-­‐stimulated	  
glucose	   oxidation	   (r=-­‐0.364,	   P=0.048	   and	   r=-­‐0.347,	   P=0.083,	   respectively),	   indicative	   of	  
improved	  metabolic	  flexibility.	  
	  
	  
Figure	  4.	  Protein	  expression	  of	  ATGL	  (A)	  and	  CGI-­‐58	  (B)	   in	   in	  vastus	   lateralis	  muscle,	  before	  (white	  
bars)	   and	   after	   training	   (black	   bars).	   Data	   are	   expressed	   as	  mean	   (in	   arbitrary	   units,	   AU)	   ±	   SEM.	  
*P<0.05.	  
	  
To	   examine	   if	   the	   response	   in	   PLINs,	   ATGL	   and	   CGI58	   translated	   in	   altered	   lipolytic	  
capacity,	   we	   performed	   ex	   vivo	   TAG	   and	   DAG	   hydrolase	   activity	   assays.	   TAG	   hydrolase	  
capacity	   pre-­‐training	  was	   similar	   in	   C	   and	   T2D	   (0.85	   ±	   0.16	   nmol/mg/h	   and	   0.90	   ±	   0.11	  
nmol/mg/h	   in	   C	   and	   T2D	   respectively;	   P=0.78,	   Figure	   5A).	   Interestingly,	   post-­‐training	  
lipolytic	  activity	  decreased	  similarly	  in	  both	  groups	  (towards	  0.59	  ±	  0.11	  nmol/mg/h	  in	  C;	  
P=0.03,	  and	  towards	  0.72	  ±	  0.10	  nmol/mg/h	   in	  T2D;	  P=0.048,	  Figure	  5A).	  DAG	  hydrolase	  
activity	  was	   comparable	  between	  groups	  before	   training	   (10.57	  ±	  1.47	  and	  12.08	  ±	  1.02	  
nmol/mg/h	  in	  C	  and	  T2D	  respectively;	  P=0.41,	  Figure	  5B)	  and	  was	  not	  significantly	  (P=0.13	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Figure	  5.	  TAG	  hydrolase	  (A)	  and	  DAG	  hydrolase	  (B)	  activity	  in	  vastus	  lateralis	  muscle,	  before	  (white	  
bars)	  and	  after	  training	  (black	  bars).	  Data	  are	  expressed	  as	  mean	  (in	  arbitrary	  units)	  ±	  SEM.	  *P<0.05.	  
	  
DISCUSSION	  
In	   light	   of	   our	   previous	   observations	   that	  myocellular	   overexpression	   of	   either	   PLIN2	  or	  
PLIN5	  resulted	  in	  massive	  accretion	  of	  fat	   in	  the	  muscle	  while	  maintaining	  muscle	  insulin	  
sensitivity	  [14,	  15]	  and	  the	  cross	  sectional	  observation	  that	  trained	  athletes	  have	  high	  LD	  
content	  with	  high	  PLIN5	   levels	  whilst	  being	  very	   insulin	  sensitive,	  we	  set-­‐out	  to	  measure	  
contents	  of	  proteins	  involved	  in	  LD	  assembly,	  maturation,	  localization	  and	  mobilization	  in	  
obese	   normoglycemic	   subjects	   and	   subjects	   with	   T2D.	   Moreover,	   we	   examined	   the	  
putative	   involvement	   of	   these	   proteins	   in	   metabolic	   flexibility	   and	   training	   mediated	  
improvements	  herein.	  As	  we	  previously	  observed	  that	  the	  quantity	  of	  LD	  coat	  proteins	  in	  
animal	   models	   tracked	   with	   the	   LD	   content	   [34]	   and	   LD	   content	   associates	   with	   BMI,	  
subjects	  were	  carefully	  matched	  for	  BMI.	  
Thus,	  we	  were	  able	   to	   show	  that	   in	   the	   face	  of	   similar	  myocellular	   LD	  content,	   the	  
protein	  content	  of	  the	  nascent	  LD	  coating	  protein	  PLIN3	  and	  of	  OPA1,	  a	  protein	  putatively	  
involved	   in	   facilitating	   LD	  mitochondrial	   interaction	   [33],	  were	   significantly	   lower	   in	   T2D	  
patients	   compared	   to	   obese	   normoglycemic	   control	   subjects	   (C).	  While	   training	   did	   not	  
affect	   abundance	   of	   proteins	   involved	   in	   LD	   assembly	   (FIT1,	   FIT2	   or	   FSP27),	   profound	  
increases	  in	  the	  perilipins	  (PLIN2,	  3	  and	  5)	  were	  observed	  in	  both	  C	  and	  T2D.	  Post-­‐training,	  
the	  major	  lipase	  ATGL	  was	  significantly	  higher	  in	  T2D	  compared	  with	  C.	  The	  proteins	  which	  
were	  down	  in	  T2D	  pre-­‐training	  (PLIN3	  and	  OPA1)	  restored	  to	  levels	  observed	  in	  C	  after	  the	  
training	   program.	   Ex	   vivo,	   these	   adaptations	   translated	   into	   a	   reduced	   TAG	   hydrolase	  
activity	   which	   occurred	   in	   face	   of	   improved	   insulin	   mediated	   glucose	   uptake	   and	  
metabolic	   flexibility	   in	   vivo.	   Correlative	   analyses	   underpin	   the	   suggestion	   that	   adaptive	  
induction	   of	   a	   LD	   program	   by	   exercise	   training	   contributes	   to	   the	   improvements	   in	  
substrate	  selection	  upon	  altered	  substrate	  availability	  and/or	  demand.	  	  
The	   observation	   that	   PLIN3	   is	   the	   only	   LD	   coat	   protein	  which	  was	   down	   in	   T2D	   is	  





















































in	  Hela	  cells	  prevents	  nascent	  LDs	  from	  maturation,	  hence	  sequestering	  of	  fatty-­‐acids	  (or	  
their	   insulin	   desensitizing	   derivatives)	   into	   LDs	   and	   maturation	   of	   LDs	   is	   blunted	   [35].	  
Training	  restored	  PLIN3	  content	  in	  T2D	  to	  levels	  similar	  to	  age-­‐	  and	  BMI	  matched	  control.	  
This	  adaptive	  response	  may	  facilitate	  the	  maturation	  of	  nascent	  LDs.	  
The	  essentially	  similar	  level	  of	  PLIN2	  and	  PLIN5	  in	  muscle	  from	  C	  and	  T2D	  patients	  is	  
compatible	   with	   previous	   findings	   from	   our	   lab	   [34].	   Given	   the	   lack	   of	   differences	   in	  
content	  of	  PLIN2	  and	  PLIN5,	  it	  is	  not	  likely	  that	  these	  proteins	  mediate	  flaws	  in	  fatty	  acid	  
sequestering	   or	   lipolytic	   control	   responsible	   for	   the	   obvious	   differences	   in	   insulin-­‐
mediated	  glucose	  uptake	  between	  C	  and	  T2D.	  On	  the	  other	  hand,	  we	  previously	  observed	  
that	  myocellular	  overexpression	  of	  either	  PLIN2	  or	  PLIN5	  both	  ameliorated	   lipid-­‐induced	  
insulin	   resistance	   [14,	   15].	   This	   indicates	   that	   augmenting	   PLIN2	   and	   PLIN5	   content	  
contributes	  to	  preserving	  muscle	  insulin	  sensitivity.	  	  
Although	  PLIN2	  and	  PLIN5	  are	  both	  present	  in	  muscle	  and	  share	  a	  high	  homology	  [6,	  
36],	   overexpression	   of	   either	   protein	   has	   differential	   effects.	   Evidently,	   overexpressing	  
PLIN2	   or	   PLIN5	   both	   result	   in	   increased	   myocellular	   LD	   content.	   Despite	   a	   profound	  
increase	  in	  LD	  content,	  PLIN2	  overexpression	  did	  not	  promote	  PLIN5	  content	  and	  inversely	  
PLIN5	  overexpression	  did	  not	  affect	  PLIN2	  content	  [14,	  15].	  Overexpressing	  PLIN2	  resulted	  
in	   a	   gene	   expression	   profile	   favoring	   efficient	   myocellular	   fat	   storage	   as	   triacylglycerol	  
rather	   than	   promoting	   fatty	   acid	   oxidation,	   while	   overexpression	   of	   PLIN5	   in	   muscle	  
promoted	  expression	  of	  a	  cluster	  of	  genes	  under	  control	  of	  PPARα	  and	  PGC1α	  involved	  in	  
fatty	  acid	  catabolism	  and	  mitochondrial	  oxidation	  [15].	  Recently,	  we	  reported	  that	  PGC1α,	  
a	  recognized	  player	  in	  mediating	  the	  adaptive	  response	  to	  exercise	  training,	  not	  only	  plays	  
a	  prominent	   role	   in	   regulating	  mitochondrial	  biogenesis	  and	  oxidative	  metabolism	  but	   is	  
also	   involved	   in	   orchestrating	   the	   response	   to	   exercise	   of	   a	   LD	  program.	  While	   in	   a	   cell	  
autonomous	   system,	  overexpression	  of	  PGC1α	  profoundly	   induced	  PLIN5	  but	  not	  PLIN2,	  
muscle	  specific	  overexpression	  of	  PGC1α	  in	  vivo	  promoted	  LD	  content	  with	  a	  concomitant	  
increase	  both	  PLIN2	  and	  PLIN5	  [18],	   suggesting	   joint	   regulation	  of	  PLIN2	  and	  PLIN5.	  This	  
suggestion	  is	  substantiated	  by	  our	  observation	  that	  training	   induced	  a	  similar	   increase	   in	  
PLIN2	  and	  PLIN5	  protein	  content	  in	  C	  and	  T2D	  and	  by	  the	  observation	  that	  the	  change	  in	  
these	  proteins	  correlated	  tightly.	  	  
Although	   the	   precise	   role	   of	   PLIN2	   and	   PLIN5	   in	  muscle	   remains	   to	   be	   elucidated,	  
overexpression	  of	  PLIN2	  reduces	  TAG	  hydrolase	  activity	  by	  inhibiting	  accessibility	  of	  ATGL	  
to	  the	  LD	  [9,	  37].	  ATGL,	  in	  turn,	  requires	  CGI58	  to	  exert	  its	  full	  lipolytic	  capacity	  [38].	  While	  
CGI58	   clearly	   is	   indispensable	   for	   LD	   lipolysis,	   levels	   of	   CGI58	   appeared	   not	   to	   be	   rate-­‐
limiting	   for	   either	   basal	   or	   stimulated	   lipolysis	   in	   mouse	   adipose	   tissue	   [39].	   Thus,	   the	  
decline	  we	  observed	   in	   TAG	  hydrolase	   activity	   in	   response	   to	   training	  matches	  with	   the	  
concomitant	  increase	  in	  PLIN2	  levels	  in	  C	  and	  T2D.	  While	  CGI58	  levels	  tended	  to	  be	  lower	  
in	   patients	  with	   T2D	   pre-­‐	   and	   posttraining,	   ATGL	   levels	  were	   significantly	   higher	   in	   T2D	  
than	  in	  C	  after	  the	  training	  program.	  The	  divergent	  response	  of	  ATGL	  to	  exercise	  training	  
in	   T2D	   compared	   to	   C	   may	   originate	   from	   the	   significant	   drop	   in	   insulin	   (a	   negative	  
regulator	  of	  ATGL	  expression	  [40])	  post-­‐training	  in	  T2D.	  	  
Perilipins	  in	  type	  2	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  muscle	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Data	   in	   exercising	   mice	   lacking	   ATGL	   in	   skeletal	   muscle	   indicate	   that	   ATGL	   is	  
obligatory	   to	   liberate	   fatty	   acids	   for	   mitochondrial	   oxidation	   from	   intramyocellular	   LD	  
during	  exercise	  [41,	  42].	  Interestingly,	  PLIN5	  has	  recently	  also	  been	  implicated	  in	  oxidative	  
lipolysis;	  PLIN5	  retains	   fatty	  acids	  within	  LD	  by	   inhibiting	   lipolysis	  under	  basal	  conditions	  
while	  upon	  stimulated	  LD	  lipolysis,	  fatty	  acids	  are	  released	  for	  oxidation	  [8,	  10,	  43].	  These	  
findings	  nicely	  match	  with	  our	  observation	  that	  pre-­‐exercise	  PLIN5	  content	  correlates	  with	  
training-­‐mediated	   increases	   in	   multiple	   structural	   components	   of	   the	   oxidative	  
phosphorylation	  system.	  Furthermore,	  PLIN5	  was	  shown	  to	   facilitate	   fatty	  acid	  oxidation	  
by	  recruiting	  mitochondria	  to	  LDs	  [32]	  possibly	  via	  OPA1	  [33]	  to	  reduce	  lipotoxic	  effects	  of	  
fatty	   acids.	   Thus,	   we	   examined	   OPA1	   content	   and	   fascinatingly	   observed	   significantly	  
reduced	  OPA1	  content	   in	  T2D	  which	  remarkably	  restored	  to	  control	   levels	  upon	  training.	  
Moreover,	  pre-­‐training	   levels	  of	  PLIN5	  correlated	  with	  OPA1,	  suggesting	  a	  functional	   link	  
between	   PLIN5	   and	   OPA1.	   Although	  we	   did	   not	   observe	   correlations	   between	   training-­‐
induced	  changes	   in	  markers	  of	  mitochondrial	  density	  and	  OPA1,	   it	   could	  be	  argued	   that	  
the	  change	  in	  OPA1	  after	  exercise	  training	  merely	  reflects	  mitochondrial	  density	  and	  is	  not	  
related	  to	  changes	  in	  PLIN5	  levels.	  Thus,	  by	  promoting	  PLIN5	  content	  in	  rat	  skeletal	  muscle	  
by	   gene	   electroporation	   we	   observed	   that	   a	   two-­‐fold	   increase	   in	   PLIN5	   content	  
significantly	   increased	   OPA1	   content	   without	   significant	   effects	   on	   mitochondrial	   mass,	  
indicating	   that	   PLIN5	   and	   OPA1	   may	   functionally	   interact	   to	   protect	   lipotoxicity	   if	   LD	  
lipolysis	  does	  not	  match	  mitochondrial	   fat	  oxidation.	  This	   is	   in	   line	  with	  our	  observation	  
that	   mitochondria	   isolated	   from	   PLIN5	   overexpressing	   muscle	   are	   less	   sensitive	   to	  
lipotoxicity.	   These	   observations	   may	   indicate	   that	   exercise	   training	   in	   C	   and	   T2D,	   by	  
promoting	   PLIN2	   and	   PLIN5	   content	   and	   restoring	   PLIN3	   and	   OPA1,	   results	   in	   a	   LD	  
phenotype	   characterized	   by	   increased	   capacity	   to	   sequester	   fatty	   acids	   in	   LD	  which	   are	  
shielded	   for	   uncontrolled	  basal	   lipolysis	   but	   at	   the	   same	   time	   are	   equipped	   to	   promote	  
oxidative	  LD	  lipolysis	  upon	  increased	  energy	  demand.	  
While	   we	   have	   no	   hard	   data	   on	   the	   functional	   consequences	   of	   these	   adaptive	  
responses	   in	   vivo,	   it	   is	   of	   interest	   to	   know	   that	   training-­‐induced	   increases	   in	   PLIN2	   and	  
changes	   in	   resting	   fat	   and	   carbohydrate	   oxidation	   rates	   correlate	   tightly,	   indicating	   that	  
PLIN2	   is	   somehow	   involved	   in	   substrate	   selection	   and	  may	   balance	   the	   release	   of	   fatty	  
acids	   from	   the	   LD	   with	   mitochondrial	   fat	   oxidation	   rates.	   Interestingly,	   putative	  
involvement	  of	  PLIN	  proteins	  in	  substrate	  switching	  extends	  to	  insulin-­‐mediated	  substrate	  
switching	   (metabolic	   flexibility)	   and	   the	   training-­‐induced	   improvement	  herein.	   Thus,	   the	  
increase	   in	   PLIN2	   and	   PLIN5	   content	   correlated	   positively	   with	   the	   training-­‐induced	  
improvement	   in	   insulin	   mediated	   suppression	   in	   fat	   oxidation	   and	   negatively	   with	   the	  
change	  in	  insulin-­‐stimulated	  glucose	  oxidation.	  	  
Altogether	   the	   present	   study	   shows	   that	   exercise	   training	   results	   in	   adaptive	  
responses	  in	  PLIN	  proteins,	  OPA1	  and	  ATGL,	  priming	  the	  muscle	  to	  increase	  lipolytic	  flux	  in	  
times	  of	  increased	  demand.	  At	  the	  same	  time	  these	  adaptive	  responses	  may	  contribute	  to	  
improved	   control	   on	   basal	   lipolysis	   and	   post-­‐prandial	   substrate	   selection.	   While	   pre-­‐
training	  data	  of	  the	  PLIN	  proteins	  or	  indices	  of	  muscle	  lipolysis	  indicate	  that	  these	  proteins	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are	  unlikely	  to	  have	  direct	  effects	  on	  reduced	  insulin	  sensitivity	   in	  T2D	  patients,	  training-­‐
mediated	   changes	   render	   a	   favourable	  myocellular	   LD	   phenotype	   facilitating	   changes	   in	  
substrate	  selection	  during	  submaximal	  exercise	  and	   improved	  metabolic	   flexibility	  under	  
insulin-­‐stimulated	  conditions,	  both	  of	  which	  are	  mediators	  of	  insulin	  sensitivity.	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The	  current	  obesity	  epidemic	  warrants	  further	  research	   into	  the	  mechanisms	   involved	   in	  
the	   etiology	   of	   obesity-­‐associated	   comorbidities	   like	   type	   2	   diabetes	   (T2D).	   Obesity	   is	  
associated	   with	   increased	   lipid	   supply	   to	   skeletal	   muscle	   and	   this	   intramyocellular	   lipid	  
(IMCL)	  accumulation	   correlates	  with	   insulin	   resistance	   in	   sedentary	  obese	   individuals	   [1,	  
2].	  Yet,	  the	  exact	  mechanistic	  link	  between	  IMCL	  accumulation	  and	  impairments	  in	  insulin	  
signaling	   is	  unclear	   (reviewed	   in	  chapter	  2).	   Skeletal	  muscle	   is	   the	   largest	   contributor	   to	  
glucose	   clearance	   in	   the	   postprandial	   state.	   Furthermore,	   insulin	   resistance	   in	   skeletal	  
muscle	  has	  been	  hypothesized	  to	  serve	  as	  underlying	  cause	  for	  hyperlipidemia	  and	  hepatic	  
steatosis	   [3,	   4].	   Elevated	   lipid	   supply,	   increased	   skeletal	   muscle	   fatty	   acid	   uptake,	  
disturbed	   lipid	   metabolism	   (lipid	   storage	   and	   lipid	   turnover)	   and	   reduced	   oxidative	  
capacity	  have	  been	  identified	  as	  underlying	  factors	  for	  the	  development	  of	  skeletal	  muscle	  
insulin	  resistance	  (reviewed	  in	  chapter	  2	  and	  [5,	  6]).	  Therefore,	  improvements	  in	  skeletal	  
muscle	  lipid	  handling	  may	  potentially	  result	  in	  improvements	  in	  insulin	  sensitivity.	  	  
Lipid	   droplets	   (LDs)	   serve	   as	   dynamic	   intramyocellular	   lipid	   depots.	   These	   lipid	  
reservoirs	   provide	   quickly	   accessible	   pools	   of	   substrates	   in	   periods	   of	   energy	   demand.	  
Moreover,	  LDs	  serve	  as	  storage	  depots	  for	  lipids	  needed	  as	  building	  blocks	  for	  membrane	  
synthesis	   [7]	   and	   bioactive	   lipids	   that	   function	   as	   intracellular	   messengers	   [8,	   9].	  
Therefore,	   impairments	   in	   LD	   dynamics	   affect	   many	   important	   intracellular	   metabolic	  
processes.	   LDs	   consist	   of	   a	   neutral	   lipid	   core	   surrounded	   by	   a	   phospholipid	  monolayer.	  
Sufficient	   provision	   of	   phospholipids	   is	   essential	   for	   LD	   synthesis	   and	   growth	   [10].	   The	  
phospholipid	  monolayer	   is	  decorated	  with	  proteins.	  These	  LD	  coat	  proteins	  modulate	  LD	  
dynamics,	  including	  LD	  synthesis	  and	  degradation,	  motility	  and	  interorganelle	  interactions	  
[11,	   12].	   Furthermore,	   LD	   coat	   proteins	   regulate	   lipid	   metabolism.	   The	   discovery	   of	  
proteins	   in	   the	  LD	  coat	  as	  modulators	  of	   lipid	  storage	  and	  metabolism	   [13]	  opened	  new	  
doors	   for	   research	   into	  mechanisms	   involved	   in	   lipid-­‐induced	   insulin	   resistance	  and	  may	  
provide	  targets	  for	  intervention.	  
The	  aim	  of	  the	  research	  presented	  in	  this	  thesis	  was	  to	  investigate	  the	  role	  of	  the	  LD	  
coat	   proteins	   perilipin	   (PLIN)	   2	   and	   5	   in	   skeletal	   muscle	   lipid	   metabolism	   and	   insulin	  
resistance.	  In	  this	  chapter	  the	  results	  are	  interpreted	  and	  discussed	  in	  the	  light	  of	  recent	  
advances	   in	   the	   field.	   The	   following	   research	   questions	  will	   be	   discussed:	   (9.1)	   does	   an	  
increased	  capacity	   for	   intramyocellular	  neutral	   lipid	  storage	  protect	  against	   lipid-­‐induced	  
insulin	   resistance?;	   (9.2)	   are	   the	   lipid	   droplet	   coat	   proteins	   PLIN2	   and	  PLIN5	   involved	   in	  
neutral	   lipid	   storage	   in	   skeletal	   muscle?;	   (9.3)	   are	   PLIN2	   and	   PLIN5	   involved	   in	   the	  
regulation	  of	  oxidative	  fatty	  acid	  metabolism?;	  and	  (9.4)	  does	  a	  higher	  availability	  of	  PLINs	  
protect	   against	   lipid-­‐induced	   insulin	   resistance?.	   General	   conclusions	   and	   future	  
perspectives	  are	  presented	  in	  paragraph	  9.5.	  
	  
9.1	  Neutral	  lipid	  storage	  versus	  lipid	  intermediate	  accumulation	  
On	  the	  basis	  of	  chemical	  classification,	  neutral	  lipids	  encompass	  TAG,	  diacylglycerol	  (DAG)	  
and	  cholesterol(-­‐esters).	  The	  LD	  is	  the	  main	  storage	  site	  for	  neutral	  lipids.	  TAG	  is	  the	  inert	  
storage	   form	   for	   lipids	   and	   is	   the	   major	   storage	   form	   for	   lipids	   in	   LDs	   [14].	   The	   data	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presented	  in	  chapter	  3	  show	  that	   individuals	  with	  a	   larger	   increase	  in	  storage	  of	   IMCL	  in	  
LDs	   after	   a	   prolonged	   fast	   become	   less	   insulin	   resistant.	   This	   suggests	   that	   under	   acute	  
conditions	  of	  high	  lipid	  supply	  an	  increased	  storage	  of	  neutral	  lipids	  protects	  against	  lipid-­‐
induced	   insulin	   resistance.	   Furthermore,	   a	   lower	   incorporation	   of	   fatty	   acids	   (FAs)	   into	  
neutral	   lipids	  was	   shown	   in	   skeletal	  muscle	   from	  obese	   T2D	   compared	   to	   BMI-­‐matched	  
controls	   both	  ex	   vivo	   and	   in	   vitro	   (chapter	   4).	  Myotubes	   established	   from	   satellite	   cells	  
mainly	   reflect	   the	  profile	  of	   the	  donor.	  Therefore,	   the	   fact	   that	   this	   reduced	  capacity	   to	  
store	  FAs	  as	  neutral	  lipids	  is	  retained	  in	  vitro	  suggests	  that	  neutral	  lipid	  storage	  capacity	  is	  
an	   intrinsic	  characteristic	  of	  muscle	  cells	  and	  may	  be	  considered	  one	  of	  the	  explanations	  
for	   the	   fact	   that	  not	  all	   (severely)	  obese	   subjects	  develop	   insulin	   resistance	   [15].	  Hence,	  
expanding	   the	   neutral	   lipid	   storage	   capacity	   in	   skeletal	   muscle	   may	   be	   a	   strategy	   to	  
prevent	  obesity-­‐associated	  insulin	  resistance.	  
In	  chapter	  8	  we	  show	  that	  a	  12-­‐week	  training	  program	  in	  type	  2	  diabetic	  individuals	  
improves	   insulin	   sensitivity	   in	   parallel	  with	  modestly	   increased	   IMCL	   storage,	   consistent	  
with	  the	  paper	  of	  Dubé	  et	  al.	  [16],	  in	  which	  it	  was	  furthermore	  reported	  that	  the	  increased	  
IMCL	  storage	  upon	  training	  mainly	  consisted	  of	  TAG	  storage	  [16].	  This	  is	  in	  harmony	  with	  
earlier	  reports	  describing	  the	  athlete’s	  paradox:	  endurance-­‐trained	  athletes	  have	  elevated	  
IMCL	  levels,	  despite	  being	  highly	  insulin	  sensitive	  [2,	  17].	  By	  use	  of	  in	  vivo	  infusion	  of	  13C-­‐
palmitate,	  Bergman	  et	  al.	   [18]	   showed	   that	  palmitate	   incorporation	   into	   skeletal	  muscle	  
TAG	   was	   increased	   in	   endurance	   trained	   athletes	   compared	   with	   sedentary	   controls.	  
Further	   support	   for	   the	   proposed	   beneficial	   role	   for	   the	   neutral	   lipid	   storage	   capacity	  
came	  from	  Schenk	  et	  al.	  [19],	  who	  showed	  that	  one	  exercise	  session	  protects	  against	  lipid-­‐
induced	  insulin	  resistance	  by	  channeling	  FAs	  towards	  TAG	  synthesis	  [19].	  Collectively,	  the	  
findings	  reported	  in	  this	  thesis	  and	  earlier	  and	  more	  recent	  literature	  in	  this	  area	  indicate	  
that	  IMCL	  accumulation	  is	  not	  per	  se	  detrimental	  and	  that	  a	  high	  capacity	  to	  channel	  FAs	  
towards	   intramyocellular	   neutral	   lipid	   storage	   protects	   against	   lipid-­‐induced	   insulin	  
resistance.	  	  
Besides	  storage	  of	  FAs	   in	  the	  form	  of	   inert	  TAG,	  FAs	  can	  accumulate	   in	  the	  form	  of	  
lipid	  intermediates	  like	  FA-­‐CoA,	  acylcarnitines,	  ceramides	  and	  diacylglycerol	  (DAG).	  Animal	  
and	  cell	  studies	  demonstrated	  that	  these	  lipid	  intermediates	  have	  the	  potential	  to	  induce	  
insulin	   resistance,	   but	   human	   studies	   show	   conflicting	   and	   merely	   correlative	   results	  
(reviewed	  in	  chapter	  2).	  Moreover,	  interventions	  that	  result	  in	  elevated	  lipid	  intermediate	  
accumulation	  do	  not	  necessarily	  result	   in	   insulin	  resistance.	  For	  example,	  we	  (chapter	  5)	  
and	   others	   [20]	   have	   shown	   that	   interventions	   that	   are	   associated	   with	   increased	  
ceramide	   levels	   do	  not	   necessarily	   impair	   insulin	   sensitivity.	   The	   results	   reported	   in	   this	  
thesis	  mainly	  reflect	  a	  beneficial	  role	  for	  neutral	  lipid	  storage	  in	  LDs	  in	  general,	  rather	  than	  
that	   levels	   of	   individual	   lipid	   species	   would	   determine	   insulin	   resistance.	   For	   example,	  
skeletal	   muscle	   of	   T2D	   subjects	   did	   not	   show	   an	   increased	   channeling	   of	   FAs	   towards	  
accumulation	  in	  the	  form	  of	  DAG	  when	  compared	  to	  BMI-­‐matched	  controls.	  Furthermore,	  
muscle	  cells	  from	  obese	  nondiabetic	  donors	  showed	  increased	  channeling	  of	  FAs	  towards	  
the	   total	   neutral	   lipid	   pool	   which	   could	   not	   solely	   be	   accounted	   for	   by	   the	   increased	  
channeling	   towards	   TAG	   (chapter	   4).	   An	   important	  question	   to	  be	   answered	   is	  whether	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lipid	   intermediates	   stored	   in	   the	   LD	   (as	   opposed	   to	   lipid	   intermediates	   stored	   in/near	  
cellular	  and	  organellar	  membranes)	  can	  affect	  cellular	  function.	  In	  order	  to	  interfere	  with	  
insulin	   signaling,	   lipid	   intermediates	   in	   the	   LD	   should	   be	   capable	   of	   activating	   a	   second	  
messenger	   that	   will	   translocate	   to	   the	   plasma	   membrane	   to	   interfere	   with	   insulin	  
signaling.	   This	   phenomenon	   was	   recently	   described	   for	   DAG-­‐induced	   insulin	   resistance	  
[21].	  However,	  further	  support	  for	  this	  hypothesis	   is	   lacking	  and	  the	  question	  arises	  how	  
lipids	   in	   the	   LD	   can	   pass	   through	   the	   phospholipid	   monolayer	   to	   activate	   the	   second	  
messenger.	   Furthermore,	   this	   hypothesis	   contrasts	   with	   the	   findings	   of	   Bergman	   et	   al.	  
[22],	  who	  demonstrated	   that	  DAG	  accumulation	   in	   the	  membranes	  was	   associated	  with	  
insulin	   resistance.	   Furthermore,	   it	   was	   shown	   that	   athletes	   have	   higher	   DAG	   levels	  
compared	   to	   sedentary	   controls	   [23],	   but	   that	   athletes	   accumulate	   less	   DAG	   in/near	  
membranes	   [22],	   indicating	   that	   not	   DAG	   accumulation	   in	   LDs	   but	   accumulation	   in	   the	  
membrane	  is	   linked	  to	   insulin	  resistance.	  Additionally,	   it	  was	  recently	  demonstrated	  that	  
1,2-­‐DAG,	   the	  DAG-­‐isoform	   that	   activates	   PKCs	   thereby	   impairing	   insulin	   signaling,	   is	   not	  
produced	  by	  lipolysis	  [24].	  Therefore,	  DAG	  released	  from	  the	  LD	  by	  lipolysis	  is	  an	  unlikely	  
candidate	  to	  activate	  PKCs.	  Because	  of	  the	  inconsistencies	  [25]	  and	  the	  scarce	  information	  
available,	   further	   studies	   on	   lipid	   intermediate	   subspecies	   and	   their	   intracellular	  
localization	  are	  warranted.	  	  
In	   general,	   lipid	   intermediate	   levels	   are	   merely	   snap-­‐shots	   of	   highly	   complex	   and	  
dynamic	  processes.	  These	  lipid	  intermediates	  are	  important	  intracellular	  messengers	  and	  
are	   precursors	   for	   membrane	   lipids	   [26-­‐29].	   Therefore,	   increases	   in	   lipid	   intermediate	  
levels	   may	   represent	   increased	   lipid	   turnover	   and	   activation	   of	   intracellular	   signaling	  
pathways.	  Furthermore,	  one	  may	  speculate	  that	   lipid	   intermediate	  storage	  in	  the	  LD	  -­‐	  as	  
opposed	  to	  accumulation	   in	  cellular	  and	  organellar	  membranes	   -­‐	  will	   reduce	   its	   lipotoxic	  
potential.	  Likewise,	  numerous	  studies	  have	  shown	  that	   lipid	   intermediate	  build-­‐up	   is	  not	  
necessarily	   detrimental	   (reviewed	   in	   chapter	   2).	   On	   the	   other	   hand,	   a	   disbalance	   in	  
skeletal	  muscle	   lipid	   influx,	   lipid	  metabolism	  and	  oxidative	   capacity	  may	   result	   in	  excess	  
lipid	  intermediate	  accumulation	  ultimately	  resulting	  in	  the	  development	  of	  lipotoxicity	  and	  
insulin	   resistance.	   Restoring	   this	   balance	   is	   advantageous	   and	   may	   involve	   creation	   of	  
neutral	  lipid	  storage	  depots.	  Approaches	  to	  increase	  neutral	  lipid	  storage	  capacity	  include	  
increasing	  the	  channeling	  of	  FAs	  towards	  neutral	   lipid	  synthesis,	   inhibiting	  (uncontrolled)	  
lipolysis,	  and	  expanding	  the	  storage	  space	  by	  increasing	  LD	  number,	  -­‐size	  and/or	  stability.	  	  
	  
9.2	  The	  role	  of	  PLIN2	  and	  PLIN5	  in	  intramyocellular	  neutral	  lipid	  storage	  
9.2.1	  Lipid	  droplet	  coat	  proteins	  in	  skeletal	  muscle	  
A	  unique	   characteristic	   of	   LDs	   in	   comparison	  with	   other	   organelles	   is	   the	   fact	   that	   cells	  
harbor	   a	   heterogeneous	   population	   of	   LDs	   with	   different	   metabolic	   fates	   and	   hence	  
varying	   proteins	   in	   the	   LD	   coat.	  While	   the	   skeletal	  muscle	   LD	   proteome	   contains	  more	  
than	  300	  different	  proteins	  [30],	  little	  is	  known	  to	  date	  about	  the	  function	  of	  the	  individual	  
LD	  proteins	   in	  skeletal	  muscle.	  The	  perilipin	   (PLIN)	  protein	   family	  was	   the	   first	   identified	  
family	   of	   LD	   coat	   proteins	   [13].	   PLIN2	   and	   PLIN5	   are	   abundantly	   expressed	   in	   skeletal	  
muscle	  [31-­‐35],	  but	  information	  on	  their	  function	  is	  still	  limited.	  The	  research	  presented	  in	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this	  thesis	  advances	  the	  knowledge	  on	  the	  function	  of	  PLIN2	  and	  PLIN5	  in	  skeletal	  muscle.	  
PLIN2	   is	   an	   LD	   coat	   protein	   expressed	   in	   the	  majority	   of	   nonadipose	   tissues	   [36,	   37].	   In	  
human	   skeletal	   muscle	   about	   60%	   of	   the	   LDs	   are	   coated	   with	   PLIN2	   [32].	   PLIN5	   is	  
expressed	   in	   tissues	   with	   a	   high	   fat	   oxidative	   capacity,	   including	   brown	   adipose	   tissue,	  
heart	   and	   skeletal	   muscle	   [38,	   39].	   PLIN2	   expression	   is	   strongly	   induced	   in	   vitro	   by	  
increased	   FA	   supply	   (chapter	   5	   and	   [40-­‐42].	   PLIN2	   protein	   content	   increased	   with	   FA	  
loading	   of	   myotubes	   and	   with	   in	   vivo	   interventions	   in	   mice	   that	   increase	   IMCL	   levels	  
(consumption	  of	  a	  high	  fat	  diet	  and	  fasting)	  (chapter	  5).	  Contrastingly,	  PLIN5	  is	  expressed	  
at	   very	   low	   levels	   in	   cultured	   cells	   exposed	   to	   FAs	   and	   high	   fat	   feeding	   increases	   PLIN5	  
expression	  only	  modestly	  in	  skeletal	  muscle	  [39].	  Both	  PLIN2	  and	  PLIN5	  contain	  a	  PPRE	  in	  
their	  promotor	   region	  and	  hence	  are	  PPAR	   target	  genes	   [41,	  43-­‐45].	   In	  hepatocytes	  and	  
macrophages,	   induction	  of	  PLIN2	  expression	  by	  unsaturated	  FAs	  requires	  both	  PPAR	  and	  
AP-­‐1	  activation	   [41,	  46].	   Similarly,	   an	  oral	   gavage	  with	   the	  PPARα	   agonists	  Wy14,643	  or	  
fenofibrate	   induced	  PLIN5	  but	  not	  PLIN2	  expression	   in	  mouse	  skeletal	  muscle	   (Appendix	  
1).	   Thus,	   PLIN5	   is	   a	   PPARα	   target	   gene	   in	   skeletal	  muscle	   (Appendix	   1	   and	   [39]),	   PLIN2	  
expression	  in	  skeletal	  muscle	  is	  mainly	  induced	  by	  increased	  supply	  of	  (unsaturated)	  FAs,	  
which	  is	  partly	  mediated	  by	  PPAR	  signaling.	  The	  role	  of	  PLIN2	  and	  PLIN5	  in	  skeletal	  muscle	  
lipid	  metabolism	  is	  discussed	  below.	  
	  
9.2.2	  PLIN2	  and	  intramyocellular	  lipid	  storage	  
In	   chapter	   5	   we	   show	   that	   PLIN2	   is	   essential	   for	   intramyocellular	   TAG	   accumulation.	  
Knockdown	  of	  PLIN2	  prevented	  oleate-­‐induced	  intramyocellular	  TAG	  accumulation	  and	  LD	  
storage.	   In	   the	   absence	   of	   PLIN2,	   LD	   accumulation	   was	   restricted	   to	   a	   few	   LDs	   per	  
myotube.	   Moreover,	   overexpression	   of	   PLIN2	   in	   vitro	   and	   in	   vivo	   resulted	   in	   elevated	  
neutral	   IMCL	   levels.	  These	  data	   indicate	  that	  PLIN2	   is	   involved	   in	  LD	  synthesis	  and/or	  LD	  
stability	   and	  neutral	   lipid	   (TAG)	   storage.	   Consistently,	   Bell	   et	   al.	   [47]	   showed	   that	   PLIN2	  
knockdown	  in	   liver	  cells	  decreased	  LD	  number.	  The	  fundamental	  role	  of	  PLIN2	  in	  neutral	  
lipid	  storage	  has	  been	  firmly	  established	  in	  a	  range	  of	  in	  vivo	  and	   in	  vitro	  studies	  [47-­‐53].	  
Furthermore,	   it	  was	   suggested	   that	  PLIN2	  might	  be	   involved	   in	  budding	  of	   LDs	   from	  the	  
endoplasmic	   reticulum	   [54].	   Moreover,	   PLIN2	   overexpression	   increased	   expression	  
profiles	  of	  genes	   involved	   in	   lipid	  synthesis	   (chapter	  5),	   consistent	  with	   findings	   in	  other	  
models	  [55]	  and	  indicating	  that	  PLIN2	  builds	  fat	  stores.	  In	  addition,	  PLIN2	  overexpression	  
was	  shown	  to	  be	  associated	  with	   increased	  FA	  uptake	   [56],	  while	  PLIN2	  knockdown	  was	  
paralleled	  with	  decreased	  FA	  uptake	   [51].	  We	  did	  not	  observe	  changes	   in	   short-­‐term	  FA	  
uptake	  rates	  upon	  PLIN2	  knockdown	  and	  overexpression	  (Appendix	  2),	  arguing	  against	  a	  
direct	  role	  for	  PLIN2	   in	  FA	  uptake.	  On	  the	  other	  hand,	  total	   incorporation	   into	   lipids	  was	  
lower	   in	   the	   PLIN2	   knockdown	   cells,	   while	   FA	   oxidation	   only	   tended	   to	   be	   modestly	  
increased	  (chapter	  5).	  This	  may	  indicate	  that	  feedback	  mechanisms	  exist	  that	  synchronize	  
lipid	  storage	  capacity	  with	  FA	  uptake	  in	  the	  longer	  term.	  	  
Besides	   influencing	   lipid	   synthesis	   and	   storage,	   modulation	   of	   lipolysis	   is	   an	  
alternative	   way	   of	   influencing	   IMCL	   storage	   and	   lipid	   (intermediate)	   accumulation.	   The	  
results	   presented	   in	   chapter	   5	   indicate	   that	   PLIN2	   is	   involved	   in	   both	   lipid	   (droplet)	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synthesis	   and	   inhibition	  of	   lipolysis.	   Consistently,	   PLIN2	  was	   shown	   to	   inhibit	   lipolysis	   in	  
several	  cell	  models	   [47,	  57,	  58].	  Nonetheless,	  ATGL-­‐inhibition	  by	  the	  compound	  BEL	  was	  
not	   sufficient	   to	   restore	  TAG	   levels	  upon	  oleate	   incubation	   (Appendix	  3),	   indicating	   that	  
PLIN2-­‐mediated	   IMCL	  accumulation	   is	  not	   solely	  mediated	  by	  a	  decrease	   in	   lipolysis	  and	  
that	  PLIN2	  availability	  is	  essential	  for	  TAG	  storage.	  Shepherd	  et	  al.	  [34]	  showed	  that	  PLIN2-­‐
associated	  lipid	  droplets	  were	  preferentially	  depleted	  upon	  acute	  exercise	  [34].	  Moreover,	  
PLIN2	   was	   shown	   to	   colocalize	   with	   and	   bind	   to	   CGI-­‐58	   [59,	   60]	   and	   HSL	   [61].	   HSL	  
translocates	   to	   PLIN2-­‐coated	   LDs	   upon	   muscle	   contraction	   [62].	   Therefore,	   the	   energy	  
demand	  may	  govern	  whether	  PLIN2	  inhibits	  lipolysis.	  The	  findings	  described	  in	  this	  thesis	  
in	   combination	  with	   relevant	   literature	   indicate	   that	   PLIN2	   is	   an	   important	   facilitator	   of	  
IMCL	   storage	   by	   influencing	   both	   LD	   storage	   and	   stability	   as	   well	   as	   (uncontrolled)	  
lipolysis.	  	  
	  
9.2.3	  PLIN5	  and	  intramyocellular	  lipid	  accumulation	  
Consistent	   with	   the	   effects	   of	   PLIN2,	   PLIN5	   overexpression	   resulted	   in	   elevated	   neutral	  
lipid	  content	  mainly	  consisting	  of	  TAG	  (chapter	  7).	  This	  is	  consistent	  with	  findings	  in	  other	  
cell	  types	  [39,	  63,	  64].	  It	  remains	  unclear	  exactly	  which	  mechanisms	  explain	  the	  increased	  
IMCL	  accumulation	  upon	  PLIN5	  overexpression	  (chapters	  6	  and	  7).	  The	  increased	  LD	  size	  
and	   TAG	   storage	   upon	   PLIN5	   overexpression	   (chapter	   7)	  may	   serve	   as	   an	   indication	   for	  
inhibition	   of	   lipolysis	   by	   PLIN5.	   Likewise,	   PLIN5	   was	   described	   to	   inhibit	   lipolysis	   under	  
basal	  conditions	  in	  heart	  and	  liver	  [59,	  63,	  65].	  On	  the	  other	  hand,	  PLIN5	  was	  shown	  to	  be	  
essential	   for	  ATGL-­‐mediated	   lipolysis	   [64,	  66]	  and	  was	  demonstrated	   to	   stimulate	  ATGL-­‐
mediated	   lipolysis	   in	   hepatocytes	   specifically	   upon	  PKA	   stimulation	   [59].	   This	  may	   imply	  
that	  the	  higher	  availability	  of	  both	  PLIN5	  and	  ATGL	  upon	  PLIN5	  overexpression	  (chapter	  7)	  
results	  in	  a	  higher	  lipolytic	  capacity	  in	  conditions	  of	  increased	  energy	  demand.	  Therefore,	  
the	   function	   of	   PLIN5	   in	   regulating	   lipolysis	   in	   skeletal	   muscle	   appears	   complex	   and	  
deserves	   further	   attention.	   Additionally,	   the	   increased	   TAG	   storage	   upon	   PLIN5	  
overexpression	  presumably	  does	  not	  solely	  result	  from	  inhibition	  of	  lipolysis.	  It	  was	  shown	  
in	  liver	  cells	  that	  PLIN5	  overexpression	  increased	  the	  incorporation	  of	  palmitate	  into	  TAG	  
[67].	  Furthermore,	   in	  our	   in	  vivo	  gene	  electroporation	  studies,	  gene	  expression	  of	  the	  FA	  
transporter	   CD36	   was	   increased	   1.5-­‐fold	   upon	   PLIN5	   overexpression.	   Moreover,	   PLIN5	  
overexpression	  resulted	  in	  increased	  expression	  of	  genes	  under	  control	  of	  PGC1α	  (chapter	  
7).	  PGC1α	  activation	  is	  known	  to	  stimulate	  both	  oxidative	  capacity	  and	  IMCL	  synthesis	  [68-­‐
71].	   Therefore,	   PLIN5	   is	   likely	   to	   be	   involved	   in	   the	   induction	   of	   a	   feed-­‐forward	   loop,	  
increasing	  both	   lipid	   storage	  and	   the	   capacity	   to	   liberate	  and	  oxidize	   FA.	   The	   regulatory	  
role	  of	  PLIN5	  in	  FA	  oxidative	  metabolism	  is	  discussed	  below.	  	  
	  
9.3	  PLINs	  2	  and	  5	  &	  oxidative	  capacity	  
9.3.1	  PLIN5	  and	  interorganelle	  interactions	  
Classical	   studies	   in	   the	   sixties	   [72]	   and	   seventies	   [73]	   already	   showed	   interaction	  of	   LDs	  
with	   mitochondria	   in	   skeletal	   muscle.	   More	   recent	   publications	   indicated	   that	   the	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proteome	  of	   isolated	   LDs	   contains	  many	  mitochondrial	   proteins,	  which	   provides	   further	  
support	   for	   regular	   interactions	  between	   these	  cellular	  organelles	   [30,	  74].	  Nonetheless,	  
little	  is	  known	  about	  how	  these	  interactions	  are	  regulated.	  The	  close	  proximity	  of	  LDs	  and	  
mitochondria	   facilitates	   shuttling	   of	   FAs	   towards	   mitochondrial	   oxidation,	   thus	  
maintaining	   low	   cellular	   concentrations	   of	   FAs,	   which	   are	   potentially	   toxic.	   Training	  
increases	  the	  number	  of	  LDs	  in	  contact	  with	  mitochondria	  [75].	  Additionally,	  older	  adults	  
have	   larger	   intramyocellular	   LDs,	   fewer	  mitochondria,	   and	   a	   lower	   proportion	   of	   LDs	   in	  
contact	  with	  mitochondria	  [76].	  In	  chapter	  6	  we	  show	  that	  PLIN5	  localizes	  to	  both	  LDs	  and	  
mitochondria.	  PLIN5	  overexpression	  resulted	  in	  more	  intimate	  interactions	  between	  these	  
two	   organelles;	   almost	   all	   LDs	   in	   PLIN5	   overexpressing	   muscle	   were	   in	   contact	   with	  
mitochondria.	  Mitochondria	  in	  PLIN5	  overexpressing	  muscle	  sometimes	  even	  appeared	  to	  
envelop	   the	  LD	   (chapter	  6).	   It	   should	  however	  be	  noted	   that	   this	   is	  a	  qualitative	   finding	  
based	  on	  ultrastructural	  analysis	  by	  electron	  microscopy.	  Yet,	  consistent	  with	  our	  findings,	  
Wang	   et	   al.	   [67]	   demonstrated	   that	   PLIN5	   recruits	  mitochondria	   to	   the	   LD	   surface	   in	   a	  
range	  of	  different	   cell	   types	  and	   that	  mitochondria	   in	   interaction	  with	  PLIN5-­‐coated	  LDs	  
are	  not	  as	  mobile	  and	  dynamic	  as	  mitochondria	  in	  cells	  with	  PLIN2-­‐coated	  LDs,	  providing	  
further	  support	  for	  the	  notion	  that	  PLIN5	  is	  involved	  in	  interactions	  between	  mitochondria	  
and	  LDs.	  Using	   immunogold	  electron	  microscopy,	  we	   showed	   that	  PLIN5	  was	  present	  at	  
the	   interface	   of	   LDs	   with	   mitochondria	   as	   well	   as	   in	   the	   mitochondria	   (chapter	   6).	   FA	  
oxidation	   was	   improved,	   indicating	   that	   these	   more	   intimate	   interactions	   between	   LDs	  
and	  mitochondria	  do	  not	  negatively	  impact	  on	  mitochondrial	  function.	  Further	  research	  is	  
warranted	   to	   study	   the	   function	   of	   PLIN5	   in	   interactions	   of	   mitochondria	   with	   LDs,	  
primarily	   the	   exact	   localization	   of	   PLIN5	   (inner-­‐	   or	   outermitochondrial	   membranes	   or	  
matrix)	  and	  its	  interaction	  partners.	  PLIN5	  was	  shown	  to	  form	  homo-­‐oligomers	  [64].	  One	  
may	   speculate	   that	   the	   formation	   of	   oligomeric	   protein	   complexes,	   by	   interactions	  
between	  PLIN5	  molecules	  on	  LDs	  and	  mitochondria	  is	  important	  for	  interactions	  between	  
LDs	  and	  mitochondria.	  Furthermore,	   the	   interactions	  with	   lipolytic	  enzymes,	  would	   then	  
ensure	   that	   lipases	   are	   targeted	   to	   the	   right	   subcellular	   location	   hence	   ensuring	   lipid	  
delivery	  at	  the	  right	  place	  and	  preventing	  unnecessary	  FA-­‐intermediate	  accumulation.	  	  	  
	  
9.3.2	  PLINs	  and	  oxidative	  capacity	  
PLIN5	   is	  expressed	   in	   tissues	  with	  a	  high	   fat	  oxidative	  capacity,	   including	  brown	  adipose	  
tissue,	  heart	  and	  skeletal	  muscle	  [38,	  39].	  Furthermore,	  PLIN5	  overexpression	  in	  vitro	  was	  
shown	   to	   increase	   FA	   oxidation	   [39].	   In	   chapter	   6	   we	   show	   that	   PLIN5	   correlates	   with	  
markers	   for	   oxidative	   capacity,	   including	   mitochondrial	   function	   and	   mitochondrial	  
density.	   The	   latter	   was	   confirmed	   by	   Peters	   et	   al.	   [77]	   and	   indicates	   that	   increased	  
abundance	  of	  PLIN5	  is	  associated	  with	  improved	  oxidative	  capacity.	  Recently,	  Kuramoto	  et	  
al.	   [65]	  described	   the	  phenotype	  of	  PLIN5	  knockout	  mice.	  These	  mice	   lacked	  detectable	  
LDs	   in	   the	   heart,	   LDs	   in	   skeletal	   muscle	   were	   smaller	   and	   less	   abundant	   compared	   to	  
wildtype	  mice.	  Cultured	  cardiomyocytes	  from	  PLIN5	  knockout	  mice	  showed	  a	  higher	  rate	  
of	   FA	   oxidation,	   but	   this	   likely	   reflects	   compensation	   for	   the	   lack	   of	   LD	   stability	   and	  
storage	  capacity	  as	  a	  result	  of	  the	  increased	  lipase	  activity.	  Yet,	  the	  increased	  FA	  oxidation	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was	   associated	   with	   increased	   accumulation	   of	   acid	   soluble	   metabolites	   (metabolites	  
originating	   from	   β-­‐oxidation	   and	   the	   TCA-­‐cycle)	   and	   reactive	   oxygen	   species	   as	   well	   as	  
impaired	  cardiac	  function	  [65].	  In	  chapter	  6	  we	  show	  that	  PLIN5	  overexpression	  in	  tibialis	  
anterior	  muscle	  was	  associated	  with	  increased	  complete	  FA	  oxidation	  towards	  CO2	  in	  the	  
absence	   of	   an	   increased	   accumulation	   of	   acid	   soluble	   metabolites,	   indicating	   that	   an	  
increased	  abundance	  of	  PLIN5	  results	  in	  improved	  FA	  oxidation.	  	  
Furthermore,	   PLIN5	   overexpression	   resulted	   in	   a	   transcriptomic	   profile	   suggesting	  
improved	   oxidative	   capacity	   (chapter	   7).	   In	   normal	   physiology,	   ectopic	   lipid	   storage,	  
lipolysis	  and	  β-­‐oxidation	  are	  well	  coupled	  thus	  preventing	  lipid	  intermediate	  build-­‐up	  [78].	  
Type	   2	   diabetes	   development	   is	   associated	   with	   reduced	   oxidative	   capacity	   [79].	  
Moreover,	   strategies	   that	   improve	   skeletal	  muscle	   oxidative	   capacity	   and	  mitochondrial	  
function	   improve	   insulin	  sensitivity	   [80-­‐82].	   Interestingly,	   strategies	   to	   improve	  oxidative	  
capacity	   in	   skeletal	  muscle	   usually	   go	   hand	   in	   hand	  with	   increased	   neutral	   lipid	   storage	  
[68-­‐70,	   81].	   This	   indicates	   that	   storage	  of	   lipids	   in	   LDs	  and	  downstream	  metabolism	  are	  
highly	  interrelated	  and	  share	  regulatory	  processes.	  The	  major	  regulator	  of	  skeletal	  muscle	  
oxidative	   capacity	   is	   the	   transcriptional	   coactivator	   PGC1α	   [83],	   which	   is	   exercise-­‐
responsive	  and	  regulates	  both	  mitochondrial	  FA	  oxidative	  capacity	  and	  LD	  dynamics	  [71].	  
PLIN2	  and	  PLIN5	  are	  induced	  upon	  PGC1α	  activation	  [71].	  The	  induction	  of	  PLIN2	  is	  likely	  
to	  be	  solely	  associated	  –	  either	  regulatory	  or	  as	  a	  consequence	  of	  increased	  PLIN2	  stability	  
by	   increased	   lipid	   storage	  –	  with	   the	   expansion	  of	   the	   lipid	   stores	  upon	   training/PGC1α	  
activation,	  since	  we	  do	  not	  have	  any	  indications	  for	  involvement	  of	  PLIN2	  in	  FA	  oxidative	  
metabolism.	   Interestingly,	   we	   show	   in	   chapter	   7	   that	   PLIN5	   overexpression	   promoted	  
expression	   of	   a	   cluster	   of	   genes	   under	   control	   of	   PPARs/PGC1α,	   indicative	   of	   a	   feed-­‐
forward	  loop	  of	  PGC1α-­‐activation	  by	  a	  downstream	  target.	  It	  remains	  unclear	  how	  PLIN5	  
overexpression	  leads	  to	  increased	  expression	  of	  PGC1α	  target	  genes.	  Possibilities	  include	  
involvement	   of	   PLIN5	   in	   liberation	   of	   PPAR	   ligands,	   ligand	   transport	   to	   the	   nucleus	   or	  
direct	   interaction	  with	  PGC1α.	  Nevertheless,	  PLIN5	  overexpression	   resulted	   in	   increased	  
neutral	   lipid	   storage	   paralleled	   with	   a	   transcriptional	   profile	   representing	   increased	  
oxidative	   capacity.	   Furthermore,	   PLIN5	   overexpression	   resulted	   in	   more	   intimate	  
interactions	   between	   mitochondria	   and	   LDs	   (chapter	   6).	   Hence,	   the	   capacity	   for	   FA	  
liberation	   and	   FA	   oxidation	   is	   utilized	   in	   the	   most	   efficient	   way.	   PLIN5	   expression	   is	  
induced	  upon	  acute	  exercise	  [71]	  and	  its	  activity	  is	  regulated	  by	  PKA	  phosphorylation	  [67].	  
Therefore,	   PLIN5	   appears	   to	   have	   the	   potential	   to	   be	   a	   key	   player	   in	   regulating	   cellular	  
metabolism	  upon	  energy	  demand	  by	  regulating	  lipolysis	  and	  interactions	  between	  LDs	  and	  
mitochondria.	  Moreover,	  by	  indirectly	  or	  directly	  promoting	  expression	  of	  genes	  involved	  
in	   FA	   oxidative	  metabolism	   and	  mitochondrial	   function,	   PLIN5	   could	   potentially	   balance	  
intramyocellular	   lipid	   load	  with	  downstream	  catabolic	  machinery	   thus	  enhancing	   the	   fat	  
oxidative	   capacity.	   Therefore,	   based	   on	   our	   data	   in	   combination	   with	   the	   relevant	  
literature,	   one	   could	   speculate	   that	   PLIN5	   induces	   a	   feed-­‐forward	   loop	   to	   match	   the	  
capacity	  to	  store	  IMCL	  with	  the	  ability	  to	  liberate	  and	  oxidize	  FA.	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9.4	  PLIN2	  and	  PLIN5	  availability	   in	   relation	  to	  skeletal	  muscle	   lipid	  metabolism	  
and	  insulin	  sensitivity	  
9.4.1	  PLINs	  and	  insulin	  sensitivity	  
As	  discussed	  above,	  PLIN2	  and	  PLIN5	  facilitate	  neutral	  lipid	  storage.	  Hence,	  these	  proteins	  
may	  protect	  against	  lipid-­‐induced	  insulin	  resistance.	  Indeed,	  our	  mechanistic	  studies	  show	  
that	   increased	   PLIN2	   or	   PLIN5	   levels	   facilitate	   neutral	   lipid	   storage	   in	   skeletal	   muscle	  
without	   impairing	   insulin	   sensitivity	   (chapters	   5	   and	   7).	   Consistent	   with	   our	   findings	   in	  
skeletal	  muscle	  (chapter	  5),	  PLIN2	  overexpression	  in	  liver	  improved	  insulin	  sensitivity	  [53].	  
Furthermore,	   skeletal	  muscle	  PLIN2	  and	  PLIN5	  protein	  content	   is	   increased	  after	   insulin-­‐
sensitizing	  strategies	  like	  exercise	  (both	  PLIN2	  and	  PLIN5)	  (chapter	  8	  and	  [33,	  77]),	  weight	  
loss	  and	  metformin	  treatment	  (PLIN2,	  no	  data	  available	  on	  PLIN5)	  [84].	  Coen	  et	  al.	  showed	  
a	   lower	   PLIN2	   gene	   expression	   in	  muscle	   of	   T2D	   subjects	   compared	  with	   BMI-­‐matched	  
controls	   [85].	   Yet,	   a	   low	   PLIN2	   protein	   content	   does	   not	   seem	   to	   be	   a	   general	  
characteristic	  of	  T2D	  muscle	  (chapter	  8	  and	  [31,	  84]	  and	  PLIN2	  and	  PLIN5	  expression	  does	  
not	   necessarily	   correlate	   with	   insulin	   sensitivity	   (chapters	   3	   and	   8).	   Nevertheless,	   in	  
chapter	  3	  it	  is	  shown	  that	  individuals	  with	  high	  PLIN2	  protein	  content	  store	  more	  lipids	  in	  
LDs	   upon	   an	   increased	   plasma	   lipid	   load	   (fasting)	   (chapter	   3).	   Additionally,	   PLIN2	   and	  
PLIN5	   expression	   are	   markedly	   increased	   in	   endurance-­‐trained	   athletes	   in	   comparison	  
with	  sedentary	  BMI-­‐matched	  controls	  [23,	  71].	  Therefore,	  PLIN2	  and	  PLIN5	  expression	  can	  
be	   considered	   components	   of	   a	   profile	   reflecting	   improved	   intramyocellular	   lipid	  
metabolism.	  Interestingly,	  PLIN5	  was	  shown	  to	  be	  a	  strong	  predictor	  for	  insulin	  sensitivity	  
in	  endurance-­‐trained	  young	  men	   [71].	  One	  may	  argue	   that	  a	  balance	   in	   LD	  coat	  protein	  
expression	  facilitating	  sufficient	  neutral	  lipid	  storage	  space	  and	  dynamic	  lipid	  metabolism	  
may	  protect	  against	  lipid-­‐induced	  insulin	  resistance.	  PLIN2	  and	  PLIN5	  are	  two	  examples	  of	  
proteins	  facilitating	  neutral	  IMCL	  storage,	  other	  candidates	  may	  include	  enzymes	  involved	  
in	  TAG	  synthesis	  and	  proteins	  involved	  in	  lipid	  incorporation	  into	  the	  LD,	  LD	  synthesis	  and	  
LD	  stability.	  Hence,	  a	  genetic	  profile	  facilitating	  a	  high	  protein	  expression	  and/or	  activity	  of	  
proteins	   facilitating	   intramyocellular	   neutral	   lipid	   storage	   may	   protect	   against	   lipid-­‐
induced	   insulin	   resistance.	   Likewise,	   in	   chapter	   4	  we	  observed	  both	  ex	   vivo	   and	   in	   vitro	  
that	  T2D	   subjects	  have	  a	   lower	   capacity	  of	   channeling	  FAs	   towards	  neutral	   lipid	   storage	  
compared	  with	  obese	  nondiabetics,	  indicating	  that	  impaired	  neutral	  lipid	  storage	  capacity	  
is	   an	   intrinsic	   characteristic	   of	   the	   type	   2	   diabetic	   myotube	   and	   may	   determine	  
predisposition	  towards	  the	  development	  of	  obesity-­‐associated	  type	  2	  diabetes.	  	  
	  
9.4.2	  Strategies	  to	  improve	  intramyocellular	  lipid	  storage	  
Given	   the	   beneficial	   effects	   of	   increasing	   neutral	   lipid	   storage	   capacity	   and	   PLIN2	   and	  
PLIN5	  expression,	  it	   is	  tempting	  to	  investigate	  which	  strategies	  are	  effective	  in	  improving	  
these	  parameters.	  An	  obvious	  candidate	  strategy	  is	  exercise	  training.	  Indeed,	  in	  chapter	  8	  
we	   show	   that	   PLIN2	   and	   PLIN5	   protein	   expression	   are	   increased	   after	   a	   12-­‐week	  
endurance	   training	  program	   in	  obese	  men,	  consistent	  with	  previously	  published	   findings	  
[33,	  77,	  86].	  Acute	  exercise	   induces	  channeling	  of	  FAs	   towards	  neutral	   lipid	   storage	   [19]	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and	  induces	  gene	  expression	  of	  multiple	  genes	  involved	  in	  TAG	  synthesis	  and	  LD	  assembly	  
and	  mobilization	   in	  mouse	   skeletal	  muscle	   [71].	   Regular	   exercise	   induces	   lipid	   turnover	  
and	  the	  increase	  in	  LD	  and	  neutral	  lipid	  synthesis	  upon	  acute	  exercise	  allows	  the	  muscle	  to	  
better	  cope	  with	  a	  subsequent	   lipid	   load	   [19].	   Interestingly,	   it	  was	  demonstrated	   that	   in	  
endurance-­‐trained	   muscle,	   pre-­‐exercise	   IMCL	   levels	   determine	   the	   degree	   of	   IMCL	  
depletion	   [87].	   Furthermore,	   subjecting	   sedentary	   subjects	   to	   an	   endurance	   training	  
program	  was	   shown	   to	  enhance	  muscle	   reliance	  on	   local	   lipids	   [88].	  One	  may	   speculate	  
that	   lipid	   depletion	   during	   exercise	   and	   increased	   lipid	   turnover	   upon	   exercise	   training	  
may	   result	   in	   mobilization	   and	   catabolism	   of	   lipid	   intermediates	   that	   under	   sedentary	  
conditions	  would	  not	  have	  been	  preferentially	  utilized.	  Moreover,	  exercise	  training	  results	  
in	   a	   balanced	   system	   of	   neutral	   lipid	   storage	   capacity	   and	   downstream	   mitochondrial	  
machinery.	  	  
Another	  approach	  to	  influence	  skeletal	  muscle	  lipid	  metabolism	  is	  diet	  composition.	  
Low	  calorie	  diets	   improve	  skeletal	  muscle	   insulin	  sensitivity	  even	   in	   lean	   insulin	  resistant	  
subjects	   [89].	   Interestingly,	   this	   improvement	   in	   insulin	   sensitivity	   with	  weight	   loss	   was	  
paralleled	  by	  an	  increase	  in	  LD	  density,	  while	  IMCL	  storage	  was	  decreased	  [89],	  indicating	  
a	   remodeling	   of	   intramyocellular	   lipid	   metabolism.	   Additionally,	   it	   was	   shown	   that	   a	  
weight	   loss	   intervention	   in	   obese	   subjects	   resulted	   in	   increased	   PLIN2	   protein	   content	  
[84].	  In	  addition	  to	  low-­‐calorie	  diets,	  the	  fat	  composition	  of	  the	  diet	  may	  influence	  skeletal	  
muscle	   lipid	  metabolism.	  That	   is,	   in	  addition	   to	  availability	  of	   the	  glycerol	  backbone	   [90,	  
91],	   long	   chain	   unsaturated	   FAs	   like	   oleate	   should	   be	   available	   in	   sufficient	   amounts	   to	  
build	  TAG	  stores	  [92].	  Oleate	  treatment	  results	  in	  increased	  LD	  size	  and	  recruits	  PLIN2	  to	  
the	   LDs	   [92].	   Hence,	   oleate	   increases	   neutral	   lipid	   storage	   and	   TAG	   synthesis.	   The	   co-­‐
incubation	   of	   muscle	   cells	   with	   oleate	   and	   palmitate	   increases	   the	   channeling	   of	   the	  
saturated	   FA	   palmitate	   towards	   storage	   in	   the	   form	   of	   TAG	   thereby	   rescuing	   the	  
palmitate-­‐induced	   lipotoxicity	  [93-­‐96].	   Interestingly,	   the	  differential	  effects	  of	  oleate	  and	  
palmitate	   on	   PLIN2	   expression	   in	   C2C12	   myotubes	   even	   exceed	   the	   difference	   in	   TAG	  
accumulation	   (chapter	   5)	   and	   PLIN2	   expression	   is	   primarily	   induced	   in	   mouse	   skeletal	  
muscle	   upon	   consumption	   of	   a	   diet	   rich	   in	   monounsaturated	   fatty	   acids	   (Appendix	   4).	  
Thus,	  based	  on	  the	  above	  and	  following	  the	  general	  lifestyle	  guidelines,	  a	  combination	  of	  
exercise	   and	   diet	   composition	   in	   addition	   to	   the	   genetic	   profile	   determines	   the	  muscle	  
neutral	  lipid	  storage	  capacity.	  
Pharmacological	   and	  nutraceutical	   approaches	   targeting	  AMPK,	   thereby	   influencing	  
the	  cellular	  energy	  status,	  offer	  a	  third	  strategy	  to	  improve	  skeletal	  muscle	  lipid	  handling.	  
The	  thiazolidinediones	  are	  insulin-­‐sensitizing	  drugs	  serving	  as	  agonists	  for	  PPARγ,	  but	  also	  
target	   AMPK	   [97].	   The	   thiazolidinedione	   rosiglitazone	   was	   shown	   to	   increase	   lipid	  
accumulation	   in	  the	  form	  of	  TAG	  and	  to	  decrease	  saturation	  status	  of	  FAs	   in	  the	  neutral	  
lipid	   fraction	   of	   mouse	   skeletal	   muscle	   [98].	   Yet,	   rosiglitazone	   treatment	   for	   8	   weeks	  
downregulated	  PLIN2	  and	  PLIN5	  expression	   in	  human	  skeletal	  muscle	  [31].	   In	  contrast,	  a	  
3-­‐month	   treatment	   period	   with	   troglitazone,	   another	   thiazolidinedione,	   was	   shown	   to	  
increase	   skeletal	  muscle	   PLIN2	   protein	   content	   in	   parallel	   with	   improvements	   in	   insulin	  
sensitivity	   [84].	  PPARγ	  agonists	  have	  been	  used	   in	   the	  treatment	  of	   type	  2	  diabetes,	  but	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are	  –except	   for	  pioglitazone	  –	   currently	  no	   longer	  prescribed	  because	   they	   increase	   the	  
risk	  for	  heart	  failure	  [99].	  Metformin,	  another	  AMPK	  activator	  and	  the	  primary	  drug	  used	  
in	   the	   treatment	   of	   type	   2	   diabetes,	   also	   increases	   PLIN2	   protein	   content	   in	   skeletal	  
muscle	   [84]	   and	   leads	   to	   neutral	   lipid	   accumulation	   in	   human	   primary	  myotubes	   [100].	  
Thus,	   several	   lifestyle	   and	   pharmaceutical	   approaches	   have	   the	   potential	   to	   improve	  
skeletal	  muscle	  neutral	  lipid	  storage	  capacity	  and	  lipid	  handling.	  
	  
9.5	  Conclusions	  and	  future	  perspectives	  
Overall,	   the	   findings	   described	   in	   this	   thesis	   indicate	   that	   creating	   neutral	   lipid	   storage	  
capacity	   protects	   against	   obesity-­‐associated	   insulin	   resistance.	   Both	   PLIN2	   and	   PLIN5	  
increase	  neutral	  lipid	  storage	  space	  without	  negatively	  impacting	  on	  insulin	  sensitivity,	  at	  
least	   on	   the	   short	   term.	   Given	   the	   beneficial	   effects	   of	   increasing	   neutral	   lipid	   storage	  
capacity	   in	   skeletal	   muscle,	   further	   research	   into	   nutraceutical	   and	   pharmacological	  
strategies	   to	   improve	   PLIN	   function	   and	   LD	   dynamics	   is	   promising	   with	   respect	   to	  
metabolic	  health.	  	  
	  
Several	  questions	  arise	  which	  may	  be	  addressed	  in	  future	  research:	  
1. We	   show	   that	   promoting	   intramyocellular	   neutral	   lipid	   content	   is	   associated	   with	  
improved	  insulin	  sensitivity.	  Ultimately,	   lipid	  turnover	  will	  need	  to	  be	  matched	  with	  
the	   increased	   IMCL	   storage	   to	   ensure	   continuous	   storage	   space	   for	   excess	   lipids.	  
Further	   mechanistic	   research	   should	   be	   directed	   towards	   characterizing	   key	  
regulators	   of	   intramyocellular	   lipid	   storage	   capacity	   and	   lipid	   turnover.	   In	   addition,	  
the	   question	   arises	   whether	   sufficient	   provision	   of	   phospholipids	   and	   LD	   coat	  
proteins	   is	   a	   limiting	   factor	   for	   neutral	   lipid	   storage	   capacity.	   Furthermore,	   future	  
research	  may	   elucidate	   how	   lipids	   enter	   LDs,	  whether	   strategies	   exist	   to	   target	   FA	  
metabolites	   towards	   storage	   in	   the	   LD	  and	  whether	   creation	  of	   lipid	   storage	   space	  
also	  creates	  space	  for	  inert	  storage	  of	  lipid	  intermediates.	  	  
2. It	   would	   be	   valuable	   to	   study	   intramyocellular	   LD	   dynamics	   in	   vivo.	   Technical	  
advances,	   for	   instance	  multiphoton	  microscopy,	  may	  make	   this	   possible	   at	   least	   in	  
animal	  models.	   LD	   dynamics	   could	   then	   be	   studied	   in	   situations	   of	   increased	   lipid	  
supply	  and/or	  increased	  energy	  demand.	  This	  would	  also	  provide	  the	  opportunity	  to	  
investigate	  whether	   LD	   dynamics	   are	   altered	   in	  models	   of	   obesity	   and	   diabetes	   as	  
compared	  to	  healthy	  and/or	  trained	  muscle.	  For	  example	  one	  may	  question	  whether	  
lipid	  oversupply	  results	  in	  accumulation	  of	  LDs	  with	  a	  low	  turnover	  rate.	  	  
Alternatively,	   establishing	   primary	   human	   myotubes	   offers	   the	   opportunity	   to	  
extensively	  study	  intramyocellular	  lipid	  dynamics	  from	  the	  perspective	  of	  the	  genetic	  
background	   of	   the	   donor	   (chapter	   4).	   Challenging	   these	  myotubes	  with	   an	   energy	  
demand	   and	   silencing	   and	   overexpression	   strategies	   could	   provide	   further	  
mechanistic	   insight	   into	   skeletal	   muscle	   lipid	   handling.	   Furthermore,	   novel	  
compound	   testing	   could	   provide	   potential	   therapeutics	   improving	   intramyocellular	  
lipid	  handling	  to	  be	  validated	  in	  vivo.	  	  
General	  discussion	  
	  192	  
3. With	   regard	   to	   PLIN2,	   it	   will	   need	   to	   be	   established	  what	   the	   exact	   function	   is	   of	  
PLIN2	   in	   TAG	   storage	   and	   LD	   synthesis.	   We	   showed	   that	   PLIN2	   is	   essential	   for	  
intramyocellular	  TAG	  storage,	  but	  it	  remains	  unclear	  whether	  the	  presence	  of	  PLIN2	  
on	   the	   ER	   and/or	   the	   LD	   is	   a	   prerequisite	   for	   TAG	   and	   LD	   synthesis.	   PLIN2	   may	  
interact	   with	   enzymes	   involved	   in	   neutral	   lipid	   synthesis.	   On	   the	   other	   hand,	   TAG	  
may	   quickly	   be	   degraded	   in	   the	   absence	   of	   PLIN2.	   Furthermore,	   since	   regulatory	  
factors	  of	  PLIN2	  expression	  and	  stabilization	  remain	  unclear,	  future	  research	  may	  be	  
dedicated	  to	  the	  transcriptional	  and	  posttranslational	  regulation	  of	  PLIN2	  expression	  
in	  skeletal	  muscle.	  Additionally,	  we	  demonstrated	  that	  short-­‐term	  (7	  day)	   increases	  
in	   PLIN2	   abundance	   were	   beneficial,	   although	   high	   fat	   diet-­‐induced	   induction	   of	  
oxidative	   capacity	   was	   reduced.	   It	   remains	   to	   be	   investigated	   whether	   increased	  
PLIN2	  abundance	  is	  advantageous	  with	  respect	  to	  intramyocellular	  lipid	  handling	  and	  
insulin	  sensitivity	  in	  the	  long	  term.	  	  
4. Concerning	   PLIN5,	   its	   intramitochondrial	   localization	   and	   function	   and	   interaction	  
partners	  will	  need	  to	  be	  examined.	  This	  could	  lead	  to	  identification	  of	  the	  function	  of	  
mitochondrial	   PLIN5.	   In	   addition,	   the	   mechanism	   behind	   the	   increased	   expression	  
levels	  of	  PGC1α	  target	  genes	  deserves	  further	  attention.	  Following	  up	  on	  that	  aspect,	  
it	   would	   be	   interesting	   to	   study	   PLIN5	   function	   in	   situations	   of	   increased	   energy	  
demand.	   PGC1α	   was	   shown	   to	   improve	   skeletal	   muscle	   insulin	   sensitivity	   in	   an	  
activity-­‐dependent	  manner	  [101].	  Subjecting	  muscle-­‐specific	  PLIN5	  knockout	  mice	  to	  
acute	   exercise	   and	   exercise	   training	   could	   point	   out	  whether	   PLIN5	   is	   essential	   for	  
provision	  of	  energy	  from	  fat	  stores	  and	  whether	  PLIN5	  plays	  a	  vital	  role	  in	  the	  feed-­‐
forward	  mechanism	  of	  PGC1α	  function	  in	  response	  to	  training.	  
5. Interactions	   between	   LDs	   and	   mitochondria	   are	   presumably	   very	   important	   for	  
substrate	   provision	   for	   skeletal	   muscle	   oxidative	   metabolism.	   Exercise	   training	  
increases	   the	   proportion	   of	   LDs	   in	   contact	  with	  mitochondria	   [73].	   Interestingly,	   it	  
was	   shown	   that	   LDs	   and	   mitochondria	   appear	   to	   share	   portions	   of	   the	   same	  
membrane	  [102].	  It	  remains	  to	  be	  investigated	  how	  these	  interactions	  are	  regulated	  
and	   whether	   membrane	   fusions	   are	   in	   fact	   involved.	   Furthermore,	   little	   is	   known	  
about	  organelle	  trafficking	  and	  its	  stimulatory	  and	  regulatory	  factors.	  Moreover,	  the	  
question	  arises	  whether	  the	  interaction	  between	  LDs	  and	  mitochondria	  is	  reversible	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Appendix	   1.	   Effects	   of	   an	   oral	   gavage	   of	  
Wy14,643	   or	   fenofibreate	   (PPARα	  
agonists).	   The	   animals	   were	   fasted	   for	   4	  
hours,	  followed	  by	  the	  intragastric	  gavage.	  
WY14,643	   and	   fenofibrate	   were	   given	   as	  
10	   mg/ml	   suspension	   in	   0.5%	  
carboxymethyl	  cellulose,	  which	  also	  served	  
as	   control	   treatment	   (400	   µl).	   The	   mice	  
were	  killed	  6	  hours	  thereafter.	  
	  
	  
Appendix	   2.	   (A)	   14C-­‐palmitate	   uptake	   in	  
C2C12	   myotubes	   transfected	   with	  
scrambled	   control	   or	   PLIN2	   RNAi.	   (B)	   14C-­‐
palmitate	   uptake	   in	   C2C12	   myotubes	  
transfected	   with	   empty	   vector	   (EV)	   or	  
































































































Appendix	  3.	   Inhibition	  of	  ATGL	  by	  the	  
compound	   bromoenol	   lactone	   (BEL)	  
does	  not	  rescue	  TAG	  storage	  in	  PLIN2-­‐
knockdown	   myotubes.	   S:	   scrambled	  
siRNA,	   P:	   PLIN2	   siRNA,	   OA:	   oleate	  
(bound	  to	  BSA),	  C:	  control	  (BSA).	  
	  
	  
Appendix	  4.	  PLIN2	  protein	  
abundance	   in	   tibialis	  
anterior	   muscle	   of	   C57Bl6	  
mice	   fed	   a	   low	   fat	   diet	  
containing	   palm	   oil	   (LFD-­‐
PO)	  or	  one	  of	   the	  high	   fat	  
diets	   (HFD)	   for	   8	   weeks;	  
PO:	   palm	   oil,	   CB:	   cacao	  
butter,	   OO:	   olive	   oil.	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SUMMARY	  
Western	  style	  diets,	  excess	  calorie	  intake	  and	  low	  physical	  activity	  levels	  have	  resulted	  in	  a	  
strong	   increase	   in	   the	  prevalence	  of	  obesity.	   This	  obesity	  epidemic	   is	   currently	  affecting	  
more	   than	   one	   in	   ten	   of	   the	   world’s	   population	   and	   the	   epidemic	   is	   still	   expanding	  
dramatically	   in	   adults	   as	   well	   as	   in	   children.	   Obesity	   is	   associated	   with	   a	   range	   of	  
comorbidities.	  One	  of	   the	  major	   complications	   of	   obesity	   is	   impaired	   glucose	   tolerance,	  
which	   may	   deteriorate	   towards	   type	   2	   diabetes.	   Impaired	   glucose	   tolerance	   is	  
characterized	   by	   insulin	   resistance	   -­‐	   an	   impaired	   ability	   of	   the	   hormone	   insulin	   to	  
stimulate	   glucose	   disposal	   by	   skeletal	   muscle	   and	   liver	   and	   to	   inhibit	   hepatic	   glucose	  
production	   -­‐	   and	   a	   reduced	   secretion	   of	   insulin	   by	   the	   pancreas.	   This	   reduced	   glucose	  
tolerance	   may	   deteriorate	   towards	   type	   2	   diabetes,	   which	   is	   characterized	   by	   β-­‐cell	  
dysfunction	   and	   hyperglycemia,	   reflecting	   the	   disability	   of	   the	   pancreatic	   β-­‐cells	   to	  
compensate	   for	   the	   peripheral	   insulin	   resistance.	   Approximately	   90	   percent	   of	   type	   2	  
diabetics	   are	   overweight.	   Yet,	   the	   fact	   that	   ‘only’	   approximately	   30	   percent	   of	   obese	  
people	  have	  type	  2	  diabetes	  indicates	  that	  genetic	  and/or	  epigenetic	  predisposition	  plays	  
an	  important	  role	  in	  the	  etiology	  of	  obesity-­‐associated	  insulin	  resistance	  and	  progression	  
towards	  type	  2	  diabetes.	  
	   The	   skeletal	  muscle	   accounts	   for	  more	   than	   80	   percent	   of	   the	   postprandial	   whole	  
body	   glucose	   uptake	   and	   therefore	   plays	   an	   important	   role	   in	   glucose	   homeostasis.	  
Skeletal	   muscle	   lipid	   levels	   –	   intramyocellular	   lipids	   (IMCL)	   –	   correlate	   negatively	   with	  
insulin	   sensitivity	   in	   a	   sedentary	   population	   and	   hence	   were	   considered	   predictive	   for	  
insulin	   resistance	   and	   causative	   in	   obesity-­‐associated	   insulin	   resistance.	   However,	  
endurance	  athletes	  also	  have	  high	  IMCL	  levels	  despite	  being	  highly	  insulin	  sensitive,	  which	  
indicates	  that	  not	  the	  level	  of	  IMCL	  accumulation	  per	  se,	  but	  rather	  the	  characteristics	  of	  
this	  intramyocellular	  fat	  determine	  whether	  it	  negatively	  affects	  insulin	  signaling.	  	  
	   Upon	  entrance	  of	  the	  cell,	  fatty	  acids	  can	  be	  converted	  to	  different	  types	  of	  lipids	  for	  
storage.	   Triacylglycerol	   (TAG)	   consists	   of	   three	   fatty	   acids	   bound	   to	   a	   glycerol	  molecule	  
and	   is	   considered	   the	  most	   neutral	   and	   harmless	   type	   of	   intracellular	   lipid	   storage.	   The	  
majority	  of	  the	  IMCL	  that	   is	  stored	  in	  muscle	  cells	  of	  endurance-­‐trained	  athletes	  consists	  
of	   TAG.	   Besides,	   fatty	   acids	   can	   be	   converted	   to	   lipid	   intermediates	   like	   diacylglycerol	  
(DAG),	   ceramides	   and	   fatty	   acyl-­‐CoAs.	   These	   lipid	   intermediates	   can	   impair	   insulin	  
signaling,	   which	   is	   referred	   to	   as	   lipid-­‐induced	   insulin	   resistance	   and	   lipotoxicity.	  
Intramyocellular	   lipids	   are	  mainly	   stored	   in	   lipid	  droplets,	   the	  organelles	   for	   fat	   storage.	  
Initially,	  these	  lipid	  droplets	  were	  considered	  to	  merely	  serve	  as	  fat	  depots,	  but	  since	  the	  
discovery	   in	   the	   nineties	   of	   proteins	   in	   the	   lipid	   droplet	   coat	   that	   regulate	   lipid	   droplet	  
dynamics	  and	   lipid	  metabolism,	   lipid	  droplets	  are	  seen	  as	  highly	  dynamic	  organelles	  that	  
play	   a	   very	   important	   role	   in	   the	   regulation	   of	   intracellular	   lipid	   storage	   and	   lipid	  
metabolism.	  
	  
This	   thesis	   focuses	  on	  two	   lipid	  droplet	  coat	  proteins:	   the	  perilipins	   (PLINs)	  2	  and	  5.	  The	  
perilipin	   family	  was	   the	   first	   characterized	  group	  of	   lipid	  droplet	   coat	  proteins,	  but	   their	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function	   is	  mainly	   studied	   in	   adipose	   tissue	   and	   liver.	   The	   general	   goal	   of	   the	   research	  
presented	   in	   this	   thesis	  was	   to	   investigate	   the	   potential	   role	   of	   these	   lipid	   droplet	   coat	  
proteins	   in	  the	  regulation	  of	  skeletal	  muscle	   lipid	  metabolism	  and	  the	  protection	  against	  
lipid-­‐induced	   insulin	   resistance	   by	   creation	   of	   synthesis-­‐	   and	   storage	   capacity	   for	   lipids.	  
This	  thesis	  project	  encompasses	  a	  series	  of	  cell,	  animal	  and	  human	  studies	  -­‐	  as	  well	  as	  a	  
combination	  of	  in	  vivo,	  ex	  vivo,	  and	  in	  vitro	  techniques.	  
	  
Chapter	  2	  gives	  an	  overview	  and	  interpretation	  of	  the	  recent	  literature	  on	  the	  relationship	  
between	  intramyocellular	   lipid	  storage	  and	   insulin	  resistance.	  This	  review	  focuses	  on	  the	  
evidence	   from	   human	   studies,	   in	   combination	   with	   supporting	  mechanistic	   information	  
obtained	  from	  cell-­‐	  and	  animal	  studies.	  Evidently,	  lipid	  accumulation	  in	  skeletal	  muscle	  is	  
an	   important	   parameter	   in	   the	   development	   of	   obesity-­‐associated	   type	   2	   diabetes.	  
Accumulation	   of	   the	   lipid	   intermediates	   diacylglycerol,	   ceramides	   and	   fatty	   acyl-­‐CoAs	   is	  
associated	   with	   insulin	   resistance.	   However,	   the	   results	   of	   the	   human	   studies	   are	  
inconsistent.	  Moreover,	  increased	  levels	  of	  these	  intermediates	  in	  skeletal	  muscle	  do	  not	  
necessarily	   result	   in	   insulin	   resistance.	  Rather,	   the	   results	  of	   the	  array	  of	  human	  studies	  
performed	   to	   date	   indicate	   that	   there	   are	   different	   routes	   towards	   lipid-­‐induced	   insulin	  
resistance.	   Besides	   augmented	   synthesis	   and	   accumulation	   of	   lipid	   intermediates,	  
probably	  also	  the	  intracellular	  localization	  –	  in	  lipid	  droplets	  or	  in/near	  membranes	  –	  and	  
lipid	  metabolism	  (lipid	  turnover)	  are	  of	  importance.	  
	   Increased	  lipid	  supply	  to	  muscle	  is	  considered	  to	  be	  one	  of	  the	  explanations	  for	  the	  
increased	   intramyocellular	   lipid	   storage	   in	   obese	   individuals.	   Storage	   of	   lipids	   in	   lipid	  
droplets	  may	  prevent	  that	  lipid	  intermediates	  interfere	  with	  the	  insulin	  signaling	  cascade	  
in/near	   the	   cell	   membranes.	   The	   capacity	   for	   lipid	   storage	   in	   intramyocellular	   lipid	  
droplets	   and	   the	   abundance	   of	   lipid	   droplet	   coat	   proteins	   may	   therefore	   determine	  
interindividual	   variation	   in	   sensitivity	   for	   the	   development	   of	   insulin	   resistance	   in	  
situations	   of	   increased	   lipid	   supply.	   Fasting	   and	   consumption	   of	   a	   high	   fat	   diet	   are	   two	  
human	  models	   for	   increased	   fatty	  acid	   supply	   to	   the	  muscle.	   In	  chapter	  3	   the	  effects	  of	  
fasting	   for	   60	   hours	   and	   consumption	   of	   a	   high	   fat	   diet	   for	   three	   weeks	   on	  
intramyocellular	   lipid	  accumulation,	   insulin	  sensitivity	  and	  the	  expression	  of	   lipid	  droplet	  
coat	  proteins	  are	  discussed.	  Fasting	  resulted	  in	  a	  pronounced	  increase	  in	  plasma	  free	  fatty	  
acid	   levels,	   intramyocellular	   lipid	   accumulation	  and	   insulin	   resistance.	  However,	   a	   larger	  
increase	  in	  lipid	  storage	  in	  intramyocellular	  lipid	  droplets	  upon	  fasting	  was	  associated	  with	  
a	  lower	  reduction	  in	  insulin	  sensitivity.	  This	  phenomenon	  was	  not	  apparent	  in	  the	  high	  fat	  
diet	  intervention,	  which	  indicates	  that	  the	  protective	  role	  of	  lipid	  storage	  capacity	  in	  lipid	  
droplets	   is	   specifically	   of	   importance	   under	   acute	   conditions	   of	   high	   lipid	   supply.	   PLIN2	  
and	  PLIN5	   levels	  were	  not	   increased	  after	   fasting,	   in	   contrast	   to	   animal	   studies.	   In	  both	  
interventions,	  PLIN2	  levels	  correlated	  positively	  with	  intramyocellular	  lipid	  content	  in	  lipid	  
droplets.	  
	   Increased	   fatty	   acid	   uptake,	   reduced	   oxidative	   capacity	   and	   disturbances	   in	  
intramyocellular	   lipid	   metabolism	   have	   been	   suggested	   as	   explanations	   for	   lipotoxicity	  
resulting	   in	   insulin	   resistance.	   In	   chapter	   4,	   intramyocellular	   lipid	   metabolism	   was	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explored	  in	  skeletal	  muscle	  of	  obese	  individuals	  with	  type	  2	  diabetes	  compared	  with	  BMI-­‐	  
and	   age-­‐matched	   control	   subjects.	   Lipid	  metabolism	  was	   investigated	   ex	   vivo	   in	  muscle	  
biopsy	   tissue	   and	   in	   vitro	   in	   cultured	   muscle	   cells	   (myotubes).	   These	   muscle	   cells	   are	  
cultured	   from	   satellite	   cells	   and	   therefore	   mainly	   represent	   the	   genetic	   profile	   of	   the	  
donor.	  With	  this	  study	  set	  up	  we	  were	  able	  to	   investigate	  both	  acquired	  disturbances	   in	  
skeletal	  muscle	  lipid	  metabolism	  as	  a	  consequence	  of	  lifestyle	  and	  diabetes	  development	  
and	  genetic	  differences	  in	  lipid	  metabolism	  that	  could	  potentially	  explain	  the	  susceptibility	  
for	   type	  2	  diabetes	  development.	  Ex	   vivo	   fatty	   acid	  oxidation	  and	   incorporation	  of	   fatty	  
acids	  into	  TAG	  were	  lower	  in	  type	  2	  diabetics	  compared	  with	  control	  subjects.	  In	  contrast,	  
in	   vitro	   fatty	   acid	   oxidation	   was	   similar	   in	   myotubes	   established	   from	   diabetics	   and	  
controls.	  Similar	  to	  the	  ex	  vivo	  findings,	   in	  vitro	   incorporation	  of	  fatty	  acids	  into	  TAG	  was	  
significantly	  lower	  in	  the	  type	  2	  diabetics.	  Fatty	  acid	  uptake	  was	  similar	  in	  the	  two	  groups.	  
These	  results	  show	  that	  a	  reduced	  capacity	  for	  storage	  of	  fatty	  acids	  in	  the	  form	  of	  TAG	  is	  
an	  inherent	  characteristic	  of	  the	  diabetic	  muscle	  cell.	  
	   These	   first	   chapters	   indicate	   that	  an	   increased	  capacity	   for	   storage	  of	   fatty	  acids	   in	  
the	  form	  of	  TAG	  is	  associated	  with	  higher	  insulin	  sensitivity.	  Lipid	  droplet	  coat	  proteins	  are	  
involved	  in	  the	  regulation	  of	  intracellular	  lipid	  storage.	  Yet,	  little	  is	  known	  about	  the	  role	  of	  
lipid	   droplet	   coat	   proteins	   in	   skeletal	   muscle.	   Chapter	   5	   shows	   that	   PLIN2	   facilitates	  
neutral	  lipid	  storage	  in	  skeletal	  muscle.	  PLIN2	  is	  essential	  for	  intramyocellular	  TAG	  storage;	  
knockdown	   of	   PLIN2	   in	   cultured	  myotubes	   by	  means	   of	   siRNA	   resulted	   into	   lower	   TAG	  
levels,	  reduced	  incorporation	  of	  fatty	  acids	  into	  TAG	  and	  a	  lower	  number	  of	  lipid	  droplets.	  
Overexpression	  of	  PLIN2	   in	   vitro	   in	   cultured	  myotubes	  and	   in	   vivo	   in	   rat	   tibialis	   anterior	  
muscle	  resulted	  in	  increased	  intramyocellular	  neutral	  lipid	  storage	  while	  insulin	  sensitivity	  
was	  improved.	  In	  conclusion,	  PLIN2	  facilitates	  the	  storage	  of	  potentially	  toxic	  fatty	  acids	  in	  
the	  form	  of	  neutral	  TAG	  hence	  improving	  insulin	  sensitivity.	  
	   Chapter	  6	  describes	  the	  subcellular	  localization	  of	  PLIN5.	  PLIN5	  not	  only	  localizes	  to	  
lipid	   droplets,	   but	   also	   to	   mitochondria.	   Skeletal	   muscle	   PLIN5	   content	   correlates	   with	  
markers	   for	   oxidative	   capacity.	   Unilateral	   overexpression	   of	   PLIN5	   overexpression	   in	   rat	  
tibialis	  anterior	  muscle	  resulted	  in	  increased	  intramyocellular	   lipid	  content	  and	  increased	  
fatty	  acid	  oxidation.	  Chapter	  7	  builds	  on	  the	  previous	  chapter	  and	  further	  identifies	  effects	  
of	  PLIN5	  overexpression	  –	   in	  comparison	  with	  effects	  of	  PLIN2	  –	  on	  skeletal	  muscle	   lipid	  
accumulation,	   insulin	   sensitivity	   and	   gene	   expression	   profiles.	   Both	   PLIN2	   and	   PLIN5	  
overexpression	   resulted	   in	   increased	   neutral	   intramyocellular	   lipid	   content	   without	  
negatively	  impacting	  on	  insulin	  sensitivity.	  Interestingly,	  as	  opposed	  to	  the	  effects	  of	  PLIN2	  
overexpression,	  overexpression	  of	  PLIN5	  promoted	  expression	  of	  a	  cluster	  of	  genes	  under	  
control	   of	   PPARα	   and	   PGC1α	   involved	   in	   fatty	   acid	   catabolism	   and	   mitochondrial	  
oxidation.	  This	  suggests	  a	  role	  for	  PLIN5,	  either	  directly	  or	  indirectly,	  in	  mediating	  skeletal	  
muscle	  oxidative	  gene	  expression.	  	  
	   Insulin-­‐sensitizing	  strategies	  may	  involve	  adaptations	  in	  intramyocellular	  lipid	  droplet	  
dynamics.	   In	  chapter	  8	  the	  effects	  of	  an	  endurance	  training	  program	  on	  intramyocellular	  
lipid	   storage	   and	   PLIN	   protein	   expression	   are	   described.	   Eighteen	  male	   type	   2	   diabetics	  
and	  twenty	  BMI-­‐	  and	  age-­‐matched	  normoglycemic	  controls	  exercise-­‐trained	  for	  12	  weeks.	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Intramyocellular	  lipid	  content	  was	  modestly	  increased	  after	  the	  training	  period,	  while	  the	  
skeletal	  muscle	  protein	  content	  of	  PLIN2	  and	  PLIN5	  was	  doubled.	  
	  
In	  conclusion,	   the	  findings	  described	   in	  this	   thesis	   indicate	  that	  creating	   intramyocellular	  
neutral	   lipid	   storage	   capacity	   protects	   against	   obesity-­‐associated	   insulin	   resistance	   in	  
skeletal	   muscle.	   Both	   PLIN2	   and	   PLIN5	   increase	   intramyocellular	   neutral	   lipid	   storage	  
space	  without	  negatively	  impacting	  on	  insulin	  sensitivity,	  at	  least	  on	  the	  short	  term.	  Given	  
the	  beneficial	  effects	  of	  increasing	  neutral	  lipid	  storage	  capacity	  in	  skeletal	  muscle,	  further	  
research	   into	  nutraceutical	  and	  pharmacological	  strategies	  to	   improve	  PLIN	  function	  and	  
LD	  dynamics	  is	  promising	  with	  respect	  to	  metabolic	  health.	  	  
	  	  208	  
SAMENVATTING	  
Het	   veranderde	  voedingspatroon,	  overmatige	   calorie-­‐inname	  en	  de	  verminderde	   fysieke	  
activiteit	   hebben	   de	   afgelopen	   decennia	   geresulteerd	   in	   een	   sterke	   toename	   in	   de	  
prevalentie	   van	   obesitas.	  Momenteel	   leidt	   een	   op	   de	   tien	   volwassenen	  wereldwijd	   aan	  
obesitas	   en	   deze	   epidemie	   is	   nog	   altijd	   exponentieel	   aan	   het	   toenemen.	   Obesitas	   is	  
geassocieerd	  met	  een	  scala	  aan	  comorbiditeiten,	  waaronder	  type	  2	  diabetes.	  	  
Een	  verminderde	  glucosetolerantie	  is	  een	  voorstadium	  van	  type	  2	  diabetes	  en	  wordt	  
gekenmerkt	  door	  insulineresistentie;	  een	  verminderde	  gevoeligheid	  van	  weefsels	  voor	  het	  
hormoon	   insuline	   –	   insuline	   faciliteert	   de	   opname	   van	   glucose	   in	   de	   perifere	   weefsels	  
waaronder	  de	  spier	  en	  remt	  de	  glucose	  productie	  in	  de	  lever	  –	  en	  een	  verlaagde	  secretie	  
van	   insuline	  door	  de	  pancreas.	  Deze	  verminderde	  glucose	  tolerantie	  kan	  zich	  uiteindelijk	  
ontwikkelen	   richting	   type	   2	   diabetes,	   wat	   gekenmerkt	   wordt	   door	   verhoogde	   glucose	  
niveaus	   in	   het	   bloed	   doordat	   het	   lichaam	   de	   glucosespiegels	   niet	   meer	   voldoende	   kan	  
reguleren.	   Ongeveer	   90	   procent	   van	   de	   type	   2	   diabetes	   patiënten	   heeft	   overgewicht.	  
Echter,	  ‘slechts’	  30	  procent	  van	  de	  personen	  die	  lijden	  aan	  obesitas	  heeft	  type	  2	  diabetes,	  
wat	  impliceert	  dat	  genetische	  aanleg	  zeer	  waarschijnlijk	  een	  rol	  speelt	  bij	  de	  ontwikkeling	  
van	  type	  2	  diabetes.	  	  
De	  skeletspieren	  zijn	  verantwoordelijk	  voor	  80	  procent	  van	  de	  postprandiale	  glucose	  
opname	   in	  het	   lichaam	  en	  spelen	  daarom	  een	  belangrijke	   rol	  bij	  de	  glucosehuishouding.	  
Vetstapeling	   in	   de	   spier	   wordt	   in	   verband	   gebracht	   met	   de	   ontwikkeling	   van	  
insulineresistentie.	   Obesitas	   gaat	   gepaard	   met	   vetstapeling	   in	   de	   spier	   als	   gevolg	   van	  
verhoogde	  vetzuurniveaus	  in	  de	  bloedbaan	  en	  een	  verminderde	  vetopslagcapaciteit	  in	  het	  
vetweefsel.	  Echter,	  ook	  duurgetrainde	  atleten	  hebben	  een	  grote	  mate	  van	  vetopslag	  in	  de	  
spieren,	  terwijl	  atleten	  juist	  zeer	  insulinegevoelig	  zijn,	  wat	  suggereert	  dat	  niet	  de	  mate	  van	  
vetstapeling,	   maar	   de	   eigenschappen	   van	   dit	   vet	   bepalen	   of	   het	   de	   insulinesignalering	  
hindert.	  	  
Vetzuren	   kunnen	   in	   de	   cel	   worden	   opgeslagen	   in	   verschillende	   vormen.	  
Triacylglycerol	  (TAG)	  bestaat	  uit	  een	  glycerol	  molecuul	  met	  daaraan	  3	  vetzuren	  gebonden	  
en	   wordt	   beschouwd	   als	   de	   meest	   neutrale	   en	   onschadelijke	   vorm	   van	   intracellulaire	  
vetopslag.	  De	  spiercellen	  van	  duurgetrainde	  atleten	  bevatten	  veel	  TAG.	  Daarnaast	  kunnen	  
vetzuren	   omgezet	  worden	   in	   onder	   andere	   diacylglycerol	   (DAG),	   ceramiden	   en	   vetzuur-­‐
CoAs,	   de	   zogeheten	   lipidintermediairen.	   Deze	   lipidintermediaren	   kunnen	   de	  
insulinesignalering	   negatief	   beïnvloeden,	   wat	   omschreven	   wordt	   als	   lipid-­‐geïnduceerde	  
insulineresistentie	  en	  lipotoxiciteit.	  Vetten	  (lipiden)	  in	  de	  spiercel	  zijn	  voor	  het	  merendeel	  
opgeslagen	   in	   lipidendruppels,	   de	   organellen	   voor	   vetopslag.	   Initieel	   werd	   aangenomen	  
dat	  deze	  lipidendruppels	  enkel	  dienen	  als	  vetdepots,	  maar	  sinds	  de	  ontdekking	  in	  de	  jaren	  
’90	   van	   eiwitten	   op	   de	   lipidendruppel	   die	   de	   dynamiek	   van	   lipidendruppels	   en	   het	  
vetmetabolisme	   reguleren,	   worden	   deze	   lipidendruppels	   gezien	   als	   dynamische	  





In	  dit	  proefschrift	  is	  staan	  twee	  lipidendruppel-­‐eiwitten	  centraal:	  de	  perilipines	  (PLIN)	  2	  en	  
5.	  De	  perilipine	  familie	  was	  de	  eerste	  groep	  eiwitten	  gekarakteriseerd	  als	  lipidendruppel-­‐
eiwitten,	  maar	  de	   functie	   van	  deze	  eiwitten	   is	   tot	  op	  heden	  voornamelijk	  bestudeerd	   in	  
vetweefsel	   en	   lever.	   De	   algemene	   doelstelling	   van	   het	   onderzoek	   beschreven	   in	   dit	  
proefschrift	  was	  het	  inventariseren	  van	  de	  potentiële	  rol	  van	  deze	  lipidendruppel-­‐eiwitten	  
in	   de	   regulatie	   van	   het	   vetmetabolisme	   in	   de	   spier	   en	   de	   bescherming	   tegen	   insuline	  
resistentie	  door	  middel	  van	  het	  creëren	  van	  synthese-­‐	  en	  opslagcapaciteit	  voor	  lipiden.	  Dit	  
proefschrift	  is	  gebaseerd	  op	  een	  translationele	  benadering,	  het	  is	  een	  combinatie	  van	  cel,	  
dier-­‐	  en,	  humane	  studies	  alsmede	  in	  vivo,	  ex	  vivo	  en	  in	  vitro	  technieken.	  
	  
In	   hoofdstuk	   2	   wordt	   een	   overzicht	   en	   interpretatie	   van	   de	   recente	   literatuur	   op	   het	  
gebied	  van	  de	  relatie	  tussen	  vetstapeling	  in	  de	  spier	  en	  insulineresistentie	  gegeven.	  Hierin	  
staan	  de	  resultaten	  van	  humane	  studies	  centraal,	  maar	  ook	  de	  voorgestelde	  mechanismen	  
ter	  verklaring	  van	  de	  relatie	  tussen	  vetstapeling	  in	  de	  spier	  en	  insulineresistentie	  worden	  
besproken	   aan	   de	   hand	   van	   de	   uitkomsten	   van	   cel-­‐	   en	   dierstudies.	   Het	   is	   evident	   dat	  
vetstapeling	   in	   de	   spier	   een	   belangrijke	   factor	   is	   in	   het	   ontstaan	   van	   obesitas-­‐
geassocieerde	   type	   2	   diabetes.	   Stapeling	   van	   lipidintermediairen	   zoals	   diacylglycerol,	  
ceramiden	  en	  vetzuur-­‐CoAs	  wordt	  in	  verband	  gebracht	  met	  insulineresistentie.	  Echter,	  de	  
resultaten	   van	   de	   humane	   studies	   geven	   geen	   consistent	   beeld.	   Bovendien	   leiden	  
verhoogde	   concentraties	   van	  deze	   intermediairen	   in	   de	   skeletspier	   niet	   noodzakelijk	   tot	  
insulineresistentie.	   Er	   bestaan	   waarschijnlijk	   verschillende	   routes	   richting	  
lipidgeïnduceerde	   insulineresistentie.	   Naast	   verhoogde	   vorming	   en	   stapeling	   van	  
lipidintermediairen	  spelen	  hoogstwaarschijnlijk	  ook	  de	   intracellulaire	   lokalisatie	  van	  deze	  
intermediairen	  –	   in	   lipidendruppels	  of	   in/nabij	  membranen	  –	  en	  het	   lipidenmetabolisme	  
(lipidturnover)	  een	  rol.	  	  
Een	   verhoogde	   vet-­‐toevoer	   naar	   de	   spier,	   door	   middel	   van	   verhoogde	  
lipidenwaarden	  in	  het	  bloed,	  wordt	  beschouwd	  als	  een	  van	  de	  onderliggende	  verklaringen	  
voor	   de	   toegenomen	   vetstapeling	   in	   de	   spier	   bij	   obesitas.	   Opslag	   van	   lipiden	   in	  
lipidendruppels	   zou	   mogelijk	   kunnen	   voorkomen	   dat	   lipidenintermediaren	   de	  
insulinesignaleringscascade	  in	  de	  celmembranen	  hinderen.	  De	  capaciteit	  voor	  vetopslag	  in	  
lipidendruppels	  in	  de	  spier	  en	  de	  mate	  van	  aanwezigheid	  van	  lipidendruppel-­‐eiwitten	  zou	  
daarom	   de	   interindividuele	   verschillen	   in	   gevoeligheid	   voor	   het	   ontwikkelen	   van	  
insulineresistentie	  bij	   verhoogde	  vettoevoer	   kunnen	  verklaren.	   Twee	  modellen	  voor	  een	  
verhoogde	   vettoevoer	   zijn	   vasten	   en	   een	   dieet	   rijk	   in	   vet.	   In	   hoofdstuk	   3	   worden	   de	  
effecten	  van	  vasten	  (60	  uur)	  en	  consumptie	  van	  een	  dieet	  rijk	  in	  vet	  gedurende	  drie	  weken	  
op	  vetstapeling	   in	  de	  spier,	   insulinegevoeligheid	  en	  expressieniveaus	  van	   lipidendruppel-­‐
eiwitten	   besproken.	   Vasten	   leidde	   tot	   sterk	   verhoogde	   vetzuurniveaus	   in	   de	   bloedbaan,	  
vetstapeling	   in	   de	   spier	   en	   insulineresistentie.	   Echter,	   een	   grotere	   toename	   in	   de	  
vetstapeling	  in	  lipidendruppels	  na	  vasten	  was	  geassocieerd	  met	  een	  verminderde	  inductie	  
van	  insulineresistentie.	  Dit	  fenomeen	  was	  niet	  van	  kracht	  in	  de	  hoog	  vet-­‐dieet	  interventie,	  
wat	  impliceert	  dat	  de	  beschermende	  rol	  van	  de	  vetstapelingscapaciteit	  in	  lipidendruppels	  
met	   name	   van	   kracht	   is	   in	   acute	   condities	   van	   verhoogde	   vettoevoer.	   PLIN2	   en	   PLIN5	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niveaus	  waren	   niet	   verhoogd	   na	   vasten	   in	   humaan	   spierweefsel,	   in	   tegenstelling	   tot	   de	  
resultaten	   van	   dierstudies.	   In	   beide	   studies	   correleerden	   PLIN2	   niveaus	   met	   de	  
hoeveelheid	  vetstapeling	  in	  lipidendruppels.	  
Een	  verhoogde	  vetzuuropname,	  een	  verlaagde	  vet-­‐oxidatieve	  capaciteit	  (afbraak	  van	  
vetten	  voor	  energievoorziening)	  en	  verstoringen	  in	  het	  lipidenmetabolisme	  in	  de	  spiercel	  
zijn	  gesuggereerd	  als	  verklaringen	  voor	   lipotoxiciteit	   resulterend	   in	   insulineresistentie.	   In	  
hoofdstuk	   4	   is	   het	   lipidenmetabolisme	   in	   de	   spier	   van	   obese	   personen	   met	   type	   2	  
diabetes	   vergeleken	   met	   obese	   controle	   personen.	   In	   deze	   studie	   hebben	   we	   gekeken	  
naar	  het	  lipidenmetabolisme	  in	  spierbiopten	  (ex	  vivo),	  maar	  ook	  in	  gekweekte	  spiercellen	  
(in	   vitro).	   Deze	   spiercellen	   worden	   gekweekt	   vanuit	   satellietcellen	   en	   representeren	  
daarom	  voornamelijk	  het	  genetische	  profiel	  van	  de	  donor.	  Met	  deze	  studieopzet	  konden	  
we	  daarom	  kijken	  naar	  zowel	  verworven	  defecten	  in	  spier-­‐lipidenmetabolisme	  als	  gevolg	  
van	   de	   leefstijl	   en	   diabetesontwikkeling	   alsmede	   genetische	   verschillen	   in	  
lipidenmetabolisme	   die	   potentieel	   de	   aanleg	   voor	   de	   ontwikkeling	   van	   obesitas-­‐
geassocieerde	  type	  2	  diabetes	  kunnen	  verklaren.	  Ex	  vivo	  hadden	  de	  type	  2	  diabeten	  een	  
lagere	  vetzuur	  oxidatie	  en	  een	  lagere	  incorporatie	  van	  vetzuren	  in	  TAG	  in	  het	  spierweefsel.	  
In	  vitro	  echter,	  was	  de	  vetzuur	  oxidatiecapaciteit	  gelijk	   in	  spiercellen	  van	  diabeten	  en	  de	  
obese	  controles,	  terwijl	  de	  incorporatie	  van	  vetzuren	  in	  TAG	  zowel	  ex	  vivo	  als	  in	  vitro	  lager	  
was	   in	   de	   groep	   diabeten.	   De	   vetzuuropname	   was	   gelijk	   in	   de	   twee	   groepen.	   Deze	  
resultaten	  tonen	  aan	  dat	  een	  gereduceerde	  capaciteit	  voor	  het	  opslaan	  van	  vetzuren	  in	  de	  
vorm	  van	  TAG	  een	  intrinsiek	  kenmerk	  is	  van	  de	  diabete	  spiercel.	  	  
De	  bovenstaande	  hoofstukken	   laten	   zien	  dat	  een	  verhoogde	   capaciteit	   voor	  opslag	  
van	   vetten	   in	   de	   vorm	   van	   TAG	   in	   lipidendruppels	   geassocieerd	   is	   met	   een	   hogere	  
insulinegevoeligheid.	   Lipidendruppel-­‐coatende	   eiwitten	   zijn	   betrokken	   bij	   het	   reguleren	  
van	   intracellulaire	   vetopslag.	   Echter,	   er	   is	   nog	   weinig	   bekend	   over	   de	   rol	   van	  
lipidendruppel-­‐eiwitten	   in	   de	   skeletspier.	   In	   hoofdstuk	   5	   is	   aangetoond	   dat	   het	  
lipidendruppel-­‐eiwit	   PLIN2	   neutrale	   vetopslag	   in	   de	   spier	   faciliteert.	   PLIN2	   is	   essentieel	  
voor	   opslag	   van	   TAG	   in	   de	   spiercel;	   het	   verminderen	   van	   de	   PLIN2	   eiwitniveaus	   in	  
gekweekte	   spiercellen	   door	   middel	   van	   siRNA	   zorgde	   voor	   lagere	   TAG	   niveaus,	  
verminderde	   incorporatie	  van	  vetzuren	   in	  TAG	  en	  een	   lager	  aantal	   lipidendruppels	   in	  de	  
spiercellen.	  Verhogen	  van	  de	  aanwezigheid	  van	  PLIN2	  in	  vitro	  in	  gekweekte	  spiercellen	  en	  
in	   vivo	   in	   rat	   spier	   leidde	   tot	   verhoogde	   vetstapeling	   in	   de	   spiercel,	   terwijl	   de	  
insulinegevoeligheid	   was	   toegenomen.	   In	   conclusie,	   PLIN2	   faciliteert	   de	   opslag	   van	  
potentieel	   toxische	  vetzuren	   in	  de	  vorm	  van	  het	  neutrale	  TAG	  en	  verbetert	  daardoor	  de	  
insulinegevoeligheid.	  
Hoofdstuk	   6	   beschrijft	   de	   lokalisatie	   van	   PLIN5.	   Naast	   de	   aanwezigheid	   op	   de	  
lipidendruppel,	  tonen	  wij	  aan	  dat	  PLIN5	  ook	  aanwezig	  is	  in	  skeletspier	  mitochondriën.	  De	  
hoeveelheid	  PLIN5	  correleerde	  met	  markers	  voor	  oxidatieve	  capaciteit.	  Het	  verhogen	  van	  
de	  aanwezigheid	  van	  PLIN5	  in	  de	  spier	  door	  middel	  van	  genelectroporatie	   leidde	  tot	  een	  
verhoogde	  vetstapeling	  in	  de	  spier	  en	  een	  verhoogde	  vetzuuroxidatie.	  Hoofdstuk	  7	  geeft	  
hieraan	  een	  vervolg.	   In	  dit	  hoofdstuk	  worden	  de	  effecten	  van	  PLIN5	  overexpressie	  –	  een	  
verhoogde	  aanwezigheid	  van	  PLIN5	  in	  de	  skeletspier	  tibialis	  anterior	  –	  vergeleken	  met	  de	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effecten	   van	   PLIN2	   overexpressie	   op	   het	   niveau	   van	   stapeling	   van	   verschillende	   typen	  
lipiden,	  insulinegevoeligheid	  en	  genexpressie	  profielen.	  Zowel	  overexpressie	  van	  PLIN2	  als	  
van	  PLIN5	  verhoogden	  de	  stapeling	  van	  TAG	   in	  de	  spier	  en	  deze	  verhoogde	  vetstapeling	  
leidde	   in	   beide	   gevallen	   niet	   tot	   verminderde	   insulinegevoeligheid.	   Een	   interessant	  
contrast	  was	  echter,	  dan	  PLIN2	  leidde	  tot	  een	  verlaagde	  expressie	  van	  genen	  betrokken	  bij	  
vetzuuroxidatie,	   terwijl	   overexpressie	   van	  PLIN5	   leidde	   tot	  een	  verhoogde	  expressie	   van	  
genen	  betrokken	  bij	  vetzuuroxidatie	  en	  mitochondriële	  functie.	  
Strategieën	  ter	  verbetering	  van	  de	  insulinegevoeligheid,	  zoals	  training,	  zouden	  hand	  
in	   hand	   kunnen	   gaan	   met	   een	   verbeterd	   lipidendruppelmetabolisme.	   In	   hoofdstuk	   8	  
worden	   de	   effecten	   beschreven	   van	   een	   trainingsprogramma	   van	   12	   weken	   (een	  
combinatie	   van	   kracht-­‐	   en	   duursport)	   in	   obese	   personen	   en	   type	   2	   diabeten	   op	  
vetstapeling	  in	  de	  spier	  en	  het	  expressieniveau	  van	  een	  cluster	  lipidendruppel-­‐eiwitten.	  De	  
vetopslag	  in	  lipidendruppels	  in	  de	  spier	  was	  licht	  verhoogd	  na	  de	  trainingsperiode,	  terwijl	  
de	  expressie	  van	  PLIN2	  en	  PLIN5	  was	  verdubbeld.	  
	  
In	   conclusie,	   de	   resultaten	   van	   deze	   serie	   studies	   tonen	   aan	   dat	   het	   creëren	   van	  
opslagcapaciteit	   voor	   neutrale	   lipiden	   beschermt	   tegen	   obesitas-­‐geassocieerde	   insuline	  
resistentie	   in	   de	   spier.	   Een	   verhoogde	   aanwezigheid	   van	   PLIN2	   of	   PLIN5	   leidt	   tot	   een	  
verhoogde	   vetstapeling	   in	   lipidendruppels	   zonder	   de	   insulinegevoeligheid	   van	   de	   spier	  
negatief	   te	   beïnvloeden.	   Verder	   onderzoek	   naar	   interventies	   die	   de	   PLIN	   functie	   en	  
lipidendruppeldynamiek	   positief	   beïnvloeden	   -­‐	   zoals	   farmacologische-­‐,	   voedings-­‐	   en	  
bewegingsstrategieën	   -­‐	   	   is	   daarom	   veelbelovend	   in	   het	   kader	   van	   de	   preventie	   en	  
behandeling	  van	  type	  2	  diabetes.	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Hier	   is	   ‘t	   dan;	   mijn	   proefschrift.	   Ik	   had	   mij	   nooit	   gerealiseerd	   hoe	   zwaar	   een	  
promotietraject	  kan	  zijn.	  Maar	  hoe	  zwaar	  ook,	  het	  eindresultaat	  is	  daar	  en	  ik	  kan	  zeggen	  
dat	   ik	  naast	  wetenschappelijke	   kennis	   en	  ervaring	  heel	   veel	   geleerd	  heb	  over	  mijzelf	   en	  
mijn	   omgeving,	  wat	   zo’n	   traject	   nog	  waardevoller	  maakt.	   De	   laatste	   twee	   jaar	   duurden	  
lang,	  maar	  het	  enorme	  plezier	   in	  het	  bedrijven	  van	  wetenschap	   is	   altijd	  blijven	  bestaan.	  
Zonder	  doorzettingsvermogen	  had	   ik	  dit	  proefschrift	  nooit	  binnen	  4	   jaar	  afgerond,	  maar	  
dat	  was	  natuurlijk	  ook	  nooit	  gelukt	  zonder	  de	  hulp	  van	  velen.	  Waarvoor	  mijn	  grote	  dank!	  	  
	  
Beste	   Patrick,	   Matthijs	   en	   Sander,	   heren	   professoren,	   ontzettend	   bedankt	   voor	   de	  
begeleiding	  van	  mijn	  promotietraject!	   Jullie	  vormden	  een	  promotieteam	  met	  een	  mooie	  
combinatie	   van	   expertises.	   Het	   was	   een	   ontzettend	   leerzame	   periode.	   Ik	   wil	   jullie	  
bedanken	  voor	  het	  feit	  dat	  ik	  echt	  mijn	  eigen	  stempel	  heb	  kunnen	  drukken	  op	  dit	  project	  
en	   dat	   ik	   ervaring	   op	   heb	   kunnen	   doen	   met	   vele	   technieken.	   Bedankt	   voor	   het	   in	   mij	  
gestelde	  vertrouwen;	  met	  name	  in	  de	  eerste	  2	  jaar	  had	  ik	  min	  of	  meer	  de	  vrije	  hand	  om	  de	  
PLIN	  experimenten	  en	  mijn	  promotie-­‐traject	  vorm	  te	  geven.	   Ik	  heb	  goede	  herinneringen	  
aan	  de	  meetings	  met	  z’n	  vieren,	  maar	  ik	  heb	  eigenlijk	  nog	  meer	  gehad	  aan	  de	  interacties	  
met	  elk	  van	  jullie.	  Ik	  heb	  het	  heel	  waardevol	  gevonden	  dat	  ik	  zoveel	  van	  jullie	  heb	  kunnen	  
leren.	  	  
Patrick:	   jij	   was	   als	   eerste	   begeleider	   het	   meest	   betrokken	   bij	   dit	   project.	   We	   zaten	  
regelmatig	   niet	   op	   dezelfde	   lijn,	   maar	   dat	   leidde	   dan	   meestal	   wel	   weer	   tot	   de	   juiste	  
compromissen	  en	  eigenlijk	  denk	   ik	  ook	  dat	  het	  goed	   is	  dat	   je	  het	   in	  de	  wetenschap	  niet	  
altijd	  eens	  bent,	  want	  juist	  door	  die	  discussies	  kom	  je	  tot	  nieuwe	  inzichten	  en	  strategieën.	  
Op	  de	  momenten	  dat	  ik	  een	  discussie	  probeerde	  te	  omzeilen	  door	  mee	  te	  gaan	  in	  plaats	  
van	  er	  tegenin	  dan	  werkte	  dat	  ook	  vaak	  niet,	  want	  acteertalent	  heb	  ik	  niet.	  Maar	  het	  heeft	  
geresulteerd	  in	  een	  mooi	  project.	  Bedankt	  voor	  alle	  begeleiding,	  zowel	  op	  het	  gebied	  van	  
mijn	  promotietraject	  als	  op	  carrière	  vlak!	  
Matthijs:	   jouw	   enthousiasme	   voor	   het	   lipidendruppel-­‐onderzoek	   was	   aanstekelijk.	   wij	  
begrepen	  elkaar	  niet	  altijd,	  maar	  ook	  dat	  is	  inzichtelijk	  geweest.	  Ik	  kan	  me	  ons	  tripje	  naar	  
Steamboat	   Springs	   van	   2,5	   jaar	   geleden	   nog	   goed	   herinneren,	   dat	   is	   echt	   een	   van	   de	  
hoogtepunten	   geweest	   van	   mijn	   promotietraject.	   Die	   congresweek	   bood	   uitdaging	   en	  
inspiratie.	  Stiekem	  vind	  ik	  het	  toch	  wel	  een	  beetje	  jammer	  dat	  ik	  het	  lipidendruppelveld	  ga	  
verlaten	  (al	  blijf	  ik	  nog	  wel	  wat	  onderzoek	  doen	  op	  dat	  vlak).	  Het	  is	  een	  ontzettend	  leuk	  en	  
relevant	  onderzoeksgebied	  dat	  nog	  vele	  mogelijkheden	  biedt!	  
Sander:	  jij	  was	  meer	  op	  de	  achtergrond	  aanwezig,	  maar	  zeker	  een	  hele	  waardevolle	  kracht	  
in	  het	  promotorenteam!	  De	  meetings	  met	  z’n	  vieren	  die	  we	  een	  paar	  keer	  per	  jaar	  hielden	  
waren	   voor	   mij	   heel	   inzichtelijk	   en	   overzichtelijk	   en	   jouw	  moleculair-­‐biologische	   kennis	  
bood	   dan	   weer	   inspiratie	   voor	   de	   te	   kiezen	   vervolgstappen.	   Al	   tijdens	   mijn	   master	   in	  
Wageningen	  heb	  jij	  mij	  weten	  te	  inspireren	  tot	  het	  zoeken	  van	  uitdagingen.	  Mijn	  stage	  in	  
New	  York	  was	   daarvoor	   een	   belangrijke	   stap.	  Wat	  mij	   ook	   altijd	   bij	   zal	   blijven	   is	   dat	   jij,	  
maar	   zeker	   ook	   Guido,	   mij	   destijds	   hebben	   aangeraden	   steeds	   op	   zoek	   te	   gaan	   naar	  
personen	  om	  je	  heen	  waarvan	  je	  kunt	  leren	  en	  die	  je	  inspireren.	  Dat	  is	  het	  pad	  dat	  ik	  nog	  
altijd	  probeer	  te	  volgen.	  Bedankt	  voor	  alle	  adviezen	  gedurende	  de	  afgelopen	  jaren!	  
	  	  215	  
	  
Prof.	  dr.	  Glatz,	  Prof.	  dr.	  Biessen,	  Prof.	  dr.	  Havekes,	  Prof.	  dr.	  Karpe	  and	  dr.	  Shiri-­‐Sverdlov:	  
thank	  you	  very	  much	  for	  evaluating	  my	  thesis.	  
	  
Lieve	   Karina,	   ik	   ben	   heel	   blij	   dat	   jij	   deze	   dag	   achter	   mij	   staat	   als	   paranimf!	   Onze	  
vriendschap	   heeft	   zich	   de	   afgelopen	   jaren	   ontwikkeld	   tot	   een	   zeer	   hechte	   band.	   Wat	  
hebben	  we	  samen	  veel	  meegemaakt	  de	  afgelopen	  jaren.	  Ik	  kan	  bij	   jou	  altijd	  terecht	  voor	  
goede	   gesprekken,	   afleiding	   en	   vooral	   ook	   samen	   genieten	   van	   het	   goede	   leven.	  
Ontzettend	  bedankt	  voor	  alle	  steun	  en	  betrokkenheid	  de	  afgelopen	  jaren!	  
	  
Lieve	  Silvie,	  ik	  vond	  het	  heel	  speciaal	  om	  jouw	  paranimf	  te	  mogen	  zijn	  en	  ik	  vind	  het	  super	  
dat	   jij	  ook	  mij	  bijstaat	  tijdens	  mijn	  verdediging!	   Ik	  waardeer	  het	  enorm	  dat	   ik	  altijd	  bij	   je	  
terecht	  kan	  voor	  steun,	  overleg	  en	  gezelligheid.	  Je	  bent	  al	  heel	  goed	  op	  weg	  richting	  een	  
mooie	  carrière	  in	  de	  wetenschap.	  Ik	  hoop	  dat	  we	  in	  de	  toekomst	  ook	  op	  afstand	  nog	  altijd	  
bij	  elkaar	  terecht	  kunnen!	  
	  
Collega’s	  HB	  en	  BW:	  naast	  alle	  praktische	  hulp,	  bedankt	  voor	  alle	  gezelligheid;	  de	  praatjes	  
bij	   het	   koffiezetapparaat,	   de	   borrels	   en	   etentjes.	   Al	   heb	   ik	   al	   best	   wat	   van	   de	   wereld	  
gezien,	  wonen	  in	  Limburg	  voelde	  voor	  mij	  regelmatig	  als	  buitenlandervaring.	  De	  cultuur	  is	  
nooit	  de	  mijne	  geworden,	  maar	  ik	  heb	  kennis	  kunnen	  maken	  met	  carnaval	  en	  heb	  genoten	  
van	  het	  bourgondische	   leven.	   Jos:	  bedankt	  voor	  het	  organiseren	  van	  de	  borrels!	  Ook	  de	  
uitstapjes	  en	  weekenden	  waren	  altijd	  super	  gezellig!	  
	  
Collega’s	   en	   oud-­‐collega’s	   van	   het	   SHOCk-­‐team:	   heel	   hartelijk	   bedankt	   voor	   de	  
samenwerking	   en	   de	   inspirerende	   meetings.	   De	   wekelijkse	   meetings	   en	   journalclubs	  
waren	  altijd	  nuttig	  en	  inzichtelijk,	  waardoor	  ik	  ook	  buiten	  mijn	  onderzoeksgebied	  veel	  heb	  
kunnen	   leren.	  Allemaal	  heel	  hartelijk	  bedankt!	  Lauren,	  you	  were	   involved	   in	  most	  of	  my	  
projects,	  so	  a	  special	  thanks	  to	  you!	  	  
	  
Kamergenoten:	   Anja,	   Hazibe,	   Bianca,	   Guy	   en	   Lisje,	   bedankt	   voor	   de	   fijne	   tijd	   op	   kamer	  
2.306!	   Anja,	   bedankt	   voor	   alle	   support	   en	   gezelligheid	   tijdens	  mijn	   opstartfase.	   Hazibe,	  
bedankt	  voor	  4	   jaar	  betrokkenheid	  en	  gezelligheid!	  Bianca,	  bedankt	  voor	  alles,	   zowel	  op	  
het	   werk	   als	   daarbuiten	   en	   wat	   hebben	   we	   samen	  mooie	   reizen	   gemaakt!	   Guy,	   ook	   jij	  
bedankt	   voor	   de	   gezelligheid	   en	   betrokkenheid,	   ik	   heb	   enorm	   veel	   respect	   voor	   jouw	  
ambities	  en	  werkwijze.	  Lisje,	  het	  was	  kort	  maar	  heel	  gezellig!	  
	  
Ik	  wil	  ook	  graag	  de	  secretaresses	  en	  analisten	  van	  HB	  en	  BW	  en	  de	  medewerkers	  van	  het	  
RNL	  en	  het	  CPV	  bedanken	  voor	  alle	  hulp.	  In	  het	  bijzonder	  wil	   ik	  Gert,	  Esther,	  Johanna	  en	  
Denis	  heel	  graag	  bedanken	  voor	  alle	  hulp	  maar	  ook	  zeker	  voor	  de	  goede	  sfeer	  in	  het	  lab!	  	  
Daarnaast,	  alle	  coauteurs:	  heel	  hartelijk	  bedankt	  voor	  jullie	  bijdrages	  aan	  de	  artikelen!	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Pontus:	   thanks	   for	   the	   giving	  me	   the	  opportunity	   to	   start	   as	   a	  postdoc	   in	   your	   research	  
group.	  I	  already	  knew	  for	  more	  than	  6	  months	  that	  I	  would	  be	  joining	  the	  lab	  and	  finally	  
the	  time	  has	  come.	  This	   is	  the	  challenging	  and	  inspiring	  research	  environment	  that	  I	  was	  
looking	  for	  as	  the	  next	  step	  in	  my	  career!	  	  	  
Colleagues	  of	  Boström/Andersson	   lab,	  many	   thanks	   for	   the	  warm	  welcome!	   It’s	  great	   to	  
work	  in	  such	  a	  strong	  and	  enthusiastic	  team.	  
	  
Anke,	   Annemarie,	   Eline,	   Frederike,	   Geerke,	  Marijke,	   Nynke	   en	   Sietske:	   geweldig	   dat	  wij	  
elkaar	  nog	  zo	  regelmatig	  zien!	  Ik	  heb	  hele	  goede	  herinneringen	  aan	  mijn	  studententijd	  in	  
Wageningen	  en	  de	   jaren	  daarna,	  waarin	  we	   zoveel	  met	  elkaar	  hebben	  beleefd.	   Bedankt	  
voor	  alles.	  Waar	  ter	  wereld	  we	  ook	  wonen	  en	  hoe	  onze	  levens	  er	  ook	  uit	  zien,	  de	  sterke	  
band	  blijft	  bestaan,	  super!	  
	  
Else,	  Mirjam	  en	  Victoria:	   super	  dat	  onze	  vriendschap	  al	   ruim	  13	   jaar	   stand	  houdt	   terwijl	  
onze	  levens	  inmiddels	  sterk	  uiteen	  lopen!	  	  
	  
Familie:	  bedankt	  voor	  alles;	  de	  getoonde	  interesse,	  gezelligheid	  en	  betrokkenheid.	  Robert,	  
Almer	  en	  Lisa	  in	  het	  bijzonder;	  bedankt	  voor	  alle	  steun	  en	  gezelligheid!	  
	  
Leave	   heit	   en	   mem,	   tige	   tank	   foar	   alles,	   woorden	   schieten	   natuurlijk	   tekort	   om	   uit	   te	  
drukken	  hoeveel	  dank	   ik	   jullie	  verschuldigd	  ben.	  Fijn	  om	  altijd	  terug	  te	  kunnen	  vallen	  op	  
een	  stabiele,	  fijne	  basis.	  Bedankt	  voor	  de	  hulp	  bij	  alle	  verhuizingen	  en	  ontzettend	  bedankt	  
voor	  alle	  steun	  op	  moeilijke	  momenten.	  Super	  dat	   jullie	  mij	  onvoorwaardelijk	  steunen	  in	  
alle	  keuzes	  die	  ik	  maak!	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